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ABSTRACT 
 
THE VAGINAL MICROBIOTA IMPACT OF ANTIBIOTIC AND PROBIOTIC COMPOUNDS AND 
POINT-OF-CARE TESTING FOR VAGINAL DYSBIOSIS AND SEXUALLY TRANSMITTED 
INFECTIONS by Marijn Verwijs 
 
Studies employing modern molecular techniques have shown that the vaginal microbiota (VMB) of 
most women is dominated by beneficial Lactobacillus species. However, about one-third of women 
worldwide at any given time point have a non-optimal VMB, referred to as vaginal dysbiosis. The most 
common bacterial vaginal dysbiosis is bacterial vaginosis (BV), which is characterised by a decrease in 
lactobacilli and an increase in BV-associated anaerobic bacteria. The most common type of fungal 
vaginal dysbiosis is vulvovaginal candidiasis (VVC), which is characterised by the presence of Candida 
yeasts, usually in the presence of lactobacilli. BV and VVC have been associated with HIV acquisition, 
and BV also with adverse pregnancy outcomes. BV can be treated with the antibiotics metronidazole or 
clindamycin, but recurrence is common. Better therapies to treat BV and prevent its recurrence are 
needed. 
 
The prevalences of BV and sexually transmitted infections (STIs) are high worldwide but are highest in 
sub-Saharan Africa. Many sub-Saharan African countries rely on the World Health Organisation 
(WHO) syndromic management algorithms to treat symptomatic women given their limited clinic and 
laboratory infrastructure. These algorithms provide guidance on which urogenital infections to treat 
when certain urogenital symptoms (referred to as ‘syndromes’) are reported by the patient, without the 
need for diagnostic testing (and with pelvic examinations being optional). A syndrome is treated for all 
infections that might cause that syndrome. The performances of the WHO algorithms for vaginal 
discharge syndrome and lower abdominal pain syndrome in women are known to be poor, and 
asymptomatic infections are missed by definition. Support for the introduction of point-of-care testing 
(POCT) is mounting but has been hampered by the lack of ASSURED (‘Affordable, Sensitive, Specific, 
User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end users’) POCTs for some 
urogenital infections. 
 
This thesis describes the results of two studies that we conducted at a research clinic in Kigali, Rwanda, 
and the results of a systematic review. The first study (referred to as the Rwanda VMB study) 
investigated the impact of oral metronidazole and two different vaginal probiotics on the VMB and on 
BV recurrence. Sixty-eight HIV-negative and non-pregnant women with laboratory-confirmed BV 
and/or Trichomonas vaginalis (TV) received a seven-day oral metronidazole treatment course. We 
assessed their VMB before and after treatment by Gram stain Nugent scoring and 16S rRNA gene 
HiSeq sequencing (relative abundances) combined with 16S rRNA gene qPCR (to estimate bacterial 
concentrations). As expected, metronidazole decreased the overall bacterial load, and the relative 
abundances and concentrations of BV-anaerobes (all BV-anaerobes combined, as well as those of key 
BV-anaerobe taxa). However, metronidazole also increased the relative abundances and concentrations 
of lactobacilli (all lactobacilli combined, as well as increases in all key Lactobacillus taxa). Pre-
treatment pathobionts concentration (defined as Proteobacteria, streptococci, staphylococci, enterococci, 
and a few others), and having a pre-treatment vaginal microbiota type containing more than 50% 
Gardnerella vaginalis (compared to BV-like VMB types with less than 50% G. vaginalis), were 
associated with increased likelihood of treatment failure, although the latter did not reach statistical 
significance (p=0.044 and p=0.084, respectively). 
 
All 68 women were subsequently randomised to four groups (n=17 each): behavioural counselling only 
(negative control group), intermittent use of oral metronidazole, intermittent use of Ecologic Femi+ 
vaginal probiotic capsule (containing multiple Lactobacillus and one Bifidobacterium species; 
Winclove Probiotics, Amsterdam, Netherlands), or intermittent use of Gynophilus LP vaginal probiotic 
tablet (containing L. rhamnosus 35; Biose, Arpajon-sur-Cère, France). Participants used the 
interventions for two months and VMB assessments were done at baseline, Day 7, Month 1, Month 2, 
and Month 6. Adherence was assessed by triangulating multiple adherence assessments and was taken 
into account in our analyses. All three interventions were safe and the preliminary efficacies were 
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promising. BV (Nugent 7-10) incidence was 10.18 per person-year at risk in the control group, and 
lower in the metronidazole (1.41/person-year; p=0.004), Ecologic Femi+ (3.58/person-year; p=0.043), 
and Gynophilus LP groups (5.36/person-year; p=0.220). In mixed effects models adjusted for hormonal 
contraception/pregnancy, sexual risk-taking, and age, metronidazole and Ecologic Femi+ users, each 
compared to controls, had higher Lactobacillus and lower BV-anaerobes concentrations and/or relative 
abundances, and were less likely to have a dysbiotic VMB type by sequencing. However, inter-
individual variability was high and effects disappeared soon after intervention cessation. We also 
assessed the acceptability of the interventions using structured questionnaires and semi-structured focus 
group discussions and in-depth interviews and found that acceptability was high. Finally, we identified 
a need for information, education and counselling campaigns to inform at-risk women about steps they 
can take to prevent BV, VVC, and STIs.  
 
In a systematic review, we evaluated the impact of lactobacilli-containing vaginal probiotics on BV and 
VVC cure and/or recurrence, as well as VMB composition and vaginal detection of probiotic strains, to 
compare the results of our own study with the published literature. We identified 34 studies evaluating 
22 different vaginal probiotics. Unfortunately, most identified studies were under-powered and of poor 
methodological quality (for example, only two studies – including our own – differentiated between 
probiotic and autologous lactobacilli), and methodological heterogeneity between studies was high. Our 
conclusions were that vaginal lactobacilli-containing probiotics are safe and hold promise for BV cure 
and prevention, but are much less promising for VVC cure and prevention. Vaginal detection of 
probiotic strains never lasted long beyond the dosing period, suggesting that the probiotic lactobacilli 
used to date do not colonise the vagina. 
 
The aim of the second study (referred to as the WISH study) was to compare the performances of 
vaginal discharge/lower abdominal pain algorithms incorporating POCTs (the WISH algorithms), with 
traditional WHO syndromic management algorithms, and with nucleic acid amplification test (NAAT; 
gold standard) results. The POCTs we evaluated included the EcoCare vaginal pH swab (Merete 
Medical, Luckenwalde, Germany; pH≥5.0 was considered BV) and the TV OSOM assay (Sekisui 
Diagnostics, Lexington, USA) for BV and TV, both regardless of symptom-reporting. Women with a 
positive risk score were POC-tested for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG; by 
GeneXpert, Cepheid, Sunnyvale, USA). VVC was treated presumptively based on reported symptoms. 
We enrolled 705 Rwandan women at risk of STIs, regardless of HIV and pregnancy status, and 
regardless of the presence or absence of urogenital symptoms. The study showed that POCT integration 
was feasible in a Rwandan setting, and acceptable to participants and staff. NAAT-based urogenital 
infection prevalences were: CT 8.5%, NG 7.1%, TV 16.1%, BV 18.1%, and VVC 8.6%. Infection-
specific sensitivities of the WHO syndromic management algorithms compared to the gold standards 
ranged from 58.3-74.6%, and specificities from 44.7-50.6%. WISH POCT-based algorithms had good 
sensitivity (68.5-76.0%) and specificity (97.4-100%) for CT, NG, and TV but low specificity for BV 
(41.2%; sensitivity 95.2%), and modest sensitivity (64.4%) and specificity (69.4%) for VVC. 
Sensitivity (73.6%) and specificity (100%) for BV can be improved by screening all women for vaginal 
pH and conduct confirmatory testing (such as Nugent scoring or a molecular test) in women with a 
vaginal pH≥5.5 (n=275 in the WISH study). Based on these data, we concluded that existing POCTs 
should be introduced when feasible, and that POCT development should continue, including the 
development of ASSURED POCTs with multiple testing targets.  
 
Taken together, the data in this thesis suggest that urogenital infection epidemics in sub-Saharan Africa 
could potentially be reduced by the introduction of existing POCTs, the development of additional 
ASSURED POCTs, the expansion of the evidence-base for lactobacilli-containing vaginal probiotics 
using improved trial designs that incorporate molecular techniques, and the development of improved 
vaginal probiotics and other therapies to cure and/or prevent BV. Such new tools may have the potential 
to ultimately lower incidence of HIV and adverse pregnancy outcomes in at-risk women. 
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Chapter 1 - General Introduction 
 
1.1 Vaginal Microbiota Compositions 
The term microbiota refers to ‘the assemblage of microorganisms present in a defined environment’, be 
it commensal, symbiotic, or pathogenic.1,2 We have known since the end of the 19th century that the 
vagina of most women contains lactobacilli.3,4 Modern molecular methods such as 16S rRNA gene 
sequencing and quantitative polymerase chain reaction (qPCR) have greatly increased vaginal 
microbiota (VMB) composition knowledge.4 These studies have shown that most women have a low-
diversity, optimal VMB that is dominated by beneficial lactobacilli. This optimal VMB state is also 
referred to as eubiosis.5  
 
The VMB of most women is dominated by either L. iners or L. crispatus.4 L. iners is more common in 
African and African-American women, while L. crispatus is more common in Caucasian and Asian 
women. Lactobacilli produce lactic acid which acidifies the vagina, thereby causing the vagina to have a 
low pH (<4.5) in normal conditions.6 Lactic acid has important antimicrobial, antiviral, and 
immunomodulatory properties.6,7 The role of L. iners is subject to debate, as it seems to protect women 
less well from other organisms than other Lactobacillus species: L. iners has been associated with more 
frequent transitions to non-optimal microbiota states than L. crispatus in longitudinal studies.4,8–11 L. 
iners does produce lactic acid, but in lower quantities than L. crispatus. In some women the VMB is 
dominated by L. gasseri, L. jensenii, or L. vaginalis instead, but these species are less common and less 
well studied. The reasons for the ethnic differences in Lactobacillus domination are unclear as of yet but 
may depend on genetic, behavioural, and dietary factors.4,8  
 
Some women have a non-optimal VMB in which there is no domination by lactobacilli. This is referred 
to as vaginal dysbiosis.4,5,9 In this thesis, we use the term vaginal dysbiosis to refer to all VMB states in 
which there is a microbiological deviation from the optimal Lactobacillus-dominated low-diversity 
state, or states in which lactobacilli still form a majority but with important contributions of organisms 
with a relatively high pathogenicity index (which we refer to as pathobionts as explained later on in this 
chapter).9 All forms of vaginal dysbiosis are associated with significant but differing degrees of vaginal 
inflammation, regardless of whether the affected woman experiences symptoms or not.12 This thesis 
will therefore use the term vaginal dysbiosis regardless of patient symptomatology. The most common 
forms of vaginal dysbiosis are bacterial vaginosis (BV), low-diversity anaerobic dysbiosis (most 
commonly domination by Gardnerella vaginalis), bacterial dysbiosis characterised by high relative 
abundance of pathobionts, and the fungal dysbiosis vulvovaginal candidiasis (VVC).  
 
BV is the most common vaginal dysbiosis. It is a state in which multiple fastidious anaerobic bacterial 
species dominate the VMB.4 This process is associated with a loss of lactobacilli. The decrease in 
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Lactobacillus concentration results in a lower production of lactic acid and therefore an increase in the 
vaginal pH.7 Examples of BV-associated anaerobic species that are often described are Gardnerella 
vaginalis, Atopobium vaginae, Dialister spp., BV-associated bacterium type 1 and 2 (BVAB-1 and 
BVAB-2), Prevotella spp., Parvimonas spp., Mobiluncus spp., Megasphaera spp., and Mageeibacillus 
indolicus (formerly BVAB-3).4,13 These species often co-occur in BV in a highly diverse bacterial 
community, which is why the bacterial richness (total number of species observed in a given sample) 
and the alpha diversity index (a measure to quantify the diversity of the vaginal community in a given 
sample) of the VMB in these women is higher than in Lactobacillus-dominated women.14,15 BV is 
associated with inflammation, but is not as inflammatory as the bacterial sexually transmitted infections 
(STIs) or VVC,16 which is why the term ‘vaginosis’ was used instead of ‘vaginitis’.5 This may also 
explain why BV is often asymptomatic. BV is associated with important sequelae, such as increased 
rates of HIV transmission (both male-to-female and female-to-male), increased rates of the acquisition 
of other STIs, pelvic inflammatory disease, and adverse pregnancy outcomes such as stillbirth, invasive 
neonatal infections, and preterm birth.9,17–20 These associations have also been found in asymptomatic 
women. Most medical guidelines worldwide recommend that BV is only treated when the woman has 
urogenital symptoms.21–24 In some European countries, asymptomatic BV in pregnant women with a 
history of pre-term birth does get treated.23 BV is generally not considered an STI but both its 
prevalence and recurrence are associated with sexual behaviours, and couples studies have shown that 
BV-associated anaerobic species are sexually transmitted.4,25 BV is also positively associated with 
vaginal hygiene practices and menses, and negatively associated with hormonal contraception.25–27 
 
Another type of anaerobic vaginal dysbiosis is when one single (facultative) anaerobic species 
dominates the VMB, such as G. vaginalis, A. vaginae, or Prevotella species. We will refer to this as 
low-diversity (anaerobic) dysbiosis.5 Compared to classical BV, this form of vaginal dysbiosis has a low 
alpha diversity.4,5,9 At the moment, classical high diversity BV and low diversity anaerobic dysbiosis are 
not considered separate entities from a clinical perspective,5 and the treatment is the same. 
 
A third type of bacterial vaginal dysbiosis is a VMB characterised by a high abundance or concentration 
of pathobionts.9 Pathobionts have higher intrinsic pathogenicity than BV-associated anaerobes. They are 
often present in the VMB without causing problems, but they can cause serious illness in certain 
circumstances, for example when transmitted from a mother to a neonate.5,28 Important examples in the 
vaginal niche are Streptococcus agalactiae (also known as Group B Streptococcus), Staphylococcus 
aureus, and several Enterobacteriaceae such as Escherichia coli (a complete list of organisms that we 
considered to be pathobionts is given in Appendix A). They generally do not dominate the VMB in the 
way BV-anaerobes or lactobacilli do, but are present at low or modest concentrations. At the moment, 
this type of vaginal dysbiosis is not recognised as a clinical entity and we will refer to it as ‘pathobiont-
dysbiosis’ in the remainder of this thesis, regardless of symptomatology. 
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VVC is a type of vaginal dysbiosis caused by vaginal yeasts. The most common causative organism is 
Candida albicans which accounts for 70-95% of the cases.29,30 C. albicans is highly inflammatory and it 
has been hypothesised that asymptomatic carriage only occurs at low concentrations.30–32 Asymptomatic 
carriage is common, but when VVC is symptomatic, many clinicians believe that it is associated with a 
triad of typical symptoms (curd-like vaginal discharge, genital itching/ burning, and soreness) and 
typical signs (vulval erythema, excoriations, and oedema).21 VVC often co-exists in a Lactobacillus-
dominated VMB at a normal vaginal pH, and has been negatively associated with BV in many 
epidemiological studies.4,9,30 VVC is also associated with an increased likelihood of HIV acquisition 
when exposed to HIV.18 
 
Trichomoniasis is caused by a single-celled protozoa called T. vaginalis (TV). TV is sometimes 
described as a cause of vaginal dysbiosis as it often co-occurs with BV-anaerobes such as Mycoplasma, 
Parvimonas and Sneathia, and with BV in general.33,34 However, TV is an STI, and is mostly 
asymptomatic in both men and women.34 TV is also associated with other STIs, pelvic inflammatory 
disease, adverse pregnancy outcomes such as preterm delivery and premature rupture of membranes, as 
well as with increased HIV acquisition.34,35 
 
1.2 Urogenital Infections Prevalences Worldwide and in Sub-Saharan Africa 
BV is the most common curable vaginal infection worldwide, but other urogenital infections are also 
prevalent (note that BV is a polymicrobial condition but we will occasionally refer to it as a urogenital 
infection to improve readability). According to 2019 estimates, the prevalence of BV (defined as a 
Nugent score of 7-10 regardless of symptoms) ranges between 23-29% worldwide, and was estimated at 
25% in sub-Saharan Africa.36 However, the 2018 estimates from an individual participant meta-analysis 
of 18 HIV prevention studies in sub-Saharan Africa were much higher at 42.1% among 15-24-year-old 
women and 41.2% among women aged 25-49 years.37 This meta-analysis included studies that 
preferentially enrolled participants with higher sexual risk behaviours than the general population. 
 
2012 World Health Organisation estimates of the worldwide prevalence of the four main curable STIs 
among women were: Chlamydia trachomatis (CT) 4.2%, Neisseria gonorrhoeae (NG) 0.8%, TV 5.0% 
and syphilis 0.5%.38 The combined incidence of these four curable STIs among men and women was 
estimated at one million cases per day. The aforementioned 2018 individual patient meta-analysis 
estimated the prevalence of these four STIs in HIV-negative sub-Saharan African women at 15.1% for 
CT, 4.6% for NG, 0.4% for active syphilis, and 7.9% for TV among 15-24-year-olds, and 7.0% for CT, 
2.5% for NG, 1.0% for high-titer syphilis, and 8.6% TV among 25-49-year-olds.37 Most studies 
included in the meta-analysis showed that TV is the most common of these four curable STIs.34 Two 
common viral STIs other than HIV are herpes simplex virus type 2 and human papillomavirus. Both 
16 
viruses are incurable, and are more highly prevalent than the four curable STIs mentioned previously. 
The WHO estimated in 2012 that 416 million people were living with herpes simplex virus type 2, of 
which 267 million were women, corresponding to a global prevalence of 14.8% among women.39 The 
2018 meta-analysis among HIV-negative sub-Saharan African women estimated the prevalence of 
herpes simplex virus type 2 among women aged 15-24 years to be 39.3% and in women aged 25-49 
years 77.8%.37 The annual incidence of herpes simplex virus type 2 among 15-49-year-old women was 
estimated to be 0.6% worldwide and 3.4% in Africa.39 The worldwide prevalence of human 
papillomavirus in women (with normal cytology) has been estimated at 10.4%, corresponding to 291 
million women, and was highest in sub-Saharan Africa at 22.1%.40,41 
 
The prevalences of VVC and pathobionts (except for group B Streptococcus by rectovaginal culture) 
are currently not precisely known. Current VVC estimates are often based on self-reporting by women 
rather than on laboratory-confirmed VVC.42 In a 2018 systematic review, it was estimated that 138 
million women are affected by recurrent VVC annually; the prevalence of recurrent VVC in women 
aged 25-34 years was estimated at 9%.43 A 2013 study found that up to 50% of women had self-
reported, health care provider-diagnosed vaginal yeast infections in their lifetime; around 23% of them 
suffer from recurrent VVC.44 The presence of C. albicans (including low-concentration) carriage in the 
VMB of asymptomatic women is around 20%.30 The epidemiology of pathobiont-dysbiosis is also 
largely unknown because it has not yet been recognised as a specific clinical entity. A 2016 meta-
analysis estimated the worldwide prevalence of maternal S. agalactiae carriage by rectovaginal culture 
at 17.9%, and at 22.4% in sub-Saharan Africa.45  
 
1.3 Impact of Antibiotics on the Vaginal Microbiota 
Metronidazole and clindamycin are the most commonly prescribed antibiotics for vaginal dysbiosis.46,47 
These antibiotics are also prescribed for the syndromic management of vaginal discharge syndrome and 
pelvic inflammatory disease, intending to cover both BV and TV, or after laboratory-confirmed 
diagnosis of (symptomatic) BV and/or TV. Multi-day treatment of BV with metronidazole or 
clindamycin is often effective, with cure rates directly after treatment being between 65-90%.22,46–49 
Metronidazole and clindamycin can both be given in oral and vaginal formulations, and bio-availability 
in the vagina is excellent after oral administration.50 The cure rates of oral and vaginal formulations of 
metronidazole and clindamycin do not differ significantly.48,49 The recurrence of (symptomatic) BV 
after metronidazole treatment is high, at rates of over 50% within a year.47,51,52 BV recurrence is thought 
not to be driven by antibiotic resistance, because resistance to metronidazole (contrary to resistance to 
clindamycin) has not commonly been described in culture-based BV treatment studies.46,52,53 However, 
some studies contradict this and do report metronidazole resistance in women with recurrent BV, 
particularly in isolates with high G. vaginalis concentrations.54–56 The efficacy of a seven-day oral 
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metronidazole treatment course for TV is high; a single-dose treatment is often given to maximise 
adherence but is not as effective.57 Metronidazole is a nitroimidazole-class drug which is metabolised 
into nitroso radicals by anaerobic species and TV, which break microbial DNA and cause cell lysis.58,59 
Although it is sometimes assumed that metronidazole suppresses lactobacilli, culture-based studies 
show that lactobacilli are not sensitive to metronidazole.60–63 The impact of metronidazole on the VMB 
using modern sequencing methods had not been extensively studied at the time of our study. 
 
Clindamycin is also commonly prescribed for BV.46 Culture-based studies show that L. crispatus and 
jensenii are (partially) sensitive to clindamycin, whereas other lactobacilli such as L. iners are not.61,62 
Treatment with clindamycin could therefore theoretically decrease both BV-anaerobes and L. crispatus, 
causing the non-optimal L. iners species to proliferate instead and increasing the risk of BV recurrence 
(compared to a L. crispatus-dominated VMB). However, this has not been studied in molecular studies. 
Clindamycin has also been described as being effective treatment for some pathobiont species such as S. 
agalactiae,28,64 but this has not been studied in-depth in randomised controlled trials. No studies have 
comprehensively assessed the impact on the VMB of antibiotics given for non-gynaecological 
infections, but VVC has commonly been described as a side-effect of (systemic) antibiotic use.65–67 
 
1.4 Impact of Vaginal Lactobacilli-Containing Probiotics on the Vaginal Microbiota 
An alternative to antibiotics for the treatment or prevention of vaginal dysbiosis is the vaginal delivery 
of exogenous, beneficial live bacteria, most often lactobacilli.68–70 These products are commonly called 
probiotics or, more recently, live biotherapeutic products (LBPs).71 Probiotic therapy is designed to 
increase the number of beneficial lactobacilli and restore the dominance of lactobacilli in the 
vagina.46,47,68 Probiotics do not cause antibiotic resistance by definition, and may prevent BV and VVC 
recurrence.69 They can be given as main therapy for vaginal dysbiosis, or as adjuvant treatment together 
with antibiotics or antifungals. They can also be given after (successful) antibiotic/antifungal treatment 
to maintain an optimal VMB. It is unclear whether probiotics can only be successful if they colonise the 
vagina and therefore should be given at high concentrations to ultimately dominate the VMB, or 
whether probiotics can optimise the VMB without domination but by increasing lactic acid secretion, by 
modulation of local cervicovaginal mucosal immune responses, by the action of metabolites contained 
in the products, and/or by inhibition of biofilm formation.6,12,72–74 Furthermore, it is unclear whether 
probiotics can decrease BV-anaerobes. 
 
Some believe that probiotics to prevent BV or VVC could also be given orally. The rationale behind 
this is that there is a high degree of microbiological cross-talk between the gut/anal microbiota and the 
VMB: orally administered lactobacilli have been recovered from the vagina in some studies.69,75 This 
recoverability may depend on multiple factors: the capacity of probiotic strains to survive the passage 
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through the stomach, the delay in vaginal colonisation after administration, and the Lactobacillus 
concentration that will finally be delivered in the vagina.69 It is unclear whether oral probiotics are 
equally effective as vaginal probiotics: the effect of oral probiotics may be more diluted than that of 
vaginal probiotics as the former are not delivered directly at the intended target site. We have therefore 
focussed on vaginal probiotics in this thesis. In the past, probiotics could be marketed without the need 
of robust evidence for their effectiveness. The regulatory landscape for vaginal probiotics has, however, 
changed considerably in recent years. When health claims are made, the US Food and Drug 
Administration has required human drug approval for probiotics since 2016, and the European 
Medicines Authority will follow suit per 1 May 2020. As far as we know, only one of the products 
included in this review is being developed as a drug for human use: Lactin-V. It contains a L. crispatus 
strain (CTV-05) that was isolated from a healthy woman.76 
 
1.5 Tests and Algorithms for Diagnosing Urogenital Infections 
Gold standard laboratory tests of urogenital infections 
BV is commonly treated by syndromic management or presumptively (see section ‘Syndromic and 
presumptive management’). However, in some specialised urogenital disease clinics and in research 
settings, the Amsel criteria are used.77,78 A woman is considered to have BV by Amsel criteria if three or 
more of the following criteria are present: 1) clue cells observed by microscopy on a wet mount 
preparation (often, a cut-off of ≥20% clue cells is used) 2) a positive whiff test, with a ‘fishy odour’ 
detected when adding 10% KOH to vaginal secretions 3) a vaginal pH of ≥4.5, and/or 4) the presence of 
a thin, homogenous vaginal discharge.77 In some research settings (including in this thesis), a modified 
version of the Amsel criteria is used in which the fourth criterion is disregarded because of its subjective 
nature: the modified Amsel criteria are positive if two out of the three remaining objective criteria are 
present. Some argue that vaginal pH alone, for example in settings where microscopy is not available, 
might be sufficient to diagnose BV.79 The Nugent score is generally used in research settings only, and 
is a standardised scoring system of a Gram stain preparation, in which three bacterial morphotypes are 
visualised: Gram-positive rods thought to be lactobacilli, small Gram-negative or Gram-variable rods 
thought to be Gardnerella/Bacteroides, and curved Gram-variable rods thought to be Mobiluncus. 
Vaginal smears receive a score of 0-10, with 0-3 indicating normal microbiota, 4-6 intermediate 
microbiota, and 7-10 BV.78 While currently still considered the gold standard diagnostic test for BV, 
Gram stain Nugent scoring is not fully quantitative, cannot differentiate between different types of 
lactobacilli, does not comprehensively assess all BV-associated anaerobes, and sometimes misclassifies 
key species.80–82 New qPCR-based multiplex tests (generally targeting Lactobacillus concentration 
and/or Gardnerella concentration) and scoring systems have been developed to improve BV diagnosis, 
but their performance has typically been compared to Nugent scoring rather than used to establish novel 
molecular-based definitions of BV and other types of vaginal dysbiosis.83–86 One major obstacle is that 
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we currently do not know what the lactobacilli concentration threshold is below which we should 
diagnose and treat vaginal dysbiosis. 
 
No gold standard test for VVC exists.42,65,87 Some articles state that mycological culture is the gold 
standard (in symptomatic patients), because (q)PCR detection of Candida species would result in 
overtreatment of women with low Candida concentrations.65,88 As with BV, a major obstacle is that we 
currently do not know what the Candida concentration threshold is above which we should diagnose 
and treat VVC.30 However, Candida is highly inflammatory and asymptomatic carriage may be less 
harmless than often presumed.65,89 
 
The gold standard test for TV is by nucleic acid amplification test (NAAT).34 In many settings, 
microscopy (by observation of trichomonads on a wet mount) or TV culture are used, but these result in 
low sensitivity.34,90 The gold standard laboratory tests for both CT and NG are also by NAAT.91 
Usually, laboratory tests for CT and NG are multiplexed in a single device or test.92  
 
Syndromic and presumptive management 
Urogenital infections, including BV and VVC, are most commonly diagnosed and treated by syndromic 
management in resource-poor settings, and presumptively in resource-rich settings. The WHO-
recommended guidelines for the management of urogenital infections are based on reported symptoms 
alone, without the need for laboratory testing, to accommodate resource-poor countries and settings in 
which laboratory infrastructure is lacking and/or too expensive.21 Each patient-reported symptom, 
potentially augmented by clinician-observed signs during a physical examination, is treated for all 
organisms that might cause that symptom. The four main syndromes in women are (figure 1.1): vaginal 
discharge (VDS) without lower abdominal pain (LAP); LAP regardless of the presence of VDS; genital 
ulcers regardless of the presence of inguinal buboes; and inguinal buboes without genital ulcers. The 
WHO recommends that VDS without LAP, the most common of the four,93,94 is treated for BV and TV 
in all cases. VDS without LAP is also treated for CT and NG in the case of high risk due to a high 
CT/NG prevalence in the target population or high personal sexual risk (as determined by locally 
designed risk assessments). If the VDS is curd-like and vulval oedema, erythema, and/or excoriations 
are observed, the WHO recommends treatment for VVC as well.21 Oedema, erythema, and excoriations 
can only be diagnosed by a clinician during a physical (preferably pelvic) examination, which are often 
not available. Local guidelines (including those in Rwanda) therefore often replace them with patient-
reported VVC symptoms (e.g. curd-like discharge, genital burning and/or itching, soreness).24 
Syndromic management algorithms for urogenital symptoms in men are also available,21,24 but are 
beyond the scope of this thesis. 
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Figure 1.1: Summary of the WHO syndromic management algorithms 
 
BV bacterial vaginosis, CT Chlamydia trachomatis, GUD genital ulcer disease, HSV2 Herpes simplex virus type 2, LAP lower abdominal pain, 
LGV lymphogranuloma venereum, NG Neisseria gonorrhoeae, PID pelvic inflammatory disease, TV Trichomonas vaginalis, Vag vaginal, VDS 
vaginal discharge syndrome, VVC vulvovaginal candidiasis. 
The top rows are symptoms reported by participants. For details about the syndromic management algorithms, see WHO guidelines.21  
*LAP requires examination. Alarm signs: missed/overdue period, recent delivery/abortion/miscarriage, abdominal guarding and/or rebound 
tenderness, abnormal vaginal bleeding, and abdominal mass. Treated for PID if no alarm signs but cervical motion, uterine, and/or adnexal 
tenderness are present, or when lower abdominal tenderness and VDS are present. PID treatment covers CT/NG/TV/BV. The VDS algorithm is 
followed if there are no alarm signs or if no PID is present. 
 
In other settings, such as primary care clinics in Europe, urogenital symptoms are often treated 
presumptively.95,96 This approach is less well standardised than syndromic management and relies 
heavily on individual clinical judgments. A physician will treat patient-reported symptoms for what s/he 
considers the most likely diagnosis, and will treat for the next most likely diagnosis if the symptoms 
persist after treatment. Diagnostic testing is typically only done when earlier treatment efforts fail.  
 
The main problem of the syndromic and presumptive approaches is that all women with asymptomatic 
infections are missed by definition, as well as women with symptoms who do not seek care for those 
symptoms (which may or may not be a problem for BV and VVC as discussed in this thesis: 
asymptomatic BV and VVC have been associated with the same complications as symptomatic BV and 
VVC).9,87 Syndromic management can lead to undertreatment when asymptomatic infections are 
untreated, and overtreatment when (multiple) urogenital infections are treated for without being present. 
The performance of four syndromic management algorithms in women are all suboptimal, with low 
sensitivity and specificity, even in studies that displayed a high degree of selection bias by only 
enrolling symptomatic women.94,97–101 Furthermore, algorithms are often not applied well by clinicians, 
even further reducing their performances.102,103 
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Point-of-care testing 
Syndromic management performs poorly and gold standard laboratory testing is often not feasible or 
cost-effective, not even in resource-rich settings. The introduction of point-of-care testing (POCTs) 
might offer a reasonable alternative, preferably enabling clinicians to provide treatment for positive 
results at the same visit without needing a patient to return and thereby minimising loss to follow-
up.104,105 POC testing could also be used to screen asymptomatic women at risk of STIs or pregnant 
women (for whom the risk of sequelae is higher than in the general population).106 Additional 
advantages of POC testing include increased willingness to co-operate in partner notification and 
treatment due to the availability of a specific, laboratory-confirmed diagnosis, etc.107 Many POCTs have 
been developed over the past decades, but their characteristics vary greatly.106 For this reason, the WHO 
devised criteria that POCTs ideally should adhere to, the so-called ASSURED criteria: they should be 
‘Affordable, Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, and Deliverable to 
end users’.104,106,108  
 
ASSURED POCTs are available and widely used for HIV, syphilis, and pregnancy, including in 
resource-poor settings.109,110 However, no ASSURED POCTs are available for CT, NG, TV, and BV. In 
addition, gold standard diagnosis for BV and VVC (as well as other types of vaginal dysbiosis) are 
currently suboptimal (see “Gold standard laboratory tests of urogenital infections”), which complicates 
POCT performance assessments.105,106,108 Other challenges that may hinder POCT integration include: 
cost-effectiveness considerations,79,111,112 increased waiting times in clinics when implementing POC or 
laboratory testing,113 a lack of willingness to be tested in certain settings if a someone is 
asymptomatic,114 and barriers at health-system level, whether local, regional, or national.79 A short 
overview of the most promising POCTs available on the market for each urogenital disease, including 
the ones we chose to investigate in this thesis, is presented in Appendix E. 
 
1.6 Aims of this Thesis and Overview of Chapters 
The main aim of this thesis is to assess interventions that can potentially be used to improve sexual and 
reproductive health in sub-Saharan African women. The thesis consists of seven chapters: Chapter 1 is 
a general introduction to this thesis. Chapters 2-4 describe the results of the Rwanda VMB study, 
conducted in Kigali, Rwanda. In Chapter 2, the impact of a seven-day oral metronidazole treatment 
course on the VMB of 68 women diagnosed with BV and/or TV is discussed. Their VMB 
characteristics before and after treatment are compared, as well as sociodemographic and microbiologic 
factors associated with treatment failure. In Chapter 3, the safety and preliminary efficacy results of a 
pilot clinical trial in which these same 68 women were enrolled are presented. In this trial, women were 
randomised to intermittent use of oral metronidazole or two different vaginal probiotics, each compared 
to a control group of women receiving behavioural counselling only. Chapter 4 provides more detail on 
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the adherence to the interventions in the trial, as well as acceptability of the interventions as assessed by 
structured face-to-face interviews and semi-structured focus-group discussions and in-depth interviews. 
The chapter also includes the results of a structured face-to-face survey held among 131 Rwandan 
women (some of whom participated in the trial and some did not) about their knowledge of and 
attitudes towards urogenital infections. Chapter 5 describes a systematic review of published 
lactobacilli-containing vaginal probiotic studies with BV and/or VVC cure or prevention outcomes. The 
chapter also includes the results of our own pilot trial as well as recommendations for future vaginal 
probiotic clinical trial designs. In Chapter 6, we report the results of the WISH study, which was also 
conducted in Kigali, Rwanda. The study evaluated the feasibility, acceptability and performance of 
POCT integration on urogenital disease case-finding and management in 705 women. Potential 
challenges related to POCT integration in STI or primary care clinics are discussed. Chapter 7 is the 
final chapter, which synthesises and discusses the key findings of this thesis. 
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Chapter 2 - Impact of Oral Metronidazole Treatment on the Vaginal Microbiota and Correlates 
of Treatment Failure. 
 
This chapter has been submitted to the international peer-reviewed journal American Journal of 
Obstetrics and Gynecology, and has been accepted for publication: Verwijs MC, Agaba SK, Darby AC, 
van de Wijgert JHHM. Impact of oral metronidazole treatment on the vaginal microbiota and correlates 
of treatment failure. AJOG 2019; doi:10.1016/j.ajog.2019.08.008. [Epub ahead of print]. The version 
presented here is the author-approved AJOG-accepted version with only minor modifications 
(numbering of figures, tables, and references). The methods used in Chapters 2 and 3 overlap 
considerably, and I have therefore combined the supplementary methods into one Appendix that applies 
to both chapters (Appendix A). 
 
I reviewed the clinical data that had been collected by the Rinda Ubuzima team, and conducted the site 
close-out visit, in Kigali, Rwanda, under the supervision of Professor Janneke van de Wijgert (my 
primary supervisor). I subsequently coordinated the shipments of the stored vaginal samples from 
Kigali to Liverpool, and prepared them for sequencing at the University of Liverpool Centre for 
Genomic Research under the supervision of Professor Alistair Darby (my secondary supervisor). I 
processed the raw sequencing data, derived various VMB variables, and added them to the clinical 
database with the help of both my supervisors as well as fellow PhD student Christina Gill. I developed 
the analytical approach and performed the statistical analyses together with my primary supervisor. I 
wrote the first draft of the manuscript. All co-authors commented on and approved the final manuscript.  
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Abstract 
Introduction: Metronidazole is the first-line treatment for bacterial vaginosis (BV), but cure rates are 
suboptimal and recurrence rates high.  
Materials and methods: The objective of this study was to evaluate the impact of a standard course of 
oral metronidazole treatment (500 mg twice per day for seven days) on the vaginal microbiota of 
Rwandan bacterial vaginosis patients using microscopy and 16S rRNA gene sequencing, and to 
evaluate correlates of treatment failure. HIV-negative, non-pregnant women aged 18-45 with BV and/or 
Trichomonas vaginalis (TV; total N=68) were interviewed and sampled before and after metronidazole 
treatment. They were also screened, and treated if applicable, for other urogenital infections. The 
vaginal microbiota was assessed by Gram stain Nugent scoring, Illumina 16S rRNA HiSeq sequencing 
(relative abundances), and BactQuant 16S gene qPCR (estimated concentrations). Only women with a 
pre-treatment Nugent score of 7-10 and a valid post-treatment Nugent score (N=55) were included in 
metronidazole treatment failure analyses, with treatment failure defined as a post-treatment Nugent 
score of 4-10. 
Results: The BV cure rate by Nugent scoring was 54.5%. The mean total vaginal bacterial 
concentration declined from 6.59 to 5.85 log10 cells/μl (p<0.001), which was mostly due to a reduction 
in mean BV-anaerobes concentration (all BV-associated anaerobe taxa combined) from 6.23 to 4.55 
log10 cells/μl (p<0.001). However, only 16.4% of women had a BV-anaerobes concentration reduction 
of more than 50%, and only three women had complete eradication. The mean concentration of 
lactobacilli (all species combined) increased from 4.98 to 5.56 log10 cells/μl (p=0.017), with 
Lactobacillus iners being the most common species pre- and post-treatment. The mean concentration of 
pathobionts (defined as Proteobacteria, streptococci, staphylococci, enterococci, and a few others) did 
not change significantly: from 1.92 log10 cells/μL pre-treatment to 2.01 log10 cells/μL post-treatment 
(p=0.939). Pre-treatment pathobionts concentration, and having a pre-treatment vaginal microbiota type 
containing more than 50% Gardnerella vaginalis (compared to less than 50%), were associated with 
increased likelihood of treatment failure, but the latter did not reach statistical significance (p=0.044 and 
p=0.084, respectively). 
Discussion: Metronidazole alone may not cure women with high G. vaginalis relative abundance, 
potentially due to biofilm presence, and women with high pathobionts concentration. These women may 
benefit from additional biofilm-disrupting and/or pathobiont-targeting treatments. 
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2.1 Introduction 
Most women have an optimal vaginal microbiota (VMB) dominated by lactobacilli, but vaginal 
dysbiosis is highly prevalent.4,9 The most common type of vaginal dysbiosis is bacterial vaginosis (BV), 
which is characterised by a reduction of lactobacilli and an increase of other anaerobes, usually leading 
to increased species diversity.4,9 Other women carry microorganisms that do not necessarily dominate 
the VMB but have a higher pathogenic potential than BV-anaerobes, such as bacterial pathobionts 
(including most Proteobacteria, streptococci, staphylococci, and enterococci), Candida albicans (which 
is the main cause of vulvovaginal candidiasis) or Trichomonas vaginalis.4,9 
 
Vaginal dysbiosis can cause symptoms but is often asymptomatic.4,9 Both symptomatic and 
asymptomatic vaginal dysbiosis have been associated with pelvic inflammatory disease, HIV 
acquisition, and adverse pregnancy outcomes, with substantial attributable risk due to its prevalence.9,17–
19 Symptomatic dysbiosis is most commonly diagnosed empirically or syndromically without laboratory 
testing.21 However, in research settings, BV is diagnosed by Nugent scoring of vaginal Gram stains or 
by the Amsel criteria.77,78 BV is treated with antibiotics, of which oral and vaginal formulations of 
metronidazole or clindamycin are most commonly used.47 While short-term BV cure rates of multi-day 
oral and vaginal metronidazole regimens are 65-90%,48,49 recurrence rates are high.51,52 
 
Metronidazole is a nitroimidazole-class drug. Under anaerobic conditions, anaerobic bacteria and some 
parasites (including T. vaginalis) metabolise metronidazole into nitroso radicals, which break microbial 
DNA and cause cell lysis.58,115 Culture studies have shown that lactobacilli are not sensitive to 
metronidazole.63 Metronidazole has thus far been associated with low levels of antimicrobial 
resistance.50 The high recurrence rate is therefore often hypothesised to be due to vaginal mucosal 
biofilm formation by G. vaginalis and other BV-associated anaerobes, but has not been confirmed.116  
 
We investigated the impact of the most commonly used oral metronidazole treatment regimen, 500 mg 
twice per day for seven days, on the VMB of Rwandan women with BV and/or T. vaginalis. We 
compared their VMB compositions as assessed by microscopy and sequencing pre- and post-treatment, 
and determined sociodemographic and biological correlates of treatment failure. 
 
2.2 Materials and Methods 
Data were collected at the Rinda Ubuzima research clinic in Kigali, Rwanda, in 2015 (figure 2.1). HIV-
negative, non-pregnant women, aged 18-45, and in good overall physical and mental health, were 
screened at a pre-treatment visit. Recruitment targeted women at high risk of BV/T. vaginalis, defined 
as having had more than one sex partner, or having been treated for BV and/or a sexually transmitted 
infection, in the last 12 months. Women who were BV-positive (by Nugent 7-10 and/or modified Amsel 
criteria as defined below), and/or T. vaginalis-positive (by wet mount and/or by culture), regardless of 
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symptomatology, were treated with seven days of 500 mg generic oral metronidazole (Tricozole; 
Laboratory & Allied ltd, Nairobi, Kenya) twice daily. Women were also tested, and treated or referred, 
for pregnancy, HIV, syphilis, Chlamydia trachomatis, Neisseria gonorrhoeae, vulvovaginal candidiasis, 
and urinary tract infections, using local guidelines.24 Women returned for a post-treatment visit within 
three days after metronidazole treatment completion, and were re-tested for BV, T. vaginalis, and 
vulvovaginal candidiasis. Dacron vaginal swabs for molecular VMB testing were collected during 
speculum examinations at both visits, and stored dry at -80 °C.  
 
Figure 2.1: Flowchart of the VMB study 
 
BV bacterial vaginosis, M6 Month 6 visit, RU Rinda Ubuzima, STI sexually transmitted infection, TV Trichomonas vaginalis, UTI urinary tract 
infection. 
Flowchart of the VMB study, including the randomised vaginal microbiota maintenance component (Chapter 3). 
*Valid Nugent data available for 67 women; valid rarefied sequencing data available for 67 women; valid qPCR-based estimated 
concentrations available for 66 women. †Valid Nugent data available for 66 women; valid rarefied sequencing data available for 67 women; 
valid qPCR-based estimated concentrations available for 63 women. Valid concentration data for both pre- and post-treatment were available 
for 61 women. ‡Totals to 110 reasons among 102 women because multiple reasons could have been reported by one woman. §Reasons: 
outside of metronidazole treatment window (n=5), enrolment target already met (n=4), has a mental disorder (n=1), did not complete screening 
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procedures and was subsequently lost to follow=up (n=1), withdrew consent during the pre-treatment (Screening) visit because she thought the 
reimbursement was too low (n=1) ¶No data are available for these two women; no vaginal swabs were taken as these women did not pass 
subsequent enrolment procedures. ||Successful treatment was defined as having a Nugent score of 7-10 before treatment and 0-3 after treatment 
(N=30), while treatment failure was defined as having a Nugent score of 7-10 before treatment and 4-10 after treatment (N=25). Thirteen 
women were excluded from these analyses because they did not have Nugent 7-10 at the pre-treatment visit (N=12) or did not have a valid 
Nugent result at the post-treatment visit (N=1). 
 
Diagnostic procedures 
BV was diagnosed by Gram stain Nugent scoring (a score of 0-3 was considered optimal, 4-6 
intermediate microbiota, and 7-10 BV),78 and by modified Amsel criteria (defined as the presence of at 
least two of the following criteria: vaginal pH>4.5, positive whiff test, and/or ≥20% clue cells).77 
Vaginal pH was measured by pressing a pH paper strip (pH range 3.6-6.1 with 0.3 increments; 
Machery-Nagel, Düren, Germany) against the vaginal wall. T. vaginalis was diagnosed when the T. 
vaginalis InPouch culture (Biomed Diagnostics, White City, OR, USA) was positive and/or if motile 
trichomonads were observed on wet mount. Vulvovaginal candidiasis was diagnosed when budding 
yeasts and (pseudo)hyphae were seen on wet mount. Other diagnostic testing is described in Appendix 
A. 
 
Molecular VMB testing 
DNA was extracted from one swab per woman per visit (N=136), using lysozyme lysis and bead-
beating procedures combined with the Qiagen DNeasy Blood and Tissue kit (Qiagen, Manchester, UK) 
(Appendix A).117 The V3-V4 region of 16S rRNA genes were amplified and sequenced on an Illumina 
HiSeq 2500 instrument (Illumina, San Diego, CA, USA) run in rapid mode, 2x300bp using a 250PE and 
50PE kit. The panbacterial 16S rRNA gene copy concentration per sample was determined using the 
BactQuant quantitative PCR assay.118 
 
Molecular data processing 
Molecular data processing steps are described in Appendix A. Briefly, DADA2119 in R 3.2.3 (R 
foundation for Statistical Computing 2016, Vienna, Austria) was used to assign reads to amplicon 
sequence variants (ASVs) using Silva v128 as the reference database,120 with additional taxonomic 
assignments made using other databases (Appendix A). Relative abundances were rarefied at 1,111 
reads using the GUniFrac 1.0 package in R.121 The rarefied ASV relative abundance table consisted of 
204 ASVs in 134 samples, mapping to species (133; 65.2%), genus (55; 27.0%), or higher taxonomic 
levels (16; 7.8%). Bacterial cell concentrations in cells/μl per ASV per sample were estimated by 
multiplying the ASV-specific copy-normalised relative abundance by the sample-specific 16S rRNA 
gene copies concentration (Appendix A). This yielded estimated concentrations of 204 ASVs in 129 
samples, which were log10-transformed. Of the 204 ASVs, 108 ASVs were present at a relative 
abundance of at least 1% in at least one sample; the other 96 ASVs were minority species. 
 
Data reduction was required for some biostatistical analyses, and was done in three different ways. 
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First, the inverse Simpson diversity index was calculated for each sample. Second, each ASV was 
assigned to one of four ‘bacterial groups’ based on the published literature (Appendix A; overview in 
table A.1): 1) lactobacilli; 2) BV-anaerobes (this group ended up containing all Actinobacteria, 
Bacteroidetes, Firmicutes, Fusobacteria, and Tenericutes except those included in the other three 
groups); 3) pathobionts (most Proteobacteria, and streptococci, staphylococci, enterococci, 
Spirochaetaceae, Listeria, C. trachomatis, and N. gonorrhoeae); and 4) ‘other bacteria’ (a rest group, 
containing Actinobacteria that are known to be (facultative) aerobic skin bacteria, Bifidobacterium 
species, and seven difficult to classify minority species). Within each sample, read counts of ASVs 
belonging to the same bacterial group were summed (Appendix A). Third, we used hierarchical 
clustering based on Euclidean distance to pool samples into seven VMB types: 1) L. iners-dominated 
(Li; >75% lactobacilli of which L. iners was the most common; n=45 samples); 2) other lactobacilli-
dominated (Lo; also >75% lactobacilli of which L. jensenii and L. gasseri were the most common; n=2); 
3) lactobacilli and anaerobes (LA; 25-75% lactobacilli; n=30); 4) polybacterial G. vaginalis-containing 
(BV_GV; <25% lactobacilli and 10-50% G. vaginalis; n=30), 5) other polybacterial low-G. vaginalis 
(BV_noGV; <25% lactobacilli and <10% G. vaginalis; n=8), 6) G. vaginalis-dominated (GV; <25% 
lactobacilli and >50% G. vaginalis; n=12); and 7) pathobionts-containing (PB; >20% pathobionts; n=7). 
The samples in VMB types 1-6 had a maximum of 0.1-15.9% pathobionts per VMB type.  
 
Statistical analyses 
Statistical analyses were performed using Stata version 13 (StataCorp, College Station, TX, USA) and 
R. VMB characteristics pre- and post-treatment were compared using the Stuart-Maxwell test for 
matched categorical data, and Wilcoxon signed-rank test for matched continuous data, for all women, 
and women stratified by treatment success/failure (women who had Nugent 7-10 pre-treatment and a 
valid Nugent score at post-treatment; N=55), pre-treatment C. trachomatis/N. gonorrhoeae status 
(results became available after metronidazole treatment completion; N=67 due to one missing result), 
having received another antibiotic in addition to metronidazole at the pre-treatment visit or not (N=68), 
and having reported unusual vaginal discharge pre-treatment or not (N=68). Successful treatment was 
defined as Nugent 7-10 pre-treatment and Nugent 0-3 post-treatment, and treatment failure as Nugent 7-
10 pre-treatment and Nugent 4-10 post-treatment. Kruskal-Wallis test for continuous variables, and 
Fisher’s exact test for binary variables, were used for cross-sectional comparisons. Bivariable logistic 
regression was used to investigate associations between individual baseline sociodemographic and 
biological characteristics and treatment failure.  
 
Ethical statement 
All participants provided written informed consent. The study was conducted in accordance with the 
Helsinki Declaration, and approved by the National Ethics Committee of Rwanda and the University of 
Liverpool Research Ethics Subcommittee for Physical Interventions. 
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2.3 Results 
We screened 176 women, and 68 women completed metronidazole treatment (ineligibility reasons in 
figure 2.1): 82.4% had BV alone, 2.9% had T. vaginalis alone, and 14.7% had both BV and T. vaginalis. 
Four of the 176 women were not eligible because they did not complete the treatment. The median age 
was 31 years (range 19-42) and most were sex workers (table 2.1). 
 
Table 2.1: Baseline characteristics of participants 
Sociodemographics and sexual behavior Pre-treatment 
(N=68) 
Post-treatment 
(N=68) 
Age (median, IQR) 31 (27 – 35) NA 
Marital status (n %) 
- Never married 
- Married 
- Divorced 
- Widowed 
 
50 (73.5) 
5 (7.4) 
12 (17.6) 
1 (1.5) 
NA 
Education level (n %) 
- No schooling 
- Primary school not completed 
- Primary school completed 
- Secondary school not completed 
- Secondary school completed 
 
14 (20.6) 
31 (45.6) 
17 (25.0) 
6 (8.8) 
0 
NA 
Number of sex partners in lifetime (median, IQR) 30 (7 – 463) NA 
Number of sex partners in last 12 months (pre-treatment) or month (post-
treatment) (median, IQR) 11 (4 – 152) 5 (3 – 15.5)* 
Exchanged sex for money/goods in past month (n %) 63 (92.6) 60 (92.3)* 
Vaginal sex frequency last two weeks (median, IQR) 12 (8 – 18) 11 (8 – 19)* 
Any condom use in past two weeks (n %) 
- Always 
- Sometimes but not always 
- Never 
- No sex in the past two weeks 
 
14 (20.6) 
51 (75.0) 
3 (4.4) 
0 
 
23 (33.8) 
36 (52.9) 
6 (8.8) 
3 (4.4) 
Condom use during last sex act (n %) 36 (52.9) 44 (64.7)* 
Currently using hormonal contraception (n %) 42 (61.8) 42 (62.7)* 
Currently breastfeeding (n %) 14 (21.2)* NA 
Inserted anything inside the vagina in the last 12 months (n %) NA 26 (38.2) 
Had menses in the seven days prior to the visit (n %) NA 11 (16.2) 
Any current urogenital symptoms (at pre-treatment visit, including last two 
weeks), patient-reported (n %) 49 (72.1) 0 
Current unusual vaginal discharge (at pre-treatment visit, including last two 
weeks), patient-reported (n %)  13 (26.5) 0 
Received antibiotic in addition to metronidazole at pre-treatment visit (n %)† 18 (26.5) NA 
Received antifungal treatment at pre-treatment visit n (%)‡ 6 (8.8) NA 
Laboratory results (N=68) (N=68) 
HIV by serology (n %)§ 0 NA 
Positive urine pregnancy test (n %)§ 0 0* 
BV by Nugent 7-10 (n %)* 56 (83.6) 17 (25.8) 
BV by modified Amsel criteria¶ (n %) 49 (72.1) 0 
Trichomonas vaginalis on wet mount (n %)* 6 (8.8) 0 
T. vaginalis by InPouch culture (n %) 11 (16.4) 0 
Yeasts on wet mount (n %) 6 (8.9) 4 (5.9) 
Positive urinalysis test (n %) 17 (25.0) 0* 
Syphilis by serology (n %) 4 (5.9) NA 
Positive herpes simplex virus type 2 serology (n %) 44 (64.7) NA 
Chlamydia trachomatis by PCR (n %) 20 (29.4) NA 
Neisseria gonorrhoeae by PCR (n %) 13 (19.1) NA 
30 
BV bacterial vaginosis, IQR inter-quartile range, NA not assessed, PCR polymerase chain reaction. 
*1-3 missing values. †Includes ciprofloxacin for urinary tract infection and penicillin for syphilis. ‡Three women received both an antifungal 
and another antibiotic in addition to metronidazole. §All enrolled participants were HIV-negative and non-pregnant by design. ¶Two or more 
positive of: vaginal pH>4.5, positive whiff test, and/or ≥20% clue cells observed on wet mount. 
 
Thirteen women (26.5%) reported unusual vaginal discharge at the pre-treatment visit. Some women 
(26.5%) received another antibiotic in addition to metronidazole for another condition, or had an 
ongoing C. trachomatis and/or N. gonorrhoeae infection during metronidazole treatment (38.2%; table 
2.1). At the post-treatment visit, all women were BV-negative by modified Amsel criteria and T. 
vaginalis-negative by culture and wet mount, and no women reported urogenital symptoms (including 
unusual vaginal discharge), adverse events (including vomiting), or social harms. Of the 56 women with 
Nugent 7-10 pre-treatment, 30 (54.5%) had Nugent 0-3, 11 (20.0%) Nugent 4-6, and 14 Nugent 7-10 
post-treatment (table 2.2).  
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Table 2.2: VMB characteristics before and after metronidazole treatment, including stratification by treatment success/failure 
VMB Outcomes 
All participants Successful treatment† Treatment failure† 
Pre-treatment 
(n = 68) 
Post-treatment 
(n = 68) p* 
Pre-treatment 
(n = 30) 
Post-treatment 
(n = 30) p* 
Pre-treatment 
(n = 25) 
Post-treatment 
(n = 25) p* 
Nugent categories (n %)‡ 
 0-3 
 4-6 
 7-10 
 
5 (7.5) 
6 (9.0) 
56 (83.6) 
 
36 (54.6) 
13 (19.7) 
17 (25.8) 
<0.001 
 
0 
0 
30 (100) 
 
30 (100) 
0 
0 
NA§ 
 
0 
0 
25 (100) 
 
0 
11 (44.0) 
14 (56.0) 
NA§ 
Mean inverse Simpson diversity 
index (95% CI)¶ 
0.67 
(0.60 – 0.73) 
0.31 
(0.25 – 0.38) <0.001 
0.70 
(0.61 – 0.80) 
0.13 
(0.06 – 0.21) <0.001 
0.77 
(0.70 – 0.85) 
0.47 
(0.39 – 0.56) 0.001 
VMB type (n %)¶:  
– Li 
 Lo 
 LA 
 BV_GV 
 BV_noGV 
 GV 
 PB 
 
10 (14.9) 
0 
12 (17.9) 
28 (41.8) 
8 (11.9) 
8 (11.9) 
1 (1.5) 
 
35 (52.2) 
2 (3.0) 
18 (26.9) 
2 (3.0) 
0 
4 (6.0) 
6 (9.0) 
<0.001 
 
2 (6.9) 
0 
7 (24.1) 
13 (44.8) 
4 (13.8) 
3 (10.3) 
0 
 
23 (79.3) 
1 (3.5) 
2 (6.9) 
0 
0 
1 (3.5) 
2 (6.9) 
<0.001 
 
1 (4.0) 
0 
2 (8.0) 
14 (56.0) 
3 (12.0) 
5 (20.0) 
0 
 
6 (24.0) 
0 
14 (56.0) 
2 (8.0) 
0 
2 (8.0) 
1 (4.0) 
0.002 
Vaginal pH, median (IQR) 5.3 (5.0 – 5.6) 
4.4 
(3.6 – 4.6) <0.001 
5.3 
(5.0 – 5.6) 
4.1 
(3.6 – 4.4) <0.001 
5.6 
(5.0 – 5.6) 
4.4 
(4.4 – 4.7) <0.001 
Vulvovaginal candidiasis (n %) 6 (8.8) 4 (5.9) 0.527 1 (3.3) 3 (10.0) 0.317 1 (4.0) 1 (4.0) 1.00 
Bacterial group relative abundances: mean (95% CI)¶ 
Total lactobacilli 0.24 (0.15 – 0.32) 
0.72 
(0.64 – 0.80) <0.001 
0.18 
(0.08 – 0.27) 
0.88 
(0.78 – 0.98) <0.001 
0.10 
(0.02 – 0.18) 
0.56 
(0.45 – 0.68) <0.001 
Total BV-anaerobes 0.75 (0.67 – 0.83) 
0.23 
(0.16 – 0.30) <0.001 
0.81 
(0.71 – 0.91) 
0.07 
(0 – 0.15) <0.001 
0.89 
(0.81 – 0.97) 
0.40 
(0.29 – 0.52) <0.001 
Total pathobionts 0.02 (0.01 – 0.03) 
0.05 
(0.02 – 0.09) 0.050 
0.01 
(0 – 0.02) 
0.05 
(-0.02 – 0.11) 0.118 
0.01 
(0 – 0.03) 
0.03 
(0.01 – 0.05) 0.173 
Total other bacteria 0 (0 – 0) 
0 
(0 – 0) 0.674 
0 
(0 – 0) 
0 
(0 – 0) 0.173 
0 
(0 – 0) 
0 
(0 – 0) 0.764 
Bacterial group concentrations in log10 cells/μL: mean (95% CI)|| 
Total bacteria 6.59 (6.39 – 6.78) 
5.85 
(5.66 – 6.04) <0.001 
6.59  
(6.31 – 6.86) 
5.65  
(5.38 – 5.91) <0.001 
6.68  
(6.36 – 7.01) 
6.23  
(5.93 – 6.54) 0.028 
Total lactobacilli 4.98 (4.61 – 5.35) 
5.56 
(5.34 – 5.78) 0.017 
4.92  
(4.36 – 5.49) 
5.47 
 (5.16 – 5.77) 0.124 
4.62  
(3.92 – 5.31) 
5.80  
(5.38 – 6.21) 0.001 
Total BV-anaerobes 6.23 (5.88 – 6.57) 
4.55 
(4.14 – 4.95) <0.001 
6.46  
(6.14 – 6.78) 
3.81 
(3.23 – 4.38) <0.001 
6.62  
(6.26 – 6.97) 
5.79  
(5.45 – 6.13) 0.003 
Total pathobionts 1.92 (1.36 – 2.48) 
2.01 
(1.48 – 2.54) 0.939 
1.09 
(0.32 – 1.87) 
1.48 
(0.74 – 2.21) 0.649 
2.30 
(1.40 – 3.19) 
2.66 
(1.65 – 3.66) 0.637 
32 
VMB Outcomes 
All participants Successful treatment† Treatment failure† 
Pre-treatment 
(n = 68) 
Post-treatment 
(n = 68) p* 
Pre-treatment 
(n = 30) 
Post-treatment 
(n = 30) p* 
Pre-treatment 
(n = 25) 
Post-treatment 
(n = 25) p* 
Total other bacteria 1.85 (1.36 – 2.35) 
1.46 
(1.01 – 1.92) 0.176 
1.71 
(0.96 – 2.45) 
0.91 
(0.36 – 1.47) 0.043 
2.44 
(1.56 – 3.31) 
2.34 
(1.41 – 3.27) 0.525 
Individual bacteria concentrations in log10 cells/μL: mean (95% CI)|| 
L. iners 4.81 (4.38 – 5.24) 
5.28 
(4.94 – 5.62) 0.072 
4.91  
(4.34 – 5.48) 
5.10  
(4.54 – 5.65) 0.501 
4.27  
(3.89 – 5.14) 
5.63  
(5.10 – 6.17) <0.001 
L. crispatus** 0.15 (-0.02 – 0.33) 
0.51 
(0.16 – 0.85) 0.089 
0  
(0 – 0) 
0.47  
(-0.08 – 1.01) 0.083 
0.25 
(-0.12 – 0.62) 
0.55  
(-0.08 – 1.19) 0.330 
Other lactobacilli†† 1.46 (0.97 – 1.94) 
3.03 
(2.57 – 3.48) <0.001 
0.67  
(0.15 – 1.19) 
2.62  
(1.93 – 3.31) <0.001 
1.18 
(0.45 – 1.91) 
3.31  
(2.45 – 4.17) 0.001 
Gardnerella vaginalis  5.62 (5.20 – 6.03) 
4.12 
(3.63 – 4.61) <0.001 
6.00 
(5.69 – 6.31) 
3.29 
(2.62 – 3.96) <0.001 
6.11 
(5.74 – 6.47) 
5.66 
(5.30 – 6.01) 0.115 
Atopobium vaginae 4.58 (4.00 – 5.16) 
1.54 
(1.06 – 2.02) <0.001 
4.91 
(4.14 – 5.67) 
1.44 
(0.76 – 2.11) <0.001 
5.43 
(4.83 – 6.03) 
1.76 
(0.78 – 2.73) <0.001 
Prevotella species 4.67 (4.18 – 5.16) 
1.35 
(0.90 – 1.79) <0.001 
5.07 
(4.59 – 5.55) 
1.31 
(0.71 – 1.90) <0.001 
5.24 
(4.47 – 6.00) 
1.62 
(0.69 – 2.54) <0.001 
Sneathia species 4.18 (3.63 – 4.73) 
1.08 
(0.63 – 1.54) <0.001 
4.38 
(3.64 – 5.14) 
1.10 
(0.45 – 1.76) <0.001 
4.90 
(4.16 – 5.63) 
1.43 
(0.51 – 2.36) <0.001 
Megasphaera species 3.17 (2.56 – 3.79) 
0.22 
(-0.01 – 0.44) <0.001 
3.96 
(3.10 – 4.81) 
0 
(0 – 0) <0.001 
3.34 
(2.32 – 4.35) 
0.55 
(-0.09 – 1.18) 0.001 
Veillonella species 2.37 (1.75 – 3.00) 
0.28 
(0.01 – 0.56) <0.001 
1.85 
(0.89 – 2.81) 
0.27 
(-0.12 – 0.66) 0.005 
2.83 
(1.79 – 3.87) 
0.22 
(-0.24 – 0.68) 0.002 
BVAB1 1.76 (1.11 – 2.42) 
0.46 
(0.15 – 0.77) <0.001 
2.08 
(0.97 – 3.19) 
0.34 
(0.01 – 0.67) 0.002 
2.00 
(0.84 – 3.15) 
0.75 
(-0.02 – 1.53) 0.067 
Fusobacterium species 0.53 (0.17 – 0.89) 
0 
(0 – 0) 0.008 
0.44 
(-0.06 – 0.95) 
0 
(0 – 0) 0.008 
0.68 
(0.02 – 1.34) 
0 
(0 – 0) 0.046 
Streptococcus species 1.47 (0.92 – 2.02) 
1.34 
(0.84 – 1.85) 0.453 
0.83 
(0.10 – 1.55) 
0.85 
(0.18 – 1.52) 0.286 
1.76 
(0.83 – 2.68) 
2.05 
(1.06 – 3.05) 0.767 
Staphylococcus species  0.26 (0.05 – 0.47) 
0.60 
(0.27 – 0.93) 0.655 
0.09 
(-0.10 – 0.29) 
0.34 
(-0.01 – 0.70) ND 
0.34 
(-0.05 – 0.72) 
0.87 
(0.12 – 1.63) 0.317 
Escherichia/Shigella species 0.10 (-0.04 – 0.25) 
0.86 
(0.45 – 1.27) 0.317 
0.24 
(-0.10 – 0.59) 
0.41 
(0.00 – 0.83) 0.317 
0 
(0 – 0) 
1.41 
(0.52 – 2.29) ND 
BV bacterial vaginosis, BVAB1 BV-associated bacterium type 1, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, CI confidence interval, GV G. vaginalis-dominated, 
LA lactobacilli and anaerobes, Li L. iners-dominated, Lo other lactobacilli-dominated, NA not applicable, ND not determinable, PB pathobionts-containing, VMB vaginal microbiota. 
*Stuart-Maxwell test for matched categorical data and Wilcoxon signed-rank test for matched continuous data. †Successful treatment was defined as having a Nugent score of 7-10 before treatment and 0-3 after treatment 
(N=30), while treatment failure was defined as having a Nugent score of 7-10 before treatment and 4-10 after treatment (N=25). Thirteen women were excluded from these analyses because they did not have Nugent 7-10 
at the pre-treatment visit (N=12) or did not have a valid Nugent result at the post-treatment visit (N=1). ‡Valid Nugent data available for 67 participants at the pre-treatment visit and 66 participants at the post-treatment 
visit. §The definition of treatment success/failure was based on Nugent scores and these p-values are therefore meaningless. ¶Relative abundance, Simpson diversity indices, and VMB type data available for 67 
participants at each visit. ||Concentration data may contain at most five missing values (see Appendix A). **Includes all amplicon sequence variants attributed to L. crispatus, also those with multiple species assignments. 
††Includes amplicon sequence variants attributed to L. jensenii, L. delbrueckii, L. fermentum, L. gasseri, L. johnsonii, and Lactobacillus genus, as well as 11 other minority amplicon sequence variants. 
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Figure 2.2: Heatmaps of 16S rRNA gene sequencing data pre- and post-treatment 
a b 
  
BVAB1 bacterial vaginosis-associated bacterium type 1. 
a-b Heatmaps at the pre-treatment (a) and the post-treatment visit (b) depicting the 20 amplicon sequence variants with the highest mean relative abundance on the y-axis and samples (n=67 at each visit) on the x-axis. 
The dendrogram above the heatmap depicts vaginal microbiota clusters based on Euclidean distance. The bar below the dendrogram depicts Nugent score categories (see legend; black means no score available).  
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Pre- and post-treatment 16S microbiome data shows a shift towards increased relative abundance of 
lactobacilli (mainly L. iners) and decreased relative abundances of several BV-anaerobes (figure 2.2). 
The mean bacterial group relative abundance data confirmed this (table 2.2, figure 2.3b) and 
additionally showed that the mean relative abundance of pathobionts increased post-treatment 
(Wilcoxon signed rank p=0.050).  
 
Figure 2.3: Nugent scores, mean bacterial group relative abundances, and vaginal microbiota 
type pre- and post-treatment 
a 
 
 
b 
 
c 
 
d 
 
BV bacterial vaginosis, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, GV G. vaginalis-
dominated, IQR inter-quartile range, LA lactobacilli and anaerobes, Li Lactobacillus iners-dominated, Lo other lactobacilli-dominated, PB 
pathobionts-containing, Pre-tx pre-treatment visit, Post-tx post-treatment visit. 
a-c Changes in vaginal microbiota characteristics before and after metronidazole treatment: Nugent scores (a), mean bacterial group relative 
abundances (b), vaginal microbiota types (c). d Three-dimensional non-metric multidimensional scaling plot based on rarefied relative 
abundances of samples before and after metronidazole treatment. The figure shows that samples cluster together by visit (and hence, treatment 
status). 
 
Metronidazole treatment was associated with a significant decrease in the mean concentration of total 
bacteria from 6.59 log10 cells/μL pre-treatment to 5.85 log10 cells/μL post-treatment (p<0.001; table 2.2). 
The mean BV-anaerobes concentration decreased from 6.23 log10 cells/μL to 4.55 log10 cells/μL 
(p<0.001), the mean Lactobacillus concentration increased from 4.98 log10 cells/μL to 5.56 log10 
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cells/μL (p=0.017), and the mean concentrations of pathobionts (1.92 log10 cells/μL pre-treatment and 
2.01 log10 cells/μL post-treatment; p=0.939) and ‘other bacteria’ (1.85 log10 cells/μL pre-treatment and 
1.46 log10 cells/μL post-treatment; p=0.176) did not change significantly. Among lactobacilli, the 
concentrations of L. iners, L. crispatus, and ‘other lactobacilli’ (mostly L. jensenii and L. gasseri) all 
increased, with L. iners having the highest concentrations before and after treatment, but ‘other 
lactobacilli’ achieving the greatest concentration increase (table 2.2). The median vaginal pH decreased 
from 5.3 to 4.4 (p<0.001). Among BV-anaerobes, the concentrations of the eight most common BV-
anaerobes in our dataset (Gardnerella, Atopobium, Prevotella, Sneathia, Megasphaera, Veillonella, and 
Fusobacterium species, and BV-associated bacterium type 1) decreased (table 2.2). The concentrations 
of the three most common pathobionts in our dataset (Streptococcus, Staphylococcus, 
Escherichia/Shigella species) did not change significantly (table 2.2).  
 
While the mean trends were clear, the inter-individual variability was high (figures 2.4a-h). Of the 61 
participants for whom pre- and post-treatment concentration data were available, most had decreases in 
total bacterial concentration (n=45) and BV-anaerobes (n=52), but not everyone (figures 2.4e, 2.4g). 
BV-anaerobes were completely eradicated in only three women (4.9%), and reduced by more than 50% 
in an additional seven women (11.5%). Pathobiont concentrations showed the most inter-individual 
variability (figure 2.4h). 
 
The mean inverse Simpson diversity index was 0.67 pre-treatment and 0.31 post-treatment (p<0.001; 
table 2.2). Metronidazole treatment changed the proportions of women with certain VMB types based 
on hierarchical clustering results: the proportions of women with lactobacilli-dominated VMB types (Li 
and Lo) and the mixed LA VMB type increased, whereas the proportions of women with the three BV-
associated VMB types (BV_GV, BV_noGV, and to a lesser extent GV) decreased (table 2.2, figure 
2.3c). The number of women with a PB VMB type increased from one (1.5%) pre-treatment to six 
(9.0%) post-treatment. Alluvial diagrams show that the majority of women transitioned from the three 
BV-associated VMB types into VMB types containing lactobacilli (Li, Lo, and LA; figures 2.5a-b). 
However, women with a BV_GV or BV_noGV VMB type transitioned more often into a lactobacilli-
dominated VMB type (16/27 (59.3%), and 4/8 (50.0%), respectively) than women with a GV VMB type 
(1/8 (12.5%); Fisher’s exact p=0.084 comparing the three groups; figure 2.5a).  
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Figure 2.4: Individual bacterial group concentrations pre- and post-treatment 
a Total bacteria b Total lactobacilli 
  
c Total BV-anaerobes d Total pathobionts 
  
e Total bacteria f Total lactobacilli 
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g Total BV-anaerobes h Total pathobionts 
  
BV bacterial vaginosis, conc concentration, Pre-tx pre-treatment visit, Post-tx post-treatment visit. 
a-d Changes in total bacterial concentrations and bacterial group concentrations before (n=66) and after metronidazole treatment (n=63): total 
bacterial concentration (a), total lactobacilli (b), total BV-anaerobes (c) and total pathobionts (d; boxplot not shown because of high 
proportion of zero values). See table 2.2 for mean concentrations and 95% confidence intervals, and statistical significance. e-h Change in 
concentrations between pre- and post-treatment, expressed as a percentage for every individual participant with valid qPCR results at both 
visits (n=61), for total bacterial concentration (e), total Lactobacillus (f), total BV-anaerobes (g), and total pathobionts (h). In some women, 
concentration went from zero to non-zero; these increases were set at 100% or the greatest increase observed among the other participants, 
whichever was greatest. 
 
Participants with treatment failure as defined by Nugent scoring had a lower mean lactobacilli relative 
abundance, smaller decreases in mean total bacteria and BV-anaerobes concentrations, and less often a 
lactobacilli-dominated VMB type, post-treatment (Appendix: figures B.1a-d). They also had a higher 
mean pathobionts concentration pre-treatment (table 2.3). Successfully treated participants had 
significant decreases in the mean concentrations of all eight most common BV-anaerobes in our dataset, 
but unsuccessfully treated participants did not have decreases in G. vaginalis and BVAB1 (table 2.2). 
Simpson diversity index did not differ by treatment success/failure (Appendix: figure B.1e). In logistic 
regression models, we did not identify any statistically significant sociodemographic or biological 
correlates of treatment failure, except for pathobionts concentration pre-treatment (p=0.044; table 2.4). 
Pre-treatment C. trachomatis/N. gonorrhoeae status, having received another antibiotic in addition to 
metronidazole, and reporting unusual vaginal discharge at the pre-treatment visit, did not modify the 
effects of metronidazole treatment on the VMB (Appendix: tables B.1, B.2, B.3, figures B.2a-f, B.3a-f, 
B.4a-f). 
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Figure 2.5: Alluvial diagrams of vaginal microbiota types pre- and post-treatment 
a b 
  
  
BV bacterial vaginosis, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, GV G. vaginalis-dominated, LA lactobacilli and anaerobes, LD Lactobacillus-dominated, 
Li L. iners-dominated, Lo other lactobacilli-dominated, PB pathobionts, Pre-tx pre-treatment visit, Post-tx post-treatment visit, VMB vaginal microbiota. 
a Changes in VMB types (n=66). Two participants with missing VMB types at either the pre-treatment (n=1) or post-treatment (n=1) visit are not shown. b Changes in pooled VMB types (n=66). VMB types were 
pooled into Lactobacillus-dominated (LD; combining VMB types Li and Lo), lactobacilli and anaerobes (LA), BV-like (combining VMB types BV_noGV, BV_GV, and GV) and pathobionts (PB). 
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Table 2.3: Bacterial group concentrations and relative abundances by treatment success 
VMB outcomes at pre-treatment visit All participants 
(n = 66) 
Successful tx* 
(n = 29) 
Unsuccessful tx† 
(n = 25) p‡ 
Mean total bacterial concentration in 
log10 cells/μL (95% CI)§ 
6.59 
(6.39 – 6.78) 
6.59 
(6.31 – 6.86) 
6.68 
(6.36 – 7.01) 0.656 
Mean total Lactobacillus concentration 
in log10 cells/μL (95% CI)§ 
4.98 
(4.61 – 5.35) 
4.92 
(4.36 – 5.49) 
4.62 
(3.92 – 5.31) 0.605 
Mean total BV-anaerobes concentration 
in log10 cells/μL (95% CI)§ 
6.23 
(5.88 – 6.57) 
6.46 
(6.14 – 6.78) 
6.62 
(6.26 – 6.97) 0.557 
Mean total pathobionts concentration in 
log10 cells/μL (95% CI)§ 
1.85 
(1.29 – 2.41) 
1.09 
(0.32 – 1.87) 
2.30 
(1.40 – 3.19) 0.037 
Mean total other bacteria concentration 
in log10 cells/μL (95% CI)§ 
3.33 
(2.84 – 3.83) 
1.71 
(0.96 – 2.45) 
2.44 
(1.56 – 3.31) 0.132 
Mean RA total Lactobacillus (95% CI) 0.24 
(0.15 – 0.32) 
0.18 
(0.08 – 0.27) 
0.10 
(0.02 – 0.18) 0.410 
Mean RA total BV-anaerobes (95% CI) 0.74 
(0.66 – 0.82) 
0.81 
(0.71 – 0.91) 
0.89 
(0.81 – 0.97) 0.263 
Mean RA total pathobionts (95% CI) 0.02 
(0.01 – 0.03) 
0.01 
(0.00 – 0.02) 
0.01 
(0.00 – 0.03) 0.079 
Mean RA total other bacteria (95% CI) 0.01 
(0 – 0.01) 
0 
(0 – 0) 
0 
(0 – 0) 0.099 
Changes in VMB outcomes 
(comparing differences between visits) 
All participants 
(n = 66) 
Successful tx* 
(n = 28) 
Unsuccessful tx† 
(n = 25) p‡ 
Difference in mean total bacterial 
concentration in log10 cells/μL (95% CI)§ 
-0.71 
(-0.95 – -0.48) 
-0.96 
(-1.29 – -0.64) 
-0.44 
(-0.82 – -0.06) 0.026 
Difference in mean total Lactobacillus 
concentration in log10 cells/μL (95% CI)§ 
0.47 
(0.11 – 0.83) 
0.45 
(-0.01 – 0.92) 
1.06 
(0.37 – 1.75) 0.095 
Difference in mean total BV-anaerobes 
concentration in log10 cells/μL (95% CI)§ 
-1.61 
(-2.07 – -1.15) 
-2.68 
(-3.28 – -2.09) 
-0.81 
(-1.32 – -0.31) <0.001 
Difference in mean total pathobionts 
concentration in log10 cells/μL (95% CI)§ 
0.09 
(-0.56 – 0.74) 
0.24 
(-0.51 – 0.98) 
0.29 
(-1.06 – 1.64) 0.790 
Difference in mean total other bacteria 
concentration in log10 cells/μL (95% CI)§ 
-1.63 
(-2.24 – -1.03) 
-0.79 
(-1.62– 0.04) 
-0.25 
(-1.36– -0.86) 0.403 
Difference in mean RA total 
Lactobacillus (95% CI) 
0.47 
(0.37 – 0.57) 
0.69 
(0.55 – 0.83) 
0.47 
(0.34 – 0.59) 0.002 
Difference in mean RA total BV-
anaerobes bacteria (95% CI) 
-0.51 
(-0.60 – -0.41) 
-0.73 
(-0.85 – -0.61) 
-0.48 
(-0.61 – -0.35) 0.001 
Difference in mean RA total pathobionts 
(95% CI) 
0.04 
(0.00 – 0.07) 
0.04 
(-0.02 – 0.10) 
0.02 
(-0.01 – 0.05) 0.689 
Difference in mean RA total other 
bacteria (95% CI) 
0 
(0 – 0) 
0 
(-0.01 – 0) 
0 
(-0.01 – 0) 0.457 
BV bacterial vaginosis, CI confidence interval, RA relative abundance, tx treatment, VMB vaginal microbiota. 
*Defined as having a Nugent score of 7-10 prior to treatment and 0-3 after treatment. †Defined as having a Nugent score of 7-10 prior to 
treatment and 4-10 after treatment. ‡By Mann-Whitney U test, comparing those with successful treatment to those with unsuccessful treatment.  
§Concentration data may contain at most five missing values due to invalid results. 
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Table 2.4: Sociodemographic and biological correlates of metronidazole treatment success 
Sociodemographic correlates of treatment success* OR (95% CI)† p† 
Age (continuous variable) 1.06 (0.97 – 1.17) 0.186 
Education level:  
- primary school not completed‡ 
- primary school completed‡ 
- secondary school not completed‡ 
1.23 (0.26 – 5.90) 
1.80 (0.31 – 10.5) 
0.33 (0.02 – 4.74) 
0.795 
0.514 
0.417 
Exchanged sex for money/goods in month prior to post-treatment visit 5.40 (0.56 – 52.1) 0.145 
Used a condom at the last vaginal sex act prior to post-treatment visit 0.99 (0.97 – 1.02) 0.678 
Condom use in the two weeks prior to post-treatment visit 
- Always versus never 
- Sometimes (but not always) versus never 
 
0.36 (0.03 – 3.92) 
0.22 (0.02 – 2.19) 
 
0.399 
0.196 
Currently using hormonal contraception at the post-treatment visit 0.69 (0.23 – 2.05) 0.499 
Currently breastfeeding at the pre-treatment visit 1.00 (0.97 – 1.03) 0.874 
Inserted anything in vagina in the 12 months prior to post-treatment visit 1.03 (0.34 – 3.10) 0.959 
Had menses in seven days prior to post-treatment visit 1.83 (0.41 – 8.23) 0.429 
Reported any urogenital symptoms at the pre-treatment visit 0.67 (0.21 – 2.11) 0.496 
Reported any urogenital symptoms at the post-treatment visit NA§ NA§ 
Biological correlates of treatment success* [at pre-treatment visit] OR (95% CI)† p† 
Total lactobacilli concentration 1.14 (0.80 – 1.62) 0.476 
Total BV-anaerobes concentration 0.79 (0.41 – 1.53) 0.489 
Total pathobionts concentration 0.76 (0.58 – 0.99) 0.044 
Total other bacteria concentration 0.83 (0.63 – 1.10) 0.191 
Gardnerella vaginalis concentration¶ 0.86 (0.44 – 1.65) 0.640 
Atopobium vaginae concentration|| 0.83 (0.59 – 1.17) 0.285 
Prevotella concentration 0.93 (0.65 – 1.33) 0.691 
Sneathia concentration 0.86 (0.63 – 1.16) 0.318 
Megasphaera concentration 1.12 (0.89 – 1.42) 0.333 
Veillonella concentration 0.85 (0.68 – 1.06) 0.157 
BVAB1 concentration 1.01 (0.83 – 1.23) 0.912 
Fusobacterium concentration 0.89 (0.61 – 1.30) 0.549 
Vaginal microbiota type: 
- LA versus Li 
- BV_GV versus Li 
- BV_noGV versus Li 
- GV versus Li 
- BV_GV versus LA 
- BV_noGV versus LA 
- GV versus LA 
 
1.75 (0.10 – 30.84) 
0.46 (0.04 – 5.75) 
0.67 (0.04 – 11.29) 
0.30 (0.02 – 4.91) 
0.27 (0.05 – 1.52) 
0.38 (0.04 – 3.34) 
0.17 (0.02 – 1.44) 
 
0.702 
0.550 
0.779 
0.398 
0.136 
0.383 
0.104 
Pooled vaginal microbiota type: 
- LA versus Lactobacillus-dominated [Li or Lo] 
- [BV_GV or BV_noGV or GV] versus Lactobacillus-dominated [Li or Lo] 
 
1.75 (0.10 – 30.84) 
0.45 (0.04 – 5.40) 
 
0.702 
0.532 
Yeasts on wet mount 0.83 (0.05 – 5.40) 0.896 
Trichomonas vaginalis on wet mount 1.71 (0.15 – 20.1) 0.661 
Positive urinalysis test 1.22 (0.33 – 4.44) 0.765 
Any bacterial sexually transmitted infection (CT/NG/syphilis) 0.65 (0.22 – 1.91) 0.435 
Positive herpes simplex virus type 2 serology 2.16 (0.70 – 6.69) 0.178 
BV bacterial vaginosis, BVAB1 BV-associated bacterium type 1, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial 
but low G. vaginalis, CI confidence interval, CT Chlamydia trachomatis, GV G. vaginalis-dominated, LA lactobacilli and anaerobes, Li L. iners-
dominated, Lo other lactobacilli-dominated, NG Neisseria gonorrhoeae, OR odds ratio, VMB vaginal microbiota. 
*Successful treatment defined as Nugent 7-10 pre- and 0-3 post-treatment (n=30 women) and treatment failure as Nugent 7-10 pre and 4-10 
post-treatment (n=25 women). †Bivariable logistic regression models. ‡Compared to no schooling. §No women reported urogenital symptoms 
at the post-treatment visit. ¶Includes reads assigned to Gardnerella genus. ||Includes reads assigned to Atopobium genus. 
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2.4 Discussion 
In this study among high-risk women in Rwanda diagnosed with BV and/or T. vaginalis, the cure rate of 
seven-day oral metronidazole treatment by Nugent scoring was only 54.5%. The sequencing data 
showed a decrease in BV-anaerobes (but a reduction of more than 50% in only 16.4% of women), an 
increase in lactobacilli, and no change in pathobionts. Treatment failure was associated with higher 
levels of pre-treatment Gardnerella vaginalis or pathobionts levels, but not with sociodemographic 
factors. 
 
Metronidazole treatment resulted in a mean BV-anaerobes concentration reduction (as well as T. 
vaginalis eradication), which is in agreement with a priori knowledge about the mechanism of action of 
metronidazole.58,115 However, the extent of BV-anaerobes reduction was more modest than expected, 
with only 16.4% of women having a reduction of more than 50%. The mean lactobacilli concentration 
increased, and mean concentrations of pathobionts and ‘other bacteria’ were low pre- and post-
treatment, resulting in an overall 5.5-fold reduction of total bacterial concentration (from 6.59 to 5.85 
log10 cells/μL). The observed increase in lactobacilli is consistent with culture studies showing that 
lactobacilli are not sensitive to metronidazole,63 but is inconsistent with claims made by some clinical 
researchers that the high BV recurrence rate may be due to detrimental effects of metronidazole on 
lactobacilli.52 The reduction in BV-anaerobes concentration clearly allows lactobacilli, which are not 
affected by metronidazole, to expand.60–62 In our study population of high-risk Rwandan women, L. 
iners was by far the most common Lactobacillus species pre- and post-treatment (4.81 and 5.28 log10 
cells/μL, respectively), ‘other lactobacilli’ (which includes L. jensenii) increased the most during 
treatment (from 1.46 to 3.03 log10 cells/μL), and L. crispatus was uncommon and increased only slightly 
(from 0.15 to 0.51 log10 cells/μL). A metronidazole study in American women also showed that L. iners 
and L. jensenii concentrations increased more than the L. crispatus concentration.122  
 
Women with a pre-treatment VMB type containing a relative abundance of >50% G. vaginalis, 
compared to ≤50%, were more likely to continue to have a dysbiotic VMB type post-treatment, but pre-
treatment G. vaginalis concentration (as a continuous variable) was not associated with achieving 
Nugent 0-3 post-treatment. Both findings are consistent with earlier studies,51,122 and with the G. 
vaginalis-containing biofilm hypothesis of treatment failure.47 Metronidazole may eliminate dispersed 
G. vaginalis at low to modest concentrations, but may no longer be able to do so when a biofilm 
(containing a high concentration of G. vaginalis) has been established. However, other hypotheses have 
also been posited. A recent metatranscriptomics study showed that the VMB of BV patients with 
treatment failure contained G. vaginalis with upregulated clustered regularly interspaced short 
palindromic repeat-associated (CRISPR)-genes, which may protect the bacteria against 
metronidazole.123 In our study, the concentrations of all other key BV-associated bacteria, including A. 
42 
vaginae, were effectively reduced by metronidazole and were not associated with treatment failure. This 
is in accordance to one study,122 but in contrast to others that have suggested that pre-treatment presence 
or concentration of A. vaginae was associated with treatment failure.124–126 
 
The concentrations of the pathobionts bacterial group were low pre- and post-treatment (1.92 and 2.01 
log10 cells/μL, respectively). However, pathobionts have higher pathogenicity potential than BV-
anaerobes,9 and may therefore be clinically relevant even at low concentrations. Unfortunately, it is 
currently unknown at which concentrations or relative abundances pathobionts in the vagina should be 
treated to prevent complications, such as transmission to neonates. In our study, metronidazole 
treatment did not change the pathobionts concentration, but did increase the relative abundance due to 
the reduction in total bacterial concentration. Furthermore, a higher pre-treatment pathobionts 
concentration was associated with increased likelihood of treatment failure. None of the 
sociodemographic factors that have been associated with VMB composition in other studies, including 
menses in the seven days prior to the post-treatment visit,127 were associated with treatment failure in 
our study. 
 
Our study has several implications. Women with persistent or recurrent BV might benefit from vaginal 
biofilm-disrupting treatment, adjuvant therapy with lactobacilli-based live biotherapeutics, or treatment 
with drugs that specifically target all G. vaginalis clades. The former two are actively researched,46,47,128 
but the latter are not yet available. Whether these strategies are efficacious in real life would have to be 
evaluated in clinical trials. Furthermore, diagnostic tests to determine the presence of a biofilm or 
concentrations of G. vaginalis are not yet available to clinicians. Women at risk of complications caused 
by vaginal pathobionts (not just Group B streptococci), such as pregnant women, might benefit from 
targeted screening and treatment. We encourage the incorporation of quantitative molecular 
characterisation of both key individual bacteria with pathogenic potential, as well as bacterial 
communities and biofilms, in future intervention studies.  
 
Limitations of our study include potentially limited generalisability of the results to lower risk and non-
African populations, and the lack of vaginal biofilm detection and characterisation pre- and post-
treatment. Recent studies have shown good correlations between the method that we used to quantify 
relative abundance data and species-specific qPCR results of non-minority species,129,130 but additional 
validation studies are desirable. While Nugent-based studies have shown that oral and vaginal 
metronidazole of similar dose and duration of use have similar efficacy for BV,48,49 molecular studies 
comparing the in-depth microbiological effects of different metronidazole formulations are desirable. A 
major strength of our study is that we used multiple laboratory and analytic methods to characterise the 
VMB, including methods that incorporated a priori knowledge about the pathogenic potential of 
specific micro-organisms and the types of communities in which they typically live.  
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Conclusions 
Oral metronidazole treatment alone may not be sufficient for women with recurrent bacterial vaginosis, 
or for women at risk of complications caused by pathobionts (such as pregnant women). Additional 
treatments are urgently needed, including biofilm-disrupting treatments and drugs that specifically 
target all G. vaginalis clades or pathobionts.  
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Chapter 3 - Intermittent Lactobacilli-containing Vaginal Probiotic or Metronidazole Use to 
Prevent Bacterial Vaginosis Recurrence: Safety and Preliminary Efficacy by Microscopy and 
Sequencing 
 
This chapter has been submitted to an international peer-reviewed journal and has been deposited on the 
pre-print server MedRxiv: van de Wijgert JHHM, Verwijs MC, Agaba SK, Bronowski C, 
Mwambarangwe L, Musengamana V, Uwineza M, Lievens E, Nivoliez A, Ravel J, Darby A. 
Intermittent lactobacilli-containing vaginal probiotic or metronidazole use to prevent bacterial vaginosis 
recurrence: safety and preliminary efficacy by microscopy and sequencing. MedRxiv 2019; 
doi:10.1101/19001156. The version presented here is the MedRxiv version with only minor 
modifications (numbering of figures, tables, and references). The methods used in Chapters 2 and 3 
overlap considerably, and I have therefore combined the supplementary methods into one Appendix that 
applies to both chapters (Appendix A). 
 
I reviewed the clinical data that had been collected by the Rinda Ubuzima team, and conducted the site 
close-out visit, in Kigali, Rwanda, under the supervision of Professor Janneke van de Wijgert (my 
primary supervisor). I subsequently coordinated the shipments of the stored vaginal samples from 
Kigali to Liverpool, and prepared them for sequencing at the University of Liverpool Centre for 
Genomic Research under the supervision of Professor Alistair Darby (my secondary supervisor). I 
processed the raw sequencing data, derived various VMB variables, and added them to the clinical 
database with the help of both my supervisors as well as fellow PhD student Christina Gill. I developed 
the analytical approach and performed the statistical analyses together with my primary supervisor. My 
primary supervisor and I wrote the first version of the manuscript together. All co-authors commented 
on and approved the final manuscript.  
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Abstract 
Introduction: Bacterial vaginosis (BV) is associated with HIV acquisition, pelvic inflammatory 
disease, and adverse pregnancy outcomes. Recurrence rates after metronidazole or clindamycin 
treatment are high.  
Materials and Methods: HIV-negative, non-pregnant Rwandan BV patients were randomised to four 
groups (n=17/group) after seven-day oral metronidazole treatment: behavioural counselling only 
(control), or counselling plus intermittent use of oral metronidazole, Ecologic Femi+ vaginal probiotic 
capsule (containing multiple lyophilised Lactobacillus and one Bifidobacterium species), or Gynophilus 
LP vaginal probiotic tablet (L. rhamnosus Lcr35) for two months. Vaginal microbiota assessments at all 
visits included Gram stain Nugent scoring and 16S rRNA gene qPCR and HiSeq sequencing.  
Results: All interventions were safe. The BV (Nugent 7-10) incidence rate was 10.18 per person-year at 
risk in the control group, and lower in the metronidazole (1.41/person-year; p=0.004), Ecologic Femi+ 
(3.58/person-year; p=0.043), and Gynophilus LP groups (5.36/person-year; p=0.220). In mixed effects 
models adjusted for hormonal contraception/pregnancy, sexual risk-taking, and age, metronidazole and 
Ecologic Femi+ users, each compared to controls, had higher Lactobacillus and lower BV-anaerobes 
concentrations and/or relative abundances, and were less likely to have a dysbiotic vaginal microbiota 
type consisting of BV-anaerobes by sequencing; non-significant trends for Gynophilus LP users were in 
the same directions. Inter-individual variability was high and the beneficial effects disappeared soon 
after cessation of use.  
Discussion: We conclude that lactobacilli-based vaginal probiotics warrant further evaluation because, 
in contrast to antibiotics, they are not expected to negatively affect microbiota or cause antimicrobial 
resistance. Next generation sequencing methods allow for much more rigorous efficacy evaluations than 
were possible in the past. 
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3.1 Introduction 
Most women have a vaginal microbiota (VMB) that consists predominantly of lactobacilli.4 The most 
common type of vaginal dysbiosis is bacterial vaginosis (BV), characterised by a decrease in lactobacilli 
and increase in fastidious anaerobes, which affects 30-40% of women worldwide.87 Other types of 
bacterial dysbiosis, vulvovaginal candidiasis, and Trichomonas vaginalis (TV) are also common. These 
conditions are associated with vaginal inflammation, thereby increasing the risk of HIV acquisition.12 
They are also associated with pelvic inflammatory disease, infertility, and adverse pregnancy 
outcomes.87 
 
The majority of women seeking care for vaginal symptoms receive antibiotic or antifungal treatment 
empirically or syndromically without any diagnostic testing.21 In some specialised clinics, women might 
be offered limited diagnostic testing, such as vaginal pH determination and/or wet mount microscopy. 
In research settings, BV is typically diagnosed by the Amsel criteria or Gram stain Nugent scoring,77,78 
with the latter currently being considered the gold standard: Gram-stained vaginal smears are scored 
based on microscopic visualisation of three bacterial morphotypes with a score of 0-3 considered 
normal, 4-6 intermediate, and 7-10 BV regardless of symptoms. In the last 15 years, molecular methods 
have become more widely available, and have been applied to the VMB, although mostly in descriptive 
studies to date.4 
 
Evidence is mounting that ‘microbiological-BV’ (by Nugent scoring or molecular methods) can cause 
long-term adverse outcomes in the presence or absence of vaginal symptoms.87 BV is notoriously 
difficult to treat.46,52,131 About 60-80% of patients are cured after a course of oral or vaginal 
metronidazole or clindamycin, but recurrence rates are high.52 Therapies to restore and maintain a 
healthy VMB after antibiotic treatment are not standard practice, but some clinicians in Europe and 
North America recommend twice weekly 0.75% metronidazole vaginal gel for 4-6 months to lower the 
risk of BV recurrence.52 This recommendation was tested in a randomised controlled trial in the USA, 
which showed a statistically significant reduction in BV recurrence (57% by Amsel criteria and 34% by 
Nugent scoring).132 In addition, two African trials evaluating oral (2g monthly) and vaginal 
metronidazole (five nights every three months) for BV prevention showed significant beneficial effects, 
but the effects were modest, most likely due to infrequent dosing.133,134 
 
Probiotic lactobacilli may be able to restore and maintain lactobacilli-dominated VMB, may be better 
able to prevent or disrupt BV-associated biofilms than antibiotics, and can likely be used safely for long 
periods without the risk of causing antimicrobial resistance.72 Lactobacilli-containing vaginal probiotic 
clinical trials to date have shown mixed results, but eight of the 12 trials showed sufficiently promising 
efficacy for BV prevention to warrant further investigation.72,135–145 Some trials used commercially 
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available probiotic strains (mostly derived from the gut or fermented foods) and others vaginal strains 
isolated from healthy women,71 but currently available efficacy signals are similar for the two probiotic 
strain categories.72,135–145 None of the trials reported major safety concerns or colonisation beyond the 
dosing period, but safety during pregnancy or in immunocompromised individuals has not been studied 
well. Because ‘natural’ strains do not seem to outperform commercially available strains, and for 
pragmatic reasons, we chose to evaluate two vaginal probiotics that are currently on the market. Our 
aim was to assess their impact on the VMB in much more detail than previous trials had done, and 
develop data analytic methods to enable use of high-dimensional 16S rRNA gene sequencing data for 
this purpose. The two probiotics that we evaluated were Ecologic Femi+ vaginal capsule (EF+; 
Winclove Probiotics, Amsterdam, The Netherlands) and Gynophilus LP vaginal tablet (GynLP; Biose, 
Aurillac, France). EF+ contains multiple lyophilised bacteria (Bifidobacterium bifidum W28, 
Lactobacillus acidophilus W70, L. helveticus W74, L. brevis W63, L. plantarum W21, and L. salivarius 
W24) in a total dose of 1.5x109 colony forming units (CFU). GynLP contains 1.6x109 CFU of Lcr 
Regenerans, a culture of the L. rhamnosus 35 (Lcr35) strain. The tablet disintegrates in the vagina after 
forming a gel to release Lcr35. Gynophilus (the same active ingredient as GynLP but a different 
formulation) had shown promise in preventing BV recurrence in a previous trial, but EF+ had not 
previously been studied for this indication.136 
 
3.2 Materials and Methods 
From June 2015 until February 2016, we conducted a randomised clinical trial in Kigali, Rwanda, to 
evaluate intermittent use of the above-mentioned vaginal probiotics as well as oral metronidazole 
(Tricozole, Laboratory & Allied ltd, Nairobi, Kenya) to prevent the recurrence of microbiological-BV 
after metronidazole treatment. The trial was a pilot trial with a modest sample size (N=68) at the request 
of the funder. 
 
Eligibility 
Women were eligible for screening if they were aged 18-45, in good overall physical and mental health, 
and at high urogenital infection risk defined as having had more than one sex partner in the last 12 
months or having been treated for a sexually transmitted infection and/or BV in the last 12 months. 
They were eligible for enrolment if they were confirmed HIV-negative and non-pregnant, were 
diagnosed with BV (by Nugent score and/or Amsel criteria) and/or TV (by wet mount and/or culture), 
and were cured after seven days of oral metronidazole treatment (500 mg twice per day).78 Cure was 
defined as no BV by Amsel criteria and no TV by wet mount.77 We did not use Nugent scores and TV 
culture as tests-of-cure to allow for same day enrolment but results became available after enrolment. At 
enrolment, 51/68 women were BV-negative by Amsel and Nugent criteria, 17/68 women were BV-
negative by Amsel but BV-positive by Nugent criteria, and all women were TV-negative by both wet 
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mount and culture and free of symptomatic vulvovaginal candidiasis, symptomatic urinary tract 
infection, syphilis, and clinician-observed genital abnormalities or vaginal discharge. We did not 
exclude women with chlamydia and/or gonorrhoea because the local testing turn-around time was slow. 
Positive herpes simplex type 2 serology was not a reason for exclusion. Additional exclusion criteria 
applied but these were rare (figure 3.1, Appendix A). 
 
Figure 3.1: Flow diagram of numbers of women seen and study procedures at each visit 
 
BV bacterial vaginosis, D7 day 7 visit, M1/2/6 Month 1/2/6 visit, RU Rinda Ubuzima, STI sexually transmitted infection, TV 
Trichomonas vaginalis, UTI urinary tract infection.  
*Totals to 110 reasons among 102 women because there could be more than one reason per woman. †No speculum exam performed; 
molecular testing of self-sampled vaginal swabs. ‡Reasons: outside of metronidazole treatment window (n=5), enrolment target already 
met (n=4), has a mental disorder (n=1), did not complete screening procedures and was subsequently lost to follow=up (n=1), withdrew 
consent during the Screening visit because she thought the reimbursement was too low (n=1). §Three women in each randomisation 
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group were selected for self-sampling every other day during the first month of follow-up. ¶Reasons: moved away from Kigali (n=2), lost 
interest because symptoms resolved (n=1), and was verbally harassed by partner and sister about study participation (n=1).  
 
Randomisation groups and visit schedule 
Women were randomised to four groups (17 women per group) within three days of completing oral 
metronidazole treatment: 1) behavioural counseling only (control group); 2) counseling plus 500 mg 
oral metronidazole twice weekly for two months; 3) counseling plus EF+ vaginal capsule once per day 
for the first five days followed by thrice weekly for a total of two months; and 4) counseling plus 
GynLP once every four days for two months. Participants applied the first dose of their intervention 
under direct observation at the enrolment visit, and returned to the clinic after seven days (D7), one 
month (M1), two months (M2; cessation of product use), and six months (M6). They were allowed to 
cease vaginal product use temporarily during menstruation. Product adherence was assessed by review 
of diary cards, used and unused products, and by a self-rating adherence scale. Symptomatic BV, 
vulvovaginal candidiasis, and urinary tract infections, and laboratory-confirmed sexually transmitted 
infections, diagnosed during follow-up were treated using standard oral therapies, and women were 
urged to continue their interventions during treatment. Visit procedures are summarised in figure 3.1 
and described in Appendix A. 
 
Diagnostic testing 
Women were tested for BV, TV, and vulvovaginal candidiasis at each visit. BV was diagnosed by Gram 
stain Nugent scoring78 and Amsel criteria77; the vaginal pH was measured by pressing a pH paper strip 
(pH range 3.6 – 6.1 with 0.3 increments; Machery-Nagel, Düren, Germany) against the vaginal wall. 
TV was diagnosed when motile trichomonads were observed on wet mount and by InPouch culture 
(Biomed Diagnostics, White City, OR, USA). Vulvovaginal candidiasis was diagnosed when budding 
yeasts and/or (pseudo)hyphae were observed on wet mount. All other diagnostic tests (Appendix A) 
were only done at screening, M6, and when judged clinically necessary by the physician, with the 
exception of pregnancy and urinalysis tests, which were repeated at enrolment prior to randomisation.  
 
16S rRNA gene sequencing and qPCR 
We collected vaginal swabs at 639 time points, including study visits of all 68 women and self-sampled 
swabs from 12 women (three per group) who had been asked to self-sample at home every Monday, 
Wednesday, and Friday during the first month. Self-sampled swabs were processed but were not 
included in analyses unless stated. DNA was extracted from one swab per time point per woman. 
Briefly, DNA was extracted using a combination of lysozyme lysis, Qiagen DNeasy Blood and Tissue 
kit (Qiagen, Manchester, UK), and bead-beating procedures. Purified DNA underwent two PCR rounds: 
amplification of the 16S rRNA gene V3-V4 region and dual-index barcoding allowing multiplexing of 
up to 384 samples. Samples were sequenced on an Illumina HiSeq 2500 instrument (Illumina, San 
Diego, CA, USA), run in rapid mode, 2x300bp using a 250PE and 50PE kit. All samples collected from 
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the same participant were included in the same run. Negative and positive controls (ZymoBiomics 
Microbial Community DNA standard; Zymo Research Corp, Irvine, USA) were incorporated 
throughout. The panbacterial 16S rRNA gene copy concentrations of physician-collected samples of 
enrolled women with valid sequencing results (N=393) were determined by BactQuant qPCR assay as 
previously described.118  
 
Molecular data processing 
Reads were demultiplexed, and primer sequences removed using Cutadapt v1.2.1.146 Error correction, 
dereplication, denoising, merging, removal of chimeras, and taxonomic assignment were performed in 
DADA2 v1.4.0 using Silva v128 as the reference database (Appendix A).119,120 Further data processing 
included removal of rare, non-bacterial, and contaminant amplicon sequence variants (ASVs), and 
identification of vaginal and probiotic sequences that are not included in the Silva database using the 
NCBI Needleman-Wunsch Global Align Nucleotide Sequences function136 (Appendix A). Silva-based 
taxonomic assignments of non-minority ASVs were double-checked using the NCBI Microbial 
Nucleotide BLAST function, using the non-redundant V3-V4 version of the Vaginal 16S rRNA 
Reference Database as a tiebreaker.147,148 We rarefied at 1,111 reads using the GUniFrac 1.0 package in 
R.121 This yielded 401 unique ASVs in 629 samples, mapping to species (n=255; 63.6%), genus (n=116; 
28.9%), or higher taxonomic level (n=30; 7.5%). Concentrations in cells/μl per ASV per sample were 
estimated by multiplying the ASV-specific copy-normalised relative abundance by the sample-specific 
16S rRNA gene copies concentration.129,130 Heatmaps of the 20 most common ASVs by sample are 
shown in figure 3.2a for relative abundances and figure 3.2b for concentrations. VMB data reduction 
was required for molecular efficacy analyses, and was done in three different ways. First, the Simpson 
diversity index (1-D) was calculated for each sample. Second, each ASV was assigned to one of four 
‘bacterial groups’ based on the published literature (Appendix A, table A.1): 1) lactobacilli (all species 
combined, but with subcategorisation into EF+ strains, the GynLP strain, and ‘natural lactobacilli’ in 
some analyses); 2) BV-anaerobes (anaerobic bacteria that have consistently been associated with BV); 
3) pathobionts (bacteria that are considered to have higher intrinsic pathogenicity than BV-anaerobes 
and have not consistently been associated with BV9); and 4) ‘other bacteria’ (a rest group, consisting 
mostly of skin bacteria and Bifidobacterium species). Within each sample, read counts of ASVs 
belonging to the same bacterial group were summed. This resulted in four relative abundances (one for 
each bacterial group) per sample, which sum to 1.0 for each sample. Third, we used hierarchical 
clustering based on Euclidean distance to pool samples into eight mutually exclusive VMB types (each 
sample was assigned to only one VMB type): 1) L. iners-dominated (Li, n=247 samples); 2) L. 
crispatus-dominated (Lcr, n=17); 3) other lactobacilli-dominated (Lo, n=28); 4) lactobacilli and 
anaerobes (LA, n=86); 5) polybacterial Gardnerella vaginalis-containing (BV_GV, n=138), 6) 
polybacterial but low-G. vaginalis (BV_noGV, n=23), 7) G. vaginalis-dominated (GV, n=41); and 8) 
pathobionts-containing (PB, n=49) (Appendix A).  
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Figure 3.2: Heatmaps of all study samples with relative abundance and concentration data 
a 
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b 
  
BVAB1 BV-associated bacterium type 1, BVAB2 BV-associated bacterium type 2, BVAB TM7 BV-associated bacterium (phylum TM7), conc 
concentration. 
a Heatmap depicting all samples (n = 629) on the x-axis and the 20 amplicon sequence variants with highest mean relative abundance on the y-
axis. The dendrogram above the heatmap depicts VMB clusters based on Euclidean distance. The bar below the dendrogram depicts Nugent 
scores (black means Nugent score unavailable). b Heatmap depicting all samples (n = 379) with valid quantitative qPCR data on the x-axis and 
the 20 amplicon sequence variants with highest mean 16S rRNA gene copy-normalised concentration on the y-axis. The bar depicts Nugent 
score categories (black means Nugent score unavailable).  
 
Downstream statistical analysis  
Adverse events were coded using the Medical Dictionary for Regulatory Activities 19.1 (McLean, VA, 
USA). Data were analysed using Stata 13 (StataCorp, College Station, TX, USA). Most statistical 
comparisons were between randomisation groups (each intervention group compared to the control 
group) at screening, enrolment, and longitudinally over time. For cross-sectional analyses, we used 
Fisher’s exact test for binary and categorical variables, and Kruskal-Wallis and Mann Whitney U tests 
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for continuous variables. For longitudinal analyses, we used incidence rates, incidence rate ratios, and 
mixed effects models. We conducted ITT analyses, and modified ITT analyses limited to women who 
were BV-negative by both Amsel and Nugent criteria at the time of randomisation (n=51 of 68). All 
mixed models included one VMB endpoint at a time as the outcome, participant identification number 
as the random effect, and randomisation group (an indicator variable with the control group as the 
reference group) as the main fixed effect. Models included samples collected during the intervention 
period only (including self-sampled time points), and adjusted for covariates that were associated with 
VMB composition in mixed effects models at p<0.05. 
 
Ethical statement 
All participants provided written informed consent. The study was conducted in accordance with the 
Declaration of Helsinki, sponsored by the University of Liverpool, approved by the Rwanda National 
Ethics Committee and the University of Liverpool Research Ethics Subcommittee for Physical 
Interventions, and registered on ClinicalTrials.gov (NCT02459665). 
 
3.3 Results 
Participant disposition 
Of the 68 randomised women, only four did not complete the trial (figure 3.1), resulting in 29.93 
person-years of data. The median age was 31 (interquartile range (IQR) 27-35) (table 3.1, Appendix 
table C.1). The majority of women (92.6%) had exchanged sex for money or goods, and had had a 
median of five (IQR 2-18) sex partners, in the past month. All but three women used condoms, but 
mostly inconsistently. Two-thirds of the women (61.8%) were using hormonal contraception, and four 
women became pregnant during the trial. Short course metronidazole/tinidazole use for other 
indications during the intervention period was evenly distributed among randomisation groups 
(Appendix table C.2: n=1-3 per group; p=0.688), as was short course use of other oral antibiotics 
(Appendix table C.2: n=2-4 per group; p=0.781). Furthermore, these other antibiotics did not impact 
lactobacilli and BV-anaerobes concentrations significantly (Appendix, table C.2, figure C.1). No 
antifungals were used. Product adherence was assessed by review of diary cards, used and unused 
products, and by a self-rating adherence scale. Most women were adherent with their study product 
>90% of the time, but this percentage was non-significantly lower in the GynLP group (68.8%) than in 
the metronidazole (82.4%; Fisher’s exact p=0.438) and EF+ groups (88.2%, Fisher’s exact p=0.225; 
Appendix table C.3).  
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Table 3.1: Baseline characteristics 
Sociodemographic 
characteristics at Scr/Enr 
Screened 
(n = 175) 
Enrolled 
(n = 68) 
Controls 
(n = 17) 
Metro 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 17) p* 
Age in years, median (IQR) 30 (27 – 34) 31 (27 – 35) 29 (24 – 36) 30 (27 – 34) 33 (28 – 35) 30 (27 – 35) 0.563 
Sex partners last mo, median (IQR) 5 (2 – 16) 5 (2 – 18) 5 (3 – 20) 5 (2 – 10) 3 (2 – 15) 3 (2 – 20) 0.624 
Condom during last sex act (n %)† 95 (54.6) 36 (52.9) 11 (64.7) 8 (47.1) 6 (35.3) 11 (64.7) 0.279 
Currently using contraception (n %): 
- None 
- Hormonal contraception 
- Copper IUD 
 
69 (40.2) 
99 (57.6) 
4 (2.3) 
 
24 (35.3) 
42‡ (61.8) 
2 (2.9) 
 
6 (35.3) 
10 (58.8) 
1 (5.9) 
 
6 (35.3) 
11 (64.7) 
0 
 
4 (23.5) 
12 (70.6) 
1 (5.9) 
 
8 (47.1) 
9 (52.9) 
0 
0.750 
Laboratory results at Scr Screened 
(n = 173) 
Enrolled 
(n = 68) 
Controls 
(n = 17) 
Metro 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 17) p* 
Nugent score, mean (95% CI)† 4.7 (4.1 – 5.3) 7.4 (6.8 – 8.0) 7.6 (6.5 – 8.6) 6.8 (5.3 – 8.3) 7.1 (5.5 – 8.6) 8.2 (7.4 – 9.0) 0.333 
Nugent categories (n %)† 
- 0-3 
- 4-6 
- 7-10 
 
55 (38.2)§ 
20 (13.9) 
69 (47.9) 
 
5 (7.5) 
6 (9.0) 
56 (83.5) 
 
1 (5.9) 
0 
16 (94.1) 
 
2 (11.8) 
4 (23.5) 
11 (64.7) 
 
2 (12.5) 
0 
14 (87.5) 
 
0 
2 (11.8) 
15 (88.2) 
0.075 
BV modified Amsel¶ (n %) 63 (43.2)|| 49 (72.1) 11 (64.7) 12 (70.6) 13 (76.5) 13 (76.5) 0.933 
Candida wet mount (n %) 14 (9.6)|| 6 (8.8) 1 (5.9) 2 (11.8) 3 (17.7) 0 0.493 
TV by wet mount positive (n %) 9 (6.2)|| 6 (8.8) 3 (17.7) 1 (5.9) 1 (5.9) 1 (5.9) 0.707 
TV InPouch positive (n %) 17 (11.8)§ 11 (16.4) 3 (18.8) 1 (5.9) 5 (29.4) 2 (11.8) 0.282 
UTI dipstick positive (n %) 33 (19.1) 17 (25.0) 4 (23.5) 6 (35.3) 4 (23.5) 3 (17.7) 0.760 
CT PCR positive (n %) 30 (20.8)§ 20 (29.4) 5 (29.4) 7 (41.2) 3 (17.7) 5 (29.4) 0.560 
NG PCR positive (n %) 18 (12.5)§ 13 (19.1) 5 (29.4) 4 (23.5) 2 (11.8) 2 (11.8) 0.555 
HIV serology positive (n %) 17 (9.8) 0 0 0 0 0 NA 
HSV2 serology positive (n %) 117 (67.6) 44 (64.7) 9 (52.9) 12 (70.6) 11 (64.7) 12 (70.6) 0.780 
Syphilis serology positive (n %) 13 (7.5) 4 (5.9) 0 1 (5.9) 0 3 (17.7) 0.182 
Pregnancy positive (n %) 7 (4.1) 0 0 0 0 0 NA 
Laboratory results at Enr** Screened 
(n = 176) 
Enrolled  
(n = 68) 
Controls 
(n = 17) 
Metro 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 17) p* 
Nugent score, mean (95% CI)† NA 3.1 (2.2 – 3.9) 3 (1.2 – 4.8) 3.3 (1.4 – 5.2) 1.7 (0.1 – 3.3) 4.3 (2.6 – 6.0) 0.187 
Nugent categories (n %)† 
- 0-3 
- 4-6 
- 7-10 
NA 
 
36 (54.6) 
13 (19.7) 
17 (25.8) 
 
8 (53.3) 
5 (33.3) 
2 (13.3) 
 
9 (52.9) 
2 (11.8) 
6 (35.3) 
 
13 (76.5) 
1 (5.9) 
3 (17.7) 
 
6 (35.3) 
5 (29.4) 
6 (35.3) 
 
0.149 
 
BV by modified Amsel¶ (n %) NA 0 0 0 0 0 NA 
Candida on wet mount (n %) NA 4 (5.9) 2 (11.8) 1 (5.9) 0 1 (5.9) 0.897 
TV by wet mount/culture (n %) NA 0 0 0 0 0 NA 
VMB outcomes at Enr Screened 
(n = 176) 
Enrolled 
(n = 67) 
Controls 
(n = 17) 
Metro 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 16) p* 
Richness, mean (95% CI) NA 12.8  (10.7 – 14.8) 
17.8  
(12.1 – 23.5) 
12.1  
(8.7 – 15.5) 
7.5‡‡  
(4.9 – 10.2) 
13.7  
(10.3 – 17.1) 0.003 
Simpson diversity index, mean  
(95% CI) NA 
0.31 
(0.25 – 0.38) 
0.38 
(0.21 – 0.54) 
0.35 
(0.20 – 0.50) 
0.15§§ 
(0.05 – 0.25) 
0.38 
(0.25 – 0.50) 0.022 
Total bacteria and bacterial group concentrations in log10 cells/μL, mean (95% CI)†† 
Total bacteria NA 5.85 (5.66 – 6.04) 
5.75 
(5.30 – 6.20) 
5.79 
(5.39 – 6.19) 
5.54 
(5.28 – 5.80) 
6.34‡‡ 
(5.95 – 6.73) 0.019 
Total Lactobacillus NA 5.56 (5.34 – 5.78) 
5.22 
(4.63 – 5.82) 
5.59 
(5.20 – 5.97) 
5.46 
(5.19 – 5.73) 
5.97 
(5.44 – 6.49) 0.092 
Total BV-anaerobes NA 4.55 (4.15 – 4.95) 
4.78 
(4.17 – 5.39) 
4.50 
(3.77 – 5.24) 
3.36‡‡ 
(2.43 – 4.29) 
5.62‡‡ 
(4.99 – 6.25) 0.002 
Total pathobionts NA 2.01 (1.48 – 2.54) 
2.36 
(1.28 – 3.44) 
2.08 
(1.00 – 3.17) 
1.34 
(0.29 – 2.39) 
2.30  
(0.98 – 3.62) 0.447 
Total other bacteria NA 1.46 (1.01 – 1.92) 
1.80 
(0.84 – 2.76) 
1.30 
(0.36 – 2.24) 
0.57 
(-0.10 – 1.24) 
2.20 
(1.07 – 3.34) 0.066 
VMB types (n %):  
- Li 
- Lcr 
- Lo 
- LA 
- BV_GV 
- BV_noGV 
- GV 
- PB 
NA 
 
35 (52.2) 
0 
2 (3.0) 
18 (26.9) 
2 (3.0) 
0 
4 (6.0) 
6 (9.0) 
 
7 (41.2) 
0 
1 (5.9) 
3 (17.7) 
1 (5.9) 
0 
2 (11.8) 
3 (17.7) 
 
9 (52.9) 
0 
1 (5.9) 
5 (29.4) 
0 
0 
0 
2 (11.8) 
 
14 (82.4) 
0 
0 
2 (11.8) 
0 
0 
0 
1 (5.9) 
 
5 (31.3) 
0 
0 
8 (50.0) 
1 (5.9) 
0 
2 (12.5) 
0 
0.048 
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BV bacterial vaginosis-like, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, CI confidence interval, conc 
concentration, CT Chlamydia trachomatis, EF+ Ecologic Femi+, Enr enrolment visit, GV G. vaginalis-dominated, GynLP Gynophilus LP, HSV2 herpes simplex virus 
type 2, IQR inter-quartile range, LA lactobacilli and anaerobes, Lcr Lactobacillus crispatus-dominated, Li L. iners-dominated, Lo other lactobacilli-dominated, Metro 
metronidazole, Mo month, NA not applicable, NG Neisseria gonorrhoeae, PB pathobionts-containing, Scr screening visit, TV Trichomonas vaginalis, UTI urinary tract 
infection, VMB vaginal microbiota.  
*Fisher’s exact test for binary/categorical outcomes and Kruskall Wallis test for continuous outcomes, between randomisation groups. †Total numbers are slightly lower 
due to 1-4 missing values. ‡Seven women reported using oral contraception, 18 hormonal injections, and 17 hormonal implants. §n=144; women at the screening visit 
that were HIV-positive and/or pregnant, or were otherwise ineligible, did not undergo testing for this urogenital disease. ¶The modified Amsel criteria were considered 
positive if two or three of the following criteria were positive: 1) >20% clue cells on wet mount 2) a positive KOH (amine) test; 3) vaginal pH>4.5. ||n = 146; women at 
the screening visit who were HIV-positive and/or pregnant, or were otherwise ineligible, did not undergo testing for this urogenital disease. **All enrolled participants 
were negative for HIV and pregnancy, and were treated for UTI and syphilis if positive at screening. Twenty-three enrolled participants (six controls, seven in the 
metronidazole group, four in the EF+ group, and six in the GynLP group) were positive for CT and/or NG at screening and had not received treatment by the enrolment 
visit. ††Total numbers are slightly lower due to invalid qPCR results: overall enrolment population is n=63, control group n = 16, and metronidazole group n = 14. 
‡‡p<0.05 by Mann Whitney U test, compared to control group. §§p<0.01 by Mann Whitney U test, compared to control group.  
 
VMB compositions at baseline 
By design, all randomised women at screening had BV (Nugent score 7-10 and/or by modified Amsel 
criteria) and/or TV (by wet mount and/or culture): 82.4% had BV alone, 14.7% had BV and TV, and 
2.9% had TV alone. Therefore, as expected, most women had dysbiotic VMB types by 16S rRNA gene 
sequencing at screening: BV_GV (41.8%), LA (17.9%), BV_noGV (11.9%), GV (11.9%), and PB 
(1.5%). However, 14.9% had a lactobacilli-dominated Li VMB type, of whom 60% were TV-negative, 
and these women would not have needed metronidazole treatment. Also by design, all randomised 
women were BV-negative (by modified Amsel criteria) and TV-negative (by wet mount and culture) at 
the time of randomisation. However, almost half of the women (44.8%) were not lactobacilli-dominated 
by sequencing at the time of randomisation, and none of them were L. crispatus-dominated (which is 
considered the most optimal VMB state): their VMB types were Li (52.2%), Lo (3.0%), LA (26.9%), 
PB (9.0%), GV (6.0%), and BV_GV (3.0%) (table 3.1; see Chapter 2). 
 
At randomisation, the mean total bacterial concentration ranged from 5.54-6.34 log10 cells/μl in the four 
randomisation groups, and these ranges were 5.22-5.97 for lactobacilli, 3.36-5.62 for BV-anaerobes, 
1.34-2.36 for pathobionts, and 0.57-2.20 for ‘other bacteria’ (table 3.1; relative abundance data in 
Appendix tables C.1 and C.4). The mean richness ranged from 7.5-17.8, and the mean Simpson 
diversity from 0.15-0.38. Randomisation did not completely balance the baseline VMB compositions of 
the four groups: the concentrations total bacteria and BV-anaerobes were higher in the GynLP group 
than the control group (Mann Whitney U test p<0.05), and the BV-anaerobes concentration (p<0.01) 
and Simpson diversity (p<0.05) were lower in the EF+ group than the control group (table 3.1).  
 
Variables that were associated with at least one VMB composition variable in unadjusted mixed effects 
models (Appendix table C.5) included currently using hormonal contraception or being pregnant 
(associated with a higher pathobionts concentration), above-average sexual risk taking based on 
reported numbers of partners and condom use (higher pathobionts concentration), aged 30 years or older 
(lower BV-anaerobes and pathobionts concentrations), and managing menses with a sanitary pad 
compared to other methods (higher Nugent score). Reporting current urogenital symptoms was also 
associated with VMB composition but this likely represents reverse causality. We could not exclude 
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women with ongoing chlamydia and/or gonorrhoea infections at randomisation because the turn-around 
time of diagnostic testing was slow, but the VMB compositions after metronidazole treatment of women 
with and without ongoing chlamydia and/or gonorrhoea infection were similar (Appendix figure C.1). 
As mentioned earlier, short course antibiotic use that was not part of the study interventions was not 
associated with VMB composition either (Appendix tables C.2 and C.5; figure C.1).  
 
Safety 
Two serious adverse events occurred but these were judged not to be related to study participation: one 
woman in the oral metronidazole group was hospitalised for typhoid fever and one woman in the EF+ 
group for malaria during pregnancy. Both events occurred after the intervention period and both women 
recovered completely. Two women reported non-serious social harms that were judged related to study 
participation. One woman in the control group was beaten by her partner because she engaged in self-
sampling; she withdrew from self-sampling but continued participation in the study. One woman in the 
GynLP group suffered verbal harassment from her partner and her sister for taking part in the study and 
elected to withdraw.  
 
During the intervention period, urogenital symptoms (mostly genital itching, burning, and pain during 
sex, but no vaginal discharge) were reported by 13.4% of participants with no differences between 
groups, and only two speculum exam, and no bimanual exam, findings were reported by the physician 
(table 3.2). After product cessation, urogenital symptom reporting was similar compared to the 
intervention period (10.8%), but the number of speculum exam findings increased (32.8%), likely 
reflecting the high urogenital infection incidence in this cohort. A total of 41 adverse events were 
spontaneously reported between enrolment and M6. All of them were judged definitely not or unlikely 
to be related to trial participation, and they were evenly distributed among groups. 
 
Table 3.2: Safety endpoints  
 Total  
(n = 68) 
Controls 
(n = 17) 
Metro 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 17) p* 
Patient-reported symptoms and clinician-observed signs at Scr and Enr 
Any (current or in last 2 weeks) self-reported 
urogenital symptoms, at Scr (n %) 49 (72.1)† 11 (64.7) 13 (76.5) 13 (76.5) 12 (70.6) 0.933 
Any (current) symptoms at Enr (n %) 0 0 0 0 0 NA 
Any abnormal pelvic exam findings at Scr, 
clinician-observed (n %)‡ 3 (4.4)§ 1 (5.9) 1 (5.9) 0 1 (5.9) 1.00 
Any abnormal pelvic exam findings at Enr, 
clinician-observed (n %)‡ 1 (1.5)¶ 0 0 0 1 (5.9) 1.00 
AEs – Structurally assessed between Enr and M2 (during product use) 
Any current urogenital symptoms (n %)|| 9 (13.4)** 2 (11.8) 2 (11.8) 2 (11.8) 3 (18.8) 0.894 
Any abnormal pelvic exam findings, clinician-
observed (n %)|| 2 (3.0)†† 0 0 0 2 (12.5) 0.054 
Any abnormal bimanual exam findings, 
clinician-observed (n %)|| 
 
0 0 0 0 0 NA 
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 Total  
(n = 68) 
Controls 
(n = 17) 
Metro 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 17) p* 
AEs – Structurally assessed between M2 and M6 (after product cessation) 
Any current urogenital symptoms (n %)|| 7 (10.8)‡‡ 3 (17.7) 1 (5.9) 1 (6.3) 2 (13.3) 0.700 
Any abnormal pelvic exam findings, clinician-
observed (n %)|| 
21 (32.8) 
§§ 6 (35.3) 5 (31.3) 6 (37.5) 4 (26.7) 0.951 
Any abnormal bimanual exam findings, 
clinician-observed (n %)|| 1 (1.6)¶¶ 0 0 0 1 (6.7) 0.234 
AEs – Not structurally assessed Total (N) Controls (N) Metro (N) EF+ (N) GynLP (N) p* 
Number of women with reported AEs|||| 27 8 4 8 7 0.439 
Total number reported AEs 41 13 6 9 13 0.324 
Between Enr - M2 32 12 4 5 11 NA 
Between M2 - M6*** 9 1 2 4 2 NA 
AEs – Not structurally assessed Total AEs 
(n = 41) 
Controls 
(n = 13) 
Metro 
(n = 6) 
EF+ 
(n = 9) 
GynLP 
(n = 13) p* 
Severity of reported AE (n %):  
- Mild 
- Moderate  
- Severe 
- Life-threatening 
 
2 (4.9) 
36 (87.8) 
3 (7.3) 
0 
 
0 
13 (100) 
0 
0 
 
0 
5 (83.3) 
1 (16.7) 
0 
 
1 (11.1) 
6 (66.7) 
2 (22.2) 
0 
 
1 (7.7) 
12 (92.3) 
0 
0 
NA 
Deemed related to study by physician (n %):  
- Definitely not related 
- Unlikely 
- Possible/probable/definitely related 
 
10 (24.4) 
31 (75.6) 
0 
 
3 (23.1) 
10 (76.9) 
0 
 
2 (33.3) 
4 (66.7) 
0 
 
3 (33.3) 
6 (66.7) 
0 
 
2 (15.4) 
11 (84.6) 
0 
NA 
Outcome of reported AE (n %):  
- Fully recovered 
- Not fully recovered/deteriorated/ 
permanent damage/death 
- Ongoing 
 
40 (97.6) 
0 
 
1 (2.4) 
 
12 (92.3) 
0 
 
1 (7.7)††† 
 
6 (100) 
0 
 
0 
 
9 (100) 
0 
 
0 
 
13 (100) 
0 
 
0 
NA 
Action taken by physician (n %):  
- None 
- Medication given 
- Study discontinuation 
- Hospitalisation‡‡‡ 
 
6 (14.6) 
35 (85.4) 
0 
0 
 
1 (7.7) 
12 (92.3) 
0 
0 
 
0 
6 (100) 
0 
0 
 
2 (22.2) 
7 (77.8) 
0 
0 
 
3 (23.1) 
10 (76.9) 
0 
0 
NA 
AE adverse event, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, M2/6 Month 2/6 visit, Metro metronidazole, NA not applicable, Scr 
screening visit.  
*Fisher’s exact test for binary outcomes and Kruskall Wallis test for continuous outcomes, between groups. †Most common symptom (89.8%) is genital 
itching. ‡No abnormal findings observed during bimanual exams. §Includes vaginal discharge (n=2) and cervical polyps (n=1). ¶Unusual cervical discharge. 
||Total numbers are slightly lower due to loss to follow-up (Fig. 1). No missing values. **Includes genital itching (n=8) and burning (n=3), pain during sex 
(n=4), and burning when urinating, lower abdominal pain, unusual vaginal discharge, and genital/anal sores (all n=1). ††One had ulcers/blisters in the vagina, 
one had lesions on the perineum and labia majora. ‡‡Includes genital itching (n=5) and burning (n=3), lower abdominal pain (n=4), pain during sex, burning 
when urinating, urinary frequency/urgency (all n=2), and unusual vaginal discharge (n=1). §§Includes unusual vaginal (n=4) and cervical (n=13) discharge, 
and cervicitis (n=10). ¶¶Cervical motion tenderness. ||||Most common AE according to MedDRA coding was “Infections and infestations” (n=14), followed by 
“Reproductive system and breast disorders” (n=9) and “Gastrointestinal disorders” (n=7). Sexually transmitted infections were not considered AEs but 
secondary outcomes. ***No AEs were reported after the M6 visit. †††Case of dental caries. ‡‡‡Both serious AEs involved hospitalisations that were not 
initiated by the study physician.  
 
Preliminary efficacy: primary microscopy endpoints 
In modified intent-to-treat (ITT) analyses that excluded women who had negative modified Amsel 
criteria but a Nugent score of 7-10 at baseline (n=17), the BV incidence rate by Nugent score during the 
intervention period was 10.18 per person-year at risk (PY) in the control group, and lower in the 
metronidazole (1.41/PY; p=0.004), EF+ (3.58/PY; p=0.043), and GynLP groups (5.36/PY; p=0.220) 
(table 3.3). Mean Nugent scores during the intervention period were highest in the control group, lowest 
in the metronidazole group, and in between in the two vaginal probiotics groups (figure 3.3a). By the 
end of the intervention period, many women had developed microbiological BV without symptoms. In 
line with standard practice, they were not treated, but they were also no longer included in the ‘person-
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years at risk’ denominator because they had already developed the endpoint. BV incidence rates were 
therefore much lower (1.26/PY overall; table 3.3) after cessation of the intervention, and similar 
between groups. The results for BV incidence by modified Amsel criteria were similar to those for 
Nugent scores, and no vulvovaginal candidiasis was diagnosed after randomisation.  
 
Table 3.3: Preliminary efficacy – primary endpoints (modified ITT analyses) 
BV IR Enr – M2 Controls Metronidazole EF+ GynLP 
n/N* IR (95% CI)† n/N* IR (95% CI)† n/N* IR (95% CI)† n/N* IR (95% CI)† 
Nugent 7-10 9/11 10.18 (5.48 – 18.92) 2/10 
1.41 
(0.35 – 5.62) 5/12 
3.58 
(1.61 – 7.96)  6/10 
5.36 
(2.41 – 11.93) 
Modified Amsel 11/15 7.53 (4.28 – 13.26) 3/11 
2.04 
(0.66 – 6.31) 6/13 
3.36 
(1.51 – 7.48) 4/9 
3.35 
(1.26 – 8.92) 
BV IR M2 – M6 
Nugent 7-10 4/11 0.91 (0.34 – 2.41) 5/8 
1.86 
(0.78 – 4.48) 6/9 
1.58 
(0.71 – 3.52) 2/7 
0.76 
(0.19 – 3.03) 
Modified Amsel 3/12 2.96 (0.33 – 3.15) 5/10 
2.25 
(0.94 – 5.40) 6/8 
3.84 
(1.72 – 8.54) 3/8 
1.83 
(0.59 – 5.67) 
BV IRR Enr – M2 Controls Metronidazole EF+ GynLP 
 IRR (95% CI)‡ IRR (95% CI)‡ IRR (95% CI)‡ 
Nugent 7-10 NA 0.14 (0.01 – 0.65) 0.35 (0.10 – 1.07) 0.53 (0.16 – 1.60) 
Modified Amsel NA 0.27 (0.05 – 1.00) 0.45 (0.14 – 1.28) 0.44 (0.10 – 1.47) 
BV IRR M2 – M6 
Nugent 7-10 NA 2.06 (0.44 – 10.37) 1.74 (0.41 – 8.41) 0.84 (0.08 – 5.85) 
Modified Amsel NA 2.22 (0.43 – 14.27) 3.78 (0.81 – 23.35) 1.80 (0.24 – 13.46) 
BV bacterial vaginosis, CI confidence interval, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, IR incidence rate IRR 
incidence rate ratio, ITT intent to treat M2/6 Month 2/6 visit, NA not applicable.  
There were no cases of vulvovaginal candidiasis during follow-up. Participants with a Nugent score of 7-10 at the enrolment visit were omitted 
from modified ITT analyses.  
*Number of women (n) who developed at least one incident infection during the specified time period as a proportion of the women who had at 
least one follow-up visit in that time period (N). †Incident infections divided by person-years at risk. Three participants in the Enr – M2 BV by 
modified Amsel model, seven in the Enr – M2 BV by Nugent model, 10 in the M2 – M6 BV by modified Amsel model, and 11 in the M2 – 
M6 BV by Nugent model were omitted due to having been at risk for less than 10 person-days. ‡Compared to the control group. 
 
Preliminary efficacy: secondary sequencing endpoints 
We took the baseline VMB composition imbalances into account by not only showing bacterial group 
means at each visit but also mean differences with enrolment (table 3.4 and figure 3.3c-l for 
concentrations, and Appendix figure C.2 and table C.4 for relative abundances), and by using mixed 
effects models including participant identification number as the random effect to determine if any 
changes were statistically significant (table 3.5).  
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Table 3.4: Preliminary efficacy – bacterial group concentrations 
VMB outcome Groups Enr (n = 63)* 
Products used Ceased 
D7 
(n = 62)* 
M1 
(n = 65)* 
M2 
(n = 63)* 
M6 
(n = 60)* 
Total 16S 
rRNA conc in 
log10 cells/μL, 
mean (95% 
CI) 
Control 6.29 (5.87 – 6.72) 
6.80 
(6.38 – 7.23) 
6.76 
(6.23 – 7.30) 
6.63 
(6.05 – 7.21) 
6.65 
(6.05 – 7.25) 
Metro 6.34 (5.95 – 6.73) 
6.52 
(6.16 – 6.87) 
6.69 
(6.25 – 7.12) 
6.58 
(6.15 – 7.01) 
6.50 
(5.95 – 7.05) 
EF+ 6.12 (5.86 – 6.39) 
6.35 
(5.93 – 6.76) 
6.42 
(6.03 – 6.82) 
6.58 
(6.26 – 6.90) 
6.65 
(6.28 – 7.02) 
GynLP 6.86 (6.46 – 7.26) 
6.54 
(6.01 – 7.06) 
6.55 
(5.94 – 7.16) 
6.97 
(6.54 – 7.40) 
7.02 
(6.45 – 7.60) 
Total bacterial 
conc in log10 
cells/μL, mean 
(95% CI) 
Control 5.75 (5.30 – 6.20) 
6.24 
(5.80 – 6.69) 
6.30 
(5.78 – 6.83) 
6.10 
(5.51 – 6.69) 
6.18 
(5.57 – 6.77) 
Metro 5.79 (5.39 – 6.19) 
5.98 
(5.63 – 6.33) 
6.15 
(5.70 – 6.60) 
6.03 
(5.59 – 6.47) 
5.99 
(5.34 – 6.58) 
EF+ 5.54 (5.28 – 5.80) 
5.77 
(5.34 – 6.21) 
5.86 
(5.44 – 6.28) 
6.05 
(5.70 – 6.40) 
6.18 
(5.78 – 6.58) 
GynLP 6.34 (5.95 – 6.73) 
6.00 
(5.45 – 6.53) 
6.03 
(5.38 – 6.68) 
6.48 
(6.02 – 6.94) 
6.53 
(5.93 – 7.13) 
Total 
Lactobacillus 
conc in log10 
cells/μL, mean 
(95% CI) 
Control 5.22 
(4.63 – 5.82) 
5.15 
(4.25 – 6.05) 
4.81 
(3.94 – 5.68) 
3.86 
(2.53 – 5.19) 
4.86 
(3.82 – 5.91) 
Metro 5.59 
(5.20 – 5.97) 
5.58 
(5.15 – 6.01) 
5.38 
(4.47 – 6.29) 
5.21 
(4.27 – 6.14) 
4.60 
(3.58 – 3.62) 
EF+ 5.46 
(5.19 – 5.73) 
5.37 
(4.96 – 5.79) 
5.14 
(4.40 – 5.87) 
5.30 
(4.97 – 5.63) 
5.25 
(4.80 – 5.70) 
GynLP 5.97 
(5.44 – 6.49) 
5.55 
(4.92 – 6.18) 
4.93 
(4.43 – 5.43) 
4.68 
(3.55 – 5.81) 
5.05 
(4.45 – 5.65) 
Total BV-
associated 
conc in log10 
cells/μL, mean 
(95% CI) 
Control 4.78 
(4.17 – 5.39) 
5.15 
(4.21 – 6.09) 
5.92 
(5.28 – 6.55) 
4.97 
(3.79 – 6.15) 
5.39 
(5.56 – 6.22) 
Metro 4.50 
(3.77 – 5.24) 
4.93 
(4.23 – 5.63) 
4.85 
(3.81 – 5.90) 
4.82 
(4.11 – 5.54) 
5.11 
(4.16 – 6.07) 
EF+ 3.36 
(2.43 – 4.29) 
4.31 
(3.51 – 5.10) 
4.25 
(3.26 – 5.23) 
4.65 
(3.47 – 5.84) 
5.26 
(4.18 – 6.33) 
GynLP 5.62 
(4.99 – 6.25) 
4.81 
(3.82 – 5.79) 
5.29 
(4.30 – 6.28) 
5.48 
(4.29 – 6.67) 
5.74 
(4.38 – 7.09) 
Total 
pathobionts 
conc in log10 
cells/μL, mean 
(95% CI) 
Control 2.36 
(1.28 – 3.45) 
2.44 
(1.08 – 3.81) 
2.34 
(1.13 – 3.54) 
3.35 
(2.21 – 4.48) 
1.73 
(0.69 – 2.77) 
Metro 2.09 
(1.00 – 3.17) 
2.62 
(1.32 – 3.91) 
2.37 
(1.18 – 3.56) 
2.87 
(1.79 – 3.95) 
2.20 
(0.99 – 3.40) 
EF+ 1.34 
(0.29 – 2.39) 
2.26 
(1.18 – 3.35) 
1.61 
(0.51 – 2.72) 
2.46 
(1.39 – 3.54) 
1.40 
(0.50 – 2.30) 
GynLP 2.30 
(0.98 – 3.62) 
2.46 
(1.30 – 3.63) 
2.33 
(0.99 – 3.68) 
2.54 
(1.24 – 3.93) 
1.68 
(0.25 – 3.12) 
Total other 
bacteria conc 
in log10 
cells/μL, mean 
(95% CI) 
Control 1.80 
(0.84 – 2.76) 
2.31 
(1.34 – 3.29) 
1.91 
(0.82 – 2.99) 
1.47 
(0.49 – 2.46) 
2.24 
(1.21 – 3.26) 
Metro 1.30 
(0.36 – 2.24) 
1.32 
(0.35 – 2.30) 
1.42 
(0.23 – 2.61) 
1.99 
(1.08 – 2.90) 
2.09 
(1.04 – 3.13) 
EF+ 0.57 
(-0.10 – 1.24) 
2.73 
(1.94 – 3.53) 
2.62 
(1.56 – 3.68) 
1.48 
(0.51 – 2.46) 
1.66 
(0.56 – 2.75) 
GynLP 2.20 
(1.07 – 3.34) 
2.34 
(1.04 – 3.63) 
2.51 
(1.26 – 3.75) 
2.22 
(1.09 – 3.34) 
2.54 
(1.17 – 3.91) 
Total EF+ 
strains conc in 
log10 cells/μL, 
mean (95% 
CI) 
Control 0.17† (-0.19 – 0.53) 
0.41† 
(-0.19 – 1.00) 
0.12† 
(-0.14 – 0.38) 
0.16† 
(-0.19 – 0.51) 
0.24† 
(-0.27 – 0.74) 
Metro 0.21† (-0.11 – 0.53) 
0.39† 
(-0.18 – 0.97) 
0.16† 
(-0.18 – 0.49) 
0.25† 
(-0.28 – 0.77) 
0.31† 
(-0.35 – 0.97) 
EF+ 0.30† (-0.14 – 0.74) 
1.92 
(0.92 – 2.91) 
1.51 
(0.41 – 2.62) 
0.48 
(-0.22 – 1.18) 
0 
(0 – 0) 
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GynLP 0.45† (-0.21 – 1.10) 
0.79† 
(-0.18 – 1.76) 
0.64† 
(-0.13 – 1.40) 
0.26† 
(-0.30 – 0.82) 
0 
(0 – 0) 
VMB Outcome Groups Enr D7 M1 M2 M6 
Total GynLP 
strain conc in 
log10 cells/μL, 
mean (95% 
CI) 
Control 0 (0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
Metro 0 (0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
EF+ 0 (0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
GynLP 0 (0 – 0) 
1.05 
(-0.22 – 2.31) 
0.88 
(-0.18 – 1.94) 
0.25 
(-0.28 – 0.78) 
0 
(0 – 0) 
Difference in 
total bacterial 
conc in log10 
cells/μL – 
compared to 
Enr visit, mean 
(95% CI) 
Control 0 0.55 (-0.02 – 1.11) 
0.52 
(-0.02 – 1.06) 
0.41 
(-0.11 – 0.94) 
0.31 
(-0.35 – 0.97) 
Metro 0 0.11 (-0.12 – 0.35) 
0.24 
(-0.39 – 0.88) 
0.21 
(-0.21 – 0.62) 
0.11 
(-0.57 – 0.79) 
EF+ 0 0.23 (-0.09 – 0.55) 
0.32 
(-0.08 – 0.73) 
0.51 
(0.06 – 0.97) 
0.66 
(0.26 – 1.07) 
GynLP 0 -0.27 (-0.72 – 0.18) 
-0.09 
(-0.65 – 0.48) 
0.32 
(0.01 – 0.63) 
0.17 
(-0.31 – 0.65) 
Difference in 
total 
Lactobacillus 
conc in log10 
cells/μL – 
compared to 
Enr visit, mean 
(95% CI) 
Control 0 0.07 (-0.52 – 0.66) 
-0.52 
(-1.21 – 0.17) 
-1.03 
(-2.14 – 0.09) 
-0.04 
(-0.72 – 0.64) 
Metro 0 -0.02 (-0.44 – 0.40) 
0.13 
(-0.62 – 0.88) 
-0.35 
(-1.46 – 0.77) 
-1.03 
(-2.42 – 0.34) 
EF+ 0 -0.09 (-0.58 – 0.41) 
-0.33 
(-1.15 – 0.50) 
-0.16 
(-0.58 – 0.25) 
-0.18 
(-0.73 – 0.36) 
GynLP 0 -0.38 (-1.12 – 0.35) 
-0.86 
(-1.16 – -0.04) 
-1.19 
(-2.52 – 0.15) 
-1.11 
(-1.78 – -0.45) 
Difference in 
total BV-
associated 
conc in log10 
cells/μL – 
compared to 
Enr visit, mean 
(95% CI) 
Control 0 0.36 (-0.71 – 1.42) 
1.10 
(0.17 – 2.04) 
0.18 
(-0.96 – 1.32) 
0.42 
(-0.62 – 1.47) 
Metro 0 0 (-1.04 – 1.03) 
0.03 
(-1.04 – 1.11) 
0.20 
(-0.56 – 0.95) 
0.30 
(-1.09 – 1.69) 
EF+ 0 0.95 (-0.04 – 1.93) 
0.89 
(-0.05 – 1.82) 
1.30 
(0.15 – 2.44) 
1.98 
(0.64 – 3.33) 
GynLP 0 -0.77 (-1.59 – 0.04) 
-0.02 
(-0.70 – 0.65) 
0.03 
(-1.02 – 1.08) 
0.55 
(-0.21 – 1.31) 
Difference in 
total 
pathobionts 
conc in log10 
cells/μL – 
compared to 
Enr visit, mean 
(95% CI) 
Control 0 0.07 (-1.87 – 2.03) 
-0.16 
(-1.46 – 1.15) 
0.66 
(-0.34 – 1.66) 
-0.93 
(-2.32 – 0.46) 
Metro 0 0.58 (-1.18 – 2.34) 
-0.15 
(-1.63 – 1.33) 
0.56 
(-0.90 – 2.01) 
0.20 
(-1.20 – 1.60) 
EF+ 0 0.92 (-0.29 – 2.13) 
0.27 
(-0.54 – 1.80) 
1.12 
(-0.03 – 2.27) 
-0.03 
(-1.30 – 1.24) 
GynLP 0 -0.23 (-1.59 – 1.13) 
0.21 
(-1.38 – 1.80) 
0.26 
(-1.58 – 2.10) 
-0.72 
(-2.99 – 1.54) 
Difference in 
total other 
bacteria conc 
in log10 
cells/μL – 
compared to 
Enr visit, mean 
(95% CI) 
Control 0 0.66 (-0.62 – 1.94) 
0.22 
(-1.09 – 1.54) 
-0.48 
(-1.88 – 0.92) 
0.37 
(-0.86 – 1.60) 
Metro 0 0.12 (-1.87 – 2.11) 
-0.39 
(-1.73 – 0.96) 
0.49 
(-0.84 – 1.81) 
1.09 
(-0.29 – 2.47) 
EF+ 0 2.17 (1.27 – 3.06) 
2.05 
(1.00 – 3.11) 
0.92 
(-0.10 – 1.94) 
1.05 
(-0.22 – 2.33) 
GynLP 0 0.09 (-1.35 – 1.54) 
0.45 
(-0.77 – 1.67) 
0.33 
(-1.30 – 1.95) 
0.90 
(-0.39 – 2.18) 
BV bacterial vaginosis, CI confidence interval, Conc concentration, D7 Day 7 visit, EF+ Ecologic Femi+, Enr enrolment visit, GynLP 
Gynophilus LP, M1/2/6 Month 1/2/6 visit, Metro metronidazole group, VMB vaginal microbiota.  
*Total numbers are slightly lower than enrolled women (and not lost to follow-up) per time point due to invalid results. Numbers missing per 
group is at most two at Enr, D7, M1, or M2 visits, and four at the M6 visit. †These are naturally occurring EF+ strains with 100% identity with 
the EF+ probiotic strains. 
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Figure 3.3: Preliminary efficacy by Nugent score, alpha diversity, and bacterial group 
concentrations 
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Conc concentration, D7 Day 7 visit, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, ITT intention to treat, M1/2/6 Month 
1/2/6 visit, Scr screening visit, VMB vaginal microbiota. 
Changes in VMB outcomes over time per randomisation group. See table 3.4 for 95% confidence intervals.  
a Mean Nugent scores over time, only including women (n=51) with Nugent scores 0-6 at enrolment (modified ITT analysis). b Mean alpha 
diversity over time. c Mean bacterial cell concentration over time. d Difference in mean bacterial cell concentration with enrolment, over time. 
e Mean lactobacilli concentration over time. f Difference in mean lactobacilli concentration with enrolment, over time. g Mean BV-associated 
anaerobes concentration over time. h Difference in mean BV-associated anaerobes concentration with enrolment, over time. i Mean 
pathobionts concentration over time. j Difference in mean pathobionts concentration with enrolment, over time. k Mean other bacteria 
concentration over time. l Difference in mean other bacteria concentration with enrolment, over time. 
 
Immediately after BV treatment completion, the VMBs of most women gradually worsened (lactobacilli 
declined and BV-anaerobes expanded) due to the high-risk nature of the cohort. The mean lactobacilli 
concentration declined to a low of 3.86 log10 cells/μl at M2 in the control group, but less so in the 
intervention groups (ranging from 4.60-5.58 log10 cells/μl at follow-up visits). In unadjusted mixed 
effects models using data from the intervention period only (table 3.5), metronidazole users had a higher 
lactobacilli concentration (p=0.043) and relative abundance (p=0.006) than controls, EF+ users had a 
higher relative abundance (p=0.014) but not concentration than controls, and GynLP users had trends in 
the same directions that were not statistically significant. The expansion of BV-anaerobes was 
significantly lower in oral metronidazole users (relative abundance; p=0.023), and in EF+ users 
(concentration; p=0.041), compared to controls. Mean pathobionts concentrations were low in all 
groups throughout, ranging from 1.61-3.35 log10 cells/μl at follow-up visits. Mixed effects models did 
not identify any significant associations between randomisation groups and pathobionts concentrations 
or relative abundances, but showed trends (0.05<p<0.1) towards lower pathobionts relative abundances 
in the two vaginal probiotics groups compared to controls (table 3.5). Mean concentrations of ‘other 
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bacteria’ were also low throughout, but highest in the EF+ group at the D7 and M1 visits (EF+ contains 
a Bifidobacterium strain). This was significant in unadjusted mixed effects models for relative 
abundances (p=0.023) but not concentrations. The proportions of women in each group at each visit 
having a particular VMB type corresponded with the concentration and relative abundance data, and 
additionally showed that – in lactobacilli-dominated women – the Li VMB type was far more common 
than the Lcr and Lo VMB types throughout (figure 3.4). Among women with dysbiosis, the LA and 
BV_GV VMB types continued to be the most common dysbiosis types during follow-up. In unadjusted 
mixed effects models using intervention period data only, metronidazole users and EF+ users, each 
compared to controls, were significantly less likely to have dysbiotic VMB types (BV_GV, BV_noGV, 
and GV combined; p=0.012 and p=0.029, respectively) (table 3.5). 
 
Table 3.5: Preliminary efficacy – mixed effects models 
Unadjusted mixed effects 
models 
Metro EF+ GynLP 
OR (95% CI)* p* OR (95% CI)* p* OR (95% CI)* p* 
Nugent score† 0.16 (0.02 – 1.09) 0.062 0.25 (0.04 – 1.66) 0.151 1.68 (0.24 – 11.56) 0.599 
Nugent score categories† 
- 4-6 vs 0-3 
- 7-10 vs 0-3 
 
1.04 (0.20 – 5.50) 
0.08 (0.01 – 0.80) 
 
0.960 
0.032 
 
0.36 (0.05 – 2.43) 
2.16 (0.38 – 12.31) 
 
0.293 
0.148 
 
2.16 (0.38 – 12.31) 
1.12 (0.15 – 8.28) 
 
0.387 
0.913 
Total bacterial conc† 0.85 (0.53 – 1.36) 0.497 0.72 (0.45 – 1.14) 0.160 0.96 (0.60 – 1.55) 0.877 
Total Lactobacillus conc† 2.14 (1.02 – 4.49) 0.043 1.86 (0.90 – 3.86) 0.095 1.43 (0.67 – 3.04) 0.352 
Total BV-associated conc† 0.58 (0.23 – 1.49) 0.260 0.38 (0.15 – 0.96) 0.041 0.89 (0.34 – 2.31) 0.812 
Total pathobionts conc† 0.91 (0.30 – 2.75) 0.865 0.57 (0.19 – 1.71) 0.318 0.79 (0.25 – 2.43) 0.676 
Total other bacteria conc† 0.72 (0.27 – 1.90) 0.507 1.42 (0.55 – 3.70) 0.471 1.60 (0.60 – 4.29) 0.349 
Total Lactobacillus RA‡ 1.36 (1.09 – 1.70) 0.006 1.32 (1.06 – 1.64) 0.014 1.10 (0.88 – 1.38) 0.408 
Total BV-associated RA‡ 0.79 (0.65 – 0.97) 0.023 0.83 (0.68 – 1.01) 0.067 1.00 (0.81 – 1.22) 0.973 
Total pathobionts RA‡ 0.93 (0.84 – 1.03) 0.159 0.92 (0.83 – 1.01) 0.093 0.92 (0.83 – 1.02) 0.100 
Total other bacteria RA‡ 1.00 (1.00– 1.01) 0.739 1.01 (1.00 – 1.01) 0.023 1.00 (1.00– 1.01) 0.671 
Pooled VMB type‡ 
- LA vs LD 
- BV vs LD 
- PB vs LD 
 
1.17 (0.24 – 5.78) 
0.02 (0.00 – 0.43) 
0.06 (0.00 – 1.54) 
 
0.849 
0.012 
0.090 
 
1.20 (0.24 – 5.92) 
0.04 (0.00 – 0.73) 
0.08 (0.00 – 1.77) 
 
0.823 
0.029 
0.109 
 
1.72 (0.33 – 9.04) 
0.39 (0.03 – 5.50) 
0.14 (0.01 – 3.34) 
 
0.520 
0.487 
0.225 
Simpson diversity index‡ 0.90 (0.77 – 1.06) 0.200 0.94 (0.80 – 1.10) 0.454 1.07 (0.91 – 1.26) 0.429 
Adjusted mixed effects models§ 
Nugent score† 0.19 (0.03 – 1.31) 0.092 0.26 (0.04 – 1.85) 0.178 2.05 (0.30 – 13.92) 0.464 
Nugent score categories† 
- 4-6 vs 0-3 
- 7-10 vs 0-3 
 
1.24 (0.20 – 7.82) 
0.06 (0.00 – 0.77) 
 
0.821 
0.031 
 
0.36 (0.04 – 3.13) 
0.19 (0.02 – 1.90) 
 
0.353 
0.156 
 
2.42 (0.36 – 16.26) 
1.42 (0.17 – 11.81) 
 
0.362 
0.747 
Total bacterial conc† 0.75 (0.47 – 1.18) 0.208 0.64 (0.40 – 1.02) 0.061 0.90 (0.57 – 1.43) 0.666 
Total Lactobacillus conc† 1.74 (0.83 – 3.67) 0.142 1.47 (0.69 – 3.16) 0.319 1.26 (0.60 – 2.68) 0.541 
Total BV-associated conc† 0.57 (0.22 – 1.47) 0.243 0.37 (0.14 – 0.98) 0.046 0.91 (0.35 – 2.36) 0.848 
Total pathobionts conc† 0.99 (0.35 – 2.77) 0.980 0.66 (0.23 – 1.81) 0.445 0.98 (0.36 – 2.90) 0.965 
Total other bacteria conc† 0.65 (0.25 – 1.69) 0.374 1.31 (0.49 – 3.50) 0.591 1.79 (0.68 – 4.71) 0.239 
Total Lactobacillus RA‡ 1.32 (1.06 – 1.65) 0.014 1.30 (1.03 – 1.64) 0.025 1.06 (0.85 – 1.33) 0.601 
Total BV-associated RA‡ 0.81 (0.66 – 1.00) 0.049 0.83 (0.67 – 1.03) 0.098 1.02 (0.83 – 1.26) 0.855 
Total pathobionts RA‡ 0.93 (0.84 – 1.03) 0.180 0.92 (0.83 – 1.02) 0.120 0.93 (0.84 – 1.03) 0.147 
Total other bacteria RA‡ 1.00 (1.00 – 1.01) 0.436 1.01 (1.00 – 1.01) 0.009 1.00 (1.00 – 1.01) 0.439 
Pooled VMB type‡ 
- LA vs LD 
- BV vs LD 
- PB vs LD 
 
1.46 (0.26 – 8.11) 
0.02 (0.00 – 0.48) 
0.08 (0.00 – 1.49) 
 
0.665 
0.017 
0.090 
 
1.59 (0.27 – 9.55) 
0.02 (0.00 – 0.64) 
0.11 (0.01 – 2.02) 
 
0.610 
0.027 
0.136 
 
2.11 (0.37 – 12.15) 
0.44 (0.02 – 7.84) 
0.21 (0.01 – 3.71) 
 
0.401 
0.575 
0.284 
Simpson diversity index‡ 0.93 (0.78 – 1.09) 0.359 0.96 (0.81 – 1.13) 0.597 1.10 (0.93 – 1.30) 0.272 
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BV bacterial vaginosis, CI confidence interval, conc concentration, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, LA lactobacilli and 
anaerobes, LD Lactobacillus-dominated, Metro metronidazole group, OR odds ratio, PB pathobionts, VMB vaginal microbiota.  
*Compared to the control group. †Including all valid samples during product use (D7, M1, and M2 visits). Self-sampled samples were also taken during 
product use, but were not Gram stained nor tested by 16S rRNA gene qPCR (see Methods). ‡Including all valid samples during product use (D7, M1, and 
M2 visits, and self-sampled samples). §Model adjusted for hormonal/pregnancy status, sexual risk taking, and age (see Materials and Methods).  
 
Figure 3.4: Changes in VMB type per randomisation group over time 
a 
 
b 
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d 
 
e 
 
 
BV bacterial vaginosis-like, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, D7 Day 7 
visit, EF+ Ecologic Femi+, Enr enrolment visit, GV G. vaginalis-dominated, GynLP Gynophilus LP, ITT intent-to-treat, LA lactobacilli and 
anaerobes, Lcr Lactobacillus crispatus-dominated, LD Lactobacillus-dominated, Li L. iners-dominated, Lo other lactobacilli-dominated, 
M1/M2/M6 month 1/2/6 visit, PB pathobionts-containing, VMB vaginal microbiota. 
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a Changes in VMB type membership per randomisation group over time. b-e Alluvial diagrams of changes in pooled VMB type over time per 
group: control group (b), metronidazole group (c), EF+ group (d), and GynLP group (e). Missing pooled VMB types at D7, M1, M2, and M6 
were imputed with the types at the preceding visit, and at enrolment with the type at D7. Alluvial diagrams also show whether the participant is 
in the modified ITT population (Nugent score 0-6 at enrolment) or not. 
 
The associations in unadjusted mixed effects models persisted after adjustment for hormonal 
contraception use/pregnancy, sexual risk taking, and age, except for the association with Lactobacillus 
concentration among metronidazole users. Metronidazole users compared to controls had a significantly 
higher Lactobacillus relative abundance (p=0.014), a significantly lower BV-associated bacteria relative 
abundance (p=0.049), and were significantly less likely to have BV by Nugent scoring (p=0.031) or by 
VMB types (BV_GV, BV_noGV, and GV combined; p=0.017) (table 3.5). EF+ users compared to 
controls had a significantly higher Lactobacillus relative abundance (p=0.025), a significantly lower 
BV-associated bacteria concentration (p=0.046), a significantly higher relative abundance of ‘other 
bacteria’ (p=0.009), and were significantly less likely to have a BV-like VMB type (p=0.027). 
 
Detection of probiotic strains 
During the intervention period, relevant probiotic strains were detected in 39% of samples from EF+ 
users and 20% of samples from GynLP users (all swabs combined, including self-sampled swabs). The 
detection percentages were 58% and 31%, respectively, in sensitivity analyses using non-rarefied 
sequencing data. Some of the EF+ strains cannot be differentiated from naturally occurring strains, and 
EF+-like strains were therefore detected (at low levels) in all groups at most time points (table 3.4, 
figure 3.5). However, the mean concentrations were highest in the EF+ group during the intervention 
period (mean concentrations 0.48-1.92 log10 cells/μl per visit for all women combined, and 3.62-4.28 
log10 cells/μl per visit for women who did have EF+ strains detected using rarefied data). The GynLP 
strain was only detected in the GynLP group during the intervention period (mean concentrations 0.25-
1.05 log10 cells/μl per visit for all women combined, and 3.72-4.55 log10 cells/μl per visit for women 
who did have GynLP detected using rarefied data). Inter- and intra-individual differences between 
participants were high: the highest vaginal probiotic concentration detected in an individual EF+ user 
was 5.51 log10 cells/μl, and in an individual GynLP user was 6.17 log10 cells/μl. During the intervention 
period, the mean relative abundances of the probiotic strains were 0.03 in both EF+ and GynLP users, 
and 0.08 and 0.15, respectively, if only samples in which any strains were detected were included.  
 
VMB transitions 
The stacked graph and alluvial diagrams (figure 3.4) show that transitions from one VMB type to 
another were common. As expected, most transitions during the intervention period were from 
Lactobacillus-dominated states to dysbiotic states, but the reverse also occurred. Transitions between 
VMB types were common in all randomisation groups. The percentage of actual transitions divided by 
potential transitions between D7 and M6 were 29/66 (43.9%) in the control group, 32/64 (50.0%) in the 
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metronidazole group, 28/67 (41.8%) in the EF+ group and 24/56 (42.9%) in the GynLP group (Fisher’s 
exact p=0.792). 
 
Figure 3.5: Detection of probiotic strains during the trial 
a b 
  
c d 
  
 
D7 Day 7 visit, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, M1/2/6 Month 1/2/6 visit, Scr screening visit.  
a,b Mean relative abundance (a) and mean concentration (b) of Lactobacillus species over time in the EF+ group. c,d Mean relative abundance 
(c) and mean concentration (d) of Lactobacillus species over time in the GynLP group. The length of bars in (a) and (c) depicts total relative 
abundance of all Lactobacillus species combined.  
 
Incidence of sexually transmitted and urinary tract infections 
As expected, the incidences of HIV (n=2), herpes simplex type 2 (n=1), syphilis (n=1), gonorrhoea 
(n=5), chlamydia (n=6), TV (n=5) and urinary tract infection (n=7) were too low to determine 
differences between randomisation groups (Appendix table C.6).  
 
3.4 Discussion 
This trial showed that all three interventions were safe. Our preliminary efficacy results confirm that 
intermittent use of metronidazole reduces BV recurrence,132–134 and suggest that intermittent use of 
lactobacilli-containing vaginal probiotics may also reduce BV recurrence. We also found that vaginal 
probiotic use is acceptable and feasible in African settings (to be reported elsewhere). These findings 
are important because many women and clinicians would prefer safe and efficacious vaginal probiotics 
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to metronidazole as they are not expected to negatively affect other body niche microbiotas or cause 
antimicrobial resistance, and may have fewer side effects. 
 
Our trial was funded as a pilot study and therefore had a modest sample size. Despite this, many of the 
preliminary efficacy associations for intermittent metronidazole and EF+ use reached statistical 
significance. While this was not the case for intermittent GynLP use, all of the trends in this group were 
in the same directions. We believe that the GynLP group suffered a few disadvantages compared to the 
other randomisation groups, which may explain the lack of statistical significance. Randomisation 
imbalances commonly occur in small trials,149 and in our trial, this led to women in the GynLP group 
being more dysbiotic at baseline than controls. We ameliorated this disadvantage in our analysis 
strategy, but we may not have been able to eradicate it. In addition, GynLP users were less adherent on 
average than metronidazole and EF+ users. Differences in adherence using triangulated data did not 
reach statistical significance, but probiotic strain detection rates (58% for EF+ samples and 31% for 
GynLP samples using non-rarefied data) support this claim. Biose has since simplified the dosing 
regimen of next generation Gynophilus products to two fixed days a week to boost adherence. Finally, 
GynLP dosing (once every four days) was similar to metronidazole dosing (twice weekly) but less 
frequent than EF+ dosing (once per day for the first five days followed by thrice weekly for the 
remainder of the intervention period).  
 
Probiotic detection rates were 58% for EF+ samples and 31% for GynLP samples, and inter- and intra-
individual variabilities were high (with probiotic concentrations ranging from zero to 6.17 log10 
cells/μl). This detection variability is consistent with most other vaginal probiotic studies that used 
sampling at non-daily intervals and molecular assessment methods.76,142,150,151 A major drawback of all 
of those studies, including ours, is that product use was not directly observed but self-reported, and 
precise information about the time period between last product insertion and sample collection was 
lacking. The average total bacterial load of a healthy vagina is currently not known.152 The average 
vaginal surface area was estimated to be 87.5 cm2.153 One Dacron swab head in this study absorbed 
about 106/μL bacteria. If we assume that one swab head absorbs on average 200 μL,154 and that this 
covers about 1 cm2 of a total of about 100 cm2 vaginal surface, the total bacterial load in the vagina 
would be in the order of 2x1010 bacteria. The vaginal probiotic strain(s) in our trial were both applied at 
about 1.5x109 CFU per dose, which would be about 7.5% of the total vaginal load after application if all 
probiotic bacteria were to remain in the vagina. We detected mean relative abundances of 7.7% for EF+ 
strains and 15.1% for GynLP when only samples with any relevant probiotic strains detected during 
product use were included (thereby eliminating any potential non-adherence). A recently published 
study of Gynophilus Slow Release tablet (which is almost identical to GynLP) in which women self-
sampled every day showed that mean vaginal concentrations of Lcr35 by qPCR were between 104 and 
106 CFU/μl in women who used the tablet once every four or five days.155 Using our estimated 
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concentration data, we detected a similar concentration range in samples with any GynLP detected. This 
consistency is reassuring, but the question remains whether probiotic concentrations of this order of 
magnitude optimally prevent BV recurrence in the long-term. Furthermore, all studies referenced in this 
paragraph, including ours, have shown that probiotic strains do not persist in the vagina after dosing has 
ceased. The second question then is whether the colonisation capacity of probiotic bacteria should be 
improved. Our data suggest that probiotic lactobacilli may boost ‘natural’ lactobacilli indirectly, which 
may be sufficient to establish vaginal eubiosis. Indirect effects may include increased localised lactic 
acid production, modulation of cervicovaginal mucosal immune responses, and/or inhibition of biofilm 
formation, by probiotic bacteria.12,74,6 
 
Additional limitations of our study include the high urogenital infection risk of this cohort (which 
makes prevention more challenging), and our inability to fully control for potential confounders. 
However, the mixed effects models were controlled for some of the best known VMB determinants 
(hormonal contraception, pregnancy, sexual risk taking, and age).4,27,127,156 We were not able to exclude 
women with chlamydia and/or gonorrhoea infection at the time of randomisation due to the slow 
laboratory turn-around time, but the VMB compositions of women with and without infection were 
similar, and we therefore think that this did not negatively affect our results. 
 
With the development of better genomic and culturing methods, we are now on the cusp of a new era in 
vaginal probiotic research. Past vaginal probiotic studies have shown mixed results,72,135–145 but almost 
all of these studies used imprecise VMB assessments based on clinical symptoms and microscopy. The 
addition of sequencing methods showed that many more women than previously thought are not 
lactobacilli-dominated after standard antibiotic BV treatment, that host responses to antibiotic and 
probiotic treatment are highly variable, and that it is possible to differentiate between probiotic strains 
and ‘natural’ lactobacilli. Furthermore, others have shown that quantifying relative abundance data in 
the same manner as we have done in this study correlates well with species-specific quantitative PCRs 
of non-minority species.129,130 This then allows for microbiota data reduction into quantitative variables 
that can be analysed in mixed effects models that adjust for repeated measures and confounding. We 
recommend that future trials incorporate these or other rigorous methods, optimise dosing and timing of 
product insertion versus sample collection, and enrol women with various urogenital risk profiles. 
Ideally, these trials would also evaluate the effects of interventions on vaginal biofilm formation, and – 
eventually – the impact on pregnancy complications, HIV epidemics, and other adverse outcomes. 
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Chapter 4 - Vaginal Probiotic Adherence and Acceptability in High-Risk Rwandan Women 
Participating in a Pilot Randomised Controlled Trial: A Mixed-Methods Approach 
 
This chapter has been submitted to an international peer-reviewed journal, has been reviewed by three 
reviewers of the journal, but has not yet been accepted for publication: Verwijs MC, Agaba SK, 
Umulisa MM, Uwineza M, Nivoliez A, Lievens E, van de Wijgert JHHM. Vaginal probiotic adherence 
and acceptability in high-risk Rwandan women participating in a pilot randomised controlled trial: a 
mixed-methods approach. 2019; (submitted for publication). The version presented here is the author-
approved second submission with only minor modifications (numbering of figures, tables, and 
references).  
 
The data described in this chapter were also collected within the Rwanda VMB trial. I reviewed the 
survey and social science data that had been collected by the Rinda Ubuzima team, and conducted the 
site close-out visit, in Kigali, Rwanda, under the supervision of Professor Janneke van de Wijgert (my 
primary supervisor). I developed the analytical approach, performed the statistical analyses, wrote the 
first draft of the manuscript, and coordinated the submission process and responses to reviewers. All 
authors commented on and approved the final manuscript. 
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Abstract 
Introduction: Bacterial vaginosis (BV) recurrence is common. We evaluated the adherence and 
acceptability of intermittent use of two vaginal probiotics and one antibiotic to prevent recurrence.  
Materials and methods: We performed repeated adherence and acceptability assessments using mixed 
methods within a pilot randomised controlled trial, conducted at a research clinic in Kigali, Rwanda. 
We included high-risk Rwandan women (n=68) with BV and/or trichomoniasis. Women were 
randomised to four groups (n=17 each) after completing metronidazole treatment: behavioural 
counselling only, or behavioural counselling plus two-month intermittent use of oral metronidazole, 
Ecologic Femi+ (EF+) vaginal capsule, or Gynophilus LP (GynLP) vaginal tablet. Adherence and 
acceptability data from randomised women were collected in structured face-to-face interviews, semi-
structured focus group discussions and in-depth interviews, daily diaries, and counting of used/unused 
study products. Randomised women and women attending recruitment sessions (n=131) were surveyed 
about vaginal infection knowledge. 
Results: Most women (93%) were sex workers. At baseline, they were unfamiliar with BV, and had 
never used probiotics. All probiotic users reported that insertion became easier over time. Triangulated 
adherence data showed that 100% of EF+ users and 81.3% of GynLP users used ≥80% of required 
doses. Younger age, asking many questions at enrolment, having menses, and reporting urogenital 
symptoms showed non-significant trends towards a lower perfect adherence likelihood. Qualitative data 
suggested that women believed that the probiotics reduced BV recurrence, but that partners were 
sometimes unsupportive of study participation. Self-reported vaginal washing practices decreased 
during follow-up, but sexual risk behaviours did not. Most women (80%) with an uncircumcised steady 
partner discussed penile hygiene with him, but many women found this difficult, especially with male 
clients. 
Discussion: High-risk women require education about vaginal infections. Vaginal probiotic 
acceptability and adherence were high in this cohort. Our results can be used to inform future product 
development and to fine-tune counselling messages in prevention programs. 
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4.1 Introduction 
Bacterial vaginosis (BV) is a vaginal condition in which fastidious anaerobes such as Gardnerella 
vaginalis increase while beneficial, lactic acid-producing lactobacilli decrease.4 Often asymptomatic, it 
is associated with increased risks of sexually transmitted infections (STIs) and HIV transmission, pelvic 
inflammatory disease, and adverse pregnancy outcomes.9,18,20,157 Although BV is treatable with 
antibiotics, the risk of recurrence is high.46,52 The prevalence of BV varies among regions and ethnic 
groups but is highest in sub-Saharan Africa, where it is estimated at 30-50%.37 
 
Vaginally-administered probiotics containing lactobacilli are considered a promising new strategy to 
restore a lactobacilli-dominated vaginal microbiota during and/or after antibiotic treatment, or to 
prevent BV.47 While some probiotics have been available on the market for several years, clinical trials 
to support beneficial effects have only recently been initiated for most products.128,137,139,141 
Acceptability is an important component of these trials, to maximise future uptake and adherence of 
vaginal probiotics should they be proven efficacious. The acceptability of a novel vaginal product 
depends on factors such as the characteristics of the population studied, characteristics of and 
experiences with the product, types of sexual relationships and partner support, and community 
perceptions.158,159 
 
We conducted a clinical trial of intermittent use of two vaginal probiotics and oral metronidazole to 
prevent BV recurrence in Rwandan women who had been treated for BV and/or Trichomonas vaginalis 
(TV). We used qualitative and quantitative research methods to assess adherence and acceptability with 
vaginal probiotic use. We triangulated various sources of adherence data to obtain adherence estimates 
per woman for each period of intermittent product use in between study visits, and determined 
correlates of adherence.  
 
4.2 Materials and Methods 
The pilot clinical trial took place from June 2015 to February 2016 at the Rinda Ubuzima research clinic 
in Kigali, Rwanda. Women who had been successfully treated for BV/TV with a seven-day course of 
oral metronidazole (Tricozole, Laboratory & Allied Ltd, Nairobi, Kenya) were randomised to four 
intervention groups (n=17 each) to prevent BV recurrence: behavioural counselling only (controls), or 
behavioural counselling plus intermittent use of two different vaginal probiotics or oral metronidazole 
for two months. Women were seen at screening, enrolment (product use initiation, if applicable), Day 7, 
Month 1, Month 2 (product use cessation, if applicable), and Month 6. Product efficacies were not 
known during the trial, and preliminary efficacy results are reported elsewhere.160 The behavioural 
counselling focussed on safer sex practices, cessation of vaginal practices, and increasing male penile 
hygiene to prevent BV.161 
 
72 
Study population 
Women aged 18-45 at risk of HIV/STIs (defined as having had more than one sex partner and/or having 
been treated for an STI and/or BV in the last 12 months) were eligible for enrolment if they were 
confirmed HIV-negative, non-pregnant, diagnosed with BV and/or TV, and cured after seven-day oral 
metronidazole treatment. Other clinical exclusion criteria were applied but were rare.160 Women were 
recruited by study staff with the assistance of Community Mobilisers who had strong ties with local 
high-risk women (particularly sex workers). 
 
Study products and dosing 
Ecologic Femi+ (EF+; Winclove Probiotics, Amsterdam, Netherlands) is a vaginal capsule containing 
lyophilised lactic acid-producing bacteria. EF+ was used once per day for five days followed by thrice 
weekly, for two months. Gynophilus LP (GynLP; Biose, Aurillac, France) is a tablet containing the 
Lactobacillus rhamnosus Lcr35 strain. The tablet disintegrates in the vagina and forms a gel that slowly 
releases the probiotic bacteria. GynLP was used once every four days for two months. The first dose 
was inserted at the clinic under direct observation of a clinician, and remaining doses were self-
administered at home. Women were asked not to cleanse or insert other products into the vagina after 
probiotic insertion to allow the probiotics to dissolve. They were also told that they were allowed to 
cease probiotic use during menses, but were encouraged to continue. Intermittent metronidazole use was 
chosen as a positive control intervention because studies conducted in the U.S. and Kenya have shown a 
30-40% reduction in BV recurrence.132,134 Metronidazole users took 500 mg generic oral metronidazole 
(Laboratory & Allied ltd, Nairobi, Kenya) twice weekly for two months. Participants and clinicians 
were not blinded.  
 
Acceptability, adherence, behavioural, and vaginal infection knowledge assessments 
Acceptability was assessed at the enrolment visit prior to product use initiation and at the Month 2 visit 
after the full two months of use. Adherence was assessed during the intervention period, at the Day 7, 
Month 1, and Month 2 visits. Sexual and other behaviours were assessed at all study visits. Participants 
were interviewed face-to-face in Kinyarwanda by a trained study nurse using structured questionnaires 
with multiple-choice questions, questions requiring a number or date, and an adherence self-rating scale 
(from 0-10). In between visits, participants used pictorial diary cards (figure 4.1) to record daily 
episodes of product use, vaginal sex, condom use, and vaginal practices. Those using study products 
returned the product packaging and unused products (if applicable) to their clinic visits, where they 
were counted by study staff. Any discrepancies between data sources were discussed with participants, 
and consensus, triangulated assessments of adherence were recorded on the questionnaires. 
Additionally, 131 women were interviewed about their knowledge of vaginal infections (such as BV 
and STIs) using a structured questionnaire during recruitment sessions (n=61; regardless of eligibility) 
and at enrolment visits (n=70; this included the 68 randomised women, and two women who attended 
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enrolment visits but turned out to be ineligible). Women were interviewed before being counselled at 
study visits or before receiving information at recruitment sessions. This questionnaire contained 
multiple-choice and open-ended questions. Responses to the open-ended questions were categorised and 
discussed by two different researchers until consensus about the answer categories was reached. 
 
Figure 4.1: Pictorial diary card 
 
The picture provided is the English translation of the pictorial card; participants received a version in Kinyarwanda. 
 
Four semi-structured focus group discussions (FGDs) with 7-11 participants per group (total n=38), and 
four semi-structured individual in-depth interviews (IDIs) were held with enrolled participants, about 
their experiences with and opinions of the products, sexual behaviour, and vaginal practices. Women 
randomised to the behavioural counselling only group were not included in the FGDs and IDIs. All had 
completed their product use period. The interviews were unlinked anonymous, and women used 
pseudonyms to enable them to talk freely despite the fact that the discussions and interviews were taped. 
All interviews took place between November 2015 and March 2016, were held in Kinyarwanda, 
recorded on tape, transcribed verbatim, and translated into English. 
 
Data analysis 
Questionnaire data were analysed using Stata 13 (StataCorp, College Station, TX, USA). The 
proportion of women with ≥80%/≥90%/100% adherence in the probiotic groups were compared by 
Fisher’s exact tests. Changes in self-reported vaginal practices and sexual behaviours over time were 
tested using McNemar’s test for binary outcomes, and Wilcoxon’s signed-rank test for continuous 
outcomes. To study associations of participant characteristics with triangulated adherence, we used 
bivariable mixed effects models, with perfect adherence (defined as having used all doses as instructed) 
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per interval between study visits during the intervention period as the outcome, participant identification 
numbers as the random effect, and one participant characteristic at the time as the fixed effect. We could 
not determine correlates of acceptability due to limited variation in the acceptability data (reported 
acceptability was high throughout the trial). 
 
The FGD and IDI transcripts were read and discussed by three researchers (MV, MU, and JvdW). The 
Chief Investigator (JvdW) decided that data saturation had been met when the fourth FGD and the 
fourth IDI transcript had become available in March 2016. The transcripts were then coded using 
NVivo 10.0 (QSR International, Melbourne, Australia) by one single researcher (MV). The discussions 
and interviews were semi-structured, with themes and associated codes prepared a priori, as well as new 
elements that emerged from the data. The codes were derived from an acceptability framework that has 
been used in studies of vaginal products for contraception or HIV prevention.158,159,162 Components of 
the framework include study population characteristics, product attributes, sexual encounter and 
relational attributes, and the contextual environment (e.g. community perceptions of product use).  
 
Ethical statement 
All participants provided written consent for study participation, and separate consent for participation 
in FGDs/IDIs. All non-married participants aged 18-20 also required parental/guardian consent per 
Rwandan law at the time of the study. The participants received 3 GBP per visit (in local currency) as a 
reimbursement for time and transport costs. Care was taken to protect participant privacy and 
confidentiality. The study was sponsored by the University of Liverpool, approved by the Rwanda 
National Ethics Committee and the University of Liverpool Research Ethics Subcommittee for Physical 
Interventions, and registered on ClinicalTrials.gov (NCT02459665). 
 
Participant and public involvement 
A subset of the enrolled participants were invited to comment on study design and experiences with the 
interventions during the FGDs/IDIs. Participants were not invited to develop outcomes, interpret the 
results, or to contribute to the writing or editing of this document for readability or accuracy. The 
preliminary results of this study were discussed with 32 stakeholders during a workshop held at the 
Ministry of Health in Kigali, Rwanda, in December 2017. These stakeholders included representatives 
of the Ministry of Health, the National University of Rwanda, the National Ethics Committee, local 
hospitals and clinics, and local non-governmental and women’s organisations. 
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4.3 Results 
Baseline characteristics 
We screened 176 women: bacterial STI prevalence was 31.3% and BV prevalence by Gram stain 
Nugent scoring was 47.9%. All 68 randomised women were at risk of STI/HIV transmission, with 
93.1% reporting having exchanged sex for money and/or goods in the previous month (figure 4.2, table 
4.1). We collected 29.93 person-years of data. Four women withdrew their informed consent during the 
study (for reasons unrelated to study product acceptability). None were lost to follow-up.  
 
Figure 4.2: Flowchart of the study 
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BV bacterial vaginosis, D7 day 7 visit, FGD focus group discussion, IDI in-depth interview, M1/2/6 Month 1/2/6 visit, RU Rinda Ubuzima, TV 
Trichomonas vaginalis. 
Acceptability assessments were made at enrolment and at the M2 visit. Adherence assessments were made using self-rated assessments, 
pictorial diary cards, and returned packaging at the D7, M1, and M2 visits (after which product use was ceased). The vaginal infection 
knowledge survey was held at recruitment sessions in the community and at the enrolment visit. Changes in sexual risk-taking and vaginal 
practices were assessed at each follow-up visits and compared to answers given during the enrol visit. All this themes were discussed during 
the eight FGDs and IDIs. 
*Totals to 110 reasons among 102 women because there could be more than one reason per woman. †Reasons: outside of metronidazole 
treatment window (n=5), enrolment target already met (n=4), has a mental disorder (n=1), did not complete screening procedures and was 
subsequently lost to follow=up (n=1), withdrew consent during the screening visit because she thought the reimbursement was too low (n=1). 
‡Reasons: moved away from Kigali (n=2), lost interest because symptoms resolved (n=1), and was verbally harassed by partner and sister 
about study participation (n=1).  
 
Table 4.1: Baseline characteristics of enrolled population 
 Controls 
(n=17) 
Metronidazole 
(n=17) 
EF+ 
(n=17) 
GynLP 
(n=17) 
Median age (IQR) 29 (24–36) 30 (27–34) 33 (28–35) 30 (27–35) 
Marital status (n %)  
- Never married 
- Married 
- Divorced  
- Widowed 
 
16 (94.1) 
1 (5.9) 
0 
0 
 
11 (64.7) 
1 (5.9) 
5 (29.4) 
0 
 
10 (58.8) 
2 (11.8) 
4 (23.5) 
1 (5.9) 
 
13 (76.5) 
1 (5.9) 
3 (17.6) 
0 
Education level (n %) 
- No schooling 
- Primary school not completed 
- Primary school completed 
- At least some secondary school 
 
5 (29.4) 
7 (41.2) 
4 (23.5) 
1 (5.9) 
 
3 (17.6) 
7 (41.2) 
5 (29.4) 
2 (11.8) 
 
3 (17.6) 
13 (76.5) 
1 (5.9) 
0 
 
3 (17.7) 
4 (23.5) 
7 (41.2) 
3 (17.7) 
Median number of sex partners last month (IQR) 5 (3–20) 5 (2–10) 3 (2–15) 3 (2–20) 
Exchanged sex for money/goods past month (n %) 17 (100) 14 (82.4) 15 (88.2) 17 (100) 
At least one laboratory-confirmed STI* (n %) 8 (47.1) 8 (47.1) 4 (23.5) 9 (52.9) 
Median weekly frequency of washing body (IQR) 7 (7–7) 7 (7–7) 7 (7–7) 7 (4–7) 
Ever washing the genitalia (n %) 
- Yes, outside only 
- Yes, both inside and outside 
- Yes, inside only 
 
12 (70.7) 
5 (29.4) 
0 
 
14 (82.4) 
3 (17.6) 
0 
 
15 (88.3) 
2 (11.7) 
0 
 
14 (82.3) 
3 (17.7) 
0 
If reports washing inside, median weekly frequency (IQR) 14 (7–16) 14 (14–14) 11 (7–14) 7 (3–12) 
EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, IQR inter-quartile range, M2 Month 2 visit, STI sexually transmitted disease. 
*Chlamydia, gonorrhoea, and/or syphilis.  
 
Adherence 
Triangulated adherence was high: 100% of EF+ users and 81.3% of GynLP users used ≥80% of 
required doses (Fisher’s exact p=0.103; table 4.2), and these percentages were 88.2% and 68.8% for 
≥90% (p=0.225), and 58.8% and 50% for 100% of required doses (p=0.732), respectively. In 
comparison, these percentages were 88.2%, 82.4%, and 70.6%, respectively, for oral metronidazole 
users. Reported reasons of non-adherence to vaginal probiotics during face-to-face interviews were 
‘simply forgetting’ (n=9), experiencing side-effects (n=2), menses (n=2), and being away from home 
and having left products at home (n=1). Additional reasons for missing doses mentioned during 
FGDs/IDIs were being drunk (n=2) and being confused about the dosing schedule (n=2). Only one 
woman in the metronidazole arm reported missing doses due to experiencing side-effects. Most women 
in FGDs reported using all doses as instructed and finding it easy to adhere, and thought that the diary 
cards served as a useful reminder to use the products.  
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Table 4.2: Adherence to study interventions 
Adherence to study products Metronidazole 
(n=17) 
EF+ 
(n=17) 
GynLP 
(n=16) 
Adherence Enr–D7, median % (IQR) 100 (100–100) 100 (100–100) 100 (100–100) 
Adherence D7–M1, median % (IQR) 100 (100–100) 100 (100–100) 100 (91.7–100) 
Adherence M1–M2, median % (IQR) 100 (100–100) 100 (100–100) 100 (92.3–100) 
Overall adherence Enr–M2, median % (IQR) 100 (96.3–100) 100 (100–100) 98.3 (89.3–100) 
Overall adherence Enr–M2 (n %) 
- Perfect* 
- Adherence ≥90% 
- Adherence ≥80% 
 
12 (70.6) 
14 (82.4) 
15 (88.2) 
 
10 (58.8) 
15 (88.2) 
17 (100) 
 
8 (50.0) 
11 (68.8) 
13 (81.3) 
Number of times menses Enr–M2 (n %)† 
- Never 
- Once 
- Twice 
 
7 (41.2) 
6 (35.3) 
4 (23.5) 
 
4 (23.5) 
5 (29.4) 
8 (47.1) 
 
2 (12.5) 
4 (25.0) 
10 (62.5) 
Did not use product during menses at least once (n %) 
- Yes 
- NA (never had menses) 
 
4 (23.5) 
7 (41.2) 
 
3 (17.6) 
4 (23.5) 
 
5 (31.3) 
2 (12.5) 
Self-reported reasons for non-adherence‡ Metronidazole EF+ GynLP 
D7: Self-reported reasons why not able to use all doses as 
instructed (n %)§  
- Simply forgot 
- Product had side effects 
 
 
0 
0 
 
 
2 (11.8) 
0 
 
 
0 
1 (6.7)¶ 
M1: Self-reported reasons why not able to use all doses as 
instructed (n %)§ 
- Simply forgot 
- Product had side effects 
- Did not like product for another reason 
- Other 
 
 
1 (6.3) 
1 (6.3)|| 
1 (6.3)|| 
1 (6.3)** 
 
 
1 (5.9) 
0 
0 
1 (5.9)†† 
 
 
1 (6.3) 
1 (6.3)‡‡ 
0 
2 (12.5)§§ 
M2: Self-reported reasons why not able to use all doses as 
instructed (n %)§  
- Simply forgot 
- Travelled and forgot to take product 
- Other 
 
 
1 (6.3) 
1 (6.3) 
0 
 
 
2 (11.8) 
0 
1 (5.9)¶¶ 
 
 
3 (18.8) 
1 (6.25) 
1 (6.3)|||| 
D7: Participant thinks she used product correctly most of the 
time (n %) 17 (100) 16 (94.1) 14 (93.3) 
M1: Participant thinks she used product correctly most of the 
time (n %)  13 (86.7) 17 (100) 11 (68.8) 
M2: Participant thinks she used product correctly most of the 
time (n %)  15 (93.7) 16 (94.1) 14 (87.5) 
D7 Day 7, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, IQR inter-quartile range, M1/2 Month 1/2, NA not applicable. 
*Defined as 100% of the prescribed doses used at the prescribed times after nurse review of the participant’s diary card and returned used 
packaging and unused product. †Number of times menses in the control group: never 2 (11.8%), once 3 (17.8%), twice 11 (64.7%), and thrice 
1 (5.9%). ‡Numbers of participants per randomisation group may very slightly due to loss to follow-up. Participants with ≥90% adherence not 
shown. §Multiple answers possible. ¶Participant reported vulval itching and burning when passing urine. ||Participant reported mild gastritis 
and wanting to withdraw from the study anyway. **Participant reported receiving oral metronidazole therapy for 7 days due to infection. 
††Participant reported having menses twice in one month; decided to use less of her product until the next study visit. ‡‡Participant reported 
genital itching, genital burning, and pain during sex. §§One participant reported missing the D7 study visit and therefore running out of 
supplies. Another participant reported not to have used the study product during menses (which she was allowed to do). ¶¶Participant reported 
being drunk and therefore forgetting to take the study product. ||||Participant reported taking the study product correctly but that the product 
came out during menses 
 
Acceptability: ease-of-use 
No participants reported having heard about probiotics before study participation. After product use, all 
vaginal probiotic users reported feeling very comfortable with insertion and that insertion became easier 
over time. All but one woman reported inserting while lying down (table 4.3). 
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Table 4.3: Acceptability of interventions 
Acceptability of study products at Enr Controls 
(n=17) 
Metronidazole 
(n=17) 
EF+ 
(n=17) 
GynLP 
(n=17) 
Nurse reports having explained intervention to participant in 
detail (n %) 
 
17 (100) 
 
17 (100) 
 
17 (100) 
 
17 (100) 
Nurse reports participant asked questions (n %)* 
- Yes, a few  
- Yes, many  
 
6 (35.3) 
0 
 
2 (11.8) 
0 
 
11 (64.7) 
0 
 
11 (64.7) 
2 (11.8) 
First dose applied† under supervision (n %) NA 17 (100) 17 (100) 17 (100) 
Median number of attempts participant made until successful 
application (IQR) NA NA 1 (1–1) 1 (1–1) 
Participant seemed comfortable with the insertion after these 
attempts, according to study nurse (n %) 
- Yes, very 
- Yes, somewhat 
NA NA 
 
 
17 (100) 
0 
 
 
16 (94.1) 
1 (5.9) 
Acceptability of study products at M2 
Self-reported usual time of insertion (n %) 
- Before going to sleep 
- After bathing in the morning 
NA NA 
 
17 (100) 
0 
 
15 (100)‡ 
0 
Level of comfort with vaginal insertion after 2 months of use, 
self-reported (n %) 
- Very comfortable 
- Somewhat comfortable 
NA NA 
 
 
17 (100) 
0 
 
 
15 (100)‡ 
0 
Reported insertion becoming easier over time (n %) NA NA 17 (100) 15 (100)‡ 
Reported manner of insertion§ (n %) 
- While lying down 
- While squatting 
NA NA 
 
17 (100) 
1 (5.9) 
 
14 (93.3)‡ 
1 (6.7) 
Acceptability of penile hygiene intervention at M2 
Reports having told main sex partner to regularly clean the 
penis, including underneath the foreskin (n %)¶ 
- Yes 
- No, because he is circumcised 
- No, other reason 
 
 
3 (17.7) 
10 (58.8) 
1 (5.9) 
 
 
3 (18.8) 
9 (56.2) 
0 
 
 
3 (17.6) 
6 (35.3) 
1 (5.9) 
 
 
3 (18.8) 
5 (31.3) 
1 (6.3) 
If yes, response by the main partner (n %)|| 
- He said that he would do so in the future 
- He said that he already does this 
- He said that he is not interested 
 
2 (66.7) 
1 (33.3) 
0 
 
1 (33.3) 
1 (33.3) 
1 (33.3) 
 
1 (33.3) 
0 
2 (66.7) 
 
1 (33.3) 
1 (33.3) 
1 (33.3) 
EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, IQR inter-quartile range, M2 Month 2 visit, NA Not applicable. 
*One missing value. †Whether oral insertion (oral metronidazole group) or vaginal insertion (Ecologic Femi+ and Gynophilus LP groups). 
‡N=15 due to participants withdrawing informed consent. §Multiple answers possible; hence totals can be more than 100%. ¶Women with no 
main sex partner not included. ||N=3 in all four groups. 
 
Acceptability: bodily changes and product perception 
During FGDs, several women using either vaginal probiotic reported the product (partially) “coming 
out” during the first few uses, but that this decreased after having gained experience. Many EF+ and 
GynLP users reported an increase in vaginal wetness, which was considered a positive attribute by 
most. Some women reported increased libido. For example, one EF+ user said: “I felt a great desire to 
[have] sex again and again.” In contrast, one metronidazole user reported a decrease in libido. Most 
women believed that the vaginal probiotics decreased the recurrence of symptomatic BV (our 
preliminary efficacy data suggest that BV incidence had in fact decreased),160 and a few believed that 
they also prevented STI acquisition (the trial had insufficient statistical power to assess this).  
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Acceptability: support 
One social harm related to vaginal probiotic use was reported: a GynLP user was verbally harassed by 
her partner and her sister because of her study participation, and opted to withdraw her informed 
consent. Reports of partner, family, and community support during the FGDs/IDIs were mixed: some 
women reported problems with loved ones. Negative reactions from male partners were more often 
based on suspicions about study participation than the products themselves. One EF+ user said: “He 
[her partner] did not accept that. He asked me to go together with him to the clinic [a local health 
centre] and check if I am not HIV-positive.” Another participant using metronidazole mentioned 
wanting to join the study to her husband, who forbade her to participate. However, she decided to join 
anyway: “he did not know that I was using the study product, because he had refused me to join [the] 
study before… I used them [the study products] without informing him.” All sex workers except one 
stated that they had not discussed study participation with male clients. 
 
Acceptability: worries and concerns 
In the FGDs, one woman reported hearing rumours prior to enrolling that vaginal products “can damage 
the uterus or cause tumours in the womb.” However, most participants thought that vaginal probiotics 
would be acceptable to Rwandan women. One GynLP user argued: “They [already] give us vaginal 
pills”, by which she meant vaginal medications for yeast infections. Some women were concerned 
about future product availability and pricing. They hoped that probiotics would be distributed cheaply 
through the Rwandan Mutuelle public health insurance because they would otherwise be inaccessible to 
many women. One metronidazole user was concerned about a limited applicability of probiotics 
because BV is not diagnosed by laboratory testing in Rwanda: “They do not have adequate medical 
instruments to test diseases, you tell the physician how […] you feel and by guessing the disease, he 
gives you at least four medications, saying that you may have trichomonas, you may have syphilis, you 
may have gonorrhoea [she refers to syndromic management.21,24] At health centre-level they do not have 
medical equipment to test diseases, meaning that they will not know who to give that 
[probiotic/antibiotic maintenance therapy] medication.” 
 
Vaginal practices and sexual risk-taking  
At enrolment, 49.3% of the women reported to never use products inside the vagina, and at Month 6, 
this increased to 81.5% (OR 5.2, 95% CI 1.96-17.34; table 4.4). During FGDs, some women understood 
that vaginal washing practices may increase the risk of vaginal infection, but others did not. A 
participant stated: “You get them [i.e., vaginal diseases] anyway… whether you wash or not”. In one 
FGD, 10 of 11 participants stated having ceased vaginal practices thanks to the study counselling. It 
should be noted that in contrast to many other African populations, Rwandan women use vaginal 
practices to increase rather than reduce vaginal lubrication. Women mentioned the use of herbs 
(umushishiro), Vaseline, and oils for this purpose. Self-reported sexual risk taking by face-to-face 
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interview did not change over time, except for a significant reduction in reported numbers of sex 
partners in the previous month at Month 6 compared to enrolment. No women in FGDs/IDIs mentioned 
adopting safer sex practices (such as consistent condom use) in response to the counselling messages. 
During face-to-face interviews at the Month 2 visit, 12 of 15 women (80%) who had an uncircumcised 
main sex partner reported asking him to regularly clean his penis in the future (table 4.3). While most 
women in FGDs understood that using condoms and improved penile hygiene could reduce BV rates, 
some mentioned that they found it difficult to discuss these topics with male partners. One participant 
stated that this is especially difficult being a sex worker: “a man gives you his own money and you start 
educating him to wash!” However, another sex worker reported refusing sex with uncircumcised 
clients: “you leave him, because he has a lot [of] germs”. Several women reported discussing 
circumcision with their partners; one participant reported telling her husband: “It is better that you do 
circumcision because it is a good thing… you would get a chance of not contracting diseases.”  
 
Table 4.4: Changes in reported vaginal cleansing practices and (sexual) behaviour between the 
enrolment and the M6 visit 
Self-reported sociodemographic characteristics Enr 
(n=71) 
M6 
(n=65) 
OR (95% CI)* 
P value* 
Reports using no products inside the vagina (other than for 
managing menses; all participants) (n %) 35 (49.3) 53 (81.5) 
5.2 (1.96–17.34) 
<0.001 
Reports using no products inside the vagina (other than for 
managing menses; controls and metronidazole users only)† (n %) 15 (44.1) 27 (79.4) 
13.0 (1.95–552.5) 
0.002 
Reports using water only (n %) 23 (32.4) 10 (15.4) 0.37 (0.13–0.92) 0.029 
Reports using water and soap (n %) 3 (4.2) 2 (3.1) 0.67 (0.06–5.82) 1.00 
Reports using paper, cloth or cotton wool (n %) 9 (12.7) 0 (0) 0.13 (0.00–0.93)‡ 0.008 
Reports using traditional herbs, stones, powders as vaginal 
cleansing practice (n %) 1 (1.4) 1 (1.5) 
1.00 (0.01–78.5)‡ 
1.00 
Mean weekly frequency of vaginal practices (95% CI) 2.15 
(0.97–3.34) 
0.64 
(0.18–1.11) 
NA 
0.328 
Median number of sex partners in last month at baseline or per 
month during follow-up period (IQR) 
5  
(3–16) 
2  
(1–4) 
NA 
<0.001 
Any condom use reported in past two weeks (Enr) or since last 
study visit (M6), versus none (n %) 64 (90.1) 60 (92.3) 
1.67 (0.32–10.7) 
0.727 
Reports exchanging sex for money/goods in past month (Enr) or 
since last study visit (M6) (n %) 65 (91.5) 58 (89.2) 
0.80 (0.16–3.72) 
1.00 
CI confidence interval, Enr enrolment visit, IQR inter-quartile range, M6 Month 6 visit, NA not applicable, OR odds ratio. 
*McNemar’s OR and p-value for binary variables and Wilcoxon signed-rank test p-value for continuous variables, comparing the response at M6 with 
the response at Enr. ORs with 95% CI were also calculated for binary pre/post data. †N=34. ‡To enable calculation of effect measures, a zero value 
was replaced by 1. 
 
Correlates of adherence 
In bivariable mixed effects models including the probiotic groups only, no participant characteristics 
were significantly associated with perfect adherence (table 4.5). However, non-significant trends were 
observed. Younger age, asking many questions at enrolment, having menses during the previous study 
interval, and reporting urogenital symptoms were associated with a lower likelihood of perfect 
adherence. When including oral metronidazole users, menses was significantly associated with a lower 
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likelihood of perfect adherence (p=0.008). There were no significant associations between 
randomisation group and perfect adherence. 
 
Table 4.5: Participant characteristics associated with perfect adherence 
Participant characteristics EF+ and GynLP users EF+, GynLP and oral 
metronidazole users 
OR (95% CI) p-value OR (95% CI) p-value 
Randomisation group: GynLP versus EF+  0.68 (0.22–2.11) 0.505 ND ND 
Randomisation group:  
- EF+ versus metronidazole  
- GynLP versus metronidazole  
ND ND 
 
0.53 (0.15–1.81) 
0.36 (0.11–1.23) 
 
0.308 
0.103 
Age in years: ≥30 years versus <30 2.66 (0.90–7.82) 0.076 1.60 (0.61–4.15) 0.336 
Marital status:  
- Married versus never married 
- Divorced versus never married 
- Widowed versus never married 
 
0.97 (0.14–6.58) 
1.18 (0.29–4.79) 
ND 
 
0.976 
0.912 
0.991 
 
1.17 (0.20–6.99) 
1.39 (0.42–4.57) 
ND 
 
0.865 
0.586 
0.990 
At least some schooling versus no schooling 1.20 (0.59–2.45) 0.619 0.80 (0.22–2.95) 0.740 
Number of sex partners last month: five or more versus 
four or less.  0.58 (0.18–1.83) 0.351 0.49 (0.17–1.37) 0.173 
Exchanged sex for money/goods past month  ND 0.990 ND 0.986 
Nurse reported participant asked questions at Enr  
- Yes, many versus none 
- Yes, a few versus none 
 
0.19 (0.02–1.52) 
0.83 (0.24–2.83) 
 
0.116 
0.761 
 
0.15 (0.02–1.19) 
0.83 (0.27–2.57) 
 
0.072 
0.744 
Had menses during study visit interval 0.41 (0.14–1.20) 0.104 0.26 (0.09–0.70) 0.008 
Reported alcohol consumption during study: 
- Once or twice per week versus never 
- More than twice per week versus never 
 
0.54 (0.14–2.12) 
0.92 (0.18–4.81) 
 
0.373 
0.920 
 
0.34 (0.11–1.08) 
0.81 (0.19–3.49) 
 
0.068 
0.774 
Reported at least one urogenital symptom during study 
interval versus none 0.11 (0.01–1.56) 0.103 0.30 (0.04–2.16) 0.231 
Reported at least one adverse event during study visit 
interval (excluding urogenital symptoms) versus none 0.43 (0.10–1.83) 0.253 0.55 (0.15–2.05) 0.371 
CI confidence interval, D7 Day 7 visit, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, M1/2 Month 1/2 visit, ND non-
determinable, OR odds ratio. 
Sociodemographic characteristics associated with perfect adherence in bivariable mixed effects models, in the enrolment–D7, D7–M1, and 
M1–M2 study visit intervals.  
 
Vaginal infection knowledge  
Almost all participants reported having heard of ‘diseases of the vagina’ and STIs before, but only 4.6% 
knew what bacteria were (table 4.6). The STIs most often spontaneously named (in numerical order) 
were HIV, gonorrhoea, and syphilis; only one participant reported having heard of BV. After having 
received an explanation about what BV is, only one woman reported ever having been diagnosed with 
BV. Most participants could name at least one cause or potential consequence of vaginal infections. 
Consequences wrongfully attributed to vaginal infections were death (4.6% of women), infant 
malformations (3.9%), and cervical cancer/tumours (3.1%).  
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Table 4.6: Vaginal infection knowledge 
 Recruitment  
(n=61) 
Enrolment 
(n=70) 
Total 
(n=131) 
Median age (IQR) 32 (27–35)* 31 (27–35) 31 (27–35) 
Has heard of diseases of the vagina before (n %) 60 (98.4) 70 (100) 130 (99.2) 
Reports knowing what bacteria are before study (n %) 5 (8.2) 1 (1.4) 6 (4.6) 
Reports having heard about STIs before study (n %) 61 (100) 70 (100) 131 (100) 
If yes, spontaneously named, without probing† (n %) 
- HIV 
- Gonorrhoea 
- Syphilis 
- Trichomoniasis 
- Hepatitis 
- Yeast infection 
- BV 
- Urinary tract infection 
- Chlamydia 
- Herpes 
- Human papillomavirus / cervical cancer 
 
58 (95.1) 
58 (95.1) 
44 (72.1) 
38 (62.3) 
3 (4.9) 
0 
0 
1 (1.6) 
0 
0 
1 (1.6) 
 
65 (92.9) 
65 (92.9) 
59 (84.3) 
48 (68.6) 
3 (4.3) 
3 (4.3) 
2 (2.9) 
1 (1.4) 
1 (1.4) 
1 (1.4) 
0 
 
123 (93.9) 
123 (93.9) 
103 (78.7) 
86 (65.7) 
6 (4.6) 
3 (2.3) 
2 (1.5) 
2 (1.5) 
1 (0.8) 
1 (0.8) 
1 (0.8) 
Reports having heard about BV before this study (n %) 1 (1.6) 0 1 (0.8) 
Spontaneously reported reasons why women get vaginal disease, 
without probing† (n %) 
- Poor toilet hygiene 
- Multiple sex partners 
- After sex 
- Dirty underwear 
- Poor vaginal hygiene 
- Poor penile hygiene of male partner(s) 
- Traditional vaginal practices and washing 
- New sex partner 
- Use of contraception 
- (Improper) use of sanitary pads or tampons 
- Other 
- Cannot name any reasons 
 
 
37 (60.7) 
28 (45.9) 
25 (41.0) 
19 (31.2) 
26 (42.6) 
4 (6.6) 
3 (4.9) 
6 (9.8) 
1 (1.6) 
1 (1.6) 
3 (4.9)‡ 
1 (1.6) 
 
 
40 (57.1) 
36 (51.4) 
30 (43.0) 
35 (50.0) 
22 (31.4) 
17 (24.3) 
12 (17.1) 
3 (4.3) 
3 (4.3) 
3 (4.3) 
1 (1.4)§ 
0 
 
 
77 (58.8) 
64 (48.9) 
55 (42.0) 
54 (41.2) 
48 (36.6) 
21 (16.0) 
15 (11.5) 
9 (6.9) 
4 (3.1) 
4 (3.1) 
4 (3.1) 
1 (0.8) 
Spontaneously reported negative consequences of vaginal disease 
being named, without probing† (n %) 
- Foul smell from the vagina 
- Difficulty getting pregnant 
- Miscarriage 
- Abnormal vaginal discharge 
- Baby born too early 
- Severe infection / fever of the woman 
- Infection / fever of the newborn baby 
- Itching 
- Other consequences to the baby 
- Cervical cancer or tumours 
- Death 
- HIV/STIs 
- Pain during intercourse 
- Cannot name any consequence 
 
 
30 (49.2) 
18 (29.5) 
16 (26.2) 
12 (19.7) 
16 (26.2) 
7 (11.5) 
5 (8.2) 
4 (6.6) 
3 (4.9) 
2 (3.3) 
4 (6.6) 
1 (1.6) 
0 
17 (27.9) 
 
 
39 (56.5) 
33 (47.8) 
33 (47.8) 
28 (40.6) 
22 (31.9) 
7 (10.1) 
3 (4.4) 
4 (5.8) 
3 (4.4) 
3 (4.4) 
0 
3 (4.4) 
3 (4.4) 
19 (27.5) 
 
 
69 (53.1) 
51 (39.2) 
49 (37.7) 
40 (30.8) 
38 (29.2) 
14 (10.8) 
8 (6.2) 
8 (6.2) 
6 (4.6) 
5 (3.9) 
4 (3.1) 
4 (3.1) 
3 (2.3) 
36 (27.7) 
BV bacterial vaginosis, IQR interquartile range, STI sexually transmitted infection. 
*One missing value. †Open-ended question. Totals may be more than 100%. ‡Participants report: “If you are infected with STIs”, sharing 
underwear, and unprotected sex. §Participant reports: vaginal medicine. 
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4.4 Discussion 
Several studies of different vaginal probiotics have been conducted, some of them in sub-Saharan 
Africa.128,137,139,141 However, none reported in-depth acceptability and adherence data. Our study 
suggests high vaginal probiotic acceptability and adherence in high-risk Rwandan women. We found no 
statistically significant correlates of perfect adherence, partially due to limited statistical power, but 
younger age, asking many questions about product use at enrolment, current menses, and reporting 
urogenital symptoms showed trends towards a lower likelihood of perfect adherence. Vaginal probiotics 
are currently unavailable on the market in most African countries, and it is important to study 
acceptability in different target populations to inform product development and future marketing 
strategies.  
 
We could not evaluate the impact of self-reported acceptability aspects on adherence because almost all 
women reported very high acceptability in face-to-face interviews throughout the trial. Such interviews 
are known to suffer from social desirability bias. However, women seemed to speak freely in the FGDs, 
and those data indicate that they did not have major issues with product attributes or insertion. 
However, some women reported difficulties due to lack of male partner support. The reported increase 
in vaginal wetness after probiotic insertion was not considered problematic, as lubrication during sex is 
preferred by most Rwandan men and women.163 This might be different in other countries where dry sex 
is preferred.164 We did find a non-significant lower adherence to GynLP compared to EF+, which might 
be explained by differences in formulation: GynLP forms a gel in the vagina whereas EF+ capsules 
merely release lyophilised bacteria. Previous research indicated high adherence to GynLP.155 
Unfortunately, the impact of these formulation differences was insufficiently probed during the FGDs. 
Participants indicated that they found the diary cards helpful in reminding them to use their products, 
and we believe that self-monitoring tools might indeed be helpful in maximising adherence.165  
 
Our data suggest that counselling was partially effective in changing behaviours that increase BV risk. 
Significantly more women reported not engaging in vaginal practices at the end of the study, and most 
women with uncircumcised steady male partners reported having discussed penile hygiene with them. 
However, many women mentioned in FGDs that they found it difficult to discuss condom use and 
penile hygiene with male partners, especially clients. Women reduced their sexual risks only to a 
limited extent during follow-up, reporting a reduction in numbers of sex partners but no differences in 
engaging in sex work and condom use in face-to-face interviews. While these results are encouraging, it 
is difficult to assess to what extent they were influenced by social desirability bias. 
 
Our survey with women at recruitment sessions and enrolment visits showed that high-risk Rwandan 
women had heard of several STIs, but were generally unaware of BV, its causes and potential 
consequences, and what they can do to prevent it. Experiences with HIV show that public health 
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interventions can only succeed if health care professionals and the public have sufficient knowledge of 
causes and consequences of disease.166–168 High-risk Rwandan women (and health care professionals) 
should therefore be educated about BV.  
 
Limitations 
Our study had limited statistical power, and social desirability bias may have affected some of our 
results, as is often the case in studies of this nature. Additionally, it should be noted that product 
efficacy, availability and cost are important determinants of acceptability, and were not evaluated in our 
study, although preliminary efficacy results in this study were promising.160 We could not directly 
compare experiences with, and opinions about, the two different vaginal probiotics because each 
woman used only one product and qualitative data depth was suboptimal. In the FGDs/IDIs, it was 
sometimes difficult to ascertain whether participants were referring to personal experiences, or to wider 
community perceptions. Strengths of our study include the use of a mixed-methods approach and 
triangulated adherence data. 
 
Conclusions 
The prevention of BV recurrence will likely have to include several components to be successful, such 
as improved diagnostics, treatments, and prophylactic products (for example probiotics), but also 
improved information, education, and counselling messages targeted to at-risk women and their 
partners. The results of this study can be used to inform future product development, and to fine-tune 
counselling messages in future trials. 
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Chapter 5 - Impact of Vaginal Probiotics on the Vaginal Microbiota: a Systematic Review 
  
This systematic review was conducted with my primary supervisor Professor van de Wijgert (JvdW) 
and a medical student (Connie Rees, CR) as a team effort in accordance with the PRISMA guidelines 
for systematic reviews.169 I was the medical student’s day-to-day supervisor on this project. I wrote the 
first draft of the systematic review protocol, and submitted it to the PROSPERO registration database 
for systematic reviews after it had been approved by my primary supervisor. The medical student and I 
performed the database searches, and independently selected eligible papers, with my primary 
supervisor acting as a tiebreaker when we did not reach consensus. The medical student and I each 
extracted data from the selected papers independently, I consolidated the data extraction results, and my 
primary supervisor reviewed and approved the consolidated data extraction database. I wrote this 
chapter based on the approved consolidated data extraction database. My primary supervisor then used 
this chapter to write a much shortened manuscript, which is currently in press at the British Journal of 
Obstetrics and Gynaecology: van de Wijgert JHHM, Verwijs MC. Lactobacilli-containing vaginal 
probiotics to cure or prevent bacterial or fungal vaginal dysbiosis: a systematic review and 
recommendations for future trial designs. BJOG 2019; doi:10.1111/1471-0528.15870. [Epub ahead of 
print]. The shortened manuscript is not presented in this thesis.  
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Abstract 
Introduction: Probiotics or live biotherapeutic products consisting of beneficial lactobacilli are often 
prescribed in clinical practice or bought over-the-counter to cure or prevent common types of vaginal 
dysbiosis such as BV or VVC. However, it is unclear whether vaginally-delivered probiotics are 
effective in promoting an optimal, Lactobacillus-dominated VMB. 
Materials and Methods: We conducted a systematic review to assess the impact of vaginal probiotics 
on the VMB. Outcomes included BV cure and/or recurrence by Nugent or Ison-Hay Gram stain scoring, 
VVC cure and/or incidence by fungal culture or KOH wet mount, and bacterial VMB composition as 
characterised by modern molecular techniques. We also assessed the risk of bias of all studies. 
Results: Our review of 34 eligible studies showed that trial designs were highly heterogeneous, 
evaluating vaginal probiotics containing different Lactobacillus strains used as main, adjuvant, and/or 
maintenance therapy. All studies were judged medium- or high-risk; no articles had a low overall risk of 
bias. All of the six results of five medium-risk of bias studies with BV and molecular VMB outcomes 
results were promising: four results were statistically significant and two were non-significant. The 
eight high-risk BV studies showed mixed results: five studies showed significant beneficial effects of 
probiotic use, one study showed non-significant Nugent results but the VMB results were significantly 
beneficial, and two studies did not show any beneficial effects. Most of the beneficial outcomes were in 
studies that used probiotics to prevent the recurrence of BV. Positive effects were limited to the period 
of probiotic use and, in the two studies that compared these directly, less efficacious than antibiotic use. 
The studies with molecular VMB outcomes showed significantly increased relative abundance or 
concentration of lactobacilli or increased prevalences of a Lactobacillus-dominated VMB during 
probiotic use. In contrast, most of the twelve studies with VVC as an outcome were single-arm pre/post 
intervention studies of high overall risk of bias. One medium-risk VVC study found no benefit of using 
probiotics. Of the eleven high-risk VVC studies, five showed significantly beneficial effects of vaginal 
probiotic use, three studies showed non-significant beneficial effects or had mixed results, and three 
studies showed no beneficial effects of probiotic use. Small-scale studies among healthy women 
reporting the detectability of probiotic strains in the VMB showed a generally low proportion of users 
with detectable probiotic strains. Many of the included studies had methodological weaknesses: most 
had a limited sample size and therefore lacked statistical power and could not compare responders to 
non-responders, only a few studies reported adherence measures in a comprehensive manner, and many 
had some degree of ascertainment bias due to their (clinical and/or laboratory) methods. Furthermore, 
few controlled for known confounding factors such as hormonal contraception use, pregnancy status, 
menses, and sexual behaviour.  
Discussion: Evidence that vaginal probiotics have a beneficial effect on the VMB is conflicting 
although some promising studies exist, mainly those using probiotic therapy to prevent BV recurrence. 
Well-powered clinical trials that incorporate in-depth molecular analyses, adjust for known confounding 
factors, and compare responders to non-responders are needed.  
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5.1 Introduction 
Vaginal dysbiosis is a condition in which the vaginal microbiota (VMB) deviates from its optimal, low-
diversity, and Lactobacillus-dominated state. The most common types of vaginal dysbiosis are bacterial 
vaginosis (BV), in which anaerobic BV-associated bacteria overgrow lactobacilli, and vulvovaginal 
candidiasis (VVC), caused by Candida albicans or other yeast species.4 Modern molecular techniques 
such as quantitative polymerase chain reaction (qPCR) and 16S rRNA gene sequencing permit in-depth 
VMB assessment.4 However, most molecular VMB studies have been descriptive only and next 
generation sequencing data have not often been incorporated as outcomes in clinical trials and other 
interventional studies thus far.170  
 
Vaginal dysbiosis is often asymptomatic and is associated with important sequelae such as pelvic 
inflammatory disease, increased acquisition of HIV and other sexually transmitted infections (STIs), 
and adverse pregnancy outcomes.18–20,87 BV can be treated with oral and vaginal antibiotics such as 
metronidazole. Treatment is often effective but recurrence rates are high.46,47 Additional interventions 
may be needed to decrease the risk of recurrence: behavioural interventions decrease BV incidence by 
decreasing engagement in sexual risk taking (e.g. consistent condom use) and vaginal hygiene practices, 
and hormonal (particularly oestrogen-containing) contraception use decreases BV incidence by 
promoting lactobacilli.26,46,47,171 It has been hypothesised that disrupting recurrence-inducing biofilms 
formed by BV-anaerobes may be a promising future strategy to reduce BV incidence.26,46,47,172  
 
Another intervention of particular interest is the use of beneficial exogenous bacteria, most often 
lactobacilli, to restore or maintain a healthy VMB as probiotics or live biotherapeutic products (LBPs; 
also known as next-generation probiotics).71 Probiotics can be delivered both vaginally and orally. A 
clear advantage of probiotic lactobacilli is that they can be used for a prolonged period of time without 
risking the development of antibiotic resistance. Possible mechanisms in which probiotic strains exert 
positive effects include replacing non-optimal bacterial species and dominating the VMB, the increased 
production of localised lactic acid, modulation of local cervicovaginal mucosal immune responses, 
inhibition of biofilm formation, and/or inhibition of C. albicans hyphae formation.6,12,72–74,173 While 
probiotics have been available on the market for decades, scientific effectiveness studies have only been 
conducted recently.46,47 It is unknown whether probiotic strains need to dominate the VMB to exert 
positive effects, or if they can also restore or maintain an optimal VMB at (relatively) low 
concentrations. It is also unclear what the best treatment strategy is: should probiotics be used to restore 
an optimal Lactobacillus-dominated VMB, as main treatment or as adjuvant treatment together with 
antibiotic or antifungal therapy, or should probiotics be used as maintenance therapy to prevent vaginal 
dysbiosis when a woman’s VMB is Lactobacillus-dominated? Therefore, we performed a systematic 
review to assess how vaginal probiotics impact the VMB.  
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5.2 Materials and Methods 
In this systematic review, we examined the impact of vaginal probiotics on the VMB, focussing on BV 
and VVC cure and/or incidence/recurrence as outcomes, and on VMB composition as measured by 
modern molecular methods. Two primary research questions (1, 2) as well as one secondary research 
question (3) were posed:  
 
1)  In sexually active women (regardless of menopausal, pregnancy, or vaginal dysbiosis status), what 
is the effect of a vaginal probiotic (used as a main, adjuvant, or maintenance therapy) on the VMB 
composition as measured by Nugent78 or Ison-Hay174 Gram stain scoring, or molecular methods? 
2)  In sexually active women (regardless of menopausal, pregnancy, or vaginal dysbiosis status), what 
is the effect of a vaginal probiotic (used as a main, adjuvant, or maintenance therapy) on the 
incidence of VVC as measured by wet mount, culture, or molecular methods? 
3)  In sexually active women (regardless of menopausal or pregnancy status) suffering from vaginal 
dysbiosis, which treatment (vaginal probiotic, vaginal probiotic dosing strategy, oral probiotic, or 
oral or vaginal probiotic) is more effective when directly compared to one another? 
 
The protocol of the systematic review is available upon request, and was registered on PROSPERO 
under the identifier CRD42017075717.175 We conducted a systematic review according to the PRISMA 
2009 guidelines.169 The bibliographic databases searched were MEDLINE176 and Embase.177 The search 
was performed on 15 January 2019 (search strategy in table 5.1). No filters were used except for 
‘English language’. The search results of the databases were compared, and duplicates were manually 
removed in Microsoft Excel. Two researchers (MV, CR) independently screened the resulting list based 
on title and abstract to identify articles that were thought to be relevant for research questions 1 and 2 
(relevant articles for research question 3 were to be selected from the articles already selected for 
questions 1 and 2). Further articles were identified by screening the reference lists of the relevant 
articles, as well as those of relevant reviews or opinion pieces. 
 
We included studies performed in sexually active women regardless of menopausal, pregnancy, or 
vaginal dysbiosis status. Studies using (modified) Amsel criteria, bacterial culture, other forms of Gram 
stain scoring (e.g. reporting Lactobacillus counts only), BV rapid testing, or symptom-based diagnoses 
were not included, and neither were studies in which the method of diagnosing BV was unclear. Studies 
reporting VVC cases based on reported symptoms and/or observed signs were not included, and neither 
were studies in which the method of diagnosing VVC was unclear. The intervention(s) used had to 
include at least one vaginal probiotic as main or adjuvant therapy (as treatment of vaginal dysbiosis) or 
maintenance therapy (to prevent vaginal dysbiosis). Any years of study publication and all research 
settings were permitted. Articles were excluded if the intervention(s) consisted of an oral probiotic only, 
if the mode of administration of the probiotics was unclear, if outcomes were based on clinical 
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signs/symptoms only, or if the probiotic administered was yoghurt (without any specification of the 
bacteria present in the yoghurt given). Discrepancies between the two screeners were discussed by full-
text screening of the article, with JvdW acting as a tie-breaker when necessary. Corresponding authors 
of articles with no available full-text were contacted by e-mail to ask for copies; articles with no 
available full-text were excluded.  
 
Table 5.1: Search strategy of the systematic review 
Pubmed version (all fields): 
Vagin* OR Vaginal AND ("bacterial vaginosis" OR vaginosis OR vaginitis OR dysbiosis OR flora OR 
microflora OR microbiome OR microbiota OR atopobium vaginae OR gardnerella OR streptococc* OR 
candid* OR mobiluncus OR bacteroides OR bifidobacteri* OR enterobacteri* OR staphylococc* OR 
trichomona* OR urinary tract infection OR UTI OR urogenital infection) AND (probio* OR yogurt OR 
yoghurt OR lactobacill* OR lactococc*) 
 
Filter: English language 
Embase version (all fields): 
 
Vagin* OR Vaginal AND ("bacterial vaginosis" OR vaginosis OR vaginitis OR dysbiosis OR flora OR 
microflora OR microbiome OR microbiota OR “atopobium vaginae” OR gardnerella OR streptococc* OR 
candid* OR mobiluncus OR bacteroides OR bifidobacteri* OR enterobacteri* OR staphylococc* OR 
trichomona* OR “urinary tract infection” OR UTI OR “urogenital infection”) AND (probio* OR yogurt OR 
yoghurt OR lactobacill* OR lactococc*) 
 
Filter: English language 
The search strategy used in this systematic review, performed on 15 January 2019. No filters were used except for ‘English language’ 
 
Three researchers (MV, CR, JvdW) performed source article data extraction and discussed 
discrepancies. Each article was assessed for risk of bias as described in the Cochrane Handbook for 
Systematic Reviews of Interventions.178 An overall risk of bias was designed by us and assessed per 
study. Articles for which all potential biases (selection, performance, detection/ ascertainment, attrition, 
reporting, and ‘other’ bias, with the latter including confounding) were assessed as ‘low risk’ were 
judged as ‘overall low risk of bias’, those with a maximum of two ‘high or ‘unclear risk’ of bias as 
‘overall medium risk of bias’, and those with three or more ‘high or unclear risk’ of bias as ‘overall high 
risk of bias’. Articles were not excluded based on risk of bias assessments.  
 
Risks of bias plots and risk of bias summaries were made using RevMan 5.3.5 (The Cochrane 
Collaboration, Copenhagen, Denmark). Probiotic therapy types were classified as ‘main therapy’ if the 
probiotic was used as sole therapy to treat a positive case of BV and/or VVC; ‘adjuvant therapy’ if the 
probiotic was given in combination with an antibiotic or antifungal drug to treat a positive case of BV 
and/or VVC; and ‘maintenance therapy’ if the probiotic was given to maintain an optimal VMB and 
prevent incident vaginal dysbiosis. Pilot trials or phase I studies among healthy women with no vaginal 
dysbiosis at baseline that were solely designed to detect the presence of probiotic strains in the VMB of 
users were classified as vaginal detection studies. If no statistical analyses were reported in the article 
but absolute numbers of cases per exposure group were available, we performed Chi-squared testing 
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(for cross-sectional comparisons between arms) and/or McNemar’s test (for pre/post within-arm 
comparisons) using Stata 13 (StataCorp, College Station, USA).  
 
In this systematic review, we also included the results of the Rwanda VMB Study (“Preparing for a 
clinical trial of interventions to maintain normal vaginal microbiota for preventing adverse reproductive 
health outcomes in Africa”) which was conducted in Rwanda in 2015-2016.160 This study tested two 
different vaginal probiotics in parallel. The results of this pilot randomised clinical trial (RCT), reported 
in Chapter 3, have been submitted to a journal and the co-author-reviewed primary data analysis report 
based on Nugent scoring, VVC by KOH wet mount, and 16S rRNA gene sequencing is available.  
 
5.3 Results 
We identified 5,416 articles using the search criteria, 2,949 unique articles after removal of duplicates, 
and identified 34 relevant articles reporting 34 separate efficacy results, including the two products from 
the aforementioned Rwanda VMB study (flow diagram in figure 5.1). Three articles were excluded 
during the data extraction stage because the data were uninterpretable, and one article was a safety study 
reporting only three VVC endpoints.179–182 We found two cases of two articles reporting distinct results 
from the same trial,128,183–185 while one publication reported results of two closely related but separately 
conducted trials.186 Of the 34 studies identified, 13 had BV and/or in-depth molecular VMB 
composition as an outcome (relating to our first primary research question)72,135–145,160 with a total of BV 
14 efficacy results, and 12 studies reported 12 results on VVC (relating to our second primary research 
question).67,145,184–194 A total of 14 studies reported 15 results that incorporated molecular outcomes 
reported vaginal detection of vaginal probiotics, or other outcomes related to the retrievability of 
probiotic strains.76,135,142,143,150,151,155,160,183,186,187,195–197 Only one study comprehensively reported BV and 
VVC efficacy rates as well as molecular VMB outcomes (the Rwanda VMB study), but however did 
not have any VVC cases during follow-up.160 Of the 16 studies that incorporated any type of molecular 
VMB (composition and/or vaginal detection) outcomes, 13 performed sequencing on bacterial culture 
isolates and five used direct sequencing of DNA extracted from vaginal swabs (two studies used a 
combination of techniques). These 16 molecular VMB studies used a wide variety of molecular 
techniques: random amplification of polymorphic DNA (RAPD), pulsed-field gel electrophoresis 
(PFGE), denaturing gradient gel electrophoresis (DGGE) followed by Sanger sequencing, repetitive 
element sequence-PCR (rep-PCR), 16S rRNA gene sequencing, and species-specific qPCRs. Most of 
the former techniques did not permit to measure the relative abundances of the probiotics studied, and 
only measured the (non-quantifiable) presence of the probiotic strains. These studies do not describe the 
impact of the vaginal probiotics on the VMB but have been classified as vaginal detection studies, as 
explained in the methods section. 
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Figure 5.1: PRISMA flow diagram  
 
VMB vaginal microbiota. 
The PRISMA flow diagram of the studies screened and included in this systematic review. 
 
The 34 studies evaluated 22 different probiotic products (see Appendix table D.1 for characteristics of 
included studies and products used, and Appendix table D.2 for summary of evidence per product). L. 
crispatus CTV-05 (Lactin-V; four studies including 132 participants),76,128,150,183,187 Gynoflor (three 
studies including 359 participants)137,184,185,188 and L. reuteri RC-14 with L. rhamnosus GR-1 (four 
studies with 47 participants)139,142,196,197 were studied most often. Most probiotics contained between 108 
and 1010 colony-forming units (CFU) of bacteria per dose. All products contained lactobacilli as active 
agents. One probiotic (Gynoflor) contained L. acidophilus KS400 in combination with 30 μg oestradiol, 
while several products contained acidifying agents: lactic acid (Kramegin, Estromineral Probiogel, and 
one unnamed L. acidophilus LA14-containing probiotic),145,189,194 citric acid (ActiCand 30),191 and a 
combination of ascorbic acid, adipic acid and stearic acid (Florisia).72,140 Two probiotic products 
contained Streptococcus thermophilus (Lactagyn, Femilac),67,193 one product contained Pediococcus 
acidilactici (Ellen capsules),195 and another Bifidobacterium bifidum (Ecologic Femi+).160  
 
The included studies were very heterogeneous (Appendix table D.1). The majority of the studies took 
place in Europe or North America, with studies elsewhere conducted in Turkey,188 Australia,67,137 
Nigeria,139 India,140 China,141 and Rwanda.160 Most studies recruited in STI clinics or health centres and 
general practices, and included pre-menopausal women only, with only two studies conducted among 
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post-menopausal women.142,184,185 No studies focussed on pregnant women exclusively. The total 
duration of probiotic use varied between three days to changing dosage schemes spanning six months, 
while the duration of follow-up ranged from seven days to over one year. Of the studies that were not 
solely vaginal detection studies but reported BV/VMB or VVC efficacy rates, ten studies evaluated 
probiotics as main therapy, three as adjuvant therapy, and 14 as maintenance therapy. It should be noted 
that some studies stated that they used probiotics as maintenance therapy, but the authors did not report 
whether the participants were successfully cured of BV or VVC at the start of probiotic 
therapy.67,137,138,192,193 We did however classify these studies as maintenance therapy studies.  
 
Quality assessments 
Most included studies had small sample sizes (ranging from 14 to 450 in BV/VMB or VVC efficacy 
studies) and were therefore underpowered, and 14 out of 34 studies did not include formal statistical 
power assessments. In only five studies responders were comprehensively compared to non-responders. 
Most BV/molecular VMB studies (11 out of 13) were RCTs but eight of the 12 VVC studies were non-
randomised, e.g. pre/post interventional studies76,143,145,184–186,188,189,191,192,194,196,197 rather than RCTs, and 
exposure groups were sometimes poorly defined. 
 
Figure 5.2: Risk of bias graph of all selected studies, per risk of bias item 
 
Each risk of bias item is presented as percentages across all selected studies. ‘Other sources of bias’ included assessments on whether 
confounding factors were included in the eligibility criteria or adjusted statistical analyses, whether the ‘intent-to-treat’ results were also 
published, and whether the statistical testing used was appropriate. 
 
Only twelve studies reported adherence data, of which only two included adherence data that were not 
self-reported.160,183 Four studies reported the impact of probiotics on molecular VMB composition in 
additional to BV (Nugent or Ison-Hay scoring) or VVC rates.141–143,160 Three studies with VMB/BV 
outcomes also included vaginal detection data,142,143,160 whereas two studies with VVC outcomes 
included vaginal detection outcomes.186,187 Few studies reported incorporating quality controls, for 
example ensuring probiotic viability,67,137 inter-user reliability of Nugent scoring,137–139,160 or 
incorporating negative and/or positive controls in molecular studies.160 
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Figure 5.3: Risk of bias summary 
 
 
The authors’ judgements about each risk of bias item per study; the studies are ordered by publication year. ‘Other sources of bias’ included 
assessments on whether confounding factors were included in the eligibility criteria or statistical analyses, whether the ‘intent-to-treat’ results 
were reported, and whether appropriate statistical was used. Studies with high overall risk of bias (seventh column) have a minus sign symbol, 
while studies with medium overall risk of bias have a plus sign symbol. No studies had low overall risk of bias. 
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In many studies the microbiological inclusion criteria differed from the microbiological outcome 
criteria (Appendix table D.1), and many reported results without detailing the statistical analyses 
performed. Others used statistical techniques that did not take confounding or repeated measures into 
account, such as the McNemar’s test for within-arm pre/post comparisons, or Fisher’s exact test to 
compare treatment arms at one timepoint. We also observed multiple instances in which erroneous 
statistical testing was performed: for example, in six studies statistical tests for independent data were 
used for pre/post comparisons, which are dependent data.145,151,185,189,191,193 Other studies did not 
statistically compare results in the intervention group to those in the control group. Twenty-six studies 
were judged to have a high overall risk of bias, eight a medium overall risk of bias, and none a low 
overall risk of bias (figures 5.2 and 5.3). Most studies were at risk of selection and performance bias; 
only ten studies were double-blinded RCTs.67,72,128,135,137,142,144,150,183,187,195 The risk of 
detection/ascertainment bias was common because outcome assessments were not done in a blinded 
fashion, or differed per exposure group. Attrition and reporting bias risk were also common: some 
studies had high loss to follow-up and multiple articles did not (fully) report intent-to-treat (ITT) 
analysis results, or misidentified the ITT population (e.g. excluding non-adherent, non-responsive or 
symptomatic participants from all analyses). The most common bias among studies was the lack of 
consideration of potential confounding factors such hormonal contraception use, pregnancy status, 
menses, vaginal practices, and sexual behaviour. 
 
Studies with BV/VMB composition as an outcome 
Thirteen studies had BV and/or molecular VMB composition as an outcome (table 5.2), resulting in 14 
BV/VMB results. One study used Ison-Hay criteria,135 whereas the other BV studies used Nugent 
criteria. Four studies used molecular methods to characterise VMB composition before, during, and 
after probiotic use in more detail.141–143,160 Five BV/VMB trials (including one study that incorporated 
molecular methods) were assessed as having an overall medium risk of bias, and the remaining eight 
were assessed as having an overall high risk of bias. Eleven out of thirteen studies were RCTs. The two 
remaining studies (both high-risk) were pre/post interventional studies with women using a vaginal 
probiotic only.143,145 
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Table 5.2: Summary of BV/VMB efficacy studies  
Reference Probiotic Study design Results 
Articles with a medium overall risk of bias 
Larsson135 EcoVag (L. gasseri 
EB01-DSM 14869 + 
L. rhamnosus Lbp 
PB01-DSM 14870) 
as adjuvant and 
maintenance tx after 
clindamycin for BV. 
RCT: placebo 
control 
10 days of EcoVag after clindamycin did not improve 
BV cure (by Ison-Hay; 32/50 cured) compared to 
placebo (37/50 cured) but significantly reduced the 
cumulative incidence of BV/intermediate microbiota 
within 4 menstrual cycles when used for 10 days after 
each menses (13/37 versus 21/39 incident cases, 
respectively). 
Petricevic136 Gynophilus (L. casei 
rhamnosus Lcr35) as 
maintenance tx after 
clindamycin for BV. 
RCT: no-
intervention 
control 
7 days of Gynophilus after clindamycin resulted in 
significantly improved BV cure (by Nugent 0-3) 
compared to women receiving clindamycin only (69/83 
versus 31/88, respectively) assessed 5 weeks after 
cessation of the intervention period. 
Mastro- 
marino72 
Florisia (L. brevis 
CD2 + L. salivarius 
subsp. salicinius FV2 
+ L. plantarum FV9) 
as main tx for BV. 
RCT: placebo 
control 
7 days of Florisia (without any antibiotic) was 
significantly more efficacious in curing BV (15/18 
Nugent 0-3, 3/18 Nugent 4-6) than placebo (2/16 
Nugent 4-6; 14/16 persistent Nugent 7-10) and was 
associated with significantly lower BV (Nugent 7-10) 
cumulative incidence in the 2 weeks after Florisia 
cessation (7/18 and 13/16, respectively). 
 Bradhaw137 Gynoflor (L. 
acidophilus KS400 + 
0.03mg oestradiol) as 
maintenance tx to 
prevent BV 
recurrence. 
RCT: placebo 
and 
clindamycin 
cream controls 
12 days of Gynoflor after oral metronidazole treatment 
for BV (Nugent 7-10) resulted in a borderline (p=0.13) 
lower BV recurrence (9/133) at M1 compared to 12 
days of placebo (13/135) but higher compared to 7 
days of vaginal clindamycin (5/140). At M6, BV 
recurrence was comparable between the three arms 
(37/133, 36/135, and 42/140, respectively). 
van de  
Wijgert160 
EF+ (B. bifidum W28 
+ L. acidophilus W70 
+ L. helveticus W74 
+ L. brevis W63 + L. 
plantarum W21 + L. 
salivarius W24) as 
maintenance tx to 
prevent BV 
recurrence. 
RCT: no-
intervention and 
oral 
metronidazole 
controls 
Intermittent EF+ use after oral metronidazole BV 
treatment resulted in significantly lower BV (Nugent 7-
10) recurrence than no-intervention (incidence 3.58/PY 
versus 10.18/PY, respectively), and significantly 
reduced BV-anaerobes concentration by sequencing, 
during the 2 months of use, but the effect disappeared 
by 4 months after cessation of use. 
van de  
Wijgert160 
GynLP (L. 
rhamnosus Lcr35 
regenerans) as 
maintenance tx to 
prevent BV 
recurrence 
RCT: no-
intervention and 
oral 
metronidazole 
controls 
Intermittent GynLP use after oral metronidazole BV 
treatment resulted in a non-significant lower BV 
(Nugent 7-10) recurrence than controls (incidence 
5.36/PY versus 10.18/PY, respectively), and non-
significantly reduced BV-anaerobes concentration by 
sequencing, during the 2 months of use, but the effect 
disappeared by 4 months after cessation of use. 
Articles with a high overall risk of bias 
Eriksson138 
 
L. gasseri + L. casei 
var rhamnosus + L. 
fermentum 
(impregnated 
tampons) as main-
tenance tx after 
clindamycin to 
prevent BV. 
RCT: placebo 
control 
Use of lactobacilli-impregnated tampons for 5 or more 
days during the first and second menses after 
clindamycin treatment was not efficacious in reducing 
BV recurrence (by Nugent 4-10) by the end of the two 
menstrual cycles (41/91) compared to placebo tampons 
(34/96). 
Anukam139 
 
GR-1/RC-14 (L. 
fermentum RC-14 + 
L. rhamnosus GR-1) 
as main tx for BV. 
RCT: 
metronidazole 
gel control 
5 days of GR-1+RC-14 capsules (without any 
antibiotic) was significantly more efficacious in curing 
BV (12/20 Nugent 0-3) than 5 days of metronidazole 
gel (6/20) when assessed directly after the intervention, 
and also in reducing BV recurrence (Nugent 7-10) up 
to 25 days post-intervention (2/17 versus 9/18, resp.). 
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Reference Probiotic Study design Results 
Hemalatha140 Florisia (L. brevis 
CD2 + L. salivarius 
subsp. salicinius + L. 
plantarum) as tx in 
women with variable 
BV status. 
RCT: pH 
lowering tablet 
control 
8 days of Florisia (without any antibiotic) was not 
efficacious in curing BV (by Nugent; 36/75 cured) 
compared to pH-lowering tablet (29/73 cured). 
Ling141 
 
L. delbrueckii subsp. 
lactis DM8909 as 
main tx for BV. 
RCT: 
metronidazole 
control 
7 days of unnamed L. delbrueckii-containing probiotic 
(without any antibiotic) was equally effective as 
vaginal metronidazole gel in curing BV (assessed 5 
days after treatment completion; 22/25 and 25/30 
cured, respectively) and was associated with a 
significantly lower recurrence 30 days after treatment 
completion than metronidazole gel (0/25 versus 5/30 
recurrences). The molecular VMB data also suggest 
benefits of using the probiotic. 
Bisanz142 
 
GR-1/RC-14 (L. 
rhamnosus GR-1 + L. 
reuteri RC-14) as 
main tx for Nugent  
4-6. 
Randomised 
controlled 
cross-over 
trial: placebo 
control 
In women with Nugent 4-6, 3 days of GR-1/RC-14 use 
(without any antibiotic) did not result in more women 
with Nugent score improvement compared to placebo 
use (2/10 and 0/10 improved one day after use, and 2/9 
and 1/8 improved 8 days after use). However, the 
Lactobacillus relative abundance was significantly 
increased, and Atopobium relative abundance 
significantly decreased, one day after use. 
Verdenelli143 SYNBIO gin (L. 
rhamnosus IMC 501 
+ L. paracasei IMC 
502) as maintenance 
tx to prevent BV and 
VVC. 
Pre-/post-
intervention 
study 
In women with Nugent 0-6, 7 days of SYNBIO gin 
(without any antibiotic) resulted in a significantly 
higher proportion of women with Nugent 0-3 directly 
after therapy (28/35 versus 21/35 at baseline), and this 
persisted for 21 days after cessation of therapy (28/35 
still had Nugent 0-3; insufficient data for McNemar 
testing). SYNBIO gin use also resulted in a significant 
increase in Lactobacillus concentration (p<0.01). 
Bohbot144 Physioflor (L. 
crispatus IP 174178) 
as maintenance tx to 
prevent BV 
recurrence.  
RCT: placebo 
control 
Physioflor for 14 days immediately after metronidazole 
therapy, plus 14 days in three subsequent menstrual 
cycles, resulted in significantly lower BV cumulative 
incidence (Nugent 7-10), and time to BV recurrence, 
compared to placebo (8/39 and 16/39 had at least one 
recurrence, respectively). However, the effects 
disappeared 84 days after product cessation (p=0.922, 
absolute numbers not given). 
Rapisarda145 L. acidophilus LA14 
as main tx for Nugent 
4-10. 
Pre-/post-
intervention 
study 
In women with Nugent 4-10, 14 days of L. acidophilus 
LA14 use (without any antibiotic) resulted in 46/60 
women cured (Nugent 0-3) at the end of therapy, and 
this persisted for 28 days after product cessation 
(50/60). 
BV bacterial vaginosis, EF+ Ecologic Femi+, GynLP Gynophilus LP, M1/6 Month 1/6, PY person-years at risk, RCT randomised controlled 
trial, tx therapy, VMB vaginal microbiota. 
Studies examining the efficacy of vaginal probiotics on BV (by Nugent or Ison-Hay scoring of Gram stains) rates and/or proportions and/or 
molecular VMB outcomes were selected for inclusion in this table. See Appendix table D.1 for in-depth study characteristics. 
 
All five BV/VMB studies with medium overall risk of bias were RCTs (table 5.2). Of the five BV/VMB 
studies (yielding a total of six BV/VMB results), four results showed significant beneficial effects, and 
two results showed non-significant but beneficial effects of vaginal probiotics use. Three of the five 
studies included placebo control groups,72,135,136 and two included both controls with no intervention and 
antibiotic controls.137,160 The three studies with placebo controls focussed on BV cure proportions: two 
of them showed significantly beneficial effects,72,136 and while the other did not show beneficial effects 
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of adjuvant probiotic use on BV cure proportions, the study did show significantly lower BV recurrence 
after use of the probiotic during the next four menstrual cycles.135 The other two BV/VMB studies 
focussed on BV recurrence: one showed a non-significantly lower BV recurrence among probiotic users 
after metronidazole compared to no-intervention controls,137 and the other study showed significantly 
lower BV recurrence, and beneficial VMB effects, for one probiotic product and non-significant lower 
BV recurrence and non-significant beneficial VMB effects for the other product.160 Both of these studies 
also included a positive antibiotic use arm which showed that the antibiotic maintenance users had 
lower BV recurrence than the probiotic maintenance users.137,160 
 
Eight BV studies (including three studies that incorporated molecular methods) were assessed as having 
an overall high risk of bias, and these studies showed comparable results to the medium-risk studies 
(table 5.2). Five studies showed significant beneficial effects of probiotic use, one study showed non-
significant Nugent results but the VMB results were significantly beneficial, and two studies did not 
show any beneficial effects. Six studies were RCTs whereas two studies were pre/post intervention 
studies in women receiving a vaginal probiotic without any antibiotic.143,145 Both pre/post intervention 
studies showed that probiotic use significantly increased the proportion of women with Nugent 0-3, and 
that these effects lasted beyond the product use period. Three of the six RCTs included placebo 
controls,138,142,144 two included antibiotic controls,139,141 and one included controls using a vaginal pH-
lowering tablet.140 Four studies evaluated BV cure: two studies showed a significant benefit of probiotic 
use compared to metronidazole use,139,141 one study was underpowered to show an effect on BV cure but 
did show beneficial VMB outcomes,142 and one showed no significant effect on BV cure compared to a 
pH-lowering tablet.140 The four studies evaluating BV recurrence showed significant reductions among 
probiotic users in three studies139,141,144 and no reduction in another.138 It should be noted that women 
enrolled in the latter study used the vaginal probiotic during menses only. 
 
Studies with VVC as an outcome 
Twelve studies had VVC as an outcome (table 5.3), using wet mount or fungal culture to detect 
Candida. None of the studies used (q)PCR-based methods. Only one study was assessed as having a 
medium overall risk of bias, the other eleven had a high overall risk of bias.  
 
The study with a medium overall risk of bias was an RCT conducted in the USA which compared five-
day Lactin-V use to placebo in BV- and VVC-negative, healthy women with a history of recurrent 
urinary tract infections.187 No women used antifungals (nor antibiotics for other indications) and the 
proportion of women with incident VVC cases up to 25 days after product cessation was similar in the 
Lactin-V group (4/15 women) compared to the placebo group (2/15).  
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Table 5.3: Summary of VVC efficacy studies  
Reference Probiotic Study design Results 
Articles with a medium overall risk of bias 
Czaja187 L. crispatus CTV-05 
(not Lactin-V) as 
recurrent UTI 
maintenance tx. VVC 
as part of safety 
assessments. 
RCT: 
placebo 
control 
 
In women with a history of recurrent UTI but without 
current dysuria, 5 days of L. crispatus CTV-05 use 
resulted in a similar VVC cumulative incidence (4/15) 
compared to placebo use (2/15) up to 25 days after 
cessation of use. 
Articles with a high overall risk of bias 
Özmen188 Gynoflor (L. 
acidophilus KS400 + 
0.03mg oestradiol) as 
main BV tx and as 
adjuvant to 
metronidazole tx. BV 
and VVC outcomes but 
BV ineligible (Amsel). 
Pre-/post-
intervention 
study in 
three 
separate, 
non-
randomised 
groups 
12 days of Gynoflor with or without metronidazole, 
compared to metronidazole alone (to treat BV), 
resulted in significantly lower cumulative VVC 
incidence (3/96 and 2/97, versus 14/114, respectively) 
in the 10-13 days after cessation of use. 
Pirotta67 Femilac (L. rhamnosus 
+ L. delbrueckki + L. 
acidophilus + S. 
thermophilus) as 
maintenance tx after 
non-metronidazole 
antibiotic to prevent 
VVC. Also Lactobac 
oral powder but results 
not reported here.  
2x2 factorial 
design RCT: 
placebo 
control 
10 days of Femilac during (6 days) and after (4 days) 
non-metronidazole antibiotic use, compared to placebo 
controls, was not effective in reducing VVC incidence 
within 18 days after cessation of Femilac use (17/59 
versus 9/54, respectively). 
Di Pierro189 Kramegin (L. 
acidophilus + Krameria 
triandra plant extract + 
15mg lactic acid) as 
main tx of VVC. 
Pre-/post-
intervention 
study 
10 days of Kramegin (without antifungal) cured 75/75 
women with acute VVC, and 20/30 women with 
recurrent VVC (both significant compared to baseline). 
Cure was assessed 7 days after last administration. 
Witt190 L. gasseri as 
(additional) 
maintenance tx together 
with itraconazole to 
prevent VVC 
recurrence. 
RCT: 
probiotic + 
itraconazole 
versus 
itraconazole 
only 
In women with acute VVC and a history of recurrent 
VVC, after induction with itraconazole twice weekly 
for one month, itraconazole (once per month) with L. 
gasseri (6 consecutive days per month) during 6 
months resulted in a similar VVC recurrence rate as 
itraconazole (once per month) only (15/45 versus 
12/31, respectively). Results were also similar 6 
months after product cessation (6/25 versus 5/23, 
respectively). 
Vicariotto191 ActiCand (L. 
fermentum LF10 + L. 
acidophilus LA02) as 
main tx for VVC. 
Pre-/post-
intervention 
study 
In women with acute VVC and a history of recurrent 
VVC, ActiCand (without antifungal; 7 consecutive 
nights, followed by 3 nights per week for 3 weeks, and 
one night per week for 4 weeks) resulted in a 
significant reduction in VVC cases to 7/30 women 
after cessation of therapy at Day 56. 
De Seta192 Gyno-Canesflor (L. 
plantarum P17630) as 
maintenance tx to 
prevent VVC 
recurrence. 
Non-
randomised 
prospective 
cohort study 
In women with acute VVC but no history of recurrent 
VVC, 34 days of Gyno-Canesflor after clotrimazole 
treatment, compared to placebo use, resulted in a (non-
significant, Fisher's p=0.095) lower cumulative VVC 
incidence (1/40 versus 5/40, respectively). 
Donders184 & 
Donders185 
Gynoflor (L. 
acidophilus KS400 + 
0.03mg oestradiol) as 
maintenance tx to 
prevent VVC. 
Pre-/post-
intervention 
study 
A 84-day single-arm Gynoflor treatment scheme (once 
daily for 4 weeks followed by thrice weekly for 8 
weeks) for atrophic vaginitis in postmenopausal 
women with breast cancer temporarily increased 
asymptomatic VVC prevalence after two weeks of use 
(from 2/14 to 7/16) but returned to baseline values after 
one (3/16), two (3/16), and three (3/13) months of use. 
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Reference Probiotic Study design Results 
Pendharkar 
- Trial II186 
EcoVag (L. gasseri 
DSM 14869 + L. 
rhamnosus DSM 
14870) as adjuvant/ 
maintenance tx to 
prevent BV and VVC 
recurrence. 
Non-
randomised 
prospective 
cohort study 
In women with recurrent VVC, fluconazole (7 days in 
cycle 1 followed by once weekly in cycles 2+3, and 
biweekly in cycles 4-6) with EcoVag (10 days in cycle 
2, and once weekly in cycles 2-6) did not significantly 
improve the VVC cure fraction 6 months after 
treatment cessation compared to the fluconazole 
regimen without EcoVag (8/9 versus 7/10, resp.) but 
almost all women in both groups were cured. 
Kovachev193 Lactagyn (L. 
acidophilus, L. 
rhamnosus, S. 
thermophilus, L. 
delbrueckii subsp. 
bulgaricus) as 
maintenance tx to 
prevent VVC 
recurrence.  
RCT: no-
intervention 
control 
In women with acute VVC, antifungal treatment 
(fluconazole and fenticonazole) followed by 10-day 
Lactagyn therapy resulted in lower VVC recurrence 
(10/209) at the final follow-up visit 25-30 days after 
product cessation than antifungal treatment alone 
(76/207). The authors report this as two non-significant 
pre/post results, but these are significant when the 
appropriate test (McNemar) is used, and when the two 
groups are compared directly. 
Rapisarda145 L. acidophilus LA14 as 
main tx for BV. VVC 
also assessed. 
Pre-/post-
intervention 
study 
In women with NS 4-10 and 21/60 with acute VVC, 14 
days of L. acidophilus LA14 without antifungals or 
antibiotics resulted in a significant reduction of VVC 
cases to 9/60 one day after cessation of use, and 6/60 4 
weeks after cessation of use. Mean Candida culture 
counts also decreased significantly. 
Murina194 Estromineral Probiogel 
(L. fermentum LF10 + 
L. plantarum LP02) as 
main tx for BV and 
VVC. 
Pre-/post-
intervention 
study 
Estromineral Probiogel (without antifungal) cured 
51/82 women with acute VVC and 27/27 in women 
with recurrent VVC between 20-30 days after therapy 
initiation (both significant compared to baseline), but 
therapy longer than the intended 6 days was required in 
57.3% and 63.0% women, respectively, due to 
persistence of symptoms. 
BV bacterial vaginosis, M1/6 Month 1/6, tx therapy, UTI urinary tract infection, VMB vaginal microbiome, VVC vulvovaginal candidiasis. 
Studies examining the efficacy of vaginal probiotics on VVC (by wet mount or fungal culture) rates were selected for inclusion in this table. 
There were no studies with Candida by molecular methods outcomes. See Appendix table D.1 for in-depth study characteristics. The Rwanda 
VMB Study is not shown in this overview as this study had no VVC cases during follow-up (see Chapter 3).  
 
We found eleven VVC articles with high overall risk of bias; six of these were pre/post interventional 
studies rather than RCTs (table 5.3).145,184,185,188,189,191,194 Two studies were non-randomised cohort 
studies with parallel comparison groups (one included a placebo comparison group,192 and one 
compared women using fluconazole together with probiotic to women using fluconazole only186), and 
three studies were RCTs (one with a placebo group,67 one study with a group without interventions,193 
and one study compared women using itraconazole together with probiotic to women using itraconazole 
only190). Of these eleven high-risk VVC studies, five showed significantly beneficial effects of vaginal 
probiotic use, three studies showed non-significant beneficial effects or had mixed results, and three 
studies showed no beneficial effects of probiotic use. Four studies focussed on VVC cure: all were 
pre/post intervention studies in which no antifungals were given to the participants.145,189,191,194 Cure 
rates were high (57-100%) but all women received the interventions, and none of the studies reported 
long-term VVC recurrence. Four other studies assessed VVC recurrence after combined 
probiotic/antifungal treatment:186,190,192,193 the two studies examining antifungal treatment combined with 
probiotic use showed no differences in VVC recurrence,186,190 whereas the two studies that compared 
probiotic after antifungals with placebo192 or no intervention193 showed significantly lower VVC 
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recurrence. Two other studies assessed VVC incidence as secondary outcomes after therapy for BV188 
or non-gynaecological infections67: the first study showed that Gynoflor with or without metronidazole 
resulted in a lower VVC incidence than when using metronidazole alone,188 whereas the second study 
showed no benefit of probiotic maintenance therapy to prevent post-antibiotic VVC.67 A study in which 
postmenopausal women atrophic vaginitis received probiotics without antifungals showed no difference 
in VVC prevalence before and after use.184,185 
 
Probiotic strain detection studies 
Fourteen studies assessed the vaginal detection of probiotic strains and/or their relative abundance, 
concentrations, or colonisation capacity (with the Rwanda VMB study reporting results for two 
probiotics; Appendix table D.3), using a variety of molecular techniques as described previously. Only 
three studies had probiotic strains detected in all probiotic users.143,196,197 Overall, probiotic strains were 
detected in 59-100% of users or in 20-39% of collected swabs during use or directly after product 
cessation. None of the vaginal detection studies accurately assessed the timing between last probiotic 
insertion and vaginal sample collection for detection measurement. In eleven products, probiotic strain 
detection was assessed more than a week after cessation of use: these studies showed that detection 
rates decreased after ceasing the product.142,143,150,151,160,186,195–197 Most studies only assessed this at one 
single timepoint, and the assessment varied widely, between two weeks to six months after product 
cessation. Three studies associated adherence to probiotic strain retrievability and found that probiotic 
strains were not always detected in women using all products according to schedule,160,183,186 but two of 
these studies only assessed adherence by self-report. There were two studies that reported individual 
cases in which probiotic strains dominated the VMB at a relative abundance of 50% or more,155,160 but 
none of the studies that combined probiotic detection with a measure of absolute concentration or 
relative abundance found that probiotic strains dominated the vagina in all users.142,143,155,160,186 Three 
studies reported probiotic concentrations: an Italian study using SYNBIO gin showed mean 
concentrations of the probiotic strains of around 9 log10 cells/μl (the article reports this as 6 log10 cells/g; 
I presumed one gram of DNA buffer equals a volume of around 1,000 μl) directly after 
administration.143 The Rwanda VMB study reported mean concentrations between 0.48-1.92 log10 
cells/μl of Ecologic Femi+ strains and mean concentrations between 0.25-1.05 log10 cells/μl of 
Gynophilus LP strains at the study visits during product use.160 These concentrations were however 
much higher in women when any probiotic strains were detected, of around 4 log10 cells/μl. A French 
phase I safety study found that Gynophilus strain concentrations were around or above 107 CFU/ml,155 
which is comparable to the concentrations found in the Rwanda VMB study. Interestingly, two studies 
found that L. crispatus CTV-05 was less often detected in women who had sexual intercourse during the 
product use period, regardless of whether the intercourse was protected or not,128,150 and four studies (of 
which three in women using L. crispatus CTV-05) found that detection was less likely if women had 
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native lactobacilli prior to probiotic use (L. crispatus in the case of the CTV-05 studies and any 
lactobacilli in the case of an EcoVag study).76,128,150,186 
 
Studies comparing multiple, differing treatment strategies 
A Turkish study in women with BV compared Gynoflor as main therapy, metronidazole with Gynoflor 
as adjuvant therapy, and metronidazole only: it was found that the cumulative incidence of VVC was 
comparable between the former two groups (3/96 and 2/97, respectively), and lower than when using 
metronidazole alone (14/114).188 A Norwegian study found that EcoVag probiotic was not effective as 
adjuvant therapy for BV compared to placebo (32/50 versus 37/50, respectively), but was effective as 
maintenance therapy as BV/intermediate microbiota recurrence during maintenance therapy was 
significantly lower in the probiotic group than in the placebo group (13/37 versus 21/39, 
respectively).135 The same probiotic but in different doses or formulations was compared in one L. 
crispatus CTV-05 study150 and in one Gynophilus study,155 but none of these studies reported efficacy 
outcomes (see Appendix table D.3 for outcomes of these two vaginal detection studies). An Australian 
study compared a vaginal (Femilac) and an oral (Lactobac) probiotic to prevent VVC in women using 
antibiotics for non-gynaecological infections, showing no benefit for either probiotic compared to 
placebo.67 Two studies compared vaginal probiotics directly with each other:160,196 one study only 
reported detection results196 (Appendix table D.3), while the Rwanda VMB study showed significantly 
lower BV recurrence, and higher Lactobacillus and lower BV-associated anaerobes relative abundance 
in intermittent Ecologic Femi+ users but not in intermittent Gynophilus LP users. However, this study 
was a pilot study with preliminary efficacy outcomes only, and all effect sizes of Gynophilus LP users 
were in the same direction as Ecologic Femi+ users.160 
 
5.4 Discussion 
We examined the impact of vaginal probiotics on the VMB in this systematic review and showed that 
published clinical efficacy studies have shown promise for BV cure and prevention but much less so for 
VVC cure and prevention. The five BV studies (with six results) with medium overall risk of bias 
suggested that vaginal probiotic use may have benefits: four results were significantly positive, and two 
were positive but non-significant. The effect of probiotics, in most cases, seemed to be greatest when 
used to prevent BV recurrence, and was limited to the period of use and disappeared after product 
cessation. The eight BV studies with a high overall risk of bias often lacked the statistical power to 
detect any robust effect, but five out of eight studies also showed positive effects. Overall, most results 
were moderate in size and probiotics were usually less effective than antibiotic use when comparisons 
of this nature were made. We also showed that vaginal probiotics may have positive effects on the 
VMB, for example by increasing the presence of Lactobacillus relative abundances and/or 
concentrations or by decreasing the prevalence of BV-like VMB types. Unfortunately, the studies with 
molecular VMB outcomes were very heterogenous, reported results were sparse, and most of these 
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trials had major methodological issues such as loss to follow-up;141 this make it difficult to interpret the 
significance of the molecular VMB results. All but one VVC efficacy studies were judged to have a 
high overall risk of bias, and many of these were pre/post interventional studies rather than RCTs. Five 
of twelve VVC efficacy studies showed positive effects, but it should be noted that four of these were 
pre/post studies with often limited follow-up time and no comparison groups. As it is known that C. 
albicans is highly inflammatory and predominantly occurs in and favours an optimal Lactobacillus-
dominated environment,4,9,87 it can be doubted whether Lactobacillus-based probiotics could be 
efficacious in reducing VVC rates.  
 
Most of the vaginal detection studies showed that the probiotic strains are not detected in all users or in 
all vaginal swabs taken during use. The concentrations or relative abundances of vaginal probiotics 
were often low when measured, and the strains generally did not persist in the vagina after product 
cessation. This is most likely due to issues regarding adherence (social desirability bias playing an 
important role), infrequent or low dosing and formulation problems, strain selection and strain 
survivability in the vagina, and/or study designs in which it was difficult to accurately associate 
probiotic insertion timing with vaginal swab sampling timing. While it could be argued that probiotics 
do not need to dominate the VMB in order to exert their beneficial effects, the findings of this review do 
beg the question whether the dose contained in vaginal probiotics, which in these studies never 
exceeded 1010 CFU/dose and was around 108 CFU/dose in most products, should be increased further to 
guarantee a higher relative abundance of probiotic strains in the VMB. Another possibility is that 
dosages should be given more frequently to ensure proper delivery in the vaginal niche. We could not 
comprehensively answer our third research question on the best treatment strategy to use probiotics. 
Antibiotic treatment of BV is often effective but recurrence rates are high.46,47 Given that we found BV 
studies using probiotics to prevent BV were successful the most often, it may be more effective to use 
vaginal probiotics either as adjuvant BV therapy together with antibiotics, or as maintenance therapy to 
prevent BV, and not as main BV therapy without antibiotic treatment. However, this point of view is a 
recommendation only and evidence in the form of studies directly comparing different treatment 
strategies is lacking. None of the probiotic studies included reported major safety concerns for vaginal 
probiotics use. 
 
The studies that we included were very heterogeneous, with little consistency when it comes to the 
products/strains used, the dosage and formulation types, the indication, the dosing strategy, or 
outcomes. Probiotics received little regulation by regulatory bodies until fairly recently and therefore 
many different products exist;71 we opted to conduct a review including all Lactobacillus-containing 
vaginal probiotics and not limit ourselves to one probiotic product. Due to heterogeneity in study design 
and a lack of studies comparing multiple types of probiotics, it is difficult to ascertain which probiotic 
strains or products were the most successful. It has previously been shown that oestrogen favours a 
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healthy VMB dominated by lactobacilli.26,171 This would make combinations of low-dose oestradiol and 
lactobacilli such as used in Gynoflor promising, especially in post-menopausal women, but there is no 
epidemiological evidence available to prove this. L. crispatus is the most favourable Lactobacillus 
species,4,8 and therefore would make a sensible probiotic candidate, but several studies show L. 
crispatus CTV-05 detectability is low in women who have native L. crispatus.76,128,150 L. crispatus may 
however be a good option for women whose native optimal VMB is composed of L. iners, e.g. in 
African or African American women, being at greatest risk of vaginal dysbiosis-related sequelae. 
However, there is no current evidence for this. In high-resource settings, stratified or personalised 
probiotic recommendations based on a woman’s individual (VMB) characteristics may be promising. 
 
The vast majority of included studies had a high overall risk of bias and many methodological flaws, 
and the interpretability of the efficacy results was therefore limited. Most studies lacked the statistical 
power to compare responders to non-responders. Future studies should be adequately powered to detect 
differences in BV/VVC cure or recurrence rates between study arms. Trials should ideally include 
negative control arms, and positive control arms with antibiotic or antifungal therapy. If probiotic 
therapy is initiated after antibiotic/antifungal treatment, laboratory and microbiological testing should 
be performed prior to initiation of probiotics to ensure a healthy VMB at baseline and allow for proper 
examination of BV/VVC recurrence. Adherence assessments should be included at regular intervals and 
reported clearly. Furthermore, RCTs using vaginal probiotics should include assessments of the efficacy 
of the products at regular intervals during product use (including precise timings of product insertion 
and vaginal swab sampling), directly after stopping study products, and at a time point after product 
cessation spanning multiple menstrual cycles. In at-risk populations HIV/STI incidence during follow-
up should be recorded. The Amsel criteria77 should not be used in clinical studies due to its low 
sensitivity and specificity. Studies should use either Nugent78 or Ison-Hay174 Gram stain scoring (both at 
baseline as part of the eligibility criteria and during follow-up), and should incorporate molecular 
methods as outcomes by (16S rRNA or cpn60 gene) sequencing and/or species-specific qPCRs. Using 
molecular methods permits to describe the VMB more in-depth than Gram stain scoring methods, and 
precision and statistical power increase when the outcomes are expressed as continuous relative 
abundances and/or concentrations rather than Gram stain scoring categories. Quantification of the 
probiotic strains and main bacterial species present in the VMB, instead of merely reporting relative 
abundances, is now obtainable and highly advisable.129,130 Future studies should incorporate more robust 
statistical analyses such as incidence rate ratios (comparing incidence in intervention groups to control 
groups), Cox regression combined with Kaplan-Meier curves in the case of BV or VVC recurrence 
rates, and/or mixed effects models. Sub-analyses (for example comparing responders to non-responders) 
or per protocol analyses should also be performed, as well as statistical analyses with adjustments for 
confounding factors known to affect the VMB, such as sexual behaviour (including condom use), 
hormonal contraception, pregnancy status, and menses,4,26,156,198 if sample size permits: while 
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confounding factors or baseline imbalances can be accounted for without statistical adjustments in 
studies with a high number of participants, this is not the case in trials with a low sample size.199 
Acceptability assessments of the vaginal products (by surveys and/or qualitative in-depth interviews) 
should be performed and reported when unknown in that specific population to ensure proper 
adherence. Finally, (serious) adverse events should be reported systematically in accordance with 
international guidelines.200,201 
 
The strength of this systematic review is that we evaluated the use of vaginal probiotics in the broadest 
way possible, assessing the impact of vaginal probiotics from several viewpoints, such as VMB 
outcomes, probiotic products/strains used, and treatment strategy of the trial. The limitation of this 
systematic review is that many of the included studies had a small number of participants, used differing 
Lactobacillus species and strains, had differing and/or no control groups, had a short follow-up, and 
were of (very) low methodological quality. Conducting a meta-analysis on BV and VVC 
rates/proportions was not possible due to the high heterogeneity of the studies and the often-unclear 
presentation of results. As well as the other risk of bias items mentioned, there is a risk of publication 
bias as studies with positive and significant results are more likely to be submitted, and to be accepted, 
for publication. We did not examine the impact of oral probiotics on the VMB in this systematic review. 
The rationale is that we thought it would be likely that the effect of oral probiotics is more diluted than 
that of vaginal probiotics as the former are not delivered directly at the intended target site; the impact 
of oral probiotics on the VMB could be the subject of a separate systematic review. 
 
To conclude, the currently available evidence that vaginal probiotics are helpful in improving VMB 
composition is limited but most studies with BV rates as an outcome showed a decrease in BV 
recurrence, and most studies with molecular VMB outcomes showed an increase in lactobacilli. The 
evidence to use vaginal probiotics to cure or prevent VVC is very limited. The interpretability of the 
results in the studies was severely hampered by their poor methodological quality. Well-powered and 
well-conducted clinical trials that incorporate in-depth molecular analyses, adjust for known 
confounding factors, and compare responders to non-responders are needed.  
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Chapter 6 - Targeted Point-of-Care Testing Compared to Syndromic Management of Urogenital 
Infections in Women: a Cross-Sectional Screening and Diagnostic Accuracy Study 
 
This chapter has been published in The Lancet Infectious Diseases. The version presented here is the 
author-approved and Lancet-accepted version with only minor modifications (title of the chapter, 
numbering of figures, tables, and references). The version that has since appeared in The Lancet 
Infectious Diseases was edited by the Lancet editorial team to conform to Lancet style: Verwijs MC, 
Agaba SK, Sumanyi JC, Umulisa MM, Mwambarangwe L, Musengamana V, Uwineza M, Cuylaerts V, 
Crucitti T, Jespers V, van de Wijgert JHHM. Targeted point-of-care testing compared with syndromic 
management of urogenital infections in women (WISH): a cross-sectional screening and diagnostic 
accuracy study. Lancet Infect Dis 2019; 19(6):658-69.  
 
I oversaw the implementation of the approved study protocol by having weekly teleconference calls 
with the study team at the Rinda Ubuzima research clinic in Kigali, Rwanda, and by conducting three 
monitoring visits to that clinic during and immediately after completion of the data collection. I 
developed the analytical approach and performed the statistical analyses under the supervision of my 
primary supervisor Professor Janneke van de Wijgert. My primary supervisor and I wrote the 
manuscript together. All authors commented on and approved the final manuscript. 
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Abstract 
Introduction: Sexually transmitted and urogenital infections are typically managed by World Health 
Organisation (WHO)-recommended syndromic algorithms in resource-poor countries, and 
presumptively in Europe. Vaginal discharge (VDS) and lower abdominal pain (LAP) algorithms in 
women perform poorly. The main aim of the WISH study was to compare the performances of 
VDS/LAP algorithms incorporating point-of-care tests (POCTs), and of WHO syndromic algorithms, 
with gold standard test results. 
Materials and Methods: At-risk Rwandan women (N=705) underwent POCTs for bacterial vaginosis 
(BV; vaginal pH≥5.0) and Trichomonas vaginalis (TV; OSOM) regardless of symptom-reporting. 
Women with a positive risk score were POC-tested for Chlamydia trachomatis and Neisseria 
gonorrhoeae (CT/NG; GeneXpert). Vulvovaginal candidiasis (VVC) was treated presumptively. 
Nucleic acid amplification tests (NAATs) were done for CT/NG, TV, BV, and VVC on everyone and 
were used as gold standards. 
Results: NAAT-based prevalences were: 60/705 (8.5%) CT, 50/705 (7.1%) NG, 111/690 (16.1%) TV, 
125/690 (18.1%) BV, and 59/690 (8.6%) VVC. Infection-specific sensitivities of the WHO VDS/LAP 
algorithms ranged from 58.3-74.6%, and specificities from 44.7-50.6%. WISH POCT-based algorithms 
had good sensitivity (68.5-76.0%) and specificity (97.4-100%) for CT, NG, and TV but low specificity 
for BV (41.2%; sensitivity 95.2%), and modest sensitivity (64.4%) and specificity (69.4%) for VVC. 
Sensitivity (73.6%) and specificity (100%) for BV improves by screening all women for vaginal pH, 
and confirmatory testing of those with pH≥5.5 (n=275). Staff and participants considered POC testing 
feasible and acceptable. 
Discussion: POC testing for urogenital infections improves performance and is feasible in resource-
poor settings. POCT development should continue, including POCTs targeting multiple conditions. 
Additional studies in other populations, including low prevalence populations, are warranted. 
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6.1 Introduction 
Sexually transmitted infections (STIs) and other urogenital infections cause a major burden of disease 
worldwide.40 The World Health Organisation (WHO) estimated that 357 million new curable infections 
caused by Chlamydia trachomatis (CT), Neisseria gonorrhoea (NG), Trichomonas vaginalis (TV), and 
Treponema pallidum (syphilis) occurred in 2012.38 Furthermore, in women, bacterial vaginosis (BV), 
vulvovaginal candidiasis (VVC), and urinary tract infections (UTIs) are common.87,202 Long-term 
sequelae include increased risk of HIV acquisition and transmission, pelvic inflammatory disease, 
pregnancy complications, and invasive neonatal infections.17,87,203  
 
Most resource-poor countries diagnose genital infections syndromically, using local guidelines that are 
based on the WHO Guidelines for the Management of Sexually Transmitted Infections (figure 6.1).21,93 
Each patient-reported symptom, potentially augmented by clinician-observed signs during physical 
examination, is treated for all organisms that might cause that symptom.21 In women, the four main 
syndromes on which the WHO algorithms are based are vaginal discharge syndrome (VDS) without 
lower abdominal pain (LAP), LAP with or without VDS, genital ulcers with or without inguinal buboes, 
and inguinal buboes without genital ulcers (figure 6.1).21 The VDS syndrome is the most common.93,94 
The WHO recommends that VDS is always treated for BV and TV, is treated for CT and NG if local 
prevalence is high and/or locally designed risk assessments are positive, and is also treated for VVC if 
the discharge is curd-like and vulval oedema, erythema, and/or excoriations are present (figure 6.1). In 
Europe, most STIs and urogenital infections in women are treated presumptively by primary care 
physicians. 
 
Syndromic and presumptive approaches miss all asymptomatic infections by definition. Asymptomatic 
infections in women are common, and are associated with the complications outlined above.9,87 
Furthermore, many studies in different countries have shown that the performance of VDS and LAP 
algorithms in symptomatic women are suboptimal, leading to under-, over-, and inadequate treatment of 
patients.94,97,98,100 
 
The Women’s Improvement of Sexual and reproductive Health Study (WISH) in Kigali, Rwanda, 
sought to improve case-finding and infection management in women by introducing point-of-care tests 
(POCT).105 Our aim was to use POCTs that comply with the WHO ASSURED criteria (Affordable, 
Sensitive, Specific, User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end users) as 
much as possible.108,106 Participants were first asked about urogenital symptoms as if we were to provide 
them with syndromic care, but were then offered POCT-based WISH algorithms (see Methods). Stored 
samples from all women were also tested by nucleic acid amplification (NAAT) gold standard tests. 
This design allowed us to compare the performance of the WISH algorithms with the WHO algorithms 
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and with gold standard results, to evaluate the feasibility and acceptability of the WISH algorithms, to 
recommend optimal algorithms given currently available POCTs, and to identify POCT development 
gaps. 
 
Figure 6.1: WHO and WISH algorithms 
WHO algorithms 
 
WISH algorithms 
 
POCT descriptions 
POCTs included in algorithms: 
 CT/NG: GeneXpert CT/NG assay (Cepheid, Sunnyvale, USA). 
 TV: TV OSOM assay (Sekisui Diagnostics, Lexington, USA). 
 BV: EcoCare vaginal pH swab (Merete Medical, Luckenwalde, Germany) with pH ≥5.0 considered positive.  
 Syphilis: Alere Determine Syphilis rapid test (Alere, Waltham, USA) with confirmation of active infection by the rapid plasma reagin 
test (SpinReact, Girona, Spain).  
POCTs not included in algorithms, and not evaluated in the WISH study, but offered to participants: 
 UTI: urinalysis dipstick test (Acon, San Diego, USA). Any nitrite and/or leukocytes were considered UTI-positive as recommended 
by the Rwandan Ministry of Health. 
 HIV: Determine HIV-1/2 rapid test (Alere, Waltham, USA), followed by Trinity Biotech Uni-gold HIV rapid test (Trinity Biotech, 
Bray, Ireland) if reactive, and Vironostika ELISA (Biomerieux, Marcy, France; performed at the National Reference Laboratory in 
Rwanda) as a tie-breaker if needed.  
 Pregnancy: Nova human chorionic gonadotropin urine dipstick test (Atlas Link Technology Co., Beijing, China).  
BV bacterial vaginosis, CT Chlamydia trachomatis, GUD genital ulcer disease, HSV2 Herpes simplex virus type 2, LAP lower abdominal pain, 
LGV lymphogranuloma venereum, NG Neisseria gonorrhoeae, PID pelvic inflammatory disease, POCT point-of-care test, TV Trichomonas 
vaginalis, UTI urinary tract infection, Vag vaginal, VDS vaginal discharge syndrome, VVC vulvovaginal candidiasis.  
The top rows are symptoms reported by participants. For details about the syndromic management algorithms, see WHO guidelines.21  
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*LAP (WHO) and LAP or pain during sex (WISH) required examination. Alarm signs: missed/overdue period, recent 
delivery/abortion/miscarriage, abdominal guarding and/or rebound tenderness, abnormal vaginal bleeding, and abdominal mass. Treated for 
PID if no alarm signs but cervical motion, uterine, and/or adnexal tenderness present, or when lower abdominal tenderness and VDS present. 
PID treatment covered CT/NG/TV/BV. The VDS algorithm is followed if no alarm signs or PID. †One or more of the following: currently 
pregnant, exchanged sex for money or goods in the past 12 months, new sexual partner in the past three months, or relevant clinical signs 
observed by a physician. For the CT/NG score, these were VDS with an offensive smell and/or PID. For the syphilis score, these were GUD 
and/or inguinal buboes observed by a physician. ‡Syphilis-negative GUD to be treated for H. ducreyi if no response to HSV2 treatment. 
 
6.2 Materials and Methods 
This cross-sectional study was carried out at the Rinda Ubuzima research clinic and laboratory in Kigali 
by staff with multiyear experience in sexual and reproductive health care. Our aim was to recruit 
women at risk of HIV and STIs but at varying degrees of risk and not exclusively sex workers. 
Recruitment activities were implemented by study staff with the help of ‘community mobilisers.’ Two 
of them were women who had taken part in previous Rinda Ubuzima studies, and one was a community 
organiser. They organised recruitment meetings, and distributed flyers at health centres, pharmacies, 
markets, and at women’s organisation and ‘umuganda’ community meetings. Participants were 
encouraged to refer their friends. Women aged 18 or older at risk of STIs (defined as having had more 
than one sex partner and/or having been treated for at least one STI in the past year) with or without 
urogenital symptoms were enrolled between July 2016 and March 2017. HIV-positive and pregnant 
women were not excluded. Women were told that they would be screened for urogenital infections free 
of charge, that they could only be screened once, and that they would not receive a monetary 
reimbursement for participation. 
 
Clinic visit procedures 
At the study visit, participants underwent a face-to-face interview that included questions about current 
(including past two weeks) urogenital symptoms. Participants were first asked if they experienced any 
symptoms without prompting (‘spontaneously reported’), followed by questions about 14 specific 
symptoms (‘structurally reported’). All women were offered comprehensive counselling and could 
select topics themselves.  
 
Next, the WISH algorithms were implemented (figure 6.1, which includes POCTs details, and 
Appendix E, pages 174-175, for reasons why these POCTs were selected). All women were offered 
HIV, pregnancy, TV, and BV testing. We used ASSURED POCTs to diagnose HIV, pregnancy, and TV 
(OSOM), and a vaginal pH swab to diagnose BV (EcoCare; pH≥5.0 was considered BV). Since 
ASSURED POCTs for CT and NG with adequate performance are not yet available,204,205 we used the 
GeneXpert CT/NG assay. This POC NAAT assay is more than 95% sensitive and specific for both 
organisms,91 but requires equipment, is expensive (we paid 18.25 USD for consumables per test), and 
takes 90 minutes to return results. We therefore only offered GeneXpert testing to women who had a 
positive CT/NG risk score (figure 6.1). We used an ASSURED POCT for syphilis (Determine, with a 
confirmatory rapid plasma reagin test), but only offered testing to women who had a positive syphilis 
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risk score (figure 6.1) because the syphilis prevalence was expected to be low.25,206  
 
The WISH algorithms called for mild VDS to be ignored if none of the POCTs were positive and for 
VVC-like symptoms to be treated for VVC presumptively. Women reporting substantial VDS not 
typical for VVC and/or LAP (including pain during sex) were to be offered a speculum and bimanual 
examination by a physician. Physician-observed substantial VDS or pelvic inflammatory disease 
resulted in a positive CT/NG score followed by CT/NG testing, and pelvic inflammatory disease was to 
be treated even if the test was negative. Women with genital ulcers/buboes would be offered inspection 
by a physician. Any visible lesions resulted in a positive syphilis risk score followed by syphilis testing, 
and would be diagnosed as syphilis, syphilis-negative genital ulcer disease, inguinal buboes without 
genital ulcers, and/or genital warts. Urinalysis testing was only offered to women reporting urinary 
symptoms and the presence of any nitrite and/or leukocytes in urine was considered a UTI. 
 
Blood (4.5 ml EDTA), urine, and TV OSOM and EcoCare vaginal swabs were collected as required to 
implement the WISH algorithms. In addition, a GeneXpert swab and two polyester vaginal swabs were 
collected from all women for gold standard testing (see below). Treatment, partner notification, and 
referral procedures are described in Appendix E, pages 178-179 and table E.1.  
 
Participants could opt out of each service offered and the reasons were recorded. Our aim was to deliver 
all services during the main visit within half a day. However, women could choose to leave before 
having received all results, and either return for a scheduled additional visit or receive instructions 
regarding the need for follow-up via letter or mobile phone. Care was taken to preserve participant 
confidentiality throughout the study. 
 
Gold standard testing 
The CT/NG GeneXpert assay was considered a gold standard because of its excellent performance 
compared to other validated CT/NG NAAT tests.91 While only women who had a positive CT/NG score 
were tested that same day, GeneXpert swabs were also taken from all other women and tested in 
batches. All other gold standard NAAT tests were conducted in the STI reference laboratory of the 
Institute of Tropical Medicine in Antwerp, Belgium: TV, Mycoplasma genitalium (MG), Candida 
albicans, Lactobacillus genus, Gardnerella vaginalis, and Atopobium vaginae on vaginal swabs, and 
Escherichia coli on urine (Appendix E, pages 175-177).83 C. albicans qPCR is not a true gold standard 
test for VVC, but we will refer to it as such in this paper (Appendix E, page 176). True BV cases were 
determined by a validated vaginal qPCR score [log10 geq/ml (Lactobacillus genus) - log10 geq/ml (G. 
vaginalis + A. vaginae) below -2] (Appendix E, page 177).85 HIV, syphilis, pregnancy, and UTI POCTs 
were offered as a service to participants and their performances were not evaluated.109,110 
 
111 
Acceptability and feasibility 
A subset of participants (n=107) were interviewed about their experiences with WISH procedures by an 
interviewer with no previous relationship with the interviewee using a semi-structured ‘client 
satisfaction survey’ (Appendix E, page 180). Another subset of participants (n=20) was observed and 
timed throughout their clinic trajectory. 
 
Statistical analysis 
The target sample size was 500 to 1,000 participants, depending on resources. With a sample size of 
500, we expected to identify 50-175 true cases of each relevant infection.25,206 Statistical analyses were 
performed using Stata 13 (StataCorp, College Station, USA). Sensitivity, specificity, positive predictive 
value (PPV), and negative predictive value (NPV) with 95% confidence intervals were calculated for 
proportions of women that would have been or were treated for a specific VDS/LAP-associated 
organism (CT, NG, TV, BV, and VVC; table 6.1) in accordance with the WHO and WISH algorithms, 
respectively, each compared to gold standard cases. We used the WHO VDS algorithm in the absence 
of physical examination and assumed that all women with VDS would have been treated for CT and NG 
(in addition to TV and BV) due to high prevalences in our study population (Appendix E).25,206 
 
Table 6.1: Conditions under which organism-specific treatments were dispensed, or would have 
been dispensed, in each algorithm 
Organism WHO algorithms WISH algorithms Gold standard 
CT  VDS and high risk or high local prevalence 
 PID (after bimanual for LAP) 
Positive CT GeneXpert, after 
positive risk-scoring‡ 
Positive CT 
GeneXpert 
NG  VDS and high risk or high local prevalence 
 PID (after bimanual for LAP) 
Positive NG GeneXpert, 
after positive risk-scoring‡ 
Positive NG 
GeneXpert 
TV  VDS 
 PID (after bimanual for LAP) 
Positive TV OSOM, on 
everyone 
Positive TV PCR 
BV  VDS 
 PID (after bimanual for LAP) 
Vaginal pH ≥5.0 on EcoCare 
pH swab, on everyone 
BV by vaginal 
qPCR score§ 
VVC − VDS that is curd-like, vulval edema, 
erythema, or excoriations present* 
VVC-like symptoms 
reported (see WHO 
algorithm) or observed 
Positive Candida 
albicans qPCR 
Syphilis − GUD (after visualisation by provider)† Positive syphilis POCT 
confirmed by RPR, after 
positive risk-scoring‡ 
Not available 
BV bacterial vaginosis, CT Chlamydia trachomatis, GUD genital ulcer disease, LAP lower abdominal pain, NG Neisseria gonorrhoeae, PID 
pelvic inflammatory disease, (q)PCR (quantitative) polymerase chain reaction, RPR rapid plasma reagin, TV Trichomonas vaginalis, VDS 
vaginal discharge syndrome, WHO World Health Organisation.  
See Appendix E for rationale behind choice for gold standard tests.  
*The latter three WHO-specified criteria (vulval edema, erythema, or excoriations) seem inappropriate for the algorithm without examinations. 
We therefore assumed that a woman would have been treated for VVC if she reported VDS, and in addition, this VDS was curd-like and/or 
occurred with genital itching or burning. †Only women with a positive RPR and no recent treatment should be treated. However, in the 
absence of this information, we assumed that all women with GUD would have been treated for syphilis. ‡See figure 6.1 for CT/NG and 
syphilis risk scores. §See methods for the vaginal qPCR score. 
 
Ethical statement 
All participants provided written informed consent. The study was sponsored by the University of 
Liverpool, approved by the Rwanda National Ethics Committee and the University of Liverpool 
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Research Ethics Subcommittee for Physical Interventions, and registered in ClinicalTrials.gov 
(NCT03045809).  
 
6.3 Results 
All 705 enrolled participants completed a study visit, and 51 women attended 53 additional visits to 
receive results and/or treatment (n=40 women), because of persistent or new symptoms (n=11), because 
of a mild allergic reaction to metronidazole (n=2; no other adverse events or social harms reported), for 
a speculum examination (n=1), and/or to obtain information (n=1). Participants were a median of 32.9 
years (range: 18-62), 65.4% were never married, 32.2% reported a new sex partner in the past three 
months, and 35.5% had engaged in sex work in the past 12 months (table 6.2). The majority of women 
reported to ever have been tested for HIV (99.0%) or to ever have been treated for an STI (71.2%), with 
19.0% reporting to be living with HIV. Most women reported at least one urogenital symptom (85.7%), 
and more symptoms were reported structurally than spontaneously (Appendix, table E.2). Of the women 
structurally reporting symptoms, 7.1% had already sought medical care for these symptoms, and 17.1% 
had used traditional medications. 
 
Algorithm performances and optimal algorithms 
Table 6.3 shows the percentages of women who were treated, or would have been treated, for specific 
infections based on WHO, WISH, and gold standard algorithms. Almost half (306/690, 44.3%) of the 
women had at least one VDS/LAP-associated infection by gold standard testing: 60/705 (8.5%) CT, 
50/705 (7.1%) NG, 111/690 (16.1%) TV, 125/690 (18.1%) BV, and 59/690 (8.6%) VVC; 229/690 
(33.2%) had one VDS/LAP-associated infection and 77/690 (11.2%) had two or more infections 
(correlation matrix of gold standard infections shown in Appendix, table E.3). 
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Table 6.2: Characteristics of study participants 
Demographic data N (% of 705)  
or median 
(IQR) 
Age, years 32.9 (28.2-38.0) 
Marital status 
- Never married 
- Married 
- Divorced 
- Widowed 
 
461 (65.4) 
209 (29.7) 
18 (2.6) 
17 (2.4) 
Highest educational level attained 
- No schooling 
- Primary school not completed 
- Primary school completed 
- Secondary school not completed 
- Secondary school completed 
- More than secondary school 
 
113 (16.0) 
159 (22.6) 
176 (25.0) 
135 (19.2) 
90 (12.8) 
32 (4.5) 
Sexual history  
Male sex partners in lifetime 4 (2-8) 
Male sex partners in past 12 months 2 (1-3) 
New sex partner in the past three months 227 (32.2) 
Currently has a main sex partner 618 (87.7) 
Number of vaginal sex acts in the past two weeks 4 (2-10) 
Has had anal sex in the past two weeks 7 (1.0) 
Condom use during vaginal sex in past 2 weeks (N=704) 
- Always 
- Sometimes but not always 
- Never 
 
24 (3.4) 
114 (16.2) 
566 (80.4) 
Used condom during last vaginal sex act (N=704) 83 (11.2) 
Exchanged sex for money or goods in past 12 months 250 (35.5) 
Reproductive and contraceptive history  
Pregnancies in lifetime 3 (2-4) 
Ever used a product to prevent pregnancy 527 (74.8) 
Currently using a product to prevent pregnancy 222 (31.5) 
 If yes, product currently using (N=222): 
- Combined estrogen/progestin pills* 
- Progestin injections† 
- Progestin implant‡ 
- Copper IUD 
- Participant is sterilised 
 
38 (17.1) 
61 (27.5) 
77 (34.7) 
37 (16.7) 
9 (4.1) 
General medical history  
Is currently taking an antibiotic or antifungal§ 134 (19.0) 
Tested for HIV in the past 698 (99.0) 
Number of times tested for HIV in lifetime 4 (3-6) 
Known to be HIV-positive prior to main visit 135 (19.2) 
Treated for an STI in the past 502 (71.2) 
Treated for BV in the past 35 (5.0) 
Treated for VVC in the past 129 (18.3) 
Treated for UTI in the past  100 (14.2) 
Participant-reported symptoms  
Any urogenital symptom – structurally reported 604 (85.7) 
VDS curd-like 265 (37.6) 
VDS offensive-smelling 119 (16.9) 
LAP 245 (34.8) 
Genital ulcers/blisters/sores 41 (5.8) 
Inguinal buboes 1 (0.1) 
Genital warts 0 
BV bacterial vaginosis, IQR interquartile range, IUD intra-uterine device, LAP lower abdominal pain, STI 
sexually transmitted infection, UTI urinary tract infection, VDS vaginal discharge syndrome.  
All data are self-reported by participants.  
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*All reported ethinylestradiol/levonorgestrel use. None reported progestin-only pills. †48 reported using depot 
medroxyprogesterone acetate, 13 reported norethisterone use. ‡All reported using a levonorgestrel-releasing 
implant. §Includes 124 HIV-positive women using trimethoprim/sulfamethoxazole prophylaxis.  
 
Table 6.3: Infections treated, or would have been treated, using different algorithms 
VDS-associated 
infections 
treated 
Gold standard 
testing 
n (% of 705) 
WHO algorithms*† 
n (% of 705) 
WISH algorithms* 
n (% of 705) 
At least one 306 (44.3)‡ 392 (55.6) 608 (86.2) 
CT 60 (8.5) 392 (55.6) 43 (6.1) 
NG 50 (7.1) 392 (55.6) 38 (5.4) 
TV 111 (16.1)‡ 392 (55.6) 92 (13.1) 
BV 125 (18.1)‡ 392 (55.6) 466 (66.1) 
VVC 59 (8.6)‡ 366 (51.9) 235 (33.3) 
Other conditions 
treated 
Gold standard 
testing 
n (% of 705) 
WHO algorithms*† 
n (% of 705) 
WISH algorithms* 
n (% of 705) 
MG 26 (3.8)‡ NA NA 
Syphilis NA 16 (2.3) 21 (3.0) 
PID NA 29 (4.1) 32 (4.5) 
HIV NA NA 55 (7.8)§ 
UTI NA NA 161 (22.8) 
Pregnancy NA NA 33 (4.7) 
Vaginal pH 
results 
Gold standard 
testing 
n (% of 705) 
WHO algorithms*† 
n (% of 705) 
WISH algorithms* 
n (% of 705) 
4.0 NA NA 68 (9.7) 
4.5 NA NA 171 (24.3) 
5.0 NA NA 180 (25.5) 
5.5 NA NA 107 (15.2) 
6.0 NA NA 137 (19.4) 
6.5 NA NA 28 (4.0) 
7.0 NA NA 11 (1.6) 
7.5 NA NA 3 (0.4) 
BV bacterial vaginosis, CT Chlamydia trachomatis, MG Mycoplasma genitalium, NA not applicable, NG Neisseria gonorrhoeae, PID pelvic 
inflammatory disease, TV Trichomonas vaginalis, VDS vaginal discharge syndrome, VVC vulvovaginal candidiasis, UTI urinary tract infection.  
*Algorithms are explained in figure 6.1 and table 6.1. †WHO published two VDS algorithms: one that incorporates speculum examinations 
and one that does not. We used the algorithm without speculum examination but with differentiation between not VVC-like (treated for CT, 
NG, TV, and BV) and VVC-like (also treated for VVC) based on structural reporting. ‡N=690 due to 15 invalid PCR results. §Only includes 
participants who tested positive for HIV at RU. Includes 24 known HIV-positive women who wanted to be retested. 
 
An additional 26/690 (3.8%) tested MG-positive, but this infection was not included in the WHO or 
WISH algorithms. If the WHO VDS/LAP algorithms had been used, 392/705 (51.9%) of the women 
would have received treatment for all five VDS/LAP-associated infections and an additional 26/705 
(3.7%) for all except VVC. The WISH algorithms identified similar numbers of CT, NG, and TV cases 
as gold standard testing, but much higher numbers of BV and VVC cases (table 6.3). Compared to gold 
standard results, the WHO VDS/LAP algorithms had moderate sensitivity (58.3-74.6%) and poor 
specificity (44.7-50.6%) for all infections (table 6.4). The WISH algorithms had good sensitivity (68.5-
76.0%) and high specificity (97.4-100%) for CT, NG, and TV but low specificity for BV (41.2%; 
sensitivity 95.2%), and moderate sensitivity (64.4%) and specificity (69.4%) for VVC.  
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Table 6.4: Performance of the WHO syndromic algorithms, WISH algorithms, and optimal BV 
algorithm compared to gold standard testing 
Conditions* 
(N=705) 
GS WHO VDS/LAP algorithms 
Neg 
n 
Pos 
n 
n POC† 
tested 
n GS† 
tested 
TP‡ 
n 
FP‡ 
n 
FN‡ 
n 
TN‡ 
n 
Sens‡ 
% 
(95% CI) 
Spec‡ 
% 
(95% CI) 
PPV‡ 
% 
(95% CI) 
NPV‡ 
% 
(95% CI) 
CT 645 60 0 0 35 357 25 288 58.3  
(45.5-70.2) 
44.7  
(40.8-48.5) 
8.9 
(6.5-12.2) 
92.0 
(88.4-94.6) 
NG 655 50 0 0 33 359 17 296 66.0 
(51.8-77.8) 
45.2 
(41.4-49.0) 
8.4 
(6.0-11.6) 
94.6 
(91.4-96.6) 
CT and/or NG 605 100 0 0 61 331 39 274 61.0 
(51.1-70.1) 
45.3 
(41.4-49.3) 
15.6 
(12.3-19.5) 
87.5 
(83.4-90.8) 
TV 579 111 0 0 67 315 44 264 60.4 
(50.9-69.1) 
45.6 
(41.6-49.7) 
17.5 
(14.0-21.7) 
85.7 
(81.3-89.2) 
BV 565 125 0 0 77 305 48 260 61.6 
(52.7-69.7) 
46.0 
(41.9-50.2) 
20.2 
(16.4-24.5) 
84.4 
(79.9-88.1) 
BV and/or TV 481 209 0 0 124 258 85 223 59.3 
(52.5-65.8) 
46.4 
(41.3-50.8) 
32.5 
(27.9-72.1) 
72.4 
(67.1-77.1) 
VVC 631 59 0 0 44 312 15 319 74.6 
(61.9-84.1) 
50.6 
(46.6-54.5) 
12.4 
(9.3-16.2) 
95.5 
(92.7-97.3) 
 GS WISH algorithms 
CT 645 60 396 0 43 0 17 645 71.7 
(58.3-81.7) 
100 
(100-100) 
100 
(100-100) 
97.4 
(95.9-98.4) 
NG 655 50 396 0 38 0 12 655 76.0 
(62.2-85.9) 
100 
(100-100) 
100 
(100-100) 
98.2 
(96.9-99.0) 
CT and/or NG 605 100 396 0 75 0 25 605 75.0 
(65.5-82.6) 
100 
(100-100) 
100 
(100-100) 
96.0 
(94.2-97.3) 
TV 579 111 690 0 76 15 35 564 68.5 
(59.2-76.5) 
97.4 
(95.7-98.4) 
83.5 
(74.4-89.8) 
94.2 
(92.0-95.8) 
BV 565 125 690 0 119 332 6 233 95.2 
(89.7-97.8) 
41.2 
(37.2-45.4) 
26.4 
(22.5-30.7) 
97.5 
(94.5-98.9) 
BV and/or TV 481 209 690 0 194 274 15 207 92.8 
(88.4-95.6) 
43.0 
(38.7-47.5) 
41.5 
(37.1-46.0) 
93.2 
(89.1-95.9) 
VVC 631 59 0 0 38 193 21 438 64.4 
(51.4-75.6) 
69.4 
(65.7-72.9) 
16.5 
(12.2-21.8) 
95.4 
(93.1-97.0) 
 GS Optimal BV and VVC algorithms§ 
BV 565 125 690 275 92 0 33 565 73.6 
(65.1-80.6) 
100 
(100-100) 
100 
(100-100) 
94.5 
(92.3-96.1) 
BV and/or TV 481 209 690 223 152 10 57 471 72.7 
(66.3-78.4) 
97.9 
(96.2-98.9) 
93.8 
(88.9-96.7) 
89.2 
(86.2-91.6) 
VVC  631 59 690 279 35 0 24 631 59.3 
(46.3-71.1) 
100 
(100-100) 
100 
(100-100) 
96.3 
(94.6-97.5) 
BV bacterial vaginosis, CI confidence interval, CT Chlamydia trachomatis, FN false negative, FP false positive, GS gold standard, LAP lower 
abdominal pain, NG Neisseria gonorrhoeae, Neg negative, NPV negative predictive value, POC point-of-care, Pos positive, PPV positive 
predictive value, Sens sensitivity, Spec specificity, TN true negative, TP true positive, TV Trichomonas vaginalis, VDS vaginal discharge 
syndrome, VVC vulvovaginal candidiasis.  
*See table 6.1 for definitions. Performance statistics were also calculated for CT and NG combined and BV and TV combined, because the 
former are assessed by one assay and the latter require the same treatment. †These are the numbers that would require POCT and gold 
standard testing if each respective algorithm were to be implemented in a real-life situation. This number is lower for BV and/or TV than for 
BV alone because women who had a positive TV POCT would already be treated with metronidazole, which also covers BV. ‡Compared to 
gold standard testing. For TV, BV, and VVC, N=690 due to 15 invalid PCR results. §All women would have a vaginal pH determined and 
those with pH ≥5.5 would also have a vaginal qPCR score done (see methods). Only women with pH ≥5.5 and a positive vaginal qPCR score 
would be treated for BV. Women would only be tested for VVC if they had VVC-like symptoms and had tested negative for CT, NG, TV, and 
BV (by optimal algorithm), or were pregnant (regardless of symptoms). 
 
We used the GeneXpert CT/NG assay in WISH and for gold standard testing, but in WISH only women 
with a positive CT/NG risk score were tested. This resulted in 56.2% of the women being tested, and 
25.0% of true infections missed (Appendix, table E.4). The TV OSOM POCT was offered to all women 
and had moderate sensitivity (68.5%). The main problem with the WISH algorithms was the high 
number of false-positive BV and VVC diagnoses. We therefore designed post-hoc ‘optimal’ BV and 
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VVC algorithms using WISH study data (Appendix E, pages 179-180). We achieved the best balance 
between reducing BV false-positives and numbers of women requiring testing by determining vaginal 
pH in all women (as had previously been done), but adding a confirmatory test when pH≥5.5 (275 
confirmatory tests required). Sensitivity, specificity, PPV and NPV were 73.6%, 100%, 100%, and 
94.5%, respectively, when using the vaginal qPCR score as the confirmatory test (table 6.4), and were 
only slightly reduced when using the Lactobacillus qPCR as a stand-alone confirmatory test (with <105 
geq/ml considered BV; Appendix, table E.5). The optimal VVC algorithm was based on the following 
observations (Appendix E, pages 179-180): 1) no vaginal pH cut-off could adequately predict VVC 
(data not shown); and 2) pregnant women were much more likely to have VVC than BV (19.4% and 
6.5%, respectively). In the optimal VVC algorithm, women would only be tested for VVC if they had 
VVC-like symptoms and had tested negative for CT, NG, TV, and BV (using the optimal algorithm) or 
were pregnant. The sensitivity, specificity, PPV, and NPV were 59.3%, 100%, 100%, and 96.3%, 
respectively.  
 
Of note, neither participant-reported symptoms nor clinician-observed signs correlated with the 
presence of any infection (table 6.5). Furthermore, performance of WISH CT, NG, TV, optimal BV, 
and optimal VVC algorithms were similar or slightly worse when restricted to a subgroup of women 
who had been seeking care or were taking traditional medications for their current symptoms 
(Appendix, table E.5). Also of note, 161/705 (22.8%) of WISH participants were treated for a UTI 
because urinalysis detected any nitrite and/or leukocytes in their urine whereas only 41/161 (25.5%) of 
their urines had an E. coli concentration of ≥105 geq/ml by qPCR (Appendix, table E.6 and page 180).  
 
Other clinical observations 
In WISH, VDS/LAP-associated POCT-confirmed infections and VVC were by far the most common 
diagnoses made, followed by urinalysis-based UTI. POCT-confirmed syphilis (n=21), and syndromic 
diagnoses of pelvic inflammatory disease (n=32), non-syphilis genital ulcers (n=16), inguinal buboes 
without genital ulcers (n=0), and genital warts (n=3) were much less common. Study physicians 
performed speculum/bimanual examinations on 56.6% of participants, which was more than had been 
anticipated (Appendix, table E.7 and page 177). Treatments and referrals were delivered as required 
with few treatment failures, but the uptake of partner notification was suboptimal: 782 identified 
partners of 201 women (28.5%) required partner notification but only 61 (7.8%) of them were treated at 
the study clinic (Appendix, table E.7 and pages 179). 
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Table 6.5: Associations between symptoms/signs and infections diagnosed by gold standard 
testing 
Symptom structurally reported 
(N=705) N  
CT/NG 
(N=100) 
TV 
(N=111) 
BV* 
(N=125) 
VVC 
(N=59) 
Syphilis 
(N=21) 
No 
infection† 
(N=377) 
No symptoms reported 136 14 (10.3) 17 (12.7) 22 (16.4) 3 (2.2) 3 (4.6) 84 (62.7) 
Any unusual VDS 386 57 (14.8) 65 (17.3) 76 (20.2) 44 (11.7) 11 (5.3) 193 (51.3) 
Curd-like VDS 265 36 (13.6) 41 (15.7) 41 (15.7) 31 (11.9) 8 (5.6) 142 (54.4) 
Any unusual VDS without other 
symptoms 25 9 (36.0) 6 (25.0) 6 (25.0) 0 0 9 (37.5) 
Genital itching and/or burning 470 68 (14.5) 80 (17.5) 85 (18.6) 51 (11.1) 16 (6.4) 239 (52.2) 
Genital itching and/or burning without 
other symptoms 
80 17 (21.3) 18 (22.8) 14 (17.7) 6 (7.6) 3 (7.5) 35 (44.3) 
LAP and/or pain during sex 308 42 (13.6) 42 (14.0) 48 (16.0) 26 (8.6) 8 (5.0) 173 (57.5) 
LAP and/or pain during sex without 
other symptoms 
31 3 (9.7) 0 4 (12.9) 2 (6.5) 1 (4.8) 22 (71.0) 
GUD (no-one reported inguinal buboes) 41 4 (9.8) 3 (7.7) 4 (10.3) 4 (10.3) 3 (10.3) 25 (64.1) 
GUD without other symptoms 3 0 0 0 0 0 3 (100) 
Sign observed during examination 
(N=399) N 
CT/NG 
(N=59) 
TV 
(N=61) 
BV* 
(N=77) 
VVC 
(N=42) 
Syphilis 
(N=15) 
No 
infection† 
(N=203) 
Any abnormal vaginal/cervical 
discharge/pus 139 44 (31.7) 34 (24.6) 31 (22.5) 25 (18.1) 5 (6.0) 47 (34.1) 
Abnormal vaginal/cervical 
discharge/pus, curd-like 66 5 (7.6) 9 (13.6) 7 (10.6) 22 (33.3) 1 (2.8) 31 (47.0) 
Abnormal genital odour 34 6 (17.7) 3 (9.1) 10 (30.3) 3 (9.1) 1 (5.3) 16 (48.5) 
Cervicitis, vaginitis and/or vulvitis 84 18 (21.4) 13 (15.9) 21 (25.6) 20 (24.4) 1 (2.4) 28 (34.2) 
Uterine, adnexal or cervical motion 
tenderness (=PID) 31 16 (51.6) 8 (26.7) 7 (23.3) 3 (10.0) 0 6 (20.0) 
GUD +/- inguinal buboes, any location 40 5 (12.5) 5 (13.5) 10 (27.0) 6 (16.2) 6 (15.0) 14 (37.8) 
Inguinal buboes (without GUD) 0 0 0 0 0 0 0 
BV bacterial vaginosis, CT Chlamydia trachomatis, GUD genital ulcer disease, LAP lower abdominal pain, NG Neisseria gonorrhoeae, PID pelvic 
inflammatory disease, POCT point-of-care test, TV Trichomonas vaginalis, VDS vaginal discharge syndrome, VVC vulvovaginal candidiasis. 
Data are n/(N %), where % are row percentages. The denominator N is the number of women reporting that specific symptom (with or without other 
symptoms as indicated), or women who underwent a speculum examination and had that specific sign (multiple signs allowed). The actual denominator 
per cell may vary slightly due to the 15 invalid gold standard results. Women could have multiple infections.  
*BV defined as vaginal qPCR score [log10 geq/ml (Lactobacillus genus) - log10 geq/ml (Gardnerella vaginalis + Atopobium vaginae)] <-2. †Defined as no 
CT/NG, TV, BV, and VVC by gold standard test, and no syphilis by POCT. 
 
Feasibility and acceptability of integrating POCTs 
Participants accepted all testing services offered to them with the exception of HIV testing (rejected by 
15.3%, mostly due to known HIV-positive status) and pregnancy testing (rejected by 17.0%, mostly 
because of reliable contraceptive use or known pregnancy) (Appendix, table E.8). Most women (86.9%) 
who were offered a CT/NG POCT chose to wait for the results, 10.4% elected to be contacted by phone 
or letter, and only 1.3% elected to schedule a follow-up appointment. All women accepted counselling, 
and a variety of topics were chosen, but only 6.2% were interested in a condom demonstration 
(Appendix, table E.9). Women who did not have to wait for a GeneXpert CT/NG result spent a median 
of 98 minutes at the clinic whereas women who did have to wait a median of 212 minutes (Appendix, 
table E.10). 
 
The 107 participants who completed a client satisfaction survey liked all WISH procedures (Appendix, 
table E.11). The main point of criticism was the visit duration: 42.1% of the women thought the visit 
was long but everyone thought that the services received were worth it. Study staff reported that the 
POCTs were easy to perform and interpret, and did not identify any major testing or clinic flow 
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problems (data not shown).  
 
6.4 Discussion 
In the WISH study, VDS (including genital itching and burning) and LAP (including pain during sex) 
were by far the most common symptoms reported. The majority of the women reporting these 
symptoms did not require immediate treatment because they either had no infection, or had mild vaginal 
dysbiosis (defined here as above-normal vaginal concentrations of inflammatory micro-organisms that 
did not reach diagnostic thresholds), which may have resolved without treatment.4,9 When a condition 
was present, patient-reported symptoms and clinician-observed signs did not accurately predict which 
one, as has been shown in other studies.94,97,98,100 We therefore believe that the WHO VDS/LAP 
algorithms should be revised and that the revised algorithms should incorporate POCTs to improve 
diagnostic accuracy. The WISH study showed that POCTs are implementable and highly acceptable in 
resource-poor settings. An additional advantage may be that clinicians improve their diagnostic skills 
over time by comparing their symptoms/signs-based diagnoses with POCT test results. However, major 
barriers include the lack of ASSURED POCTs for some infections, time constraints, and costs. The goal 
for the coming years therefore should be to continue POCT development, and design algorithms that 
maximise appropriate treatments delivered; minimise complications, overtreatment, and drug resistance; 
and minimise the number of POCTs required to achieve this. Some of the time and human resources 
required to conduct POCTs might be recuperated by integrating sexual and reproductive health services 
for women, and by minimising the number of speculum examinations. In the WISH study, these did not 
have much added value, other than identifying some cases of (suspected) pelvic inflammatory disease. 
The number of POCTs required might be reduced by risk scoring based on local epidemiology to decide 
who is tested for which infections, as we did in WISH, but risk scores would have to be locally 
validated.  
 
The WHO algorithms were designed for women seeking care for urogenital symptoms. The WISH 
study tested women at risk of urogenital infections regardless of symptoms, recognising the fact that 
asymptomatic infections are common, continue to fuel HIV/STI epidemics, and can cause 
complications.9,87 Moving forward, we recommend that guidelines address both types of case-finding. 
Women who proactively seek care for VDS/LAP symptoms because their quality of life is negatively 
affected would benefit from testing for CT, NG, TV, BV, and VVC. Pregnant women are at risk of the 
most severe complications (such as preterm birth and neonatal sepsis),87 and we therefore believe that 
they should be comprehensively screened for HIV, STIs, BV, VVC, and vaginal pathobiont carriage 
(e.g. Streptococcus agalactiae), regardless of symptoms. Women at high risk of HIV/STIs (to be 
defined locally) should be tested for HIV/STIs regardless of symptoms, and possibly also BV and VVC, 
in an effort to control HIV/STI epidemics and minimise infertility and pelvic inflammatory disease. We 
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believe that these recommendations should not just apply to resource-poor countries but also to primary 
care settings in Europe and elsewhere. 
 
ASSURED POCTs would improve feasibility, performance, and cost-effectiveness of both types of 
case-finding.106,108 HIV, syphilis, and pregnancy POCTs have already been successfully integrated in 
many clinics and screening programmes.109,110 We and others obtained good results with the GeneXpert 
CT/NG and TV OSOM POCTs,91 but the former could be improved by reducing turnaround time and 
costs, and a next generation of TV POCTs with improved performance would be welcomed. 
Furthermore, better POCTs for BV and VVC should be developed. The WISH study showed that 
vaginal pH can be used as an initial screening test for BV but would require confirmatory testing. We 
used three qPCR assays to identify true BV cases (Lactobacillus, G. vaginalis, and A. vaginae), but we 
also showed that a qPCR for Lactobacillus genus suffices. Gram stain Nugent scoring78 could also be 
used as a confirmatory test. Unfortunately, POCTs based on detecting G. vaginalis enzymes or 
metabolites, or C. albicans antigens/antibodies, have shown inadequate sensitivity and specificity thus 
far.46,207 A combined NAAT-based POCT for BV (Lactobacillus concentration), TV (presence), and 
VVC (Candida genus presence) may provide the best balance between optimising diagnostic accuracy 
and minimising required resources. Such a POCT could be used in combination with a CT/NG POCT 
(e.g. in women seeking care for VDS/LAP symptoms) and/or other POCTs (e.g. to screen pregnant 
women and women at high risk of HIV/STIs, as outlined above). The WISH data also suggest that 
better UTI POCTs should be developed.208 
 
The WISH study was implemented in a high prevalence population by highly trained and experienced 
staff who had access to adequate clinic and laboratory resources. Additional studies are required in low 
prevalence settings and in public primary care clinics. Even though we tried to recruit women with and 
without symptoms, our recruitment strategies mostly attracted women with symptoms, and it was not 
always clear which women would have sought care for their symptoms in real life. Furthermore, the 
95% confidence intervals of our sensitivity estimates were wide. Future studies should enrol women 
who are seeking care for urogenital symptoms, as well as women not seeking care, in sufficient 
numbers to achieve high precision performance estimates in both groups. As with most observational 
studies, our data collection likely suffered from selection and social-desirability bias despite our efforts 
to minimise these. Finally, the WISH study did not include a cost-effectiveness component. Cost-
effectiveness studies of different POCT-based algorithms in different settings will be essential. 
 
We conclude that POCTs should be integrated into urogenital infection algorithms directed at women 
seeking care for symptoms and vulnerable women regardless of symptoms. However, improved 
availability of ASSURED POCTs is required, and we particularly recommend the development of a 
NAAT-based POCT combining BV, TV, and VVC diagnoses. 
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Chapter 7 - Synthesis, Conclusions, and Recommendations 
 
The final chapter summarises, discusses, and synthesises the key findings of this thesis. 
 
7.1 Rationale and Aim of The Thesis 
The aim of this thesis was to inform potential improvements in the sexual and reproductive health of 
Rwandan women, with an emphasis on vaginal dysbiosis. Urogenital infections, including vaginal 
dysbiosis, are often associated with urogenital symptoms such as vaginal discharge and lower 
abdominal pain, which can cause great discomfort to women. Better diagnostics and therapeutics are 
therefore needed to cure women who present at medical practices or clinics with symptoms. However, 
better identification and treatment are also necessary to decrease the incidence of the many potential 
complications of urogenital infections, such as increased risk of HIV transmission (both male-to-female 
and female-to-male), pelvic inflammatory disease, and adverse pregnancy outcomes such as stillbirth, 
invasive neonatal infections, and preterm birth.9,17–20 Pelvic inflammatory disease can be caused by 
sexually transmitted infections (STIs) such as Chlamydia trachomatis (CT), Neisseria gonorrhoeae 
(NG), and Trichomonas vaginalis (TV), but also by bacterial vaginosis (BV)-anaerobes and 
pathobionts;19 it is associated with sequelae such as ectopic pregnancies, infertility, and chronic pelvic 
pain.87 BV is also associated with infertility in its own right, as well as with a lower success rate of in 
vitro fertilisation.209,210 
 
Urogenital infections are common worldwide. Prevalences of STIs and BV have been shown to be 
highest in resource-poor settings, particularly in sub-Saharan Africa.36,87 Improved urogenital care in 
sub-Saharan Africa is therefore urgently needed, and could be achieved by introducing better diagnostic 
and treatment options. This thesis investigated several such options. Specifically, we investigated the 
impact of oral metronidazole and two different vaginal lactobacilli-containing probiotics on the vaginal 
microbiota (VMB) and on the cure and recurrence of BV, and we studied the feasibility, acceptability 
and diagnostic accuracy of integrating point-of-care testing (POCTs) for urogenital infections into 
urogenital care. 
 
7.2 Interventions to Cure BV and/or to Reduce BV Recurrence 
VMB impact of oral metronidazole 
Chapter 2 showed that oral metronidazole use not only decreased the mean BV-anaerobes concentration 
as expected, but also increased the mean Lactobacillus concentration. However, it is important to note 
that treatment was often only partially successful: only 16.4% of women had a BV-anaerobes 
concentration reduction of more than 50%, and only 5.5% of women had complete eradication. 
Furthermore, treatment was unsuccessful (as defined by Nugent scoring) in 45.5% of women. 
Treatment failure was associated with high Gardnerella vaginalis relative abundance, potentially due to 
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biofilm presence, and with higher pathobionts concentration (its mean concentration in women with 
unsuccessful treatment was 2.30 log10 cells/μl, and in women with successful treatment 1.09 log10 
cells/μl). It is possible that metronidazole is capable of eliminating dispersed G. vaginalis at modest 
concentrations, but is less able to do so when high-concentration G. vaginalis is present and/or when G. 
vaginalis is present in a biofilm. The findings also confirm that most pathobionts are not sensitive to 
metronidazole, and that this hampers the intended cure of women with high pathobionts concentration. 
 
Chapter 3 discussed the safety and preliminary efficacy of intermittent oral metronidazole use to 
prevent BV recurrence. Metronidazole was effective in decreasing BV recurrence (at an incidence rate 
ratio [IRR] of 0.14 compared to negative controls), and had positive effects on the VMB, such as 
increasing the relative abundance of lactobacilli by 32% and reducing the relative abundance of BV-
anaerobes by 19%. However, all beneficial effects disappeared after cessation of metronidazole use, 
possibly due to the fact that our study enrolled women at very high-risk of urogenital infections.  
 
VMB impact of lactobacilli-containing vaginal probiotics 
Chapter 3 discussed the safety and preliminary efficacy of intermittent use of two lactobacilli-
containing vaginal probiotics (Ecologic Femi+ and Gynophilus LP) to prevent BV recurrence. Ecologic 
Femi+ was effective in decreasing BV recurrence (IRR 0.35 compared to negative controls), and had 
positive effects on the VMB, such as increasing the relative abundance of lactobacilli by 30%. 
Gynophilus LP also seemed to have positive VMB effects although these did not reach statistical 
significance, possibly due to insufficient statistical power. All effects disappeared after product use 
cessation, and this may again have been due to the high-risk nature of our cohort. We also showed that 
the intermittent use of vaginal probiotics was acceptable to the Rwandan participants, and that 
adherence to the interventions was high, with 100% of EF+ users and 81.3% of GynLP users using 
≥80% of required doses. Our survey data showed that behavioural counselling is needed to better 
inform women about what they can do themselves to prevent BV and STIs. 
 
We also conducted a systematic review on the impact of lactobacilli-containing vaginal probiotics on 
the VMB. None of the 34 studies included in the review reported major safety issues. Most studies were 
of poor methodological quality and were underpowered, but the overall conclusion was that lactobacilli-
containing vaginal probiotics hold promise for BV cure and prevention. All of the six results contained 
in five medium-risk of bias studies with BV and molecular VMB outcomes results were promising: four 
results were statistically significant and two were non-significant. The eight high-risk BV studies 
showed mixed results: five studies showed significant beneficial effects of probiotic use, one study 
showed non-significant Nugent results but the VMB results were significantly beneficial, and two 
studies did not show any beneficial effects. Vaginal probiotics are however less promising for 
vulvovaginal candidiasis (VVC) cure and prevention: one medium-risk VVC study found no benefit of 
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using probiotics, and of the eleven high-risk VVC studies, five showed significantly beneficial effects 
of vaginal probiotic use, three studies showed non-significant beneficial effects or had mixed results, 
and three studies showed no beneficial effects of probiotic use. Only two studies were able to 
differentiate between probiotic and autologous lactobacilli strains, including our own study.155,160 Our 
systematic review could not identify which Lactobacillus product/strain and which vaginal probiotic 
dosing strategy was the most successful.  
 
Alternative interventions, overall conclusions and future studies 
The question remains whether vaginal probiotics are sufficiently promising to warrant large clinical 
trials investigating their efficacy, or whether the focus should be on alternative interventions for treating 
or preventing BV. These could include the use of hormonal contraception, lactic acid and other 
acidifying agents, biofilm-disrupting treatment (such as vaginal boric acid, retrocyclins, and DNases), 
phage therapy, immune modifiers (such as lactoferrin), and behavioural interventions such as medical 
male circumcision and treatment of male sexual partners.26,46,47,73,116,161,211,212 In some women, it may be 
useful to alter the dose and/or formulation of metronidazole or clindamycin to achieve higher cure 
rates.213,214 Nevertheless, most of these interventions have only been studied in small studies and need to 
be assessed in well-powered clinical trials to be proven worthwhile.  
 
This thesis shows that oral metronidazole was effective in curing BV (metronidazole was effective in 
54.5% of women, although complete eradication of BV-anaerobes only occurred in 5.5%) and 
preventing BV (intermittent use of metronidazole reduced BV recurrence by 86%). However, oral 
metronidazole may not lend itself to long-term chronic use. Earlier studies had also shown that 
intermittent metronidazole was efficacious in preventing BV recurrence (by 45-57% in those 
studies)132,134,137 but this did not lead to its widespread use in clinical practice. Metronidazole use – and 
especially chronic use - likely leads to gut microbiota dysbiosis,215 which in turn causes the gastro-
intestinal side-effects that have been associated with metronidazole (particularly when used in 
combination with alcohol).50 Moreover, although resistance to metronidazole is currently not common,53 
long-term preventive use of antibiotics is not favoured in the current context of the large-scale 
introduction of antibiotic stewardship programmes. Therefore, in practice, intermittent metronidazole 
use may play a role in the management of women with severe recurrent BV, but will most likely not be 
widely introduced.  
 
This thesis also showed that vaginal lactobacilli-containing probiotics are promising in reducing BV 
recurrence (intermittent use of Gynophilus LP and Ecologic Femi+ decreased BV by Nugent recurrence 
by 47 and 65%, respectively). When direct comparisons were made with similar intermittent use of an 
antibiotic, the effectiveness of the vaginal probiotics was inferior to metronidazole (our study)160 or 
clindamycin (Bradshaw et al).137 However, all studies conducted with vaginal lactobacilli-containing 
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probiotics to date have shown that these products are safe. Furthermore, vaginal application would not 
interfere with the gut microbiota. They could therefore be sold over-the-counter without physician-
involvement. However, the regulatory landscape of probiotics will change considerably in the near 
future (see Chapter 1), with the EMA and local drug regulatory agencies requiring human drug approval 
when health claims are made. This could be considered a positive change, because in the current 
situation, many vaginal and oral lactobacilli-containing probiotics claiming BV cure and/or prevention 
of recurrence are on the market in the absence of an evidence-base. However, the majority of companies 
producing these probiotics operate in the food and cosmetics industries and do not have the capacity to 
develop human drugs. As far as we know, only one American company (Osel Inc, Mountainview, CA, 
USA) is currently developing a vaginal probiotic as a human drug (Lactin-V, containing a L. crispatus 
isolated from a healthy woman).216 
 
Expanding the evidence-base for lactobacilli-containing vaginal probiotics not only requires large 
investments by these companies and others, it also requires improved trial designs that incorporate 
molecular techniques. Randomised controlled clinical trials are far superior to observational cohort or 
pre-post treatment studies. All studies should include detailed VMB assessments at baseline just prior to 
randomisation, and as often as possible during follow-up over several menstrual cycles, to track changes 
over time at the molecular level, and to compare responders with non-responders. They should include 
at least one follow-up visit after product use cessation to assess whether the intervention(s) had any 
lasting effects beyond the period of product use. Probiotic and autologous Lactobacillus strains should 
be differentiated by molecular testing. The quantities of all key Lactobacillus strains (probiotic and 
autologous), BV-anaerobes, and pathobionts should be assessed at each time point. Ideally, the presence 
of cervicovaginal inflammation and biofilm should also be assessed at each time point. The exact 
timings of product use and sample collection, adherence, and known confounders should be assessed 
and taken into account in the statistical analyses. Eventually, the impact of product use on the incidence 
of vaginal dysbiosis-related complications (STI/HIV transmission, pelvic inflammatory disease, and 
neonatal infections whenever applicable) should also be studied. 
 
As stated earlier, our study showed that pathobionts are not sensitive to metronidazole. Other studies 
have shown that pathobiont presence in the vagina is common. For example, the prevalence in pregnant 
women of Streptococcus agalactiae, the best-studied vaginal pathobiont, is 17.9% worldwide.45 Vaginal 
pathobionts and their (epidemiological and microbiological) behaviour should therefore be investigated 
more thoroughly than has been done to date. Women with a high concentration of pathobionts who are 
symptomatic or at risk of complications (e.g. pregnant women) might benefit from antibiotic therapy 
with an antibiotic other than metronidazole; the choice of antibiotic may depend on the specific 
pathobiont genera/species that are present. Our study also showed that the presence of a high G. 
vaginalis concentration decreases metronidazole treatment success. Other studies have shown that the 
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prevalence of VMBs dominated by a single BV-anaerobe, most commonly G. vaginalis, is not as high 
as the prevalence of traditional highly diverse BV, but is sufficiently substantial to warrant further 
research.5 For example, from a therapeutic point of view, it would be useful to know what proportion of 
these women have a G. vaginalis-containing biofilm. Currently, these women are treated in the same 
manner as traditional high-diversity BV patients, but they may require higher antibiotic dosing, and may 
benefit from biofilm-disrupting agents in combination with antibiotic treatment. Potent anti-anaerobe 
antibiotics targeting all G. vaginalis clades may be useful but are currently not in development. 
 
7.3 Introduction of POC Testing to Improve Urogenital Disease Case-Finding 
Introduction of POC testing in standard urogenital care 
The WISH study showed that the introduction of POCTs in standard urogenital care for women in 
Kigali, Rwanda, was feasible, and had superior performance to the use of WHO syndromic management 
algorithms. Infection-specific sensitivities of the WHO algorithms compared to the gold standards 
ranged from 58.3-74.6%, and specificities from 44.7-50.6%. The WISH POCT-based algorithms that 
we introduced had good sensitivity (68.5-76.0%) and specificity (97.4-100%) for CT, NG, and TV but 
low specificity for BV (41.2%; sensitivity 95.2%), and modest sensitivity (64.4%) and specificity 
(69.4%) for VVC. The study also showed that POCT integration was acceptable to the Rinda Ubuzima 
staff and to the study participants. We therefore believe that the WHO syndromic management 
algorithms should be revised to incorporate the possibility of POC testing. The current syndromic 
management algorithms were designed for women seeking care for their symptoms. We showed, 
however, that urogenital symptoms reported by participants, but also physician-observed signs during 
pelvic examinations, did not correlate well with gold standard laboratory test-confirmed urogenital 
infections (see table 6.5). Therefore, the WHO sexually transmitted infections guidelines should move 
from a merely symptom-based system to a system that includes screening of at-risk populations, and 
women at risk of complications (such as pregnant women) ought to be offered testing even if they are 
asymptomatic. Nevertheless, there are major barriers that make the introduction of POC testing in 
resource-poor settings difficult. These include the current lack of ASSURED (‘Affordable, Sensitive, 
Specific, User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end users’) POCTs for 
some common infections, uncertainties about the cost-effectiveness of POCT introduction, and 
increased health care system demands, especially availability of adequately trained personnel. These 
potential barriers should be addressed in future studies. 
 
Future POCT development 
As described in the introduction, ASSURED POCTs are available and widely used for HIV, syphilis, 
and pregnancy, including in resource-poor settings.109,110 However, no ASSURED POCTs are available 
for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). The sensitivity and specificity of 
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POCTs for BV, VVC, and TV should be improved to fully adhere to the ASSURED criteria. 
Symptomatic women seeking care for their symptoms, or pregnant women, may benefit from combined 
NAAT-based tests for BV (e.g. Lactobacillus abundance), TV, and VVC. Multiplex tests may be less 
expensive than using multiple POCTs for the same clinic visit (as discussed in Appendix E). Optimised 
algorithms for selecting women to be tested for BV and VVC by traditional non-ASSURED laboratory 
testing (Chapter 6), such as Nugent scoring, culture, or qPCR, could provide an immediate way forward 
but are likely to be too complex and expensive to be routinely introduced in urogenital care in resource-
poor settings. Finally, POCTs for pathobiont carriage (e.g. Streptococcus agalactiae, staphylococci, and 
Escherichia coli) should also be developed, for example for testing pregnant women. However, the first 
priority is to improve the pathobiont evidence-base because we currently know much less about vaginal 
pathobionts than about STIs or traditional BV and VVC, and its consequences are severe. 
 
Methodology issues in the WISH study 
The reasons behind the selection of POCTs for evaluation in the WISH study are discussed in Chapter 
6. We intended to choose POCTs that complied with the ASSURED criteria, and specifically assays that 
could be conducted and interpreted by primary care clinic staff in African settings. Unfortunately, many 
of the selected POCTs did not fully adhere to these criteria as outlined in Appendix E and in the 
previous section. 
 
Appendix E also outlines the selection of clinical reference or gold standard testing in the WISH study. 
We chose nucleic acid amplification testing for CT/NG (by GeneXpert), VVC (by Candida albicans 
quantitative PCR), TV (by qualitative T. vaginalis PCR), and BV (by the vaginal qPCR score85 based on 
concentrations of Lactobacillus genus, G. vaginalis, and A. vaginae). The C. albicans qPCR is not a 
true gold standard test as VVC can be caused by other yeasts/fungi. However, this test was chosen as C. 
albicans is the principal causative organism of VVC,30 and due to the pro-inflammatory nature of C. 
albicans: asymptomatic carriage is only likely when present at low concentrations. Future research is 
needed to better determine at which concentration threshold C. albicans causes urogenital symptoms 
and/or sequelae. Similarly, the vaginal qPCR score used was not a true gold standard test; the score was 
based on comparisons with the Nugent criteria, in which [log10 geq/ml (Lactobacillus genus) - log10 
geq/ml (G. vaginalis + A. vaginae)] below -2 had the highest diagnostic accuracy compared with a 
Nugent score of 7-10.85 A cut-off of -2 means that a BV diagnosis is made when the Lactobacillus 
concentration is at least 100 times lower than the combined G. vaginalis and A. vaginae concentration; 
this cut-off is quite stringent, and we cannot discard the possibility that women with a higher vaginal 
qPCR score may still need treatment in some cases. As is the case for VVC, the lactobacilli 
concentration threshold below which treatment is needed and sequelae are prevented is currently not 
known. It should be noted that the vaginal qPCR score is by no means a POCT due to the laboratory 
infrastructure needed to perform the qPCR tests, but we do think that the vaginal health qPCR score 
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could serve as a starting point for the development of future ASSURED BV assays. It may even be 
possible to use the Lactobacillus concentration on its own instead of the combination of the three 
concentrations; our WISH data suggest that the performance would decline minimally. 
 
Future studies 
We show in this thesis that POC testing for urogenital infections improves case-finding and is feasible 
in resource-poor settings. Additional studies should be conducted to further investigate these findings, 
including in populations with lower prevalences of urogenital infections. In our view, and as outlined in 
the discussion of Chapter 6, the two most important future steps in this field are optimisation of 
diagnostic criteria (particularly for BV, pathobionts, and other poorly characterised types of vaginal 
dysbiosis), and the development of ASSURED POCTS, including POCTs targeting multiple conditions. 
 
To determine the cost-effectiveness of POC-testing for urogenital infections, large randomised clinical 
trials should be conducted and should only take place when ASSURED POCTs for all main urogenital 
infections (CT/NG, TV, BV, and VVC; potentially also pathobionts when targeting pregnant women) 
are available as outlined in the section ‘Future POCT development’. A good example would be a cluster 
randomised clinical trial comparing clinics providing WHO syndromic management (such as STI 
clinics and general practices) with clinics offering women POC-testing regardless of symptom-
reporting. However, such a design poses ethical concerns because we now have ample evidence that 
POC-testing will outperform syndromic management; the research question would not be whether POC-
testing will perform better but by how much, and what this means in terms of the incidence of 
complications and cost-effectiveness. A stepped-wedge cluster randomised clinical trial with phased 
introduction of POC testing might be a good way of dealing with these ethical concerns.217 
 
Final conclusions on POCT integration 
The uncertainties about POCTs and their cost-effectiveness should not deter the reproductive health 
care community from the fact that the status quo of urogenital infection management is unsustainable. 
This thesis clearly shows that syndromic management algorithms have poor performance, and that 
reported symptoms and observed signs do not adequately predict the presence of urogenital infections. 
It is both possible and necessary to improve urogenital disease case-finding by working towards 
introducing the currently available POCTs for CT, NG, and TV in urogenital care, including in 
resource-poor settings. 
 
7.4 General Methodological Limitations of the Studies 
In this thesis, the high-dimensional 16S rRNA gene sequencing data were reduced in both conventional 
and non-conventional ways. The most novel data reduction method that we used was the categorisation 
of amplicon sequence variants (ASVs) into four bacterial groups based on existing biological 
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knowledge of the pathogenicity of VMB bacteria. Lactobacilli were considered optimal and were 
grouped together into one group.4,8 Anaerobic bacteria that have been described in the scientific 
literature as being associated with BV were grouped together into another group that we referred to as 
‘BV-anaerobes’. Bacteria known to have higher pathogenicity than BV anaerobes, and that have been 
associated with invasive disease in vulnerable people (such as neonates and hospitalised patients) were 
categorised as ‘pathobionts’. The ASVs that could not be placed in any of these three groups formed the 
fourth group (called ‘other bacteria’), which ended up consisting of normal, harmless skin bacteria (e.g. 
Corynebacteria), Bifidobacteria, and a few other minority species. Our VMB types were not solely 
based on hierarchical clustering, as is usually the case, but also took the relative abundance of these four 
bacterial groups into account. We did this because hierarchical clustering is based on relative 
abundances only and does not take pathogenicity into account. For example, women with 70% 
lactobacilli and 30% S. agalactiae may end up in a lactobacilli-dominated cluster together with women 
who have 95-100% lactobacilli, whereas we believe that the 30% S. agalactiae may matter from a 
clinical point of view. These methods have never been used by others in the VMB field. We did present 
them to VMB experts in international conferences, and initial reactions were positive. 
 
In this thesis, we estimated bacterial group concentrations using a combination of relative abundances 
and the total 16S gene concentration of each sample while correcting for 16S copy numbers per taxa. 
This method has been used by other research groups, including research groups in the VMB 
field.118,218,219 Recently, two groups have shown that the concentrations generated with this method 
correlate well with species-specific qPCR-based concentrations for key VMB bacteria, but it should be 
noted that the method has not yet been validated for most minority species.129,130 The most important 
advantage of using estimated concentrations instead of relative abundances is that the data are no longer 
compositional; they are therefore easier to interpret and can be modelled in conventional biostatistical 
models. For example, we reported in Chapter 2 that the relative abundance of pathobionts was higher 
after metronidazole therapy compared to before therapy. This could be interpreted to mean that 
metronidazole kills anaerobes, thereby providing an opportunity for pathobionts to occupy the niche. 
However, the estimated pathobionts concentrations before and after treatment were similar; the relative 
abundance of pathobionts increased after treatment because the total bacterial concentration decreased. 
 
The discussion sections of Chapters 2-6 described the strengths and limitations of the VMB and WISH 
studies in detail. An overarching limitation is that both studies were conducted at one single study site 
in an urban setting in Kigali, Rwanda. This study site had a long history of working with women at high 
risk of STIs, which may have introduced a selection bias. This is particularly true for the Rwanda VMB 
study (Chapters 2-4); the study team did make a large effort to recruit a more diverse group of women 
in terms of STI risk for the WISH study (Chapter 6). The results described in this thesis may therefore 
not be generalisable to general populations of women, not even in Rwanda.  
128 
7.5 Final Recommendations 
To conclude, it is clear that improvements in both the diagnosis and treatment of vaginal dysbiosis and 
STIs are urgently needed, particularly in sub-Saharan Africa and in other resource-poor settings where 
the burden of these infections is highest.  
 
Based on this thesis, we make the following recommendations: 
 Definitions and clinical relevance of various VMB states should be improved and standardised. 
The microbiological knowledge that has been accumulated in recent years should be 
incorporated in these definitions. Microbiological treatment thresholds should be determined. 
 The portfolio of therapies available for vaginal dysbiosis treatment and prevention should be 
expanded, and could include (combinations of) novel/improved antibiotics, biofilm-disrupting 
agents, acidifying agents, vaginal probiotics, and female sex hormones. 
 All interventions should be evidence-based, and this evidence should include microbiological 
assessments. In the case of probiotics, the molecular techniques used should be able to 
differentiate between probiotic strains and autologous strains. 
 The WHO syndromic management guidelines should be amended to allow for, or even 
promote, POC-testing in all settings where this is possible. This should also include POC-
testing of asymptomatic women who are at risk of urogenital infections or the complications 
thereof (e.g. pregnant women). 
 ASSURED POCTs should be developed for all urogenital infections: a combined POCT for 
BV, TV, and VVC is essential, as well as POCTs for various pathobionts to be used in pregnant 
women.  
 In the context of clinical research, researchers should never solely rely on symptoms and/or 
signs for urogenital infection case identification, but should also test for them, preferably using 
highly sensitive and specific gold standard tests.  
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Appendix A  
 
Supplementary Methods (corresponding to Chapters 2 and 3) 
We conducted a randomised pilot clinical trial to determine safety, preliminary efficacy, acceptability, 
and feasibility of one antibiotic and two vaginal probiotic interventions to prevent BV recurrence in 
women diagnosed and treated for bacterial vaginosis (BV) and/or Trichomonas vaginalis (TV) in 
Kigali, Rwanda. We chose to include both women with BV and/or TV as the treatment to these two 
conditions is the same, and BV and TV are closely interlinked.9 This trial was carried out at the Rinda 
Ubuzima research clinic and laboratory in Kigali, Rwanda, from June 2015 until February 2016. The 
study was funded as a pilot study and the sample size was therefore determined by budget availability. 
In Chapter 2, the vaginal microbiota (VMB) effects of the initial metronidazole treatment for BV/TV 
prior to randomisation are reported. In Chapter 3, the VMB effects of the antibiotic and probiotic 
interventions after randomisation are assessed. A flow diagram of the entire trial is shown in figure 3.1. 
 
Recruitment, eligibility criteria, and informed consent procedures 
The target population was women at high risk of urogenital infections living in Kigali, Rwanda. 
Recruitment activities were implemented by study staff with the help of Community Mobilisers, who 
were selected due to their strong connections with high-risk women in Kigali. They helped staff 
organise recruitment meetings in relevant communities. At these meetings, an anonymous pre-screening 
checklist containing the most important eligibility criteria was used, but no information recorded, and 
potentially eligible women were referred to the Rinda Ubuzima clinic for screening. 
 
The main eligibility criteria are described in Chapter 2 and 3. We focussed on BV patients, but also 
included women diagnosed with TV because we expected most of them to also have BV (which was 
indeed the case), and because the treatment for BV and TV is identical. We chose to treat women with 
BV and/or TV with seven days of 500 mg generic oral metronidazole (Tricozole; Laboratory & Allied 
ltd, Nairobi, Kenya) twice daily. Previous studies suggest that oral and vaginal metronidazole of similar 
dose and duration of use have similar efficacy for BV,48,49 but none of the vaginal metronidazole gels 
that were available on the market when we designed our study had proven stability at 30 °C. Additional 
exclusion criteria included physician-observed genital ulcers, condylomata or other genital 
abnormalities; having had an invasive gynaecological procedure in the three months prior to screening; 
history of significant urogenital prolapse, undiagnosed vaginal bleeding, urine or faecal incontinence, or 
blood clotting disorders; allergy to metronidazole or any other components of the study drugs; not 
willing to terminate use of other oral or vaginal probiotics; or participating in another health 
intervention study. These criteria applied to only six women (figures 2.1 and 3.1). HIV-positive and 
pregnant women were referred to local HIV and antenatal care clinics for care. 
 
All participants provided written informed consent. The age of majority for Rwandan women was 21 at 
the time of study implementation, and we therefore also obtained parent/guardian consent for non-
married participants aged 18-20 years. Participants and/or parents/guardians with insufficient literacy 
could sign by thumbprint but the informed consent process was observed by an independent witness 
who co-signed the informed consent form. The witness could not be a Rinda Ubuzima staff member, 
but could be another participant. Participants received the equivalent of three GBP per visit in local 
currency as a reimbursement for time spent at the clinic and transport costs. 
 
Clinic procedures 
An overview of visit procedures is presented in figures 2.1 and 3.1. At the screening visit (referred to in 
Chapter 2 as “pre-treatment visit”), participants underwent a face-to-face interview, speculum 
examination, real-time testing for HIV, pregnancy, urinary tract infection, BV, and TV, and collection 
of samples for sexually transmitted infection and future molecular testing (see below). At the end of this 
visit, preliminary eligibility was assessed, and initial treatments and referrals were given based on 
available test results. Testing for Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum 
(syphilis) and herpes simplex virus type 2 was conducted on stored samples after the participant had left 
the clinic. Results of the syphilis and herpes simplex type 2 tests were shared with participants at a 
results visit one to two weeks after the screening visit, additional treatments were given as required, and 
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eligibility was reassessed. Positive herpes simplex type 2 serology was not a reason for exclusion. 
Chlamydia and gonorrhoea results were shared with participants as soon as they were available. We did 
not use them to determine eligibility as originally intended because the turn-around time of polymerase 
chain reaction (PCR) testing at the National Reference Laboratory in Kigali was slow. At the end of the 
screening and results visits cascade, women were either declared ineligible, or diagnosed with BV (by 
Nugent score78 and/or modified Amsel criteria,77 defined as two of three positive: vaginal pH>4.5, 
positive whiff test, or ≥20% clue cells) and/or TV (by culture and/or wet mount) and treated with 500 
mg oral metronidazole twice per day for seven days. An enrolment visit (referred to in Chapter 2 as 
“post-treatment visit”), was scheduled within three days after treatment completion, and only women 
whose treatment had been successful (no BV by modified Amsel criteria and no TV on wet mount), and 
who were still not pregnant and free of urinary tract infection and syphilis, were randomised to the four 
groups described in Chapter 3. Women could be rescreened a maximum of three times. 
 
We considered Nugent scores a more accurate marker of vaginal dysbiosis than Amsel criteria.4 
However, we used Amsel criteria to determine eligibility because results are available immediately. We 
deliberately disregarded the vaginal discharge criterion, because many studies have shown that the 
presence of vaginal discharge does not correlate well with the presence of vaginal dysbiosis.220 Studies 
have also shown that the presence of vaginal dysbiosis in the absence of vaginal discharge can be 
harmful (e.g. is associated with increased vaginal inflammation, HIV acquisition, preterm birth, etc.).87 
Finally, our intention was to use vaginal probiotics to prevent microbiological dysbiosis and not to cure 
symptoms. For all of these reasons, we decided to use modified Amsel criteria, defined as at least two of 
three laboratory criteria positive (vaginal pH>4.5, amine smell when adding KOH to the smear, and 
presence of clue cells when evaluating the smear under a microscope). 
 
The Chief Investigator (my primary supervisor, Prof. Janneke van de Wijgert) based in Liverpool used a 
random number generator to assign participant identification numbers to groups in blocks of four. At 
the Rinda Ubuzima clinic, each eligible woman was assigned the next available participant 
identification number, and the corresponding sealed envelope was opened to reveal her randomisation 
group. The laboratory technicians were blinded but it was not possible to blind the clinicians and 
participants. Behavioural counselling was offered to all participants in all randomisation groups. The 
counselling focussed on reducing known risk factors for BV such as unprotected sex, vaginal hygiene 
practices, male partner penile hygiene practices, and alcohol use (which can lead to unprotected sex and 
can cause severe side effects when used in combination with metronidazole). At follow-up visits, 
participants underwent a face-to-face interview, counselling, speculum examination, laboratory 
assessments (BV by modified Amsel criteria and Nugent scoring, TV by wet mount and culture, 
vulvovaginal candidiasis by wet mount, and additional testing if clinically indicated), and sampling for 
future molecular testing. HIV, sexually transmitted infection, urinary tract infection, and pregnancy 
tests were repeated at Month 6 (M6) only. All participants were offered male condoms free of charge at 
each study visit. Forty-six participants made unscheduled visits to collect treatment for an infection that 
was diagnosed by laboratory testing after the participant had left the clinic (n=35 women), because of 
new symptoms (n=14), and/or to withdraw informed consent (n=1). 
 
Adherence to the three antibiotic and probiotic interventions described in Chapter 3 and 4 was assessed 
at the Day 7 (D7), Month 1 (M1), and Month 2 (M2) visits by structured interviewer-administered 
questionnaire, review of a diary card that the participant completed in between study visits, review of 
returned used packaging and unused product, and by asking the participant to complete a self-rating 
adherence scale. These different sources of adherence data were triangulated to arrive at an overall level 
of adherence (between 0-100%) for each participant between visits. Women were allowed to cease 
product use during menstrual bleeding (done by 12 women), and the adherence data were not adjusted 
for this. 
 
Diagnostic testing 
All diagnostic testing was conducted onsite at the Rinda Ubuzima clinic or at the National Reference 
Laboratory in Kigali using validated procedures. Vaginal swab, blood, and urine specimens were 
processed on the collection day and either tested immediately or stored at -80°C until testing. Dacron 
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vaginal swabs were used for wet mounts, Gram stains, and TV InPouch culture (Biomed Diagnostics, 
White City, OR, USA) at all study visits, as described in the Chapter 2 and 3. All other diagnostic tests 
were only done at screening (“pre-treatment visit”), M6, and when judged clinically necessary by the 
physician, with the exception of pregnancy and urinalysis tests, which were repeated at enrolment 
(“post-treatment visit”) prior to randomisation. Whole blood was tested for HIV 1/2 using the Kehua 
HIV Rapid Test (Kehua Bio-engineering, Shanghai, China), followed by the Alere Determine HIV-1/2 
Rapid Test (Abbott Laboratories, Tokyo, Japan) for confirmation of positive results and the Unigold 
HIV Rapid Test (Trinity Biotech, Bray, Ireland) as tie-breaker (if applicable). Urine was tested for 
pregnancy using a Human chorionic gonadotropin, and for urinary tract infection using a urinalysis, 
dipstick test (both by Nova, Atlast Link Technology, Beijing, China). Endocervical swabs were tested 
for Chlamydia trachomatis (CT)/ Neisseria gonorrhoeae (NG) by real-time Polymerase Chain Reaction 
(PCR; Presto, Beek, The Netherlands).221 A sub-sample of 49 M6 samples were tested by GeneXpert 
CT/NG assay (Cepheid, CA, USA) after study completion. The sensitivities and specificities of the two 
real-time PCR assays are high and comparable.91 Plasma was tested for herpes simplex virus type 2 
serology (Kalon, Guildford, UK; using an optical density cut-off of >1.1 for a positive result and <0.9 
for a negative result) and syphilis by Rapid Plasma Reagin test followed by T. pallidum 
Hemagglutination Assay (both by Spinreact, Girona, Spain). 
 
Molecular laboratory methods 
 
Rationale for 16S rRNA gene sequencing of the VMB  
It has long been recognised that BV is a polybacterial condition. However, it has been difficult to define 
its precise microbiological nature due to the limitations of microscopy and culture.4,9 16S rRNA 
sequencing has revolutionised the field. The 16S gene is unique to bacteria, and contains highly 
preserved regions that can be used to quantify and amplify all 16S genes present in a vaginal sample, as 
well as variable regions that can be sequenced and then used to determine which bacteria are present.222 
Many sequencing studies have been conducted since the turn of the century, and these revealed that 
VMBs are usually dominated by five main Lactobacillus species (of which L. crispatus and L. iners are 
the most common).4 The most common type of vaginal dysbiosis is BV, and the long list of anaerobes 
that are typically associated with BV have now been well characterised (referred to as ‘BV-anaerobes’; 
see list in table A.1).4 Occasionally, bacteria other than lactobacilli or BV-anaerobes are identified, 
including pathobionts, skin bacteria, and Bifidobacteria.4 These bacteria have not yet been very well 
characterised epidemiologically and clinically. Pathobionts are bacteria that have a higher pathogenicity 
than BV-anaerobes, and are often associated with hospital and neonatal infections, including 
Proteobacteria, streptococci, staphylococci, and enterococci.87 We assessed pathobionts separately from 
BV-anaerobes, because they seem to behave differently (although more research is needed to evaluate 
this properly) and are not typically treated with metronidazole when they cause hospital or neonatal 
infections.  
 
DNA extraction 
For molecular testing, the physician collected two Dacron vaginal swabs per woman during speculum 
examinations at screening, enrolment, and each scheduled follow-up visit (N=1,016 swabs). The swab 
heads were stored dry at Rinda Ubuzima at -80°C on the collection day. The 12 women in the self-
sampling group (see Chapter 3 for details) self-sampled two flocked swabs (Copan Diagnostics, 
Murrieta, CA, USA) every Monday, Wednesday, and Friday of the first month after randomisation 
(N=258 swabs). The swab heads were initially stored at room temperature in the participant’s home in 
cryovials containing 1 ml RNALater (Thermo Scientific, Paisley, UK), and then at the Rinda Ubuzima 
laboratory at -80°C within seven days after collection. Frozen samples were shipped to Liverpool on dry 
ice. DNA extraction and sequencing were done at the University of Liverpool Centre for Genomic 
research.117 DNA was extracted from one sample per participant per time point (N=639 swabs, including 
the swabs self-sampled by twelve women). The samples were thawed, and DNA was extracted from 
each sample by adding 180 μl of enzymatic lysis buffer containing lysozyme (Sigma-Aldrich, Dorset, 
UK); incubation for 30 minutes at 37 0C; adding 25 μl of proteinase K and 200 μl of buffer AL using the 
Qiagen DNeasy Blood and Tissue kit (Qiagen, Manchester, UK); incubation for 30 minutes at 560 C; 
and bead-beating after adding 200 mg of 0.1 mm zirconia/silica beads (Thistle Scientific, Glasgow, UK) 
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on a Qiagen TissueLyser II (Qiagen, Manchester, UK) for 5 minutes at 25 Hz. Next, 200 μl of 100% 
ethanol was added, the sample was centrifuged, the swab head was discarded, and the pellet was 
purified in four subsequent centrifugation steps after adding one-by-one 200 μl 100% ethanol, 500 μl 
buffer AW1, 500 μl buffer AW2 and 75 μl buffer AE as per manufacturer’s instructions (Qiagen, 
Manchester, UK). We included one negative control (an empty tube) with each DNA extraction round 
of 24 study samples to be able to detect contaminants in extraction reagents downstream. The DNA 
concentration of randomly selected samples was measured by Qubit (Invitrogen, Thermo Scientific, 
Paisley, UK) and the DNA quality of all samples by Nanodrop (Thermo Scientific, Paisley, UK).  
 
PCR amplification and 16S rRNA gene sequencing 
Each of the 667 DNA samples (639 study samples and 28 negative controls) underwent two PCR 
rounds for 16S rRNA gene amplification and barcoding. In the first PCR round, the V3-V4 region of the 
16S rRNA gene was amplified as described previously.223 DNA was amplified in a 25 μl reaction 
volume using 1.25 μl of a 10 µM concentration of 319F 5’-ACTCCTACGGGAGGCAGCAG-3’ 
forward primer and 1.25 μl of a 10 µM concentration of 806R 5’-GGACTACHVGGGTWTCTAAT-3’ 
reverse primer, 12.5 μl NEB Next HF 2x PCR Master Mix (New England Biolabs, Hitchin, UK), 9 μl of 
nuclease-free water and 1 μl of DNA extraction product. The first denaturation cycle took 30 seconds at 
98 0C and was followed by 10 cycles consisting of a denaturation cycle of 10 seconds (at 98 0C), an 
annealing cycle of 30 seconds (at 58 0C), an extension cycle of 30 seconds (at 72 0C), and a final 
extension cycle of 5 minutes at 72 0C. PCR products were then purified and size-selected using 
Agencourt AMPure XP beads (Beckman Coulter, High Wycombe, UK) in a 0.8:1.0 bead-to-sample 
ratio. The second PCR round was to barcode V3-V4 sequences by a dual-index approach using standard 
Illumina Nextera XT index kit v2 (Illumina, San Diego, CA, USA), permitting multiplexing of up to 
384 samples. The barcoding was performed in a 25 μl reaction volume using 2.5 μl of Index 1 primer, 
2.5 μl of Index 2 primer, 12.5 μl NEB Next HF 2x PCR Master Mix and 7.5 μl sample. The first 
denaturation cycle took 3 minutes at 98 0C and was followed by 15 cycles consisting of a denaturation 
cycle of 30 seconds (at 98 0C), an annealing cycle of 30 seconds (at 55 0C), an extension cycle of 30 
seconds (at 72 0C), and a final extension cycle of 5 minutes at 72 0C. PCR products were then purified 
using AMPure beads as explained above, again in a 0.8:1.0 bead-to-sample ratio. We added a negative 
control to each PCR run (10 μl of nuclease-free water instead of 9 μl of nuclease-free water and 1 μl of 
DNA) to identify contaminants, as well as a commercially available positive control (10 μl of 0.2 ng/μl 
ZymoBiomics Microbial Community DNA standard; Zymo Research Corp, Irvine, CA, USA). The 
DNA extraction negative controls were also included in the PCR runs. DNA from samples collected at 
different visits but belonging to the same participant were included in the same PCR run to control for 
inherent differences between PCR runs. PCR product DNA concentrations of each sample (N=683, 
including negative and positive controls: 639 study samples, eight positive PCR controls, eight negative 
PCR controls, and 28 negative DNA extraction controls) were measured using the Qubit Fluorometer 
with the dsDNA HS Assay kit (Invitrogen, Thermo Scientific, Paisley, UK). All samples, including the 
positive and negative controls, were successfully amplified and used for subsequent steps. 
 
Amplicons from samples were evenly pooled into sequencing libraries at a mass of 0.8 ng DNA per 
amplicon. To achieve this, Qubit DNA concentrations were used to calculate the volumes of each study 
sample to be added. Samples with a DNA concentration of <0.30 ng/µl (e.g., the negative controls) 
were added in a fixed volume of 1 µl. The libraries were sequenced on an Illumina HiSeq instrument 
(Illumina, San Diego, CA, USA), run in rapid mode, 2x300bp using a 250PE and 50PE kit. DNA from 
samples collected at different visits but belonging to the same participant were included in the same 
library to control for inherent differences between sequencing runs. 
 
Panbacterial 16S rRNA gene qPCR 
The panbacterial 16S rRNA gene copy concentrations of all samples collected at study visits and 
containing at least 1,111 reads by Illumina HiSeq sequencing (N=393; see ‘Further data processing’ 
below for rationale of rarefaction) were determined at the Institute for Genome Sciences of the 
University of Maryland (Baltimore, MD, USA) using the BactQuant qPCR assay. This assay was 
developed based on an analyses of 4,938 16S rRNA gene sequences in the Greengenes database.118,224 
The DNA samples were tested as described previously.118,225 Briefly, 1.5 μl of template (1:10 diluted 
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DNA) was added to 3.5 μl of reaction mix, with the final reaction containing 1.8 μM each of the 
forward (341F) and reverse (806R) primer targeting the 16S V3-V4 region, 225 nM of the TaqManW 
probe, 1X Platinum Quantitative PCR SuperMix-UDG with ROX (Invitrogen, Thermo Scientific, 
Waltham, MA, USA) and molecular-grade water. Each experiment included an in-run standard curve 
(ranging from 10 to 108, with 102–108 in 10-fold serial linear dilutions) and no-template controls 
performed in triplicate. Amplification and real-time fluorescence detections were performed on the Bio-
Rad CFX 384 instrument (Bio-Rad Inc., Hercules, CA, USA) using the following PCR conditions: 3 
minutes at 50 °C for UDG treatment, 10 minutes at 95 °C for Taq activation, 15 seconds at 95 °C for 
denaturation and 1 minute at 60 °C for annealing and extension, times 40 cycles. Cycle threshold (Ct) 
value for each 16S qPCR reaction were obtained using a manual Ct threshold of 0.05 and automatic 
baseline. The 16S rRNA gene concentration was reported in copies/μL for each sample. 
 
Molecular data processing 
We obtained a mean raw unpaired read count of 374,543 reads per study sample (95% confidence 
interval (CI): 305,845 – 443,242) in run 1 and 302,431 reads per study sample (95% CI: 266,423 – 
338,440) in run 2. Reads were first demultiplexed, and primer sequences were removed from forward 
and reverse reads using Cutadapt 1.2.1.146 All subsequent steps were performed in the DADA2 version 
1.4.0 package for large paired end datasets in R version 3.4.3 (R core team, 2015).119 We chose DADA2 
because of its ability to resolve reads differing by only one nucleotide, thereby maximising our chances 
of differentiating probiotic reads from naturally occurring Lactobacillus species reads. Error correction 
was performed using the fastqFilter command with parameter settings aiming to maximise read 
retention. For forward and reverse reads, respectively, the minimum read lengths (truncLen) were set to 
260 and 210 based on the quality plots, maxEE to a maximum of 5 and 8 expected errors, maxN to zero 
ambiguous bases allowed, and truncQ to zero. Around 10% of reads were discarded after error 
correction. Next, error rates of forward and reverse reads were determined using the learnErrors 
command. Forward and reverse reads were dereplicated (assigned to unique amplicon sequence variants 
(ASVs)) using the derepFastq command, and denoised (ASVs with higher than average error rates 
discarded) using the dada command.119,226 Forward and reverse reads were then merged into 
overlapping reads using the mergePairs command. Bimeras (chimeric compositions of two separate 
parent ASVs) were removed using the removeBimeraDenovo command with the Silva version 128 
database as the reference database;120 10.1% of ASVs were identified as bimeric and removed. Overall, 
a median of 16% of the raw reads per study sample was removed during these DADA2 clean-up steps. 
 
Taxonomic assignment was also done in DADA2 in two steps: assignTaxonomy to map ASVs to taxa at 
genus level or above using the RDP classifier with a minimum bootstrap value of 50% and the Silva 
v128 database as the reference database,120,227 followed by addSpecies to map ASVs to species level, 
allowing only ASVs with exact (100%) identity matches with species in the Silva database to be 
assigned to that species, and allowing assignment of one ASV to multiple species. 
 
Further data processing 
Further data processing was performed in Microsoft Excel 2013 (starting with a spreadsheet containing 
the sequences, taxonomic assignments, and read counts for each ASV per sample) and STATA version 
13 (StataCorp, College Station, TX, USA). We removed all rare ASVs (defined as a read count in all 
samples combined of less than 100), four non-bacterial ASVs, and two likely contaminant ASVs (a 
Rhodanobacter glycinis/terrae and a Sneathia genus) that were present in more than one negative 
control at relative abundances higher than in any study sample. The vaginal taxa BV-associated 
bacterium 1 (BVAB1), BVAB2, Mageeibacillus indolicus (BVAB3), BVAB TM7 and Fenollaria 
massiliensis are not included in the Silva v128 database but their sequences have been published 
elsewhere. Similarly, the Lactobacillus and Bifidobacterium species included in the vaginal probiotic 
Ecologic Femi+ (EF+; Winclove Probiotics, Amsterdam, Netherlands) are not included in the Silva 
database, but their sequences were provided to us by Winclove. The vaginal probiotic Gynophilus LP 
(GynLP; Biose, Aurillac, France) contains Lactobacillus rhamnosus (Lcr strain 35), and the NCBI 
database contains a reference sequence for this probiotic strain.228 We identified all of the above species 
in our ASV spreadsheet using the Needleman-Wunsch Global Align Nucleotide Sequences function on 
the National Center for Biotechnology Information (NCBI) website,229 requiring 100% matches 
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between reference sequences and uploaded DADA2-derived ASVs of interest. The Silva-based 
taxonomic assignment of 146 ASVs with a relative abundance of at least 0.05% of the read count of all 
samples combined (out of a total of 1,797 ASVs) were double-checked using the Microbial Nucleotide 
BLAST (BLASTn) function on the NCBI website.147,230 Using the non-redundant V3-V4 version of the 
Vaginal 16S rRNA Reference Database as a tiebreaker,148 three discordances were resolved, 24 
Lactobacillus genus ASVs were reassigned to various Lactobacillus species, six Gardnerella genus 
ASVs were reassigned to G. vaginalis, and one Atopobium genus ASV was reassigned to A. vaginae. 
Next, read counts for ASVs assigned to the exact same taxonomy were summed for each sample. 
Finally, we rarefied at a depth of 1,111 reads (the lowest total read count for a specific sample above 
1,000 reads) using the GUniFrac 1.0 package in R.121 The rarefied ASV table contained 629 samples 
and 401 unique ASVs (10/639 samples became invalid due to rarefaction), with 255 (63.6%) mapping 
to species level, 116 (28.9%) to genus level, and 30 (7.5%) to higher taxonomic levels. Rarefied read 
counts were transformed into relative abundances using the prop.table function in R. Of the 401 ASVs, 
177 ASVs were present at a relative abundance of at least 1% in at least one sample; the other 224 
ASVs were minority species. 
 
Panbacterial 16S rRNA gene data 
Of the 393 samples that were tested by BactQuant assay, fourteen samples did not amplify in two of 
three, or all three, of the triplicate reactions, or had skewed low 16S rRNA gene concentration results of 
<1,000 copies/μl and were considered outliers. A total of 14/393 samples (=3.6%) were therefore 
excluded from all concentration analyses. We estimated the ASV-specific concentrations per sample 
using the sample-specific 16S rRNA gene concentration data. First, we identified the 16S rRNA gene 
copy number per ASV in the NCBI version of the rrnDB database,231 and in the case of missing data, in 
the RDP version of the rrnDB database (which only contains information at genus level and above) and 
the Greengenes database.224 If an ASV was mapped to multiple species at genus level, the mean of the 
mean 16S gene copy number for each individual species was used. If the mean 16S gene copy number 
of a species was not present in the database, we used the mean copy number of the corresponding 
genus. BVAB1 and BVAB2 belong to the Clostridiales order and lower level taxonomic information is 
not available. We therefore used the Clostridiales order copy number (=4.62). Concentrations in cells/μl 
per ASV per sample were estimated by multiplying the ASV-specific copy-normalised rarefied relative 
abundance by the sample-specific 16S rRNA gene copies concentration. This method has been shown 
by others to correlate well with species-specific quantitative PCR results for non-minority species.129,130 
It yielded concentrations for 401 ASVs in 379 samples in cells/μl, which were log10-transformed. 
Concentrations between zero and one cell/μl were set to one prior to log10-transformation to prevent 
skewed negative values. 
 
Number of samples available for analyses in Chapter 2 
We had vaginal swabs available for all 68 enrolled women prior and after metronidazole treatment 
(N=136; these are included in the 639 vaginal swabs described above). Of these vaginal swabs, 134 
study samples had at least 1,111 reads after Illumina sequencing and therefore underwent the bacterial 
16S rRNA gene qPCR. The rarefied ASV table used for the analyses in Chapter 2 contained 134 
samples and 204 unique ASVs (2/136 samples became invalid due to rarefaction), with 133 (65.2%) 
mapping to species level, 55 (27.0%) to genus level, and 16 (7.8%) to higher taxonomic levels. Of the 
134 samples that were tested by BactQuant assay, five samples did not amplify in two of three, or all 
three, of the triplicate reactions, or had skewed low 16S rRNA gene concentration results of <1,000 
copies/μl and were considered outliers. A total of 5/134 samples (= 3.7%) were therefore excluded from 
all concentration analyses. This yielded concentrations for 204 ASVs in 129 samples in cells/μl, which 
were log10-transformed. Concentrations between zero and one cell/μl were set to one prior to log10-
transformation to prevent skewed negative values. 
 
Molecular endpoints: richness, diversity, VMB types, and bacterial groups  
Data reduction was required for molecular efficacy analyses, and was done in three different ways (see 
Chapters 2 and 3 for further details). First, we calculated richness and alpha diversity for each sample 
using the rarefied relative abundance data. Richness was defined as the total number of ASVs per 
sample. Alpha diversity was determined by Simpson diversity index (1-D) using the phyloseq package 
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version 1.14.0 in R.232 Second, given that much VMB composition knowledge has become available 
since the turn of the century,4 we used this existing knowledge to assign all 401 ASVs to four bacterial 
groups (table A.1): 1) lactobacilli (with a further subdivision into EF+ strains, the GynLP strain, and 
‘natural’ lactobacilli); 2) BV-anaerobes (all Actinobacteria, Bacteroidetes, Firmicutes, Fusobacteria, and 
Tenericutes except those included in the other three groups; these have consistently been associated 
with BV); 3) pathobionts (most Proteobacteria, and streptococci, staphylococci, enterococci, 
Spirochaetaceae, Listeria, and Chlamydia trachomatis; these are considered to have higher intrinsic 
pathogenicity than BV-anaerobes and have not consistently been associated with BV9); and 4) ‘other 
bacteria’ (a rest group, containing Actinobacteria that are known to be (facultative) aerobic skin 
bacteria, Bifidobacterium species, and three difficult to classify minority species). Within each sample, 
read counts of ASVs belonging to the same bacterial group were summed. This resulted in four relative 
abundances (one for each bacterial group) per sample, which sum to 1.0 for each sample. Third, we 
clustered the rarefied relative abundance data using the phyloseq package in R using Euclidean distance 
with complete linkage.232 The generated clusters were used to assign samples to eight VMB types, as 
described in Chapter 2 and 3 (note that the dataset of 134 samples in Chapter 2 only yielded seven VMB 
types in total; there were no samples assigned to VMB type Lcr). To improve the statistical power of the 
mixed effects models, and to facilitate visualisations of VMB transitions in alluvial diagrams (Chapters 
2 and 3), the eight VMB types were condensed further into four ‘pooled VMB types’ as follows: 1) 
lactobacilli-dominated (LD; which combined original VMB types 1-3 dominated by L. iners, L. 
crispatus or other lactobacilli; n=292), 2) lactobacilli and anaerobes (LA; original VMB type 4; n=86); 
3) BV-like (BV; original VMB types 5-7 combined, which were all characterised by anaerobes other 
than lactobacilli with different proportions of G. vaginalis; n=202); and pathobionts (PB; original VMB 
type 8, which include all VMBs with ≥20% pathobionts; n=49).  
 
For further clarification, a sample containing 30% L. iners, 30% other lactobacilli, 20% G. vaginalis, 
and 20% other BV-anaerobes, would have been assigned to the LA (lactobacilli and anaerobes) VMB 
type, as the total relative abundance of lactobacilli was 0.60. If this sample contained one million 16S 
rRNA genes per μl, and each of the species included in the sample only contained one 16S rRNA gene 
copy, it would contain a lactobacilli concentration of [30%+30%] x one million = 600,000/μl, a BV-
anaerobes concentration of [20%+20%] x one million = 400,000/μl, a pathobionts concentration of 0/μl, 
and a ‘other bacteria’ concentration of 0/μl. Therefore, each sample was assigned to a mutually 
exclusive VMB type, and had relative abundance data (and, if applicable, estimated concentration data) 
for each of the four bacterial groups. 
 
All VMB types, except for the three Lactobacillus-dominated VMB types, were considered dysbiotic. 
The bacterial groups BV-anaerobes and pathobionts were also considered dysbiotic. 
 
Statistical analysis and figures in Chapter 2 
Concentration changes were expressed as percentages per individual participant as follows: 
[concentration at the enrolment/post-treatment visit] – [concentration at the screening/pre-treatment 
visit] divided by [concentration at the screening/pre-treatment visit]. When the pre-treatment 
concentration was zero and the post-treatment concentration was greater than zero, the increase was set 
to 100% or the highest value among the other participants, whichever was greatest. 
 
Bar graphs, bar charts, and scatter plots were made in STATA. Other data visualisations were made in 
R: three-dimensional plots of the three main non-metric multidimensional scaling (NMDS) vectors were 
made using vegan and plotly packages,233,234 heatmaps showing the twenty ASVs with highest median 
relative abundance were made using the gplots package,235 and alluvial diagrams were made using the 
ggalluvial package to compare (pooled) VMB types before and after treatment.236  
 
Trial endpoints and hypotheses (Chapter 3) 
The primary aims of the trial were to determine the safety and preliminary efficacy of the interventions, 
each compared to the no intervention group. We hypothesised that all interventions would be safe. The 
primary preliminary efficacy endpoints were the incidence of BV by Nugent score and modified Amsel 
criteria (which were hypothesised to decrease), and symptomatic vulvovaginal candidiasis (VVC) by 
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wet mount (which was hypothesised not to increase). The secondary preliminary efficacy endpoints 
included membership of specific VMB clusters/types and bacterial group concentrations over time as 
determined by Illumina HiSeq sequencing. 
 
Safety endpoints in Chapter 3 
The main safety endpoints were self-reported solicited and unsolicited (serious) adverse events (AEs) 
and social harms, and clinician-observed speculum exam findings. Adverse events were coded using the 
Medical Dictionary for Regulatory Activities (medDRA version 19.1, McLean, VA, USA). Laboratory 
test results were not considered AEs, but primary and secondary endpoints. 
 
Primary preliminary efficacy endpoints in Chapter 3 
For the BV by Nugent 7-10 and modified Amsel criteria and VVC endpoints, see the ‘diagnostic 
testing’ section above. Analyses were also conducted using a Nugent score of 4-10 and the full Amsel 
criteria as the definition of BV but the results are not shown in Chapter 3 because they are similar to the 
Nugent 7-10 and modified Amsel criteria results, and less informative than the molecular data. 
 
Statistical analyses (Chapter 3) 
Statistical analyses were performed using STATA version 13 (StataCorp, College Station, TX, USA). 
We used the phyloseq and gplots packages in R to make heatmaps of the 20 ASVs with the highest 
mean relative abundance (figure 3.2a) or concentration (figure 3.2b) across all study samples.235 Bar 
graphs and line graphs were made using the catplot and scatter functions in STATA and alluvial 
diagrams were made using the ggalluvial package in R.236  
 
Most statistical comparisons were between randomisation groups (each intervention group compared to 
the no-intervention group) at screening, enrolment, and longitudinally over time. For cross-sectional 
analyses, we used Fisher’s exact test to compare binary and categorical variables, Kruskal-Wallis test to 
compare continuous variables, and Mann Whitney U test for pairwise comparisons of continuous 
variables if the Kruskal-Wallis test was significant at p<0.05. For longitudinal analyses, we used 
incidence rates (IRs) and incidence rate ratios (IRRs) with 95% confidence intervals (CI; primary 
endpoints only), and mixed effects models. IRs were defined as the number of new infections during 
follow-up divided by the person-years at risk for that infection using the ststet function in STATA. 
Women who had BV recurrence within 10 days that persisted until M6 were considered persistent 
infections to prevent inflation of the IRs. IRRs were calculated by dividing the IR of each intervention 
group by the IR of the control group. Mixed effects models were done in STATA using the xtmelogit 
function for categorical endpoints and the mixed function for continuous endpoints. All models included 
one VMB endpoint at a time as the outcome, the participant identification number as the random effect, 
and randomisation group as the main fixed effect. Three variables were added as additional fixed effects 
in adjusted mixed effects models because they were associated at p<0.05 in mixed effects models with 
at least one of four a priori selected VMB endpoints (Nugent score, or concentrations of lactobacilli, 
BV-associated anaerobes, or pathobionts; table C.5), and data were available at all study visits. They 
were ‘current use of hormonal contraception or being pregnant’ (versus not using contraception and not 
being pregnant; six samples from copper intrauterine device users were excluded), a ‘sexual risk’ 
composite variable (with lower risk defined as having reported condom use at each vaginal sex act since 
the last study visit and fewer than the median of five sex partners in the past month), and ‘age’ (30 years 
or older versus younger than 30 years; the median age of the screened population was 30 years). One 
additional variable was associated with one of the a priori selected VMB outcomes at p<0.05: managing 
menses with sanitary pads versus other methods (table C.5). However, this variable was not added as an 
additional fixed effect in the adjusted mixed effects models due to only having been recorded at 
enrolment visits and not at follow-up visits. 
 
All analyses were conducted on the intent-to-treat (ITT) population (n=68), and IR and IRR analyses 
were also conducted on a modified ITT population (n=51). Women who did not have a Nugent score 0-
6 (n=17 women) at the time of randomisation were excluded from the modified ITT population. 
Another 17 women had ongoing chlamydia and/or gonorrhoea infection at the time of randomisation, 
but the molecular analyses did not identify substantial differences in the VMB compositions of women 
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with and without ongoing infection and we therefore did not exclude them (figure C.1). In accordance 
with local treatment guidelines, BV and VVC were treated when laboratory-confirmed and symptoms 
and/or clinician-observed signs were present. TV and other sexually transmitted infections were always 
treated when identified by laboratory testing. Some women received antimicrobial drugs for other 
ailments from external clinics. Antimicrobial use during the study is shown in table C.1. We took 
antimicrobial use into account to determine whether cases were likely incident or persistent, but we did 
not remove users from the modified ITT population because they were evenly distributed between the 
randomisation groups and we expected the short course treatments to have less of an effect on the VMB 
than the longer-term interventions.  
 
IR and IRR analyses were conducted for the product use period (between enrolment and M2, including 
samples from D7, M1, and M2) as well as the period between M2 and M6 (M6 samples). Mixed effects 
models were done for the product use period only (D7, M1, M2, and self-collected samples) to 
determine if any of the observed effects were statistically significant; we did not run mixed effects 
models for the period after product cessation because the IR/IRR analyses and graphs had already 
clearly shown that the observed effects during the intervention period had disappeared after cessation of 
the interventions.  
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Table A.1: List of amplicon sequence variants detected and classification into bacterial groups 
List of taxa (alphabetical order) Classification Phylum/Class (Order)* Minority 
taxon† 
Abiotrophia defectiva BV Firmicutes/Bacilli (Lactobacillales) Yes 
Actinobacillus genus Pathobionts Gammaproteobacteria (Pasteurellales) Yes 
Actinomyces family BV Actinobacteria/Actinobacteria (Actinomycetales) No 
Actinomyces genus BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Actinomyces europaeus BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Actinomyces funkei BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Actinomyces neuii BV Actinobacteria/Actinobacteria (Actinomycetales) No 
Actinomyces odontolyticus BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Actinomyces turicensis BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Actinomyces urogenitalis BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Aerococcus genus BV Firmicutes/Bacilli (Lactobacillales) No 
Aerococcus christensenii BV Firmicutes/Bacilli (Lactobacillales) No 
Aeromonas caviae/dhakensis/enteropelogenes/ 
hydrophila/jandaei/taiwanensis/veronii 
Pathobionts Gammaproteobacteria (Aeromonadales) Yes 
Alistipes finegoldii/onderdonkii BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Alloiococcus genus BV Firmicutes/Bacilli (Lactobacillales) Yes 
Alloprevotella genus BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Alloprevotella rava BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Alloscardovia omnicolens Other Actinobacteria/Actinobacteria (Bifidobacteriales) Yes 
Anaerococcus genus BV Firmicutes/Tissierellia (Tissierellales) No 
Anaerococcus hydrogenalis BV Firmicutes/Tissierellia (Tissierellales) No 
Anaerococcus lactolyticus BV Firmicutes/Tissierellia (Tissierellales) No 
Anaerococcus murdochii BV Firmicutes/Tissierellia (Tissierellales) No 
Anaerococcus obesiensis BV Firmicutes/Tissierellia (Tissierellales) No 
Anaerococcus prevotii BV Firmicutes/Tissierellia (Tissierellales) Yes 
Anaerococcus prevotii/tetradius BV Firmicutes/Tissierellia (Tissierellales) No 
Anaerococcus provenciensis BV Firmicutes/Tissierellia (Tissierellales) No 
Anaerococcus vaginalis BV Firmicutes/Tissierellia (Tissierellales) No 
Anaeroplasma genus BV Tenericutus/Mollicutus (Anaeroplasmatales) Yes 
Anaerostipes hadrus BV Firmicutes/Clostridia (Clostridiales) Yes 
Anaerotruncus genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Anaerovibrio genus BV Firmicutes/Negativicutes (Selenomonadales) Yes 
Arcanobacterium genus BV Actinobacteria/Actinobacteria (Actinomycetales) No 
Asteroleplasma genus BV Tenericutus/Mollicutus (Anaeroplasmatales) Yes 
Atopobium genus BV Actinobacteria/Coriobacteria (Coriobacteriales) No 
Atopobium deltae BV Actinobacteria/Coriobacteria (Coriobacteriales) Yes 
Atopobium vaginae BV Actinobacteria/Coriobacteria (Coriobacteriales) No 
Bacillus altitudinis/amyloliquefaciens/firmus/ 
licheniformis/mojavensis/subtilis/tequilensis/timonensis/
velezensis  
Other Firmicutes/Bacilli (Bacillales) Yes 
Bacteroidetes phylum BV Bacteroidetes Yes 
Bacteroides genus BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Bacteroidales_S24-7_group family BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Bacteroides caccae BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Bacteroides dorei/vulgatus BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Bacteroides fragilis BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Bacteroides fragilis/xylanisolvens BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Bacteroides pleibeius BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Bacteroides thetaiotaomicron BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Bacteroides uniformis BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Bacteroides vulgatus BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Betaproteobacteria class Other Betaproteobacteria Yes 
Bifidobacterium adolescentis/faecale/stercoris Other Actinobacteria/Actinobacteria (Bifidobacteriales) Yes 
Bifidobacterium breve Other Actinobacteria/Actinobacteria (Bifidobacteriales) No 
Bifidobacterium catenulatum/kashiwanohense/ 
pseudocatenulatum 
Other Actinobacteria/Actinobacteria (Bifidobacteriales) No 
Bifidobacterium kashiwanohense Other Actinobacteria/Actinobacteria (Bifidobacteriales) Yes 
Bifidobacterium longum Other Actinobacteria/Actinobacteria (Bifidobacteriales) No 
Blautia genus BV Firmicutes/Clostridia (Clostridiales) No 
Blautia faecis BV Firmicutes/Clostridia (Clostridiales) Yes 
Blautia obeum BV Firmicutes/Clostridia (Clostridiales) Yes 
Blautia obeum/wexlerae BV Firmicutes/Clostridia (Clostridiales) Yes 
Blautia stercoris BV Firmicutes/Clostridia (Clostridiales) Yes 
Brevibacterium genus Other Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Brevibacerium luteolum Other Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Brevibacterium massiliense/ravenspurgense Other Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Brevibacterium paucivorans Other Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Brevundimonas albigilva/nasdae/vesicularis Other Alphaproteobacteria (Caulobacterales) Yes 
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List of taxa (alphabetical order) Classification Phylum/Class (Order)* Minority 
taxon† 
Bulleidia genus BV Firmicutes/Erysipelotrichi (Erysipelotichales) Yes 
Butyricicoccus genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Butyrivibrio genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Butyrivibrio crossotus BV Firmicutes/Clostridia (Clostridiales) Yes 
BVAB TM7 BV Unclassified (TM7 division) No 
BVAB1 BV Firmicutes/Clostridia (Clostridiales) No 
BVAB2 BV Firmicutes/Clostridia (Clostridiales) No 
Campylobacter genus Pathobionts Epsilonproteobacteria (Campylobacterales) No 
Campylobacter hominis Pathobionts Epsilonproteobacteria (Campylobacterales) Yes 
Campylobacter ureolyticum Pathobionts Epsilonproteobacteria (Campylobacterales) Yes 
Caproiciproducens genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Carnobacteriaceae family Other Firmicutes/Bacilli (Lactobacillales) Yes 
Catenibacterium genus BV Firmicutes/Erysipelotrichi (Erysipelotichales) Yes 
Catenibacterium mitsuokai BV Firmicutes/Erysipelotrichi (Erysipelotichales) Yes 
Catonella morbi BV Firmicutes/Clostridia (Clostridiales) No 
Chlamydia trachomatis Pathobionts Chlamydiae (Chlamydiales) Yes 
Christensenellaceae_R-7_group genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Clostridiales order BV Firmicutes/Clostridia (Clostridiales) Yes 
Clostridiales_vadinBB60_group family BV Firmicutes/Clostridia (Clostridiales) Yes 
Clostridium_sensu_stricto_1 genus BV Firmicutes/Clostridia (Clostridiales) No 
Clostridium celatum/disporicum BV Firmicutes/Clostridia (Clostridiales) Yes 
Clostridium_sensu_stricto_1perfringens/thermophilus BV Firmicutes/Clostridia (Clostridiales) Yes 
Collinsella genus BV Actinobacteria/Coriobacteria (Coriobacteriales) Yes 
Collinsella aerofaciens BV Actinobacteria/Coriobacteria (Coriobacteriales) No 
Coprococcus genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Coprococcus_1 catus BV Firmicutes/Clostridia (Clostridiales) Yes 
Coprococcus_2 eutactus BV Firmicutes/Clostridia (Clostridiales) Yes 
Coprococcus_3 comes BV Firmicutes/Clostridia (Clostridiales) No 
Coriobacteriaceae family BV Actinobacteria/Coriobacteria (Coriobacteriales) Yes 
Corynebacteriaceae family Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium genus Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 genus Other Actinobacteria/Actinobacteria (Corynebacteriales) No 
Corynebacterium atypicum Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium glucuronolyticum Other Actinobacteria/Actinobacteria (Corynebacteriales) No 
Corynebacterium jeikeium Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium minutissimum/singulare Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium pyruviciproducens Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 afermentans/coyleae Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 amycolatum/jeikeium/urealyticum/ 
vitaeruminis 
Other Actinobacteria/Actinobacteria (Corynebacteriales) No 
Corynebacterium_1 aurimucosum Other Actinobacteria/Actinobacteria (Corynebacteriales) No 
Corynebacterium_1 aurimucosum/minutissimum Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 aurimucosum/pseudogenitalium/ 
tuberculostearicum 
Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 aurimucosum/simulans/striatum/ 
xerosis 
Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 aurimucosum/striatum Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 coyleae Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 freneyi/xerosis Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 genitalium Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 imitans Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 minutissimum Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 pseudogenitalium Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 riegelii Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 tuscaniense Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Corynebacterium_1 urealyticum Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Delftia acidovorans/lacustris/tsuruhatensis Other Betaproteobacteria (Burkholderiales) Yes 
Dermabacter hominis Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Dermabacter hominis/vaginalis Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Dermabacter jinjuensis Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Desulfovibrio genus BV Deltaproteobacteria (Desulfovibrionales) Yes 
Dialister genus BV Firmicutes/Negativicutes (Veillonellales) No 
Dialister micraerophilus/microaerophilus BV Firmicutes/Negativicutes (Veillonellales) No 
Dialister propionicifaciens BV Firmicutes/Negativicutes (Veillonellales) No 
Dorea genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Dorea formicigenerans BV Firmicutes/Clostridia (Clostridiales) Yes 
Dorea longicatena BV Firmicutes/Clostridia (Clostridiales) Yes 
Enterobacter genus Pathobionts Gammaproteobacteria (Enterobacterales) Yes 
Enterococcus genus Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Enterococcus azikeevi/durans/faecalis/faecium/hirae/ Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
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taxon† 
lactis/mundtii/raffinosus/ratti/rivorum/thailandicus/ 
villorum 
Enterococcus durans/faecalis/faecium Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Enterococcus durans/faecium/phoeniculicola/ 
thailandicus 
Pathobionts Firmicutes/Bacilli (Lactobacillales) Yes 
Enterococcus faecalis Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Enterococcus faecium Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Eremococcus genus BV Firmicutes/Bacilli (Lactobacillales) Yes 
Eremococcus colecola BV Firmicutes/Bacilli (Lactobacillales) Yes 
Erysipelotrichaceae family BV Firmicutes/Erysipelotrichia (Erysipelotrichales) Yes 
Erysipelotrichaceae_UCG-003 genus BV Firmicutes/Erysipelotrichia (Erysipelotrichales) Yes 
Erysipelatoclostridium ramosum BV Firmicutes/Erysipelotrichia (Erysipelotrichales) Yes 
Escherichia/Shigella genus Pathobionts Gammaproteobacteria (Enterobacterales) No 
Ezakiella genus BV Firmicutes/Tissierellia (unclassified Tissierellia) No 
Ezakiella peruensis BV Firmicutes/Tissierellia (unclassified Tissierellia) Yes 
Facklamia genus BV Firmicutes/Bacilli (Lactobacillales) Yes 
Facklamia hominis BV Firmicutes/Bacilli (Lactobacillales) Yes 
Facklamia languida BV Firmicutes/Bacilli (Lactobacillales) Yes 
Faecalibacterium genus BV Firmicutes/Clostridia (Clostridiales) No 
Faecalibacterium cf./prausnitzii BV Firmicutes/Clostridia (Clostridiales) Yes 
Faecalibacterium prausnitzii BV Firmicutes/Clostridia (Clostridiales) No 
Family_XI family Other Cyanobacteria (order not described) Yes 
Family_XIII family Other Cyanobacteria (order not described) Yes 
Family_XIII_UCG-001 genus Other Cyanobacteria (order not described) Yes 
Fastidiosipila genus BV Firmicutes/Clostridia (Clostridiales) No 
Fenollaria massiliensis strain DNF00604 BV Firmicutes/Clostridia (Clostridiales) No 
Filifactor genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Finegoldia genus BV Firmicutes/Tissierellia (Tissierellales) No 
Finegoldia magna BV Firmicutes/Tissierellia (Tissierellales) No 
Fusicatenibacter genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Fusicatenibacter saccharivorans BV Firmicutes/Clostridia (Clostridiales) Yes 
Fusobacterium genus BV Fusobacteria/Fusobacteriia (Fusobacteriales) No 
Fusobacterium equinum/gonidiaformans BV Fusobacteria/Fusobacteriia (Fusobacteriales) No 
Fusobacterium nucleatum BV Fusobacteria/Fusobacteriia (Fusobacteriales) No 
Gallicola genus BV Firmicutes/Tissierellia (Tissierellales) Yes 
Gammaproteobacteria class Pathobionts Gammaproteobacteria Yes 
Gardnerella genus BV Actinobacteria/Actinobacteria (Bifidobacteriales) No 
Gardnerella vaginalis BV Actinobacteria/Actinobacteria (Bifidobacteriales) No 
Gastranaerophilales order Other Cyanobacteria Melainabacteria Group 
(Candidatus Melainabacteria) 
Yes 
Gemella genus BV Firmicutes/Bacilli (Bacillales) No 
Gemella asaccharolytica BV Firmicutes/Bacilli (Bacillales) No 
Gemella haemolysans/sanguinis/taiwanensis BV Firmicutes/Bacilli (Bacillales) No 
Gemella parahaemolysans BV Firmicutes/Bacilli (Bacillales) No 
Globicatella sanguinis BV Firmicutes/Bacilli (Lactobacillales) Yes 
Granulicatella genus BV Firmicutes/Bacilli (Lactobacillales) No 
Granulicatella adiacens/para-adiacens BV Firmicutes/Bacilli (Lactobacillales) Yes 
Granulicatella elegans BV Firmicutes/Bacilli (Lactobacillales) No 
Haemophilus genus  Pathobionts Gammaproteobacteria (Pasteurellales) No 
Haemophilus haemolyticus Pathobionts Gammaproteobacteria (Pasteurellales) Yes 
Haemophilus haemolyticus/influenzae Pathobionts Gammaproteobacteria (Pasteurellales) Yes 
Haemophilus haemolyticus/influenzae/quentini Pathobionts Gammaproteobacteria (Pasteurellales) Yes 
Haemophilus influenzae/parainfluenzae Pathobionts Gammaproteobacteria (Pasteurellales) Yes 
Haemophilus parainfluenzae Pathobionts Gammaproteobacteria (Pasteurellales) No 
Helcobacillus genus Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Helcococcus genus BV Firmicutes/Tissierellia (Tissierellales) Yes 
Holdemanella genus BV Firmicutes/Erysipelotrichia (Erysipelotrichiales) Yes 
Holdemanella biformis BV Firmicutes/Erysipelotrichia (Erysipelotrichiales) Yes 
Howardella genus BV Firmicutes/Clostridia (Clostridiales) No 
Intestinimonas genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Intestinibacter bartletti BV Firmicutes/Clostridia (Clostridiales) Yes 
Janibacter genus Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Johnsonella genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Jonquetella anthropi BV Synergistetes/Synergistia (Synergistales) Yes 
Klebsiella granulomatis/oxytoca/pneumoniae/ 
quasipneumoniae/variicola 
Pathobionts Gammaproteobacteria (Enterobacterales) Yes 
Klebsiella oxytoca/pneumoniae Pathobionts Gammaproteobacteria (Enterobacterales) Yes 
Klebsiella oxytoca/pneumoniae/variicola Pathobionts Gammaproteobacteria (Enterobacterales) Yes 
Kocuria marina Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Lachnoclostridium genus BV Firmicutes/Clostridia (Clostridiales) No 
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Lachnospiraceae family BV Firmicutes/Clostridia (Clostridiales) No 
Lachnospiraceae_FCS020_group genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Lachnospiraceae_FE2018_group genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Lachnospiraceae_ND3007_group genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Lachnospiraceae_NK3A20_group genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Lachnospiraceae_NK4A136_group genus BV Firmicutes/Clostridia (Clostridiales) No 
Lachnospiraceae_UCG-001 genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Lachnospiraceae_UCG-004 genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Lachnospiraceae_UCG-010 genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Lachnospira genus BV Firmicutes/Clostridia (Clostridiales) No 
Lachnospira pectinoschiza  BV Firmicutes/Clostridia (Clostridiales) Yes 
Lactobacillus genus Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus agilis Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus coleohominis Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus crispatus Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus crispatus/acidophilus/casei/gallinarum Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus crispatus/gallinarum/acidophilus/ 
kitasatonis/ultunensis/helveticus/amylovorus/ 
kefiranofaciens/hamsteri 
Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus crispatus/gasseri/helveticus/johnsonii/ 
kefiranofaciens 
Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus delbrueckii Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus faecis Lactobacilli Firmicutes/Bacilli (Lactobacillales) Yes 
Lactobacillus fermentum Lactobacilli Firmicutes/Bacilli (Lactobacillales) Yes 
Lactobacillus fermentum/curieae/delbrueckii/ingluviei/ 
oris/plantarum 
Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus fermentum/gasseri/reuteri/vaginalis Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus fermentum/mucosae Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus fornicalis/jensenii Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus gasseri Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus iatae/johnsonii/taiwanensis Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus iners Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus jensenii Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus jensenii/fornicalis/psittaci Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus johnsonii/prophage/taiwanensis Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus johnsonii/taiwanensis/gasseri Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus mucosae Lactobacilli Firmicutes/Bacilli (Lactobacillales) Yes 
Lactobacillus oris Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus plantarum Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus pontis Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus reuteri Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus ruminis Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus saerimneri/sakei Lactobacilli Firmicutes/Bacilli (Lactobacillales) Yes 
Lactobacillus vaginalis Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactobacillus vaginalis/reuteri Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Lactococcus formosensis/garvieae/lactis Other Firmicutes/Bacilli (Lactobacillales) Yes 
Lawsonella genus Other Actinobacteria/Actinobacteria (Corynebacteriales) Yes 
Lawsonella clevelandensis Other Actinobacteria/Actinobacteria (Corynebacteriales) No 
Listeria innocua/ivanovii/marthii/monocytogenes/phage/ 
seeligeri/welshimeri 
Pathobionts Firmicutes/Bacilli (Bacillales) Yes 
Mageeibacillus indolicus (formerly BVAB3) BV Firmicutes/Clostridia (Clostridiales) No 
Marvinbryantia genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Megasphaera genus BV Firmicutes/Negativicutes (Veillonellales) No 
Micrococcaceae family Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Micrococcus alkanovora/aloeverae/antarcticus/ 
endophyticus/indicus/luteus/yunnanensis 
Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Micrococcus aloeverae/luteus/lylae/yunnanensis Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Micrococcus lylae Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Mitsuokella genus BV Firmicutes/Negativicutes (Veillonellales) No 
Mobiluncus genus BV Actinobacteria/Actinobacteria (Actinomycetales) No 
Mobiluncus curtisii BV Actinobacteria/Actinobacteria (Actinomycetales) No 
Mobiluncus mulieris BV Actinobacteria/Actinobacteria (Actinomycetales) No 
Moryella genus BV Firmicutes/Clostridia (Clostridiales) No 
Moryella indoligenes BV Firmicutes/Clostridia (Clostridiales) No 
Murdochiella genus BV Firmicutes/Tissierellia (Tissierellales) Yes 
Murdochiella asaccharolytica BV Firmicutes/Tissierellia (Tissierellales) Yes 
Mycoplasmataceae family BV Tenericutes/Mollicutes (Mycoplasmatales) No 
Mycoplasma genus BV Tenericutes/Mollicutes (Mycoplasmatales) No 
Mycoplasma genitalium BV Tenericutes/Mollicutes (Mycoplasmatales) Yes 
Mycoplasma hominis BV Tenericutes/Mollicutes (Mycoplasmatales) Yes 
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Mycoplasma spermatophilum BV Tenericutes/Mollicutes (Mycoplasmatales) Yes 
Negativicoccus genus  BV Firmicutes/Negativicutes (Veillonellales) Yes 
Negativicoccus succinicivorans BV Firmicutes/Negativicutes (Veillonellales) Yes 
Neisseriaceae family Pathobionts Betaproteobacteria (Neisseriales) Yes 
Neisseria genus Pathobionts Betaproteobacteria (Neisseriales) Yes 
Neisseria cinerea/meningitidis Pathobionts Betaproteobacteria (Neisseriales) Yes 
Neisseria flava/lactamica/macacae/meningitidis/ 
mucosa/perflava/sicca 
Pathobionts Betaproteobacteria (Neisseriales) Yes 
Neisseria flavescens Pathobionts Betaproteobacteria (Neisseriales) Yes 
Neisseria gonorrhoeae/meningitidis Pathobionts Betaproteobacteria (Neisseriales) No 
Neisseria mucosa Pathobionts Betaproteobacteria (Neisseriales) Yes 
Nesterenkonia lacusekhoensis Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Nosocomiicoccus genus Other Firmicutes/Bacilli (Bacillales) Yes 
Odoribacter splanchnicus BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Olsenella genus BV Actinobacteria/Coriobacteriia (Coriobacteriales) Yes 
Paeniglutamicibacter genus Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Parabacteroides genus BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Parabacteroides distasonis BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Parabacteroides merdae BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Paraprevotella genus BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Parvimonas genus BV Firmicutes/Tissierellia (Tissierellales) No 
Parvimonas micra BV Firmicutes/Tissierellia (Tissierellales) No 
Peptococcus genus BV Firmicutes/Clostridia (Clostridiales) No 
Peptococcus niger BV Firmicutes/Clostridia (Clostridiales) Yes 
Peptoniphilus genus BV Firmicutes/Tissierellia (Tissierellales) No 
Peptoniphilus asaccharolyticus BV Firmicutes/Tissierellia (Tissierellales) Yes 
Peptoniphilus asaccharolyticus/grossensis/harei BV Firmicutes/Tissierellia (Tissierellales) No 
Peptoniphilus coxii BV Firmicutes/Tissierellia (Tissierellales) No 
Peptoniphilus duerdenii BV Firmicutes/Tissierellia (Tissierellales) No 
Peptoniphilus gorbachii/rhinitidis BV Firmicutes/Tissierellia (Tissierellales) Yes 
Peptoniphilus harei BV Firmicutes/Tissierellia (Tissierellales) Yes 
Peptoniphilus lacrimalis BV Firmicutes/Tissierellia (Tissierellales) No 
Peptoniphilus massiliensis BV Firmicutes/Tissierellia (Tissierellales) Yes 
Peptostreptococcaceae family BV Firmicutes/Clostridia (Clostridiales) No 
Peptostreptococcus genus BV Firmicutes/Clostridia (Clostridiales) No 
Peptostreptococcus anaerobius BV Firmicutes/Clostridia (Clostridiales) No 
Phascolarctobacterium genus BV Firmicutes/Negativicutes (Acidaminococcales) Yes 
Phascolarctobacterium faecium BV Firmicutes/Negativicutes (Acidaminococcales) Yes 
Phascolarctobacterium succinatutens BV Firmicutes/Negativicutes (Acidaminococcales) Yes 
Porphyromonas genus BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Porphyromonas asaccharolytica BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Porphyromonas somerae BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Porphyromonas uenonis BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotellaceae family BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Prevotellaceae_NK3B31_group genus BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Prevotellaceae_UCG-003 genus BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Prevotella genus BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella amnii BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella bergensis BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Prevotella bivia BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella bivia/denticola BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella buccalis BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella colorans BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Prevotella disiens BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella intermedia BV Bacteroidetes/Bacteroidia (Bacteroidales) Yes 
Prevotella melaninogenica BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella timonensis BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella_2 stercorea BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella_6 corporis BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Prevotella_9 copri BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Propionibacterium acnes/avium Other Actinobacteria/Actinobacteria (Propionibacteriales) Yes 
Propionimicrobium genus Other Actinobacteria/Actinobacteria (Propionibacteriales) Yes 
Propionimicrobium lymphophilum Other Actinobacteria/Actinobacteria (Propionibacteriales) Yes 
Proteobacteria phylum Other Proteobacteria Yes 
Pseudomonadaceae family Pathobionts Gammaproteobacteria (Pseudomonales) Yes 
Pyramidobacter genus BV Synergistetes/Synergistia (Synergistales) Yes 
Raoultella genus Pathobionts Gammaproteobacteria (Enterobacterales) Yes 
Raoultella ornithinolytica Pathobionts Gammaproteobacteria (Enterobacterales) Yes 
Raoultella ornithinolytica/planticola Pathobionts Gammaproteobacteria (Enterobacterales) Yes 
Rickettsiales_Incertae_Sedis family Pathobionts Alphaproteobacteria (Rickettsiales) Yes 
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Rikenellaceae_RC9_gut_group genus BV Bacteroidetes/Bacteroidia (Bacteroidales) No 
Romboutsia genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Roseburia genus BV Firmicutes/Clostridia (Clostridiales) No 
Roseburia faecis BV Firmicutes/Clostridia (Clostridiales) No 
Roseburia intestinalis BV Firmicutes/Clostridia (Clostridiales) Yes 
Roseburia inulinivorans BV Firmicutes/Clostridia (Clostridiales) Yes 
Rothia genus Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Rothia mucilaginosa Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Ruminiclostridium genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Ruminococcaceae family BV Firmicutes/Clostridia (Clostridiales) Yes 
Ruminococcaceae_UCG-002 genus BV Firmicutes/Clostridia (Clostridiales) No 
Ruminococcaceae_UCG-003 genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Ruminococcaceae_UCG-005 genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Ruminococcaceae_UCG-010 genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Ruminococcaceae_UCG-013 genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Ruminococcaceae_UCG-014 genus BV Firmicutes/Clostridia (Clostridiales) No 
Ruminococcaceae_NK4A214_group genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Ruminococcus genus BV Firmicutes/Clostridia (Clostridiales) No 
Ruminococcaceae_UCG-002 bacterium BV Firmicutes/Clostridia (Clostridiales) Yes 
Ruminococcus_2 bromii BV Firmicutes/Clostridia (Clostridiales) Yes 
Saccharibacteria phylum BV Unclassified (TM7 division) No 
Sarcina genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Senegalimassilia genus BV Actinobacteria/Coriobacteriia (Coriobacteriales) No 
Senegalimassilia anaerobia BV Actinobacteria/Coriobacteriia (Coriobacteriales) Yes 
Serratia entomophila/marcescens/nematodiphila Pathobionts Gammaproteobacteria (Enterobacterales) Yes 
Shuttleworthia genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Slackia exigua BV Actinobacteria/Coriobacteriia (Eggerthellales) Yes 
Slackia isofavoniconvertens BV Actinobacteria/Coriobacteriia (Eggerthellales) Yes 
Sneathia genus BV Fusobacteria/Fusobacteriia (Fusobacteriales) No 
Sneathia amnii BV Fusobacteria/Fusobacteriia (Fusobacteriales) No 
Sneathia amnii/sanguinegens BV Fusobacteria/Fusobacteriia (Fusobacteriales) No 
Sneathia sanguinegens BV Fusobacteria/Fusobacteriia (Fusobacteriales) No 
Solobacterium genus BV Firmicutes/Erysipelotrichia (Erysipelotrichales) Yes 
Solobacterium moorei BV Firmicutes/Erysipelotrichia (Erysipelotrichales) Yes 
Spirochaetaceae family Pathobionts Spirochaetes/Spirochaetia (Spirochaetales) Yes 
SR1_(Absconditabacteria) phylum BV Unclassified (Absconditabacteria division) Yes 
Staphylococcus genus Pathobionts Firmicutes/Bacilli (Bacillales) Yes 
Staphylococcus argenteus/aureus/equorum/phage/ 
schweitzeri/simiae 
Pathobionts Firmicutes/Bacilli (Bacillales) Yes 
Staphylococcus aureus/capitis/caprae/epidermidis/ 
haemolyticus/warneri 
Pathobionts Firmicutes/Bacilli (Bacillales) No 
Staphylococcus aureus/devriesei/epidermidis/ 
haemolyticus 
Pathobionts Firmicutes/Bacilli (Bacillales) No 
Staphylococcus epidermidis Pathobionts Firmicutes/Bacilli (Bacillales) Yes 
Staphylococcus epidermidis/haemolyticus Pathobionts Firmicutes/Bacilli (Bacillales) No 
Staphylococcus epidermidis/haemolyticus/hominis Pathobionts Firmicutes/Bacilli (Bacillales) No 
Staphylococcus haemolyticus Pathobionts Firmicutes/Bacilli (Bacillales) No 
Staphylococcus haemolyticus/petrasii Pathobionts Firmicutes/Bacilli (Bacillales) No 
Staphylococcus hominis Pathobionts Firmicutes/Bacilli (Bacillales) Yes 
Stenotrophomonas maltophilia Pathobionts Gammaproteobacteria (Xanthomonadales) Yes 
Stenotrophomonas maltophilia/rhizophila Pathobionts Gammaproteobacteria (Xanthomonadales) Yes 
Streptococcus genus Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus agalactiae/pyogenes Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus alactolyticus/equinus/gallolyticus/ 
macedonicus/pasteuri/pasteurianus 
Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus anginosus/constellatus/intermedius Pathobionts Firmicutes/Bacilli (Lactobacillales) Yes 
Streptococcus anginosus/intermedius/sanguinis/suis Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus anginosus/milleri Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus australis/infantis/mitis/oralis/sanguinis Pathobionts Firmicutes/Bacilli (Lactobacillales) Yes 
Streptococcus dentisani/infantis/mitis/oligofermentans/ 
oralis/pneumoniae/pseudopneumoniae/sanguinis/ 
tigurinus 
Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus equinus/infantarius/lutetiensis Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus gordonii/mitis/oligofermentans/sanguinis Pathobionts Firmicutes/Bacilli (Lactobacillales) Yes 
Streptococcus mitis/parasanguinis Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus oralis/parasanguinis/sanguinis Pathobionts Firmicutes/Bacilli (Lactobacillales) No 
Streptococcus pneumoniae Pathobionts Firmicutes/Bacilli (Lactobacillales) Yes 
Subdoligranulum genus BV Firmicutes/Clostridia (Clostridiales) No 
Succinivibrio genus Other Gammaproteobacteria (Aeromonadales) Yes 
Sutterella genus Other Betaproteobacteria (Burkholderiales) No 
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Sutterella morbirenis/sanguinus Other Betaproteobacteria (Burkholderiales) Yes 
Sutterella wadsworthensis Other Betaproteobacteria (Burkholderiales) Yes 
Terrisporobacter genus BV Firmicutes/Clostridia (Clostridiales) Yes 
Treponema_2 genus Pathobionts Spirochaetes/Spirochaetia (Spirochaetales) Yes 
Trueperella bernardiae BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Tyzzerella_4 nexilis BV Firmicutes/Clostridia (Clostridiales) Yes 
Ureaplasma genus BV Tenericutes/Mollicutes (Mycoplasmatales) No 
Ureaplasma parvum/urealyticum BV Tenericutes/Mollicutes (Mycoplasmatales) No 
Ureaplasma urealyticum BV Tenericutes/Mollicutes (Mycoplasmatales) No 
VadinBE97 family Other Lentisphaerae: Candidate division VadinBE97 Yes 
Varibaculum genus BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Varibaculum cambriense BV Actinobacteria/Actinobacteria (Actinomycetales) Yes 
Veillonellaceae family BV Firmicutes/Negativicutes (Veillonellales) Yes 
Veillonella genus BV Firmicutes/Negativicutes (Veillonellales) No 
Veillonella atypica BV Firmicutes/Negativicutes (Veillonellales) Yes 
Veillonella dispar  BV Firmicutes/Negativicutes (Veillonellales) No 
Veillonella dispar/parvula BV Firmicutes/Negativicutes (Veillonellales) Yes 
Veillonella montpellierensis BV Firmicutes/Negativicutes (Veillonellales) No 
Veillonella parvula BV Firmicutes/Negativicutes (Veillonellales) Yes 
Veillonella parvula/rogosae BV Firmicutes/Negativicutes (Veillonellales) Yes 
Veillonella ratti/seminalis  BV Firmicutes/Negativicutes (Veillonellales) No 
Veillonella rogosae BV Firmicutes/Negativicutes (Veillonellales) Yes 
Weissella cibaria/confusa/koreensis BV Firmicutes/Bacilli (Lactobacillales) No 
Zimmermannella genus Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
Zimmermannella bifida Other Actinobacteria/Actinobacteria (Micrococcales) Yes 
EF+ BBW28 Other Actinobacteria/Actinobacteria (Bifidobacteriales) No 
EF+ LAW70 Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
EF+ LBW63 Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
EF+ LHW74 Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
EF+ LPW21 Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
EF+ LSW24 Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
Gynophilus Lactobacilli Firmicutes/Bacilli (Lactobacillales) No 
BV bacterial vaginosis, BVAB BV-associated bacterium, EF+ Ecologic Femi+.  
This list contains all 425 amplicon sequence variants of Chapter 2 (containing 204 amplicon sequence variants in all 136 samples) and Chapter 
3 (containing 425 amplicon sequence variants in all 639 samples) of this thesis, including the 24 amplicon sequence variants that were deleted 
due to rarefaction.  
*Based on NCBI taxonomy browser. †<1% relative abundance in all study samples. 
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Appendix B  
 
This appendix corresponds to Chapter 2. 
Figure B.1: VMB outcomes pre- and post-treatment, stratified by metronidazole treatment 
success 
a b 
  
c d 
  
 
e  
 
BV bacterial vaginosis, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, Conc 
concentration, GV G. vaginalis-dominated, IQR inter-quartile range, LA lactobacilli and anaerobes, Li L. iners-dominated, Lo other lactobacilli-
dominated, PB pathobionts-containing, Pre-tx pre-treatment visit, Post-tx post-treatment visit, VMB vaginal microbiota.  
a-e Figures show changes in VMB characteristics before and after metronidazole treatment: bacterial group mean relative abundances (a), 
VMB types (b), bacterial groups concentrations of women with successful treatment by Nugent scoring (n=28 at pre-tx, n=29 at post-tx; see 
table 2.2 for 95% confidence intervals) (c). d bacterial group concentrations of women with unsuccessful treatment by Nugent scoring (n=25 at 
pre-tx, n=22 at post-tx). e median inverse Simpson diversity index before and after metronidazole treatment, stratified by treatment success.  
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Figure B.2: VMB outcomes pre- and post-treatment, stratified by ongoing CT/NG infection 
a 
 
b 
 
c 
 
d 
 
e 
 
f 
 
 
BV bacterial vaginosis, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, Conc 
concentration, CT Chlamydia trachomatis, GV G. vaginalis-dominated, IQR inter-quartile range, LA lactobacilli and anaerobes, Li L. iners-
dominated, Lo other lactobacilli-dominated, NG Neisseria gonorrhoeae, PB pathobionts-containing, Pre-tx pre-treatment visit, Post-tx post-
treatment visit, VMB vaginal microbiota. 
a-f Figures show changes in VMB characteristics before and after metronidazole treatment, stratified by CT/NG status at baseline: Nugent 
score categories (a), bacterial group mean relative abundances (b), VMB types (c), and median inverse Simpson diversity index (d). e Bacterial 
group concentrations of CT/NG-negative participants at baseline (n=40 at pre-tx, n=39 at post-tx; see table B.1 for 95% confidence intervals). f 
Bacterial group concentrations of CT/NG-positive participants at baseline (n=26 at pre-tx, n=24 at post-tx).  
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Figure B.3: VMB outcomes pre- and post-treatment, stratified by additional antibiotic use 
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e 
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BV bacterial vaginosis, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, Conc 
concentration, GV G. vaginalis-dominated, IQR inter-quartile range, LA lactobacilli and anaerobes, Li L. iners-dominated, Lo other lactobacilli-
dominated, PB pathobionts-containing, Pre-tx pre-treatment visit, Post-tx post-treatment visit, VMB vaginal microbiota. 
a-f Figures show changes in VMB characteristics before and after metronidazole treatment, stratified by use of another antibiotic in addition to 
metronidazole: Nugent score categories (a), bacterial group mean relative abundances (b), VMB types (c), and median inverse Simpson 
diversity index (d). e Bacterial group concentrations of participants who received another antibiotic in addition to metronidazole at baseline 
(n=18 at pre-treatment visit, n=17 at post-treatment visit; see table B.2 for 95% confidence intervals). f Bacterial group concentrations of 
participants who only received metronidazole at baseline (n=49 at pre-treatment visit, n=50 at post-treatment visit).  
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Figure B.4: VMB outcomes pre- and post-treatment, stratified by pre-treatment vaginal 
discharge 
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BV bacterial vaginosis, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, Conc 
concentration, GV G. vaginalis-dominated, IQR inter-quartile range, LA lactobacilli and anaerobes, Li L. iners-dominated, Lo other lactobacilli-
dominated, PB pathobionts-containing, Pre-tx pre-treatment visit, Post-tx post-treatment visit, VMB vaginal microbiota. 
a-f Figures show changes in VMB characteristics before and after metronidazole treatment, stratified by unusual vaginal discharge symptoms 
at the pre-treatment visit: Nugent score categories (a), bacterial group mean relative abundances (b), VMB types (c), and median Simpson 
diversity 1-D (d). e Bacterial group concentrations of participants who did not report unusual vaginal discharge at the pre-treatment visit 
(n=13; see table B.3 for 95% confidence intervals). f Bacterial group concentrations of participants who reported unusual vaginal discharge at 
the pre-treatment visit (n=55).  
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Table B.1: VMB characteristics pre- and post-treatment, stratified by ongoing CT/NG infection 
VMB Outcomes All participants CT/NG negative at baseline† CT/NG positive at baseline† 
Pre-treatment 
(n = 68) 
Post-treatment 
(n = 68) 
p* Pre-treatment 
(n = 41) 
Post-treatment 
(n = 41) 
p* Pre-treatment 
(n = 26) 
Post-treatment 
(n = 26) 
p* 
Nugent categories (n %)‡ 
 0-3 
 4-6 
 7-10 
 
5 (7.5) 
6 (9.0) 
56 (83.6) 
 
36 (54.6) 
13 (19.7) 
17 (25.8) 
<0.001 
 
5 (12.2) 
3 (7.2) 
33 (80.5) 
 
24 (58.5) 
6 (14.6) 
11 (26.8) 
<0.001 
 
0 
3 (11.5) 
33 (88.5) 
 
12 (48.0) 
7 (28.0) 
6 (24.0) 
0.001 
Mean inverse Simpson diversity 
index (95% CI)§ 
0.67 
(0.60 – 0.73) 
0.31 
(0.25 – 0.38) <0.001 
0.63 
(0.53 – 0.72) 
0.30 
(0.21 – 0.39) <0.001 
0.74 
(0.65 – 0.82) 
0.33 
(0.22 – 0.45) <0.001 
VMB type (n %)§: 
– Li 
 Lo 
 LA 
 BV_GV 
 BV_noGV 
 GV 
 PB 
 
10 (14.9) 
0 
12 (17.9) 
28 (41.8) 
8 (11.9) 
8 (11.9) 
1 (1.5) 
 
35 (52.2) 
2 (3.0) 
18 (26.9) 
2 (3.0) 
0 
4 (6.0) 
6 (9.0) 
<0.001 
 
9 (22.0) 
0 
10 (24.4) 
15 (36.6) 
3 (7.3) 
4 (9.8) 
0 
 
20 (48.8) 
1 (2.4) 
13 (31.7) 
1 (2.4) 
0 
2 (4.9) 
4 (9.8) 
0.001 
 
1 (3.9) 
0 
2 (7.7) 
13 (50.0) 
5 (19.2) 
4 (15.4) 
1 (3.9) 
 
15 (57.7) 
1 (3.9) 
5 (19.2) 
1 (3.9) 
0 
2 (7.7) 
2 (7.7) 
0.003 
Vaginal pH, median (IQR) 5.3 
(5.0 – 5.6) 
4.4 
(3.6 – 4.6) <0.001 
5.3 
(4.7 – 5.6) 
4.3 
(3.6 – 4.4) <0.001 
5.5 
(5.0 – 5.6) 
4.4 
(3.6 – 4.7) <0.001 
Vulvovaginal candidiasis (n %) 6 (8.8) 4 (5.9) 0.527 5 (11.9) 2 (4.8) 0.257 1 (3.9) 2 (7.7) 0.564 
Bacterial group relative abundances: mean (95% CI)§ 
Total lactobacilli 0.24 
(0.15 – 0.32) 
0.72 
(0.64 – 0.80) <0.001 
0.32 
(0.20 – 0.43) 
0.73 
(0.63 – 0.83) <0.001 
0.10 
(0.02 – 0.19) 
0.70 
(0.56 – 0.84) <0.001 
Total BV-associated anaerobes 0.75 
(0.67 – 0.83) 
0.23 
(0.16 – 0.30) <0.001 
0.67 
(0.55 – 0.79) 
0.23 
(0.14 – 0.33) <0.001 
0.87 
(0.79 – 0.96) 
0.23 
(0.11 – 0.34) <0.001 
Total pathobionts 0.02 
(0.01 – 0.03) 
0.05 
(0.02 – 0.09) 0.050 
0.01 
(0 – 0.02) 
0.04 
(0.01 – 0.07) 0.821 
0.02 
(0 – 0.05) 
0.07 
(-0.01 – 0.15) 0.015 
Total other bacteria 0 
(0 – 0) 
0 
(0 – 0) 0.674 
0 
(0 – 0) 
0 
(0 – 0) 0.354 
0 
(0 – 0) 
0 
(0 – 0.01) 0.590 
Bacterial group concentrations in log10 cells/μL: mean (95% CI)¶ 
Total bacteria  6.59 
(6.39 – 6.78) 
5.85 
(5.66 – 6.04) <0.001 
6.44 
(6.20 – 6.68) 
5.90 
(5.66 – 6.13) 0.002 
6.82 
(6.49 – 7.14) 
5.78 
(5.44 – 6.11) <0.001 
Total lactobacilli 4.98 
(4.61 – 5.35) 
5.56 
(5.34 – 5.78) 0.017 
5.02 
(4.52 – 5.52) 
5.63 
(5.39 – 5.88) 0.112 
4.92 
(4.33 – 5.50) 
5.43 
(4.99 – 5.88) 0.072 
Total BV-anaerobes 6.23 
(5.88 – 6.57) 
4.55 
(4.14 – 4.95) <0.001 
5.89 
(5.40 – 6.39) 
4.44 
(3.87 – 5.01) <0.001 
6.73 
(6.36 – 7.09) 
4.73 
(4.17 – 5.28) <0.001 
Total pathobionts 1.92 
(1.36 – 2.48) 
2.01 
(1.48 – 2.54) 0.939 
1.59 
(0.91 – 2.27) 
1.65 
(0.96 – 2.32) 0.464 
2.43 
(1.43 – 3.42) 
2.60 
(1.73 – 3.47) 0.474 
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VMB Outcomes All participants CT/NG negative at baseline† CT/NG positive at baseline† 
Pre-treatment 
(n = 68) 
Post-treatment 
(n = 68) 
p* Pre-treatment 
(n = 41) 
Post-treatment 
(n = 41) 
p* Pre-treatment 
(n = 26) 
Post-treatment 
(n = 26) 
p* 
Total other bacteria 1.85 
(1.36 – 2.35) 
1.46 
(1.01 – 1.92) 0.176 
1.68 
(1.06 – 2.30) 
1.29 
(0.74 – 1.84) 0.216 
2.12 
(1.27 – 2.97) 
1.74 
(0.90 – 2.58) 0.554 
Individual bacterial species/genera concentrations in log10 cells/μL: mean (95% CI)¶ 
L. iners 4.81 
(4.38 – 5.24) 
5.28 
(4.94 – 5.62) 0.072 
4.89 
(4.32 – 5.46) 
5.33 
(4.89 – 5.76) 0.394 
4.69 
(4.00 – 5.39) 
5.21 
(4.63 – 5.80) 0.072 
L. crispatus|| 0.15 
(-0.02 – 0.33) 
0.51 
(0.16 – 0.85) 0.089 
0.25 
(-0.04 – 0.55) 
0.54 
(0.06 – 1.02) 0.388 
0 
(0 – 0) 
0.45 
(-0.07 – 0.97) 0.084 
Other lactobacilli** 1.46 
(0.97 – 1.94) 
3.03 
(2.57 – 3.48) <0.001 
1.74 
(1.11 – 2.37) 
3.17 
(2.60 – 3.74) 0.002 
1.03 
(0.23 – 1.82) 
2.79 
(1.99 – 3.85) 0.002 
Gardnerella vaginalis  5.62 
(5.20 – 6.03) 
4.12 
(3.63 – 4.61) <0.001 
5.23 
(4.60 – 5.86) 
3.96 
(3.27 – 4.65) 0.009 
6.22 
(5.85 – 6.59) 
4.37 
(3.68 – 5.07) <0.001 
Atopobium vaginae 4.58 
(4.00 – 5.16) 
1.54 
(1.06 – 2.02) <0.001 
4.13 
(3.31 – 4.94) 
1.73  
(1.10 – 2.37) <0.001 
5.27 
(4.50 – 6.03) 
1.22 
(0.45 – 1.99) <0.001 
Prevotella species 4.67 
(4.18 – 5.16) 
1.35 
(0.90 – 1.79) <0.001 
4.29 
(3.60 – 4.98) 
1.41 
(0.85 – 1.98) <0.001 
5.25 
(4.60 – 5.90) 
1.24 
(0.46 – 2.01) <0.001 
Sneathia species 4.18 (3.63 – 4.73) 
1.08 
(0.63 – 1.54) <0.001 
3.79 
(3.05 – 4.52) 
0.85 
(0.28 – 1.43) <0.001 
4.79 
(3.97 – 5.61) 
1.44 
(0.66 – 2.21) <0.001 
Megasphaera species 3.17 
(2.56 – 3.79) 
0.22 
(-0.01 – 0.44) <0.001 
2.74 
(1.91 – 3.56) 
0.13 
(-0.06 – 0.33) <0.001 
3.84 
(2.92 – 4.76) 
0.36 
(-0.16 – 0.88) <0.001 
Veillonella species 2.37 
(1.75 – 3.00) 
0.28 
(0.01 – 0.56) <0.001 
2.22 
(1.46 – 2.99) 
0.45 
(0.01 – 0.99) 0.001 
2.60 
(1.46 – 3.73) 
0 
(0 – 0) 0.001 
BVAB1 1.76 
(1.11 – 2.42) 
0.46 
(0.15 – 0.77) <0.001 
0.99 
(0.29 – 1.69) 
0.24 
(0.01 – 0.47) 0.072 
2.95 
(1.77 – 4.13) 
0.83 
(0.09 – 1.57) 0.002 
Fusobacterium species 0.53 (0.17 – 0.89) 
0 
(0 – 0) 0.008 
0.33 
(-0.05 – 0.70) 
0 
(0 – 0) 0.083 
0.85 
(0.12 – 1.57) 
0 
(0 – 0) 0.046 
Streptococcus species 1.47 
(0.92 – 2.02) 
1.34 
(0.84 – 1.85) 0.453 
1.50 
(0.82 – 2.17) 
1.14 
(0.53 – 1.75) 0.056 
1.43 
(0.44 – 2.43) 
1.67 
(0.73 – 2.60) 0.350 
Staphylococcus species  0.26 
(0.05 – 0.47) 
0.60 
(0.27 – 0.93) 0.655 
0.29 
(0.01 – 0.57) 
0.31 
(0 – 0.61) 0.317 
0.22 
(-0.10 – 0.53) 
1.07 
(0.36 – 1.79) 0.317 
Escherichia/Shigella 0.10 
(-0.04 – 0.25) 
0.86 
(0.45 – 1.27) 0.317 
0.17 
(-0.07 – 0.41) 
0.70 
(0.20 – 1.20) 0.317 
0 
(0 – 0) 
1.12 
(0.39 – 1.85) 
Not 
determinable 
BV bacterial vaginosis, BVAB1 BV-associated bacterium type 1, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial low G. vaginalis, CI confidence interval, CT Chlamydia trachomatis, GV 
G. vaginalis-dominated, LA lactobacilli and anaerobes, Li L. iners-dominated, Lo other lactobacilli-dominated, NG Neisseria gonorrhoeae, PB pathobionts-containing, VMB vaginal microbiota. 
*Stuart-Maxwell test for matched categorical data, and Wilcoxon signed-rank test for matched continuous data. †Participants included regardless of Nugent score at pre-treatment and post-treatment visits.  
‡Valid Nugent data available for 67 participants at the pre-treatment visit and 66 participants at the post-treatment visit. §Relative abundance, Simpson inverse diversity indices, and VMB type data available for 67 
participants at each visit. ¶Concentration data may contain at most five missing values (see Appendix A Supplementary Methods). ||Includes all amplicon sequence variants attributed to L. crispatus, also those with 
multiple species assignments. **Includes amplicon sequence variants attributed to L. jensenii, L. delbrueckii, L. fermentum, L. gasseri, L. johnsonii, and Lactobacillus genus, as well as 11 other minority amplicon 
sequence variants.  
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Table B.2: VMB characteristics pre- and post-treatment, stratified by antibiotic use 
VMB Outcomes All participants Used metronidazole only† Used metronidazole plus another antibiotic† 
Pre-treatment 
(n = 68) 
Post-treatment 
(n = 68) 
p* Pre-treatment 
(n = 50) 
Post-treatment 
(n = 50) 
p* Pre-treatment 
(n = 18) 
Post-treatment 
(n = 18) 
p* 
Nugent categories (n %)‡ 
 0-3 
 4-6 
 7-10 
 
5 (7.5) 
6 (9.0) 
56 (83.6) 
 
36 (54.6) 
13 (19.7) 
17 (25.8) 
<0.001 
 
3 (6.1) 
5 (10.2) 
41 (83.7) 
 
27 (55.1) 
8 (16.3) 
14 (28.6) 
<0.001 
 
2 (11.1) 
1 (5.6) 
15 (83.8) 
 
9 (52.9) 
5 (29.4) 
3 (17.7) 
0.005 
Mean inverse Simpson diversity 
index (95% CI)§ 
0.67 
(0.60 – 0.73) 
0.31 
(0.25 – 0.38) <0.001 
0.68 
(0.61 – 0.75) 
0.32 
(0.24 – 0.40) <0.001 
0.64 
(0.49 – 0.79) 
0.29 
(0.15 – 0.43) 0.005 
VMB type (n %)§: 
– Li 
 Lo 
 LA 
 BV_GV 
 BV_noGV 
 GV 
 PB 
 
10 (14.9) 
0 
12 (17.9) 
28 (41.8) 
8 (11.9) 
8 (11.9) 
1 (1.5) 
 
35 (52.2) 
2 (3.0) 
18 (26.9) 
2 (3.0) 
0 
4 (6.0) 
6 (9.0) 
<0.001 
 
7 (14.3) 
0 
9 (18.4) 
19 (38.8) 
7 (14.3) 
6 (12.2) 
1 (2.0) 
 
26 (62.0) 
2 (4.0) 
13 (26.0) 
2 (4.0) 
0 
3 (6.0) 
4 (8.0) 
<0.001 
 
3 (16.7) 
0 
3 (16.7) 
9 (50.0) 
1 (5.6) 
2 (11.1) 
0 
 
9 (52.9) 
0 
5 (29.4) 
0 
0 
1 (5.9) 
2 (11.8) 
0.054 
Vaginal pH, median (IQR) 5.3 
(5.0 – 5.6) 
4.4 
(3.6 – 4.6) <0.001 
5.3 
(5.0 – 5.6) 
4.4 
(3.6 – 5.6) <0.001 
5.5 
(5.0 – 5.6) 
4.4  
(4.1 – 4.7) <0.001 
Vulvovaginal candidiasis (n %) 6 (8.8) 4 (5.9) 0.527 3 (6.0) 4 (8.0) 0.706 3 (16.7) 0 0.083 
Bacterial group relative abundances: mean (95% CI)§ 
Total lactobacilli 0.24 
(0.15 – 0.32) 
0.72 
(0.64 – 0.80) <0.001 
0.22 
(0.13 – 0.32) 
0.71 
(0.62 – 0.81) <0.001 
0.26 
(0.08 – 0.45) 
0.72 
(0.55 – 0.89) 0.006 
Total BV-associated anaerobes 0.75 
(0.67 – 0.83) 
0.23 
(0.16 – 0.30) <0.001 
0.75 
(0.66 – 0.85) 
0.23 
(0.15 – 0.32) <0.001 
0.73 
(0.54 – 0.91) 
0.22 
(0.07 – 0.37) 0.001 
Total pathobionts 0.02 
(0.01 – 0.03) 
0.05 
(0.02 – 0.09) 0.050 
0.02 
(0.01 – 0.04) 
0.05 
(0.01 – 0.09) 0.218 
0 
(0 – 0.01) 
0.05 
(-0.01 – 0.11) 0.092 
Total other bacteria 0 
(0 – 0) 
0 
(0 – 0) 0.674 
0 
(0 – 0) 
0 
(0 – 0) 0.323 
0 
(0 – 0_ 
0.01 
(0 – 0.01) 0.416 
Bacterial group concentrations in log10 cells/μL: mean (95% CI)¶ 
Total bacteria  6.59 
(6.39 – 6.78) 
5.85 
(5.66 – 6.04) <0.001 
6.66 
(6.44 – 6.88) 
5.86 
(5.64 – 6.08) <0.001 
6.40 
(5.96 – 6.84) 
5.83 
(5.41 – 6.25) 0.114 
Total lactobacilli 4.98 
(4.61 – 5.35) 
5.56 
(5.34 – 5.78) 0.017 
4.99 
(4.51 – 5.47) 
5.54  
(5.29 – 5.80) 0.087 
4.95 
(4.42 – 5.48) 
5.60 
(5.09 – 6.10) 0.109 
Total BV-anaerobes 6.23 
(5.88 – 6.57) 
4.55 
(4.14 – 4.95) <0.001 
6.29  
(5.89 – 6.69) 
4.54 
(4.04 – 5.03) <0.001 
6.05 
(5.34 – 6.77) 
4.59 
(3.86 – 5.31) 
0.008 
 
Total pathobionts 1.92 
(1.36 – 2.48) 
2.01 
(1.48 – 2.54) 0.939 
2.02 
(1.35 – 2.70) 
1.99 
(1.36 – 2.63) 0.725 
1.65 
(0.54 – 2.75) 
2.06 
(0.98 – 3.14) 0.545 
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VMB Outcomes All participants Used metronidazole only† Used metronidazole plus another antibiotic† 
Pre-treatment 
(n = 68) 
Post-treatment 
(n = 68) 
p* Pre-treatment 
(n = 50) 
Post-treatment 
(n = 50) 
p* Pre-treatment 
(n = 18) 
Post-treatment 
(n = 18) 
p* 
Total other bacteria 1.85 
(1.36 – 2.35) 
1.46 
(1.01 – 1.92) 0.176 
1.99 
(1.41 – 2.57) 
1.39 
(0.88 – 1.90) 0.093 
1.49  
(0.50 – 2.49) 
1.67 
(0.59 – 2.76) 0.704 
Individual bacterial species/genera concentrations in log10 cells/μL: mean (95% CI)¶ 
L. iners 4.81 
(4.38 – 5.24) 
5.28 
(4.94 – 5.62) 0.072 
4.84 
(4.31 – 5.37) 
5.25 
(4.84 – 5.65) 0.291 
4.74 
(3.96 – 5.51) 
5.39 
(4.71 – 6.08) 0.109 
L. crispatus|| 0.15 
(-0.02 – 0.33) 
0.51 
(0.16 – 0.85) 0.089 
0.13 
(-0.06 – 0.32) 
0.37 
(0 – 0.75) 0.180 
0.21 
(-0.24 – 0.67) 
0.90 
(0.03 – 1.76) 0.271 
Other lactobacilli** 1.46 
(0.97 – 1.94) 
3.03 
(2.57 – 3.48) <0.001 
1.40 
(0.82 – 1.98) 
2.92 
(2.38 – 3.47) <0.001 
1.18 
(0.45 – 1.91) 
3.31 
(2.45 – 4.17) 0.046 
Gardnerella vaginalis  5.62 
(5.20 – 6.03) 
4.12 
(3.63 – 4.61) <0.001 
5.65 
(5.15 – 6.16) 
4.18 
(3.61 – 4.74) <0.001 
5.52 
(4.71 – 6.34) 
3.95 
(2.83 – 5.06) 0.070 
Atopobium vaginae 4.58 
(4.00 – 5.16) 
1.54 
(1.06 – 2.02) <0.001 
4.52 
(3.80 – 5.24) 
1.87 
(1.29 – 2.46) <0.001 
4.74 
(3.72 – 5.76) 
0.55 
(-0.11 – 1.21) 0.001 
Prevotella species 4.67 
(4.18 – 5.16) 
1.35 
(0.90 – 1.79) <0.001 
4.74 
(4.20 – 5.29) 
1.31 
(0.77 – 1.85) <0.001 
4.48 
(3.29 – 5.66) 
1.45 
(0.59 – 2.30) 0.001 
Sneathia species 4.18 (3.63 – 4.73) 
1.08 
(0.63 – 1.54) <0.001 
4.05 
(3.37 – 4.73) 
1.17 
(0.61 – 1.73) <0.001 
4.51 
(3.54 – 5.48) 
0.81 
(0.02 – 1.61) <0.001 
Megasphaera species 3.17 
(2.56 – 3.79) 
0.22 
(-0.01 – 0.44) <0.001 
3.23 
(2.50 – 3.96) 
0.26 
(-0.04 – 0.55) <0.001 
3.02 
(1.75 – 4.29) 
0.11 
(-0.12 – 0.34) 0.004 
Veillonella species 2.37 
(1.75 – 3.00) 
0.28 
(0.01 – 0.56) <0.001 
2.37 
(1.63 – 3.12) 
0.38 
(0.01 – 0.75) <0.001 
2.36 
(1.08 – 3.64) 
0 
(0 – 0) 0.005 
BVAB1 1.76 
(1.11 – 2.42) 
0.46 
(0.15 – 0.77) <0.001 
1.97 
(1.17 – 2.78) 
0.56 
(0.16 – 0.96) 0.001 
1.20 
(0.05 – 2.36) 
0.17 
(-0.19 – 0.52) 0.144 
Fusobacterium species 0.53 (0.17 – 0.89) 
0 
(0 – 0) 0.008 
0.47 
(0.06 – 0.89) 
0 
(0 – 0) 0.046 
0.69 
(-0.10 – 1.48) 
0 
(0 – 0) 0.084 
Streptococcus species 1.47 
(0.92 – 2.02) 
1.34 
(0.84 – 1.85) 0.453 
1.64 
(0.96 – 2.31) 
1.47 
(0.85 – 2.09) 0.420 
1.04 
(0.03 – 2.04) 
0.95 
(0.07 – 1.84) 0.911 
Staphylococcus species  0.26 
(0.05 – 0.47) 
0.60 
(0.27 – 0.93) 0.655 
0.18 
(-0.03 – 0.39) 
0.41 
(0.07 – 0.76) 0.317 
0.47 
(-0.07 – 1.00) 
1.14 
(0.29 – 1.99) 0.317 
Escherichia/Shigella 0.10 
(-0.04 – 0.25) 
0.86 
(0.45 – 1.27) 0.317 
0.14 
(-0.06 – 0.34) 
0.74 
(0.27 – 1.20) 0.317 
0 
(0 – 0) 
1.21 
(0.28 – 2.13) 
Not 
determinable 
BV bacterial vaginosis, BVAB1 BV-associated bacterium type 1, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, CI confidence interval, GV G. vaginalis-dominated, 
LA lactobacilli and anaerobes, Li L. iners-dominated, Lo other lactobacilli-dominated, PB pathobionts-containing, VMB vaginal microbiota. 
*Stuart-Maxwell test for matched categorical data, and Wilcoxon signed-rank test for matched continuous data. †The other antibiotic were ciprofloxacin for urinary tract infection and penicillin for syphilis. Both groups 
include three women each (total n=6) who received antifungal treatment for vulvovaginal candidiasis. ‡Valid Nugent data available for 67 participants at the pre-treatment visit and 66 participants at the post-treatment 
visit. §Relative abundance, Simpson inverse diversity indices, and VMB type data available for 67 participants at each visit. ¶Concentration data may contain at most five missing values (see Appendix A Supplementary 
Methods). ||Includes all amplicon sequence variants attributed to L. crispatus, also those with multiple species assignments. **Includes amplicon sequence variants attributed to L. jensenii, L. delbrueckii, L. fermentum, L. 
gasseri, L. johnsonii, and Lactobacillus genus, as well as 11 other minority amplicon sequence variants. 
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Table B.3: VMB characteristics pre- and post-treatment, stratified by reported vaginal discharge symptoms at the pre-treatment visit 
VMB Outcomes All participants Reported vaginal discharge  
at pre-treatment visit† 
Dit not report any vaginal discharge at pre-
treatment visit† 
Pre-treatment 
(n = 68) 
Post-treatment 
(n = 68) 
p* Pre-treatment 
(n = 13) 
Post-treatment 
(n = 13) 
p* Pre-treatment 
(n = 55) 
Post-treatment 
(n = 55) 
p* 
Nugent categories (n %)‡ 
 0-3 
 4-6 
 7-10 
 
5 (7.5) 
6 (9.0) 
56 (83.6) 
 
36 (54.6) 
13 (19.7) 
17 (25.8) 
<0.001 
 
0 
2 (16.7) 
10 (83.3) 
 
7 (53.9) 
2 (15.4) 
4 (30.8) 
0.030 
 
5 (9.1) 
4 (7.3) 
46 (83.6) 
 
29 (54.7) 
11 (20.8) 
13 (24.5) 
<0.001 
Mean inverse Simpson diversity 
index (95% CI)§ 
0.67 
(0.60 – 0.73) 
0.31 
(0.25 – 0.38) <0.001 
0.70 
(0.54 – 0.86) 
0.24 
(0.08 – 0.39) 0.006 
0.66 
(0.59 – 0.74) 
0.33 
(0.26 – 0.41) <0.001 
VMB type (n %)§: 
– Li 
 Lo 
 LA 
 BV_GV 
 BV_noGV 
 GV 
 PB 
 
10 (14.9) 
0 
12 (17.9) 
28 (41.8) 
8 (11.9) 
8 (11.9) 
1 (1.5) 
 
35 (52.2) 
2 (3.0) 
18 (26.9) 
2 (3.0) 
0 
4 (6.0) 
6 (9.0) 
<0.001 
 
2 (15.4) 
0 
2 (15.4) 
5 (38.5) 
3 (23.1) 
0 
1 (7.7) 
 
9 (69.2) 
0 
3 (23.1) 
0 
0 
1 (7.7) 
0 
0.109 
 
8 (14.8) 
0 
10 (18.5) 
23 (42.6) 
5 (9.3) 
8 (14.8) 
0 
 
26 (48.2) 
2 (3.7) 
15 (27.8) 
2 (3.7) 
0 
3 (5.6) 
6 (11.1) 
<0.001 
Vaginal pH, median (IQR) 5.3 
(5.0 – 5.6) 
4.4 
(3.6 – 4.6) <0.001 
5.3 
(5.3 – 5.6) 
4.1 
(3.6 – 4.4) 0.001 
5.3 
(4.7 – 5.6) 
4.4 
(4.1 – 4.7) <0.001 
Vulvovaginal candidiasis (n %) 6 (8.8) 4 (5.9) 0.527 0 1 (7.7) 0.317 6 (10.9) 3 (5.5) 0.317 
Bacterial group relative abundances: mean (95% CI)§ 
Total lactobacilli 0.24 
(0.15 – 0.32) 
0.72 
(0.64 – 0.80) <0.001 
0.23 
(0.03 – 0.43) 
0.77 
(0.58 – 0.96) 0.005 
0.24 
(0.14 – 0.33) 
0.70 
(0.62 – 0.79) <0.001 
Total BV-associated anaerobes 0.75 
(0.67 – 0.83) 
0.23 
(0.16 – 0.30) <0.001 
0.73 
(0.54 – 0.93) 
0.22 
(0.03 – 0.41) 0.007 
0.75 
(0.66 – 0.84) 
0.23 
(0.15 – 0.31) <0.001 
Total pathobionts 0.02 
(0.01 – 0.03) 
0.05 
(0.02 – 0.09) 0.050 
0.04 
(-0.01 – 0.08) 
0.01 
(0 – 0.02) 0.597 
0.01 
(0 – 0.02) 
0.06 
(0.02 – 0.10) 0.015 
Total other bacteria 0 
(0 – 0) 
0 
(0 – 0) 0.674 
0 
(0 – 0) 
0 
(0 – 0) 0.405 
0 
(0 – 0) 
0 
(0 – 0) 0.386 
Bacterial group concentrations in log10 cells/μL: mean (95% CI)¶ 
Total bacteria  6.59 
(6.39 – 6.78) 
5.85 
(5.66 – 6.04) <0.001 
6.47 
(6.17 – 6.77) 
5.69 
(5.43 – 5.95) 0.003 
6.62 
(6.38 – 6.85) 
5.89 
(5.66 – 6.12) <0.001 
Total lactobacilli 4.98 
(4.61 – 5.35) 
5.56 
(5.34 – 5.78) 0.017 
5.19 
(4.70 – 5.69) 
5.41 
(5.03 – 5.79) 0.433 
4.93 
(4.48 – 5.38) 
5.59 
(5.33 – 5.86) 0.026 
Total BV-anaerobes 
 
6.23 
(5.88 – 6.57) 
4.55 
(4.14 – 4.95) <0.001 
6.25 
(5.77 – 6.72) 
4.50 
(3.83 – 5.18) 0.006 
6.22 
(5.81 – 6.63) 
4.56 
(4.08 – 5.04) <0.001 
Total pathobionts 
 
1.92 
(1.36 – 2.48) 
2.01 
(1.48 – 2.54) 0.939 
2.46 
(0.96 – 3.95) 
1.75 
(0.51 – 2.99) 0.428 
1.79 
(1.17 – 2.41) 
2.07 
(1.46 – 2.68) 0.618 
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VMB Outcomes All participants Reported vaginal discharge  
at pre-treatment visit† 
Dit not report any vaginal discharge at pre-
treatment visit† 
Pre-treatment 
(n = 68) 
Post-treatment 
(n = 68) 
p* Pre-treatment 
(n = 13) 
Post-treatment 
(n = 13) 
p* Pre-treatment 
(n = 55) 
Post-treatment 
(n = 55) 
p* 
Total other bacteria 1.85 
(1.36 – 2.35) 
1.46 
(1.01 – 1.92) 0.176 
1.41 
(0.26 – 2.56) 
1.72 
(0.68 – 2.75) 1.00 
1.96 
(1.40 – 2.52) 
1.40 
(0.88 – 1.92) 0.138 
Individual bacterial species/genera concentrations in log10 cells/μL: mean (95% CI)¶ 
L. iners 4.81 
(4.38 – 5.24) 
5.28 
(4.94 – 5.62) 0.072 
5.14 
(4.64 – 5.63) 
4.85 
(3.71 – 5.99) 0.638 
4.73 
(4.21 – 5.26) 
5.39 
(5.04 – 5.73) 0.062 
L. crispatus|| 0.15 
(-0.02 – 0.33) 
0.51 
(0.16 – 0.85) 0.089 
0 
(0 – 0) 
0.43 
(-0.51 – 1.36) 0.317 
0.19 
(-0.03 – 0.41) 
0.53 
(0.14 – 0.91) 0.149 
Other lactobacilli** 1.46 
(0.97 – 1.94) 
3.03 
(2.57 – 3.48) <0.001 
1.02 
(-0.17 – 2.21) 
2.32 
(1.12 – 3.53) 0.077 
1.57 
(1.02 – 2.11) 
3.19 
(2.70 – 3.69) <0.001 
Gardnerella vaginalis  5.62 
(5.20 – 6.03) 
4.12 
(3.63 – 4.61) <0.001 
5.59 
(5.05 – 6.12) 
4.33 
(3.62 – 5.05) 0.023 
5.62 
(5.11 – 6.13) 
4.07 
(3.48 – 4.66) <0.001 
Atopobium vaginae 4.58 
(4.00 – 5.16) 
1.54 
(1.06 – 2.02) <0.001 
4.15 
(2.64 – 5.65) 
1.53 
(0.30 – 2.76) 0.016 
4.68 
(4.04 – 5.33) 
1.54 
(1.00 – 2.08) <0.001 
Prevotella species 4.67 
(4.18 – 5.16) 
1.35 
(0.90 – 1.79) <0.001 
4.87 
(4.25 – 5.50) 
1.64 
(0.51 – 2.76) 0.004 
4.62 
(4.02 – 5.22) 
1.28 
(0.78 – 1.77) <0.001 
Sneathia species 4.18 (3.63 – 4.73) 
1.08 
(0.63 – 1.54) <0.001 
4.08 
(2.92 – 5.24) 
1.24 
(0.01 – 2.47) 0.008 
4.20 
(3.56 – 4.84) 
1.05 
(0.54 – 1.55) <0.001 
Megasphaera species 3.17 
(2.56 – 3.79) 
0.22 
(-0.01 – 0.44) <0.001 
3.22 
(1.83 – 4.61) 
0 
(0 – 0) 0.006 
3.16 
(2.45 – 3.87) 
0.27 
(-0.01 – 0.55) <0.001 
Veillonella species 2.37 
(1.75 – 3.00) 
0.28 
(0.01 – 0.56) <0.001 
2.17 
(0.60 – 3.73) 
0.41 
(-0.50 – 1.33) 0.132 
2.42 
(1.72 – 3.13) 
0.25 
(-0.04 – 0.54) <0.001 
BVAB1 1.76 
(1.11 – 2.42) 
0.46 
(0.15 – 0.77) <0.001 
2.94 
(1.18 – 4.70) 
0.76 
(-0.14 – 1.66) 0.016 
1.47 
(0.77 – 2.17) 
0.39 
(0.06 – 0.73) 0.007 
Fusobacterium species 0.53 (0.17 – 0.89) 
0 
(0 – 0) 0.008 
0.66 
(-0.32 – 1.63) 
0 
(0 – 0) 0.158 
0.50 
(0.11 – 0.90) 
0 
(0 – 0) 0.025 
Streptococcus species 1.47 
(0.92 – 2.02) 
1.34 
(0.84 – 1.85) 0.453 
2.17 
(0.64 – 3.69) 
0.78 
(-0.38 – 1.93) 0.139 
1.30 
(0.71 – 1.90) 
1.47 
(0.90 – 2.05) 0.996 
Staphylococcus species  0.26 
(0.05 – 0.47) 
0.60 
(0.27 – 0.93) 0.655 
0.20 
(-0.24 – 0.64) 
0.30 
(-0.36 – 0.95) 
Not 
determinable 
0.27 
(0.04 – 0.51) 
0.67 
(0.28 – 1.06) 0.655 
Escherichia/Shigella 0.10 
(-0.04 – 0.25) 
0.86 
(0.45 – 1.27) 0.317 
0 
(0 – 0) 
0.49 
(-0.25 – 1.23) 
Not 
determinable 
0.13 
(-0.05 – 0.31) 
0.95 
(0.47 – 1.43) 0.317 
BV bacterial vaginosis, BVAB1 BV-associated bacterium type 1, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, CI confidence interval, GV G. vaginalis-dominated, 
LA lactobacilli and anaerobes, Li L. iners-dominated, Lo other lactobacilli-dominated, PB pathobionts-containing, VMB vaginal microbiota. 
*Stuart-Maxwell test for matched categorical data, and Wilcoxon signed-rank test for matched continuous data. †Current or in the past two weeks. ‡Valid Nugent data available for 67 participants at the pre-treatment visit 
and 66 participants at the post-treatment visit. §Relative abundance, Simpson inverse diversity indices, and VMB type data available for 67 participants at each visit. ¶Concentration data may contain at most five missing 
values (see Appendix A Supplementary Methods). ||Includes all amplicon sequence variants attributed to L. crispatus, also those with multiple species assignments. **Includes amplicon sequence variants attributed to L. 
jensenii, L. delbrueckii, L. fermentum, L. gasseri, L. johnsonii, and Lactobacillus genus, as well as 11 other minority amplicon sequence variants.
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Appendix C  
 
This appendix corresponds to Chapter 3. 
Figure C.1: VMB comparisons between women who received metronidazole and another 
antibiotic at screening or metronidazole only, and between women with and without Chlamydia 
trachomatis and/or Neisseria gonorrhoeae at screening and enrolment  
a 
 
b 
 
Ab antibiotics, BV bacterial vaginosis, BV_GV polybacterial Gardnerella vaginalis-containing, BV_noGV polybacterial but low G. vaginalis, 
CT Chlamydia trachomatis, D7 Day 7 visit, Enr enrolment visit, GV G. vaginalis-dominated, MTZ metronidazole, LA lactobacilli and 
anaerobes, Li L. iners-dominated, Lo other lactobacilli-dominated, NG Neisseria gonorrhoeae, PB pathobionts-containing, VMB vaginal 
microbiota. 
a Comparison of VMB type membership of enrolled participants who had used metronidazole with another antibiotic (n=18) or 
metronidazole only (n=50) between the screening and enrolment visits. b Comparison of VMB type membership of enrolled participants 
who were positive (n=26) or negative (n=41) for CT/NG at the screening visit, but received CT/NG treatment after the enrolment visit (if 
applicable). All women did use oral metronidazole for seven days between these two visits.  
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Figure C.2: Preliminary efficacy by bacterial group relative abundance 
 
a  
 
b  
 
c  
 
d 
 
e  
 
f 
 
g 
 
h 
 
BV bacterial vaginosis, D7 Day 7 visit, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, M1/M2/M6 month 1/2/6 visit, RA 
relative abundance, Scr screening visit. 
Changes in relative abundances of bacterial groups over time per randomisation group. See table C.4 for 95% confidence intervals.  
a Mean lactobacilli relative abundance over time. b Difference in mean lactobacilli relative abundance with enrolment, over time. c Mean 
BV-associated anaerobes relative abundance over time. d Difference in mean BV-associated anaerobes relative abundance with enrolment, 
over time. e Mean pathobionts relative abundance over time. f Difference in mean relative abundance with enrolment, over time. g Mean 
other bacteria relative abundance over time. h Difference in mean other bacteria relative abundance with enrolment, over time. 
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Table C.1: Additional baseline characteristics 
Sociodemographic 
characteristics at Scr/Enr 
Screened 
(n = 175) 
Enrolled 
(n = 68) 
Controls 
(n = 17) 
Metro 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 17) p* 
Marital status (n %) 
- Married 
- Never married 
- Divorced 
- Widowed 
 
8 (4.6) 
127 (72.6) 
34 (19.4) 
6 (3.4) 
 
5 (7.4) 
50 (73.5) 
12 (17.6) 
1 (1.5) 
 
1 (5.9) 
16 (94.1) 
0 
0 
 
1 (5.9) 
11 (64.7) 
5 (29.4) 
0 
 
2 (11.8) 
10 (58.8) 
4 (23.5) 
1 (5.9) 
 
1 (5.9) 
13 (76.5) 
3 (17.6) 
0 
0.199 
Educational level (n %) 
- No schooling 
- Primary school uncompleted 
- Primary school completed 
- Beyond primary school 
 
37 (21.1) 
72 (41.1) 
40 (22.9) 
26 (14.9) 
 
14 (20.6) 
31 (45.6) 
17 (25.0) 
6 (8.8) 
 
5 (29.4) 
7 (41.2) 
4 (23.5) 
1 (5.9) 
 
3 (17.6) 
7 (41.2) 
5 (29.4) 
2 (11.8) 
 
3 (17.6) 
13 (76.5) 
1 (5.9) 
0 
 
3 (17.7) 
4 (23.5) 
7 (41.2) 
3 (17.7) 
0.102 
Number of sex partners last 12 
months, median (IQR) 
15 
(4 – 144) 
11 
(4 – 152) 
15 
(4 – 160) 
20 
(5 – 106) 
8 
(3 – 50) 
6 
(4 – 240) 0.838 
Vaginal sex frequency last 2 weeks, 
median (IQR) 
13 
(8 – 20) 
12 
(8 – 18) 
12 
(8 – 18) 
12 
(8 – 16) 
12 
(7 – 18) 
11 
(8 – 30) 0.975 
Exchanged sex for money/ 
goods in past month (n %)† 
 
62 (93.1) 
 
63 (92.6) 
 
17 (100) 
 
14 (82.4) 
 
15 (88.2) 
 
17 (100) 0.155 
Any condom use past two weeks 
(n %) 
- Always 
- Sometimes but not always 
- Never 
 
 
44 (25.1) 
120 (68.6) 
11 (6.3) 
 
 
14 (20.6) 
51 (75.0) 
3 (4.4) 
 
 
4 (23.5) 
13 (76.5) 
0 
 
 
3 (17.6) 
13 (76.5) 
1 (5.9) 
 
 
2 (11.8) 
13 (76.5) 
2 (11.8) 
 
 
5 (29.4) 
12 (70.6) 
0 
0.671 
Pregnancies in lifetime, 
Median (IQR)† 
3 
(2 – 4) 
3 
(2 – 4) 
3 
(2 – 5) 
3 
(2 – 4) 
3 
(3 – 4) 
3 
(2 -4) 0.722 
Currently breastfeeding (n %)† 38 (22.1) 14 (21.2) 4 (23.5) 3 (18.8) 4 (23.5) 3 (18.8) 1.00 
Ever washing genitalia (n %)  
- Yes, outside only 
- Yes, both inside and outside‡ 
 
NA 
 
55 (80.9) 
13 (19.1) 
 
12 (70.7) 
5 (29.4) 
 
14 (82.4) 
3 (17.6) 
 
15 (88.3) 
2 (11.7) 
 
14 (82.3) 
3 (17.7) 
0.704 
Practices to manage menstrual 
blood or spotting in the past 12 
months (n %)  
- Sanitary pad 
- Others§ 
- Nothing/no menses 
NA 
 
 
 
57 (83.8) 
16 (23.5) 
3 (4.4) 
 
 
 
13 (76.5) 
4 (23.5) 
1 (5.9) 
 
 
 
15 (88.2) 
3 (17.6) 
1 (5.9) 
 
 
 
13 (76.5) 
4 (23.5) 
1 (5.9) 
 
 
 
16 (94.1) 
5 (29.4) 
0 
0.695 
Frequency eating yoghurt (n %)†,¶ 
- Never 
- Less than once per week 
- More than once per week 
NA 
 
34 (50.7) 
14 (20.9) 
-19 (28.4) 
 
8 (47.1) 
5 (29.4) 
4 (23.5) 
 
7 (41.2) 
3 (17.6) 
7 (41.2) 
 
9 (52.9) 
4 (23.5) 
4 (23.5) 
 
10 (62.5) 
2 (12.5) 
4 (25.0) 
 
0.792 
VMB outcomes at Enr Screened 
(n = 175) 
Enrolled 
(n = 67) 
Controls 
(n = 17) 
Metro 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 16) p* 
RA total Lactobacillus,  
mean (95% CI) NA 
0.72 
(0.64 – 0.80) 
0.58 
(0.38 – 0.78) 
0.72 
(0.56 – 0.88) 
0.90|| 
(0.82 – 0.98) 
0.67 
(0.51 – 0.83) 0.017 
RA total BV-associated,  
mean (95% CI) NA 
0.23 
(0.16 – 0.30) 
0.30 
(0.12 – 0.48) 
0.24 
(0.10 – 0.39) 
0.07|| 
(-0.01 – 0.15) 
0.31 
(0.14 – 0.47) 0.015 
RA total pathobionts,  
mean (95% CI) NA 
0.05 
(0.02 – 0.09) 
0.12 
(-0.01 – 0.25) 
0.04 
(-0.01 – 0.09)
0.02 
(-0.01 – 0.06) 
0.02 
(0 – 0.04) 0.303 
RA total other bacteria  
mean (95% CI) NA 
0 
(0 – 0) 
0 
(0 – 0.01) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0.01) 0.034 
BV bacterial vaginosis, CI confidence interval, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, Metro metronidazole, RA 
relative abundance.  
*Kruskall Wallis test comparing randomisation groups. †Contains between 1-4 missing values. ‡No washing or washing inside only was 
never reported. Twenty-seven women washed outside of menses, of whom 23 used water, three water/soap, and one ‘western vaginal 
medicine’. §Multiple responses possible. Other practices reported were tissue, toilet paper, paper, cloth or cotton wool put inside the vagina 
(n=8) or inside the underwear (n=8). ¶No participants had ever used or heard of probiotics before. ||p<0.05 by Mann Whitney U test, 
compared to the control group. 
 
 
158 
 
Table C.2: Antimicrobial use during the trial 
Between Enr and M2 Controls 
n women 
Metronidazole 
n women 
EF+ 
n women 
GynLP 
n women p* 
Metronidazole† 1 2 1 3  
Tinidazole‡ 1 0 0 0  
Both ‘azoles’ combined 2 2 1 3 0.688 
Other antibiotic§ 3 2 3 4 0.781 
Antifungals 0 0 0 0 1.000 
Between M2 and M6 Controls Metronidazole EF+ GynLP p* 
Metronidazole¶ 4 1 1 2 0.439 
Other antibiotic|| 9 6 5 6 0.634 
Antifungals 0 0 0 0 1.000 
Mixed effects models 
using data between 
Enr and M2 
Total Lactobacillus conc Total BV-anaerobes conc 
OR (95% CI) p OR (95% CI) p 
Antibiotic use for a non-
study indication in the 
previous 14 days 
0.94 
(0.40 – 2.21) 0.879 
0.68 
(0.23 – 1.94) 0.467 
BV bacterial vaginosis, CI confidence interval, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, M1/2 Month 1/2 visit, OR 
odds ratio, TV Trichomonas vaginalis.  
*Fisher’s exact test comparing all four groups. †Prescribed for BV, TV, or amoebiasis (the latter prescribed by an external clinic). 
‡Prescribed for amoebiasis/ dysentery (externally). §Includes amoxicillin prescribed for abortion prophylaxis, tonsillitis, dental caries, tooth 
extraction, cough, and trauma (all externally), chloramphenicol prescribed for an upper respiratory tract infection (externally), ciprofloxacin 
prescribed for urinary tract infection (at study clinic) and typhoid fever (externally), cloxacillin prescribed for a traumatic wound 
(externally), and doxycycline prescribed for chlamydia (at study clinic) and an unspecified sexually transmitted infection (externally). 
¶Prescribed for BV, TV and amoebiasis (all at the study clinic). ||Includes amoxicillin prescribed for tonsillitis and contusion (both 
externally), ciprofloxacin prescribed for gonorrhoea or urinary tract infection (of which 8/12 at the study clinic), and doxycycline for 
chlamydia (all but one at the study clinic).  
 
Table C.3: Adherence with interventions during the trial 
Adherence Metronidazole 
(n = 17) 
EF+ 
(n = 17) 
GynLP 
(n = 16) 
Adherence Enr – D7, median % (IQR) 100 (100 – 100) 100 (100 – 100) 100 (100 – 100) 
Adherence D7 – M1, median % (IQR) 100 (100 – 100) 100 (100 – 100) 100 (91.7 – 100) 
Adherence M1 – M2, median % (IQR) 100 (100 – 100) 100 (100 – 100) 100 (92.9 – 100) 
Overall adherence Enr-M2, median % (IQR) 100 (96.3 – 100) 100 (100 – 100) 98.3 (89.3 – 100) 
Overall adherence Enr – M2 (n %) 
- Perfect adherence* 
- Non-perfect adherence 
- Adherence ≥90% 
- Adherence ≥80% 
 
12 (70.6) 
5 (29.4) 
14 (82.4) 
15 (88.2) 
 
10 (58.8) 
7 (41.2) 
15 (88.2) 
17 (100) 
 
8 (50.0) 
8 (50.0) 
11 (68.8) 
13 (81.3) 
Number of times menses Enr – M2 (n %)† 
- Never 
- Once 
- Twice 
- Thrice 
 
7 (41.2) 
6 (35.3) 
4 (23.5) 
0 
 
4 (23.5) 
5 (29.4) 
8 (47.1) 
0 
 
2 (12.5) 
4 (25.0) 
10 (62.5) 
0 
Did not use product during menses at least 
once (n %) 
- Yes 
- No 
- NA (never had menses) 
 
 
4 (23.5) 
6 (35.3) 
7 (41.2) 
 
 
3 (17.6) 
10 (58.8) 
4 (23.5) 
 
 
5 (31.3) 
9 (56.2) 
2 (12.5) 
D7 day 7 visit, EF+ Ecologic Femi+, Enr enrolment visit, GynLP Gynophilus LP, M1/2 Month 1/2 visit, NA not applicable, IQR inter-
quartile range.  
*Defined as 100% of the prescribed doses used at the prescribed times after nurse review of the participant’s diary card and returned used 
packaging and unused product. †Number of times menses in the control group: Never 2 (11.8%), once 3 (17.8%), twice 11 (64.7%), and 
thrice 1 (5.9%). 
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Table C.4: Preliminary efficacy – bacterial group relative abundances 
VMB Outcome Groups Enr (n = 67)* 
Products used Ceased 
D7 
(n = 64)* 
M1 
(n = 66)* 
M2 
(n = 65)* 
M6 
(n = 64)* 
RA total 
Lactobacillus, 
mean (95%  
CI) 
Control 0.58 (0.38 – 0.78) 
0.49 
(0.25 – 0.73) 
0.28 
(0.08 – 0.48) 
0.44 
(0.18 – 0.70) 
0.45 
(0.21 – 0.68) 
Metro 0.72 (0.56 – 0.88) 
0.70 
(0.51 – 0.88) 
0.70 
(0.51 – 0.89) 
0.69 
(0.48 – 0.90) 
0.44 
(0.19 – 0.69) 
EF+ 0.90 (0.82 – 0.98) 
0.78 
(0.60 – 0.96) 
0.69 
(0.47 – 0.90) 
0.55 
(0.32 – 0.77) 
0.44 
(0.22 – 0.66) 
GynLP 0.67 (0.51 – 0.83) 
0.71 
(0.49 – 0.93) 
0.39 
(0.15 – 0.63) 
0.42 
(0.17 – 0.67) 
0.33 
(0.09 – 0.57) 
RA total BV-
associated 
bacteria, 
mean (95% 
CI) 
Control 0.30 (0.12 – 0.48) 
0.36 
(0.14 – 0.57) 
0.64 
(0.44 – 0.84) 
0.43 
(0.19 – 0.67) 
0.53 
(0.30 – 0.76) 
Metro 0.24 (0.10 – 0.39) 
0.25 
(0.09 – 0.42) 
0.25 
(0.10 – 0.40) 
0.23 
(0.04 – 0.42) 
0.49 
(0.24 – 0.74) 
EF+ 0.07 (-0.01 – 0.15) 
0.19 
(0.02 – 0.36) 
0.26 
(0.05 – 0.46) 
0.38 
(0.18 – 0.58) 
0.56 
(0.34 – 0.78) 
GynLP 0.31 (0.14 – 0.47) 
0.28 
(0.07 – 0.49) 
0.53 
(0.29 – 0.77) 
0.56 
(0.32 – 0.81) 
0.65 
(0.41 – 0.90) 
RA total 
pathobionts, 
mean (95% 
CI) 
Control 0.12 (-0.01 – 0.25) 
0.15 
(-0.01 – 0.31) 
0.08 
(0 – 0.15) 
0.13 
(-0.02 – 0.28) 
0.02 
(-0.02 – 0.06) 
Metro 0.04 (-0.01 – 0.09) 
0.05 
(-0.01 – 0.11) 
0.05 
(-0.03 – 0.12) 
0.08 
(-0.04 – 0.20) 
0.07 
(-0.04 – 0.18) 
EF+ 0.02 (-0.01 – 0.06) 
0.03 
(0 – 0.05) 
0.04 
(-0.02 – 0.11) 
0.07 
(-0.03 – 0.16) 
0 
(0 – 0) 
GynLP 0.02 (0 – 0.04) 
0 
(0 – 0.01) 
0.07 
(-0.06 – 0.20) 
0.01 
(0 – 0.03) 
0.02 
(-0.02 – 0.06) 
Mean RA 
total other 
bacteria, 
mean (95% 
CI) 
Control 0 (0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0) 
Metro 0 (0 – 0) 
0 
(0 – 0.01) 
0.01 
(0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0.01) 
EF+ 0 (0 – 0) 
0 
(0 – 0.01) 
0.01 
(0 – 0.03) 
0 
(0 – 0) 
0 
(0 – 0.01) 
GynLP 0 (0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0) 
Difference in 
RA total 
Lactobacillus 
compared to 
Enr, mean 
(95% CI) 
Control 0 -0.09 (-0.29 – 0.12) 
-0.29 
(-0.55 – -0.04) 
-0.17 
(-0.38 – 0.05) 
-0.13 
(-0.40 – 0.14) 
Metro 0 -0.02 (-0.24 – 0.20) 
-0.01 
(-0.20 – 0.19) 
-0.01 
(-0.21 – 0.19) 
-0.26 
(-0.57 – 0.05) 
EF+ 0 -0.12 (-0.31 – 0.06) 
-0.21 
(-0.43 – 0.00) 
-0.35 
(-0.58 – -0.13) 
-0.46 
(-0.72 – -0.21) 
GynLP 0 0.02 (-0.22 – 0.25) 
-0.32 
(-0.60 – -0.04) 
-0.27 
(-0.57 – 0.02) 
-0.39 
(-0.68 – -0.10) 
Difference in 
RA total BV-
associated 
bacteria 
compared to 
Enr, mean 
(95% CI) 
 
Control 0 0.06 (-0.15 – 0.27) 
0.34 
(0.09 – 0.59) 
0.17 
(-0.04 – 0.38) 
0.23 
(-0.03 – 0.49) 
Metro 0 0.01 (-0.17 – 0.19) 
0 
(-0.18 – 0.19) 
-0.03 
(-0.24 – 0.18) 
0.23 
(-0.08 – 0.54) 
EF+ 0 0.12 (-0.06 – 0.30) 
0.18 
(-0.02 – 0.39) 
0.31 
(0.10 – 0.52) 
0.48 
(0.23 – 0.73) 
GynLP 0 0 (-0.23 – 0.23) 
0.26 
(-0.01 – 0.52) 
0.28 
(-0.02 – 0.57) 
0.39 
(0.10 – 0.68) 
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VMB Outcome Groups Enr D7 M1 M2 M6 
Difference in 
RA total 
pathobionts 
compared to 
Enr, mean 
(95% CI) 
Control 0 0.03 (-0.13 – 0.19) 
-0.04 
(-0.15 – 0.06) 
0 
(-0.10 – 0.09) 
-0.10 
(-0.19 – 0) 
Metro 0 0.01 (-0.08 – 0.09) 
0 
(-0.07 – 0.08) 
0.04 
(-0.08 – 0.15) 
0.03 
(-0.10 – 0.15) 
EF+ 0 0 (-0.03 – 0.03) 
0.02 
(-0.05 – 0.09) 
0.04 
(-0.02 – 0.11) 
-0.02 
(-0.06 – 0.01) 
GynLP 0 -0.02 (-0.05 – 0.01) 
0.06 
(-0.08 – 0.20) 
0 
(-0.02 – 0.02) 
0 
(-0.05 – 0.05) 
Difference in 
RA total other 
bacteria 
compared to 
Enr, mean 
(95% CI) 
Control 0 0 (-0.01 – 0) 
0 
(-0.01 – 0.01) 
0 
(-0.01 – 0.01) 
0 
(-0.01 – 0) 
Metro 0 0 (0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0) 
0 
(0 – 0.01) 
EF+ 0 0 (0 – 0.01) 
0.01 
(0 – 0.03) 
0 
(0 – 0) 
0 
(0 – 0.01) 
GynLP 0 0 (0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0) 
0 
(0 – 0) 
RA total EF+ 
strains, mean 
(95% CI) 
Control 0 (0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
Metro 0 (0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
EF+ 0 (0 – 0) 
0.02 
(0 – 0.04) 
0.01 
(0 – 0.03) 
0 
(0 – 0.01) 
0 
(0 – 0) 
GynLP 0 (0 – 0.01)† 
0.01 
(0 – 0.01)† 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
RA total 
GynLP 
strains, mean 
(95% CI) 
 
Control 0 (0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
Metro 0 (0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
EF+ 0 (0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
0 
(0 – 0) 
GynLP 0 (0 – 0) 
0.02 
(-0.01 – 0.06) 
0 
(0 – 0.01) 
0 
(0 – 0.01) 
0 
(0 – 0) 
BV bacterial vaginosis, CI confidence interval, Conc concentration, D7 Day 7 visit, EF+ Ecologic Femi+, Enr enrolment, GynLP 
Gynophilus LP, M1/2/6 Month 1/2/6 visit, Metro oral metronidazole group, RA relative abundance, VMB vaginal microbiota.  
*Total numbers are slightly lower than enrolled women (and not lost to follow-up) per time point due to invalid results. Numbers missing 
per group is at most two at Enr, M1, M2, and M6 visits, and four at the D7 visit (GynLP group only, due to two missed visits). †These are 
naturally occurring EF+ strains with 100% identity with the EF+ probiotic strains. 
 
 
 
 
 
 
 
 
 
 
 
161 
 
Table C.5: Characteristics associated with VMB composition  
Outcome variables 
Total Lactobacillus 
conc 
Total BV-
anaerobes conc 
Total 
pathobionts conc 
Nugent score 
Characteristics OR 
(95% CI)* 
p OR 
(95% CI)* 
p OR 
(95% CI)* 
p OR 
(95% CI)* 
p 
Currently uses hormonal 
contraception or is pregnant† 
0.91 
(0.60 – 1.37) 0.638 
1.03 
(0.61 – 1.74) 0.921 
2.50 
(1.36 – 4.63 0.003 
0.96 
(0.40 – 2.28) 0.920 
Sample taken within 7 days after 
menses‡ 
0.91 
(0.65 – 1.27) 0.576 
1.30 
(0.87 – 1.94) 0.201 
0.80 
(0.47 – 1.34) 0.387 
2.26 
(0.93 – 5.52) 0.072 
Reports urogenital symptoms 0.88 
(0.62 – 1.25) 0.475 
3.05 
(2.03 – 4.60) <0.001 
1.07 
(0.63 – 1.81) 0.802 
14.81 
(6.64 – 33.08) <0.001 
Reports unusual vaginal 
discharge 
0.89 
(0.45 – 1.75) 0.734 
4.45 
(1.97 – 10.07) <0.001 
1.65 
(0.59 – 4.61) 0.339 
69.60 
(15.14 – 320.04) <0.001 
Has taken antibiotics in the 
previous 14 days§ 
0.94 
(0.40 – 2.21) 0.879 
0.68 
(0.23 – 1.94) 0.467 
1.17 
(0.87 – 11.67) 0.080 
1.22 
(0.10 – 14.88) 0.875 
Currently breastfeeding  1.01 
(0.99 – 1.03) 0.259 
1.00 
(0.98 – 1.02) 0.871 
1.00 
(0.97 – 1.03) 0.963 
0.99 
(0.95 – 1.04) 0.775 
Uses condoms consistently 1.26 
(0.93 – 1.69) 0.134 
0.79 
(0.55 – 1.15) 0.218 
0.82 
(0.52 – 1.29) 0.389 
0.49 
(0.24 – 0.99) 0.048 
Reports five or more sex 
partners in the past month¶ 
1.24 
(0.84 – 1.82) 0.276 
1.00 
(0.62 – 1.60) 0.986 
1.94 
(1.11 – 3.72) 0.019 
1.01 
(0.44 – 2.36) 0.973 
Reports ‘below average’ sexual 
risk taking|| 
1.14 
(0.78 – 1.67) 0.506 
0.98 
(0.61– 1.56) 0.918 
0.52 
(0.29 – 0.92) 0.026 
0.61 
(0.24 – 1.55) 0.299 
Exchanged sex for money and/or 
goods¶ 
1.42 
(0.76 – 2.66) 0.271 
0.63 
(0.29 – 1.37) 0.243 
0.77 
(0.30 – 2.00) 0.598 
0.53 
(0.12 – 2.33) 0.401 
Is 30 years or older** 1.20 
(0.77 – 1.89) 0.423 
0.46 
(0.27 – 0.79) 0.005 
0.47 
(0.24 – 0.92) 0.027 
0.60 
(0.24 – 1.49) 0.271 
Manages menses with sanitary 
pad (versus other methods)†† 
1.32 
(0.75 – 2.31) 0.331 
1.87 
(0.61 – 5.73) 0.274 
0.69 
(0.16 – 1.19) 0.616 
10.69 
(1.13 – 101.07) 0.039 
Consumes yoghurt <1/week or 
more (versus never)†† 
0.90 
(0.60 – 1.34) 0.596 
1.00 
(0.45 – 2.26) 0.993 
0.43 
(0.15 – 1.19) 0.103 
3.98 
(0.79 – 20.07) 0.095 
Reports ever washing inside the 
vagina 
0.92 
(0.60 – 1.41) 0.692 
0.74 
(0.45 – 1.24) 0.253 
0.99 
(0.52 – 1.88) 0.964 
0.47 
(0.16 – 1.40) 0.174 
BV bacterial vaginosis, CI confidence interval, Conc concentration, OR odds ratio.  
*Covariates were tested in mixed effects models with participant identification number as a random effect, the potential predictor as fixed 
effects, and the four vaginal microbiota outcomes as separate outcomes. All possible time points were included in the models. The potential 
predictor variables were not correlated with each other. †Women using a copper intra-uterine device were not included in this model. 
‡Versus remainder of the cycle. §Only antibiotics given for reasons not associated with the primary/secondary outcomes of the study were 
included. ¶Or in the past two months (when asked at the M2 visit), or in the past four months (when asked at the M6 visit). ||Composite 
variable of condom use consistency and number of sexual partners: women were considered low risk when they reported fewer than five 
sexual partners in the past month plus consistent condom use. The variable ‘exchanging sex for money and/or goods’ (next row) was not 
added to this composite variable because the great majority of women reported this behaviour (table C.1). **Versus 29 years old or younger. 
††Asked at the enrolment visit only.  
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Table C.6: Incidence of sexually transmitted and urinary tract infections 
 Controls Metronidazole Ecologic Femi+ Gynophilus LP Total 
n/N* IR (95% CI) n/N* IR (95% CI) n/N* IR (95% CI) n/N* IR (95% CI) n/N* IR (95% CI) 
TV InPouch: 
Enr-M2 2/17 
1.10 
(0.35 – 3.41) 0/17 0 0/17 0 0/16 0 2/67 
0.27 
(0.09 – 0.84) 
TV InPouch: 
M2-M6 1/17 
0.20 
(0.03 – 1.42) 2/16 
0.42 
(0.11 – 1.70) 0/16 0 1/15 
0.23 
(0.03 – 1.65) 4/64 
0.21 
(0.08 – 0.57) 
CT:  
Enr-M6 1/17 
0.16 
(0.09 – 1.42) 2/16 
0.36 
(0.09 – 1.42) 2/16 
0.29 
(0.07 – 1.15) 1/15 
0.18 
(0.03 – 1.29) 6/64 
0.25 
(0.11 – 0.55) 
NG:  
Enr-M6 1/17 
0.14 
(0.02 – 0.98) 2/16 
0.28 
(0.07 – 1.14) 2/16 
0.29 
(0.07 – 1.18) 0/15 0 5/64 
0.18 
(0.08 – 0.44) 
UTI†:  
Enr-M6 2/17 
0.39 
(0.13 – 1.20) 2/16 
0.27 
(0.07 – 1.09) 1/16 
0.14 
(0.02 – 0.97) 2/16 
0.29 
(0.07 – 1.14) 7/65 
0.27 
(0.14 – 0.54) 
CI confidence interval, CT Chlamydia trachomatis, Enr enrolment visit, IR incidence rate, M2/6 month 2/6 visit, NG Neisseria gonorrhoeae, STI 
sexually transmitted infection, TV Trichomonas vaginalis, UTI urinary tract infection.  
Incidence rates of STIs and UTIs during study follow-up. Incidence rate ratios were not calculated due to low number of incident cases.  
*Number of women (n) who developed at least one incident infection during the specified time period as a proportion of the women who 
completed all follow-up visits in that time period (N). †One participant in the GynLP group was tested for UTI at an unscheduled visit between 
M2 and M6 and subsequently withdrew her informed consent. 
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Appendix D  
 
This appendix corresponds to Chapter 5. 
Table D.1: Characteristics of the included studies, ordered by publication year 
Reference 
Setting, 
country 
of study 
Study 
design 
VMB status at 
baseline 
Vaginal probiotics and other intervention(s) 
(strategy: main therapy, adjuvant, maintenance,  
vaginal detection study) 
Total N of 
participants, 
comparison groups (n)  
Age 
range 
in 
years 
Pb use, 
follow-
up in 
days 
Outcome: 
BV/VVC/ 
molecular 
Özmen188 Gyn. 
clinic, 
Turkey 
NR PPIS 
in three 
groups 
BV (Amsel) + 
GV (BC) pos. 
VVC (FC) neg. 
MTZ po 500 mg bid daily, for 7d + Gynoflor Pba daily, for 12d vs. 
Gynoflor Pba only daily, for 12d vs. CG: MTZ po 500 mg twice 
daily, for 7d. Strategy: main/adjuvant. 
N=307. Ab + adjuvant 
Pb (96) vs. Pb only (97) 
vs. Ab only CG (114). 
18-53 
 
12,  
22-
35 
VVC 
Gardiner196 Unclear 
setting, 
Canada 
NB, RCT  NS ND, all high 
lactobacilli by 
BC. VVC ND. 
L. fermentum RC-14 + L. rhamnosus GR-1 Pbb for 3d vs. L. 
rhamnosus GG Pbc for 3d. Both given immediately after menses. 
Strategy: detection study only. 
N=10. RC-14/GR-1 Pb 
(5) vs. GG Pb (5).  
21-51 3,  
21 
Molecular 
Antonio & 
Hillier76 
Unclear 
setting, 
USA 
PPIS  BV (NS: 0-3 or 
0-6?) neg.; 
VVC ND. 
L. crispatus CTV-05 Pbd twice daily for 3d.  
Strategy: detection study only. 
N=9. All women used 
Pb, pre/post results 
given. 
18-40 3,  
9-11 
Molecular 
Burton197 Unclear 
setting, 
Canada 
PPIS BV/VVC tests 
ND; BV/VVC 
considered neg. 
L. fermentum RC-14 + L. rhamnosus GR-1 Pbb for 3d vs. CG: 
controls, but of unclear nature. 
Strategy: detection study only. 
N=19. Pre/post Pb users 
(10) vs. CG (9). 
Not 
cleare 
3,  
6 mo 
Molecular 
Pirotta67 GPs/ 
pharma-
cies, 
Australia 
DB, PC, 
2x2 
factorial 
RCT 
All asympto-
matic, 21.2% 
VVC (FC) pos. 
BV testing ND. 
All used Ab for non-gynaecological infections. 2x2 factorial design 
of four products: used 1/2 vag. and 1/2 oral products: Femilac vag 
pessary Pbf daily for 10d; Pb po (Lactobac), vag. placebo, and po 
placebo. Strategy: maintenance. 
N=278. Both Vag. + po 
Pb (67) vs. vag. placebo 
+ po Pb (73) vs. vag. Pb 
+ po placebo (70) vs. 
vag. + po placebo (68). 
18-50 10, 
28 
VVC 
Eriksson138 STI 
clinic, 
Scandi-
navia 
DB, PC, 
RCT 
BV (Amsel) 
pos., 69.7% NS 
7-10. All VVC 
pos. excluded. 
Ab (clindamycin 100 mg vag. ovules once daily, 3d) for all. Pb-
impregnated tampons,g to use during menses (length of use depended 
on menses, but >4 days) vs. CG: placebo tampons during menses. 
Strategy: maintenance. 
N=255. Ab + Pb (127) 
vs. Ab + placebo CG 
(128). 
18-53 >5, 
~56 
BV 
Anukam139 Clinics, 
Nigeria 
NB, RCT BV pos. (NS 7-
10); VVC neg. 
L. reuteri RC-14 + L. rhamnosus GR-1 Pbh 1x/d for 5d vs. CG: 
0.75% MTZ vag. gel twice daily, 5d. Strategy: main. 
N=40. Pb (20) vs. MTZ 
vag. gel CG (20).  
18-50 5, 
30 
BV 
Czaja187 Student 
HC, 
USA 
Phase I 
DB, PC, 
RCT 
BV & VVC 
neg. at baseline. 
L. crispatus CTV-05 suppositoriesi inserted daily for 5d vs. CG: 
placebo vag. suppository used identically, for 5d.  
Strategy: maintenance (also detection data). 
N=30. Pb (15) vs. 
placebo CG (15).  
18-35 5, 
26-
34 
VVC, 
Molecular 
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Reference Setting Study design 
VMB status at 
baseline Vaginal probiotics and other intervention(s), strategy 
Total N, comparison 
groups (n) 
Age 
range 
Follow
-up Outcome 
Larsson135 Gyn. 
clinic, 
Norway 
DB, PC, 
RCT 
BV (by Amsel) 
pos.; VVC 
(WM?) pos. 
excluded. 
Ab (2% vag. clindamycin cream, 7d) for all, before baseline. 
EcoVag Pbj capsule for 10d, and then for 10d for 3 menstrual cycles 
vs. CG: placebo vag. capsules, identical use as Pb. Strategy: 
adjuvant/maintenance. 
N=100. Ab + Pb (50) 
vs. Ab + CG (50). 
18-53 ~120,j 
~6m
o 
BV 
Petricevic136 Gyn. 
clinic, 
Austria 
RCT BV pos. (by 
NS); VVC not 
mentioned. 
Ab (clindamycin 300 mg po twice daily, 7d) for all. Gynophilus Pbk 
capsule for 7d vs. CG of unclear nature but seems non-
interventional. Strategy: maintenance. 
N=190. Ab + Pb (95) 
vs. CG: Ab only (95).  
18-45 7, 
42 
BV 
Antonio150 Clinics, 
USA 
DB, RCT BV neg. (NS, 
unclear), VVC 
(WM?) neg. 
All used L. crispatus CTV-05 capsules, twice a day for 3d; two 
groups: 106 vs. 108 CFU/dose. 
Strategy: detection study only. 
N=90. CTV-05 106 (45) 
vs. CTV-05 108 
CFU/dose (45).  
14-21 3, 
28 
Molecular 
Di Pierro189 Unclear, 
Italy (?) 
PPIS Partially (r) 
VVC (FC) pos. 
All received Krameginl vag. tablet, inserted daily for 10d. Strategy: 
main. 
N=105. All women 
used Pb.  
18-42 10, 
17 
VVC 
Mastro-
marino72 
Gyn. 
clinic, 
Italy 
DB, PC, 
RCT 
BV (Amsel) pos., 
VVC (FC) neg. 
Florisia Pb tabletm inserted daily for 7d vs. CG: placebo used 
identically, used for 7d. Strategy: main.  
N=39. Florisia Pb (20) 
vs. CG (19). 
≥18 7, 
21  
BV 
Witt190 Gyn. 
clinic, 
Austria 
NB, RCT VVC (FC) pos. 
BV status not 
specified. 
L. gasseri Pbn tablet given in six-month dosage scheme, with Af txn 
vs. Af only, given for +/- 6moo vs. classic homeopathy group (no 
Af). Strategy: maintenance. 
N=150. Pb + Af (50) 
vs. Af only (50) vs. 
homeopathy (50).  
17-56 6 
mo,n 
1y 
VVC 
Ehrström195 Gyn. 
clinic, 
Sweden 
DB, PC, 
RCT 
BV (Amsel) 
neg. VVC (FC) 
neg. 
Ab or Af for all.p LN40/LN99/LN113/LN23 Pb capsuleq used for 5d 
vs. CG: placebo group, identical use as Pb. Strategy: maintenance 
(mainly detection results). 
N=95. Pb (60) vs. CG 
(35).  
18-45 
 
 
5, 
6mo 
Molecular 
Hemmer-
ling183 & 
Ngugi128 
Research 
clinic, 
USA 
Phase II 
DB, PC, 
RCT 
BV (NS 7-10) 
pos. VVC status 
unclear. 
Ab (0.75% MTZ gel before baseline, 5d) for all. Lactin-V Pbr for 5d, 
and again at D12 and D19 vs. CG: placebo group, identical use as 
Pb. Strategy: detection study only. 
N=24. Ab + Pb (18) vs. 
Ab + placebo CG (6).  
18-50 19, 
28 
Molecular 
Bradshaw137 Sex. 
health 
clinic, 
Australia 
DB, PC, 
RCT 
Amsel pos. + 
NS 4-6, or NS 
7-10. VVC 
(FC): 11.6%.  
Ab (MTZ po 400 mg twice daily, for 7d) for all. Gynoflor Pbs daily, 
for 12d vs. Ab group: 2% vag. clindamycin cream, 7d vs. CG: 
placebo pessary, identical use as Pb. Strategy: maintenance. 
N=450. Clindamycin 
(150) vs. Pb (150) vs. 
placebo CG (150).  
18-50 12, 
6mo 
BV 
Hema-
latha140 
Unclear, 
India 
DB, RCT 117/159 NS 4-
10. VVC? 
Florisia Pbt daily, for 8d vs. CG: pH-lowering vag. tablet used 
identically as Pb. Strategy: main. 
N=159. Pb (82) vs. pH-
lowering CG (77).  
20-40 8, 
9 
BV 
Vicariotto191 Clinic, 
Italy 
Pilot PPIS ‘Severe’ VVC 
(by WM, FC). 
BV ND. 
ActiCand 30 (L. fermentum LF10 and L. acidophilus LA02 Pbu) for 
7d, and then every 3d for 21d, then every week for 28d.  
Strategy: main. 
N=30. All used Pb.  
 
23-64 56,v 
56 
VVC 
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Reference Setting Study design 
VMB status at 
baseline Vaginal probiotics and other intervention(s), strategy 
Total N, comparison 
groups (n) 
Age 
range 
Follow
-up Outcome 
Ling141 Gyn. 
clinic, 
China 
NB, RCT  BV pos. (NS 7-
10). VVC ND. 
L. delbrueckii subsp. lactis DM8909 Pbv for 10d vs. CG: vag. MTZ 
500 mg (unknown formulation: most likely gel?) once daily, 7d. 
Strategy: main. 
N=121. Pb (53) vs. 
MTZ CG (68).  
>17,w 
19-50 
10, 
37 
BV, 
Molecular 
Bisanz142 Clinic, 
Canada 
Cross-
over, PC 
DB RCT 
NS 4-6. VVC 
ND. 
L. rhamnosus GR-1 and L. reuteri RC-14 Pb,x twice a day for 3d vs. 
CG: placebo, identical use. Strategy: main (also detection results). 
N=14. Pb (7) vs. 
placebo CG (7), then 
cross-over.  
40-80 3, 
114 
BV, 
Molecular 
De Seta192 Gyn. 
clinic, 
Italy 
NR NB 
PPIS or 
RCS? 
VVC pos. (by 
WM). BV 0-6. 
Af (2% clotrimazole vag. cream daily, 3d), for all. L. plantarum 
P17630 Pby for 6d, then weekly for 28d vs. CG: vag. lubricant, 
identical use. Strategy: maintenance. 
N=89. Af + Pb (45) vs. 
Af + vag. lubricant 
(44).  
18-45 ~34, 
~124 
VVC 
Donders184 
& 
Donders185 
Clinics, 
Belgium/ 
Germany 
PPIS All atrophic 
vaginitis. 2/ 
14 VVC pos. 
All used non-steroidal aromatase inhibitors. Gynoflor Pbz once daily 
for 28d, then thrice weekly for 56d for all participants (no CG). 
Strategy: main (mainly intended as safety study). 
N=16. Pb for all. 
 
52-63 84, 
84 
VVC 
Pendharkar 
- Trial I186 
Gyn. 
clinic, 
Norway 
NR pros-
pective 
cohort 
study 
VVC (WM) 
neg. BV pos. 
(Amsel).aa 
Ab: vag. 0.75% MTZ gel, vag. and po clindamycincc for all. EcoVag 
Pbbb 1x daily for 5d, and for 5d on days 5-10 after next menstruation. 
Strategy: detection study only. 
N=10. All used Ab+Pb. 26-49 ~60, 
1y 
Molecular 
Pendharkar 
- Trial II186 
Gyn. 
clinics, 
Sweden 
NR pros-
pective 
cohort 
study 
Some BV pos. 
(Amsel), some 
VVC (WM) 
pos.bb 
BV-pos. women received Ab and EcoVag Pbcc; rVVC pos. women 
received Af tx scheme and Ecovag Pbdd; other VVC (seemingly 
rVVC) pos. women received Af tx schemeee with no Pb.  
Strategy: adjuvant/maintenance (also detection results). 
N=30. BV pos.: Ab + 
Pb (11); rVVC pos.: Af 
+ Pb (9); (r)VVC (?) 
pos.: Af + placebo (10). 
22-43 6 
mo,dd 
1y 
VVC, 
Molecular 
Tomusiak151 
 
Gyn. 
clinics, 
Poland 
DB, PC, 
RCT 
Low lactos and 
/or NS 4-6. FC 
VVC neg. 
InVag Pbff given once daily for 7d vs. CG: placebo vag. capsule, 
identical use as Pb. 
Strategy: main (only detection results eligible). 
N=160. Pb (86) vs. 
placebo CG (74).  
18-40 7, 
~21 
Molecular 
Kovachev193 Gyn. 
clinic, 
Bulgaria 
NB, RCT >99.5% VVC 
(FC) pos. BV? 
Af (single dose 150mg po fluconazole and 600 mg vag. 
fenticonazole) for all. Lactagyn Pbgg 5d after finishing Af tx scheme, 
for 10d vs. CG: received Af tx only. Strategy: maintenance. 
N=416. Af+Pb (209) 
vs. Af only CG (207).  
 
17-50 
 
10, 
35-
40 
VVC 
Verdenelli143 Gyn. 
clinic, 
Italy 
PPIS NS 0-6, VVC 
(FC?) neg. 
SYNBIO gin Pbhh given once daily for 7d.  
Strategy: maintenance (also detection results). 
N=35. Pb for all.  18-48 7, 
28 
BV, 
Molecular 
Bohbot144 
 
 
Clinics/ 
GPs, 
France 
 
DB, PC, 
RCT 
BV neg. (mod. 
Amsel). VVC 
ND. 
Ab (MTZ po 500 mg 2x daily, 7d) before baseline Physioflor Pbii 
given daily for 14d, for 4 menstrual cycles vs. CG: placebo capsule. 
Strategy: maintenance. 
N=100. Pb (52) vs. CG 
(48). 
≥18, 
mean 
35.7 
+/-
56, 
196 
BV 
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Reference Setting Study design 
VMB status at 
baseline Vaginal probiotics and other intervention(s), strategy 
Total N, comparison 
groups (n) 
Age 
range 
Follow
-up Outcome 
Rapisarda145 Gyn. 
clinic, 
Italy 
PPIS All NS 4-10, 
some VVC pos. 
(FC). 
L. acidophilus LA14 Pb (unknown dose), given daily for 14d. 
Strategy: main. 
N=106. All used Pb.  18-45 14, 
42 
BV, VVC 
Murina194 Unclear 
setting, 
Italy 
PPIS Some BV 
(Amsel) pos.,  
VVC (WM) pos. 
All received EPB Pbjj daily, for 6d, then twice weekly for 21d if 
symptoms still present.jj Strategy: main. 
N=209. BV pos. (100) 
vs. symp. VVC pos. 
(82) vs. rVVC (27).  
≥18, 
mean 
35.8 
6, 
~32 
 
VVC 
Dausset155 Clinics, 
France 
NB, RCT BV/VVC neg. 
(unclear) 
Gynophilus Pbkk 350 mg immediate release, once daily vs. Pb 1000 
mg slow-release (SR) once every 3d vs. Pb 1000 mg SR once every 
4d vs. Pb 1000 mg SR once every 5d. Strategy: detection study only. 
N=33. 350mg daily (9) 
vs. 1g SR every 3d (8) 
vs. 1g SR every 4d (9) 
vs. 1g SR every 5d (7). 
21-52 21, 
~25 
Molecular 
van de 
Wijgert160 
STI 
clinic, 
Rwanda 
NB, pilot 
RCT 
Neg. for BV 
(Amsel), VVC 
(WM). 
MTZ po 500 mg twice daily (7d) before baseline. CG (behavioural 
counselling) vs. 500mg po MTZ twice weekly, for 60d vs. EF+ Pbll 
daily for 5d, then thrice weekly for 55d vs. Gynophilus LP Pbmm 
once every 4d for 60d. Strategy: maintenance (also detection 
results). 
N=68. CG (17) vs. 
MTZ Ab (17) vs. EF+ 
Pb (17) vs. Gynophilus 
LP Pb (17).  
18-45 60,  
6mo 
 
BV, VVC, 
Molecular 
Ab antibiotics, Af antifungals, BC bacterial culture, BV bacterial vaginosis, CFU colony-forming units, CG control group, DB double-blind, EF+ Ecologic Femi+, EPB Estromineral Probiogel, FC fungal culture, GP general 
practitioner centres, GV Gardnerella vaginalis, Gyn gynaecological, HC health centre, mo months, MTZ metronidazole, NB not blinded, ND not done, Neg. negative, NR non-randomised, NS Nugent score, Pb probiotics, PC placebo-
controlled, PPIS pre-/post- interventional study, po per os (oral), Pos. positive, RCS retrospective cohort study, RCT randomised controlled trial, STI sexually transmitted infections, symp symptomatic, tx therapy, UTI urinary tract 
infection, vag. vaginal, (r)VVC (recurrent) vulvovaginal candidiasis, WM wet mount. 
The table includes all included studies in the systematic review, including studies with probiotic detection outcomes only. The days of probiotic use is the total timespan over which probiotic products were used, and may be part of 
treatment schemes in which probiotics were not used every single day. See footnotes per study for in-depth information. Follow-up days has been calculated in days after initiation of probiotic products, whenever possible. 
a. Gynoflor (Medinova AG, Zurich, Switzerland) vaginal suppository of 107 to 7x108 viable micro-organisms from a Iyophilised culture of L. acidophilus, 600mg lactose and 30 μg estriol. 
b. L. fermentum RC-14 and L. rhamnosus GR-1 were given in freeze-dried form, in a total of 109 CFU/dose. 
c. L. rhamnosus GG (ConAgra Foods, Omaha, USA) was given in vaginal capsules, containing 1010 CFU/dose. 
d. L. crispatus CTV-05 (not Lactin-V, which is given as a vaginal applicator), given as a vaginal capsule containing 108 CFU/dose. Product was inserted twice daily for 3 days. 
e. Age of participants is not reported, but all participants are premenopausal. 
f. Contains L. rhamnosus, L. delbrueckii, L. acidophilus and S. thermophilus; doses not specified. 
g. Tampons were impregnated with freeze-dried L. gasseri, L. casei var rhamnosus and L. fermentum, used as maintenance therapy. Each lactobacilli-impregnated tampon contained 108 living bacteria. Women using at least 5 
tampons were included in efficacy analyses. 
h. L. reuteri (formerly fermentum) RC-14 and L. rhamnosus GR-1, given as vaginal gelatin capsules, 109 CFU/dose of each spp., two capsules per night. Different dosage than Gardiner, 2002 & Burton 2003. 
i. Containing L. crispatus CTV-05 at 5 x 108 CFU/dose, inserted daily for 5 days. Not the commercially available Lactin-V, this product was developed later. 
j. Containing freeze-dried L. gasseri (Lba EB01-DSM 14869) and L. rhamnosus (Lbp PB01-DSM 14870) at a combined minimum of 108-9 CFU/capsule. 
k. Gynophilus vaginal capsule (Biose, Aurillac, France) contains at least 109 CFU/dose of L. rhamnosus 35. 
l. Kramegin vaginal tablet (containing 1 mg plant extract Krameria triandra root extract, L. acidophilus (1 billion UFC - presumably meant CFU.) and 15 mg lactic acid. 
m. Containing at least 109 CFU/dose of viable lactobacilli (L. brevis (CD2), L. salivarius subsp. salicinius (FV2), and L. plantarum (FV9). 
n. Lactobacilli (2x108-2x109 L. gasseri lyophilisates) in a vaginal tablet (Gebro Pharma, Fieberbrunn, Austria), as adjuvant therapy. First, women received an induction regimen of single-day itraconazole 200 mg bid. After their 
next menses, participants continued with 200 mg bid itraconazole twice weekly for 4 weeks. Then (within 1 week of their next menstruation) they received maintenance therapy of itraconazole 200 mg bid once a month, for 6 
months, as well as vaginal lactobacilli daily for 6 consecutive days, monthly, for 6 months. 
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o. Participants received an induction regimen of single-day itraconazole 200 mg bid. After their next menses, participants continued with 200 mg bid itraconazole twice weekly for 4 weeks. Then (within 1 week of their next 
menses) they received maintenance therapy of itraconazole 200 mg bid once a month, for 6 months. 
p. Before baseline, BV-pos. women were treated for BV with local clindamycin 100 mg ovules, and VVC-pos. were treated with clotrimazole 200 mg vag. tablets for 3 consecutive nights. 
q. Vaginal hydroxypropyl methylcellulose capsules (Ellen AB, Sweden) containing an inert carrying matrix (maltodextrin and magnesium stearate) and between 108 - 1010 viable cells of a probiotic substance, which was a mixture 
of freeze-dried L. gasseri LN40 (36% of weight), L. fermentum LN99 (27%) L. casei subsp. rhamnosus LN113 (27%), and P. acidilactici LN23 (10%) 
r. Containing L. crispatus CTV-05, 2x109 CFU/mL in a vaginal applicator. 
s. Gynoflor vaginal pessaries (Medinova AG, Zurich, Switzerland) containing 107 CFU/dose of live L. acidophilus KS400, 30 μg oestriol and excipients. 
t. Blend of at least 109 CFU of viable L. brevis CD2, L. salivarius subsp. salicinius, and L. plantarum; presumably same strains as article by Mastromarino et al. (2009),72 but not clear. 
u. Vaginal tablets containing > 0.4 billion live cells of both probiotic L. fermentum LF10 and L. acidophilus LA02 used as a main therapy, as part of a treatment scheme. 
v. Suppository/capsule containing at least 109 CFU/dose of live L. delbrueckii subsp. lactis DM8909, once daily at bedtime for 10 days.  
w. Ages of individual participants is only available in the supplementary materials and only available for participants who completed both FU visits (N=55). 
x. Vaginal capsules of L. rhamnosus GR-1 and L. reuteri RC-14 (2.56 x 109 CFU/dose each). 
y. Vaginal capsules of L. plantarum P17630 (Gyno-Canesflor, Bayer Canesten), >108 CFU/dose. 
z. Gynoflor (Medinova AG, Zurich, Switzerland) contains 100 million viable L. acidophilus KS400 and an dose of 30 μg E3/oestriol.  
aa. The study of Pendharkar et al. (2015) consisted of two separate but related clinical trials. We reported these separately for clarity. 
bb. All used EcoVag capsules (contain L. gasseri (DSM 14869) and L. rhamnosus (DSM 14870) at 1× 108 CFU of each strain per capsule) given as adjuvant therapy. Women in the BV group were given a seven-day course of daily 
2% vaginal clindamycin cream (Dalacin cream 2%) together with oral clindamycin 300 mg bid for 7 days. After this, therapy was started with EcoVag capsules for 5 days, as adjuvant therapy. After the next menstruation, 
women were given a 5-day course of vaginal 0.75% metronidazole gel followed by 5 more days with EcoVag. Oral clindamycin treatment was also given to sexual partners. 
cc. In this group, women used EcoVag capsules contain L. gasseri (DSM 14869) and L. rhamnosus (DSM 14870) at 1× 108 CFU of each strain per capsule, given as adjuvant therapy. Women in the BV group were given a 7-day 
course of daily 2% vaginal clindamycin cream (Dalacin 2%) together with oral clindamycin 300 mg BID for 7 days. After this, therapy was started with EcoVag capsules for 10 days, as adjuvant therapy. After the next 
menstruation, women were given a 5-day course of vaginal 0.75% metronidazole gel followed by 10 more days with EcoVag. After the second menstruation, EcoVag capsules were given once every week for the next 4 months. 
Oral clindamycin treatment was also given to the patients’ sexual partners. 
dd. Women were given 50 mg (oral?) fluconazole per day for 28 days, and EcoVag capsules for 10 days (days 18-28). After the first menses, they were given EcoVag capsules for 10 days along a weekly course of fluconazole 200 
mg for 2 months. This was followed by a third course of fluconazole 200 mg once every 2 weeks for the next 3 months. After the second menses, EcoVag was given once weekly for 4 months. 
ee. Women with VVC (unclear whether these are also women with recurrent VVC or just normal VVC) were given the same anti-fungal treatment as in the Af+EcoVag group. 
ff. InVag probiotic capsule contains 3 viable bacterial strains present at >109 CFU/ml. InVag contains 25% L. fermentum 57A, 25% L. plantarum 57B, 50% L. gasseri 57C, and excipients.  
gg. All women first received single dose fluconazole po (150 mg) and vag. fenticonazole (600 mg). Af+Pb followed this by vag. capsules of Lactagyn, containing live Lactobacillus spp: L. acidophilus, L. rhamnosus, S. 
thermophilus, L. delbrueckii subsp. bulgaricus. Strains and doses unknown. 10 Pb applications were given on the 5th day after anti-fungal treatment (for 10 days?). 
hh. Probiotic suppository SYNBIO gin, consisting of a Witepsol H15 matrix containing total of at least 109 CFU of viable lactobacilli (1:1 of L. rhamnosus IMC 501 and L. paracasei IMC 502).  
ii. L. crispatus IP 174178 (Physioflor) vaginal capsules (109 CFU/gram; total grams unclear); to be taken for 14 days, daily administration, for four consecutive menstrual cycles. 
jj. All received a vaginal gel containing lactic acid (among others) in combination with a vag. capsule (EPB) of L. fermentum LF10 (presumably 0.5 billion CFU/dose) and L. plantarum LP02 (0.5 billion) and prebiotic galacto-
oligosaccharides for six evenings; a telephone consultation was made 14d after baseline; if "troublesome symptoms" (not specified) were present, EPB was administered twice weekly for three more weeks. 
kk. Contains L. rhamnosus regenerans 35 (Lcr35). 
ll. Ecologic Femi+ (Winclove Probiotics, Amsterdam, The Netherlands) is a vaginal capsule containing lactoferrin and >1.5x109 CFU/capsule of lactic acid-producing bacteria. These bacteria include B. bifidum W28, L. 
acidophilus W70, L. helveticus W74, L. brevis W63, L. plantarum W21, and L. salivarius W24. 
mm. Gynophilus LP vaginal tablets (Biose, Aurillac, France) contain 876.9 mg L. rhamnosus regenerans 35 (Lcr35). 
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Table D.2: Summary of evidence per vaginal probiotic product, ordered by number of users 
Probiotic (brand name; 
manufacturer) Summary of evidence 
Lactobacillus acidophilus 
KS400; also contains 30 μg 
oestriol (Gynoflor; 
Medinova) 
 
3 studies (total N=359). A Turkish study showed Gynoflor given for BV, with 
metronidazole or alone, resulted in significantly lower VVC cumulative incidence, 
compared to metronidazole alone.188 An Australian study showed Gynoflor therapy 
after metronidazole resulted in lower BV recurrence than placebo, but higher than 
vaginal clindamycin after metronidazole.137 A Belgian study in which women used 
Gynoflor for atrophic vaginitis, showed an increase in VVC rates right after initiation; 
the increase was temporary only, decreasing after one month of use.184,185 
L. acidophilus, L. rhamnosus, 
Streptococcus thermophilus, 
L. delbrueckii subsp. 
bulgaricus (Lactagyn; 
Palcare Enterprises) 
1 study (N=209). A Bulgarian study showed Lactagyn therapy after antifungal 
treatment resulted in lower VVC recurrence at the final follow-up visit (25-30 days 
after product cessation) than antifungal treatment alone.193 
L. fermentum LF10, L. 
plantarum LP02 
(Estromineral Probiogel; 
Meda Pharma) 
1 study (N=209). In an Italian pre/post study women received Estromineral Probiogel 
without antifungals for incidental VVC or rVVC for six days, which resulted in high 
cure rates.194 However, more than 50% of women in both groups required prolonged 
therapy due to persistence of symptoms. 
L. rhamnosus Lcr35 
(Gynophilus; Biose) 
 
 
3 studies (total N=145). An Austrian study showed that Gynophilus after clindamycin 
reduced BV recurrence, compared to placebo after clindamycin.136 A French study 
comparing four formulations/dosages found a high conc. of probiotic strains in all 
cases and greater acceptability when using slow-release products.155 A Rwandan 
study in women using intermittent Gynophilus after metronidazole resulted in non-
significant lower BV recurrence compared to no-intervention controls.160 Probiotic 
detectability was low. There were no significant VMB changes. 
L. rhamnosus, L. delbrueckii, 
L. acidophilus, S. thermophilus 
(Femilac; now Lallemand Inc) 
1 study (N=137). An Australian study showed that ten days of Femilac during and 
after (non-metronidazole) antibiotic use, compared to placebo controls, was not 
effective in preventing VVC within 18 days after cessation of use.67 
L. crispatus CTV-05; (named 
Lactin-V when in vaginal 
applicator; Osel) 
4 studies (total N=132). An American study showed high CTV-05 detection in the 
vagina of healthy women without native L. crispatus, but not in those with native L. 
crispatus.76 A study in women with recurrent urinary tract infections showed a similar 
VVC cumulative incidence after CTV-05 initiation. It showed low CTV-05 strain 
detection.187 Another study showed that CTV-05 was only detected a few weeks after 
use, and that protected/unprotected sex and L. crispatus colonisation at baseline were 
associated with detection failure.150 A trial with 18 BV-positive CTV-05 users 
showed that BV-anaerobes at baseline were not associated with a lower likelihood of 
detection; having native L. crispatus or having protected/unprotected sex was 
associated with lower detection odds.128,183  
L. gasseri, L. casei var 
rhamnosus, L. fermentum 
(unnamed; Medipharm AB) 
1 study (N=127). A Scandinavian study using Lactobacillus-impregnated tampons 
after clindamycin treatment during menses was not efficacious in reducing BV 
recurrence compared to placebo tampons.138 
L. acidophilus LA14; also 
contains lactic acid (unknown 
brand and manufacturer) 
1 study (N=106). A single-arm Italian study in women with Nugent 4-10 showed that 
14-day LA14 use (without antibiotics or antifungals) resulted in 46/60 women cured 
(Nugent 0-3), which persisted after product cessation.145 LA14 use also significantly 
decreased VVC rates and Candida fungal culture counts. 
L. acidophilus; including 
lactic acid (Kramegin; 
PharmExtracta) 
1 study (N=105). A single-arm Italian study among women with incidental or rVVC 
showed that ten-day Kramegin use (without antifungals) was successful in curing 
VVC.189 
L. brevis CD2, L. salivarius 
subsp. salicinius FV2, L. 
plantarum FV9 (Florisia; 
VSL3 Pharmaceuticals) 
 
 
2 studies (total N=102). In an Italian study, Florisia (without antibiotics) was more 
successful in treating BV than placebo.72 This effect persisted two weeks after 
product cessation. In an Indian study, Florisia was not efficacious in curing BV, 
compared to pH-lowering tablet users.140 
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Probiotic Summary of evidence 
L. gasseri LN40, L. 
fermentum LN99, L. casei 
subsp. rhamnosus LN113, 
Pediococcus acidilactici 
LN23 (Ellen capsules; Ellen 
AB)* 
1 study (N=95). In a Swedish study, five-day probiotic use resulted in probiotic 
strains detectability in a majority of women.195 At next visits, the number of women 
with presence of one or more strains gradually decreased. 
L. fermentum 57A, L. 
plantarum 57B, L. gasseri 
57C (InVag; IBBS BioMed)* 
1 study (N=86). In a Polish study there was detection of probiotic strains in most of 
the users, but this decreased quickly after product cessation.151  
L. gasseri Lba EB01-DSM 
14869, L. rhamnosus Lbp 
PB01-DSM 14870 (EcoVag; 
Bifodan A/S) 
3 studies (total N=80). A Norwegian study showed that EcoVag (without antibiotics) 
was not better at curing BV than placebo, but EcoVag did significantly reduce the 
cumulative incidence of BV/intermediate microbiota when used after each menses, 
for four consecutive cycles.135 A Norwegian study among BV-positive (by Amsel) 
women showed that strains could be isolated in most users.186 A Swedish study in 
women with rVVC showed that fluconazole with EcoVag did not significantly 
improve VVC cure, compared to fluconazole alone. EcoVag strains were detected in 
a minority of women (more often in women without native lactobacilli).186 
L. delbrueckii subsp. lactis 
DM8909 (unnamed; 
unknown company) 
1 study (N=53). In a Chinese study, L. delbrueckii was not better than vaginal 
metronidazole as treatment for BV, but there were significantly fewer BV relapses 30 
days after product use in the women using probiotics (compared to metronidazole 
users).141 The molecular VMB assessments also showed benefits. 
L. crispatus IP 174178 
(Physioflor; IPRAD Pharma) 
1 study (N=52). A French study showed 14-day Physioflor therapy after 
metronidazole resulted in significantly lower BV cumulative incidence and longer 
time to BV recurrence, compared to placebo, but the effects disappeared after use. 150  
L. gasseri (unnamed; Gebro 
Pharma) 
1 study (N=50). An Austrian study showed no effect of using itraconazole with L. 
gasseri to prevent VVC, compared to women using itraconazole alone.190 
L. reuteri RC-14 (formerly L. 
fermentum RC-14), L. 
rhamnosus GR-1 (unnamed; 
Chr. Hansen A/S) 
4 studies (total N=47). A Canadian study showed high strain detection directly after 
use, but a decrease during follow-up; GR-1 was detected more often than RC-14.196 A 
Canadian study showed 100% detection during use but detectability decreased after 
use; RC-14 disappeared quicker than GR-1.197 A Nigerian study showed a higher BV 
cure rate of five-day RC-14/GR-1 therapy than five-day vaginal metronidazole gel 
therapy; BV recurrence after use was also lower in probiotic users.139 A Canadian 
trial in post-menopausal women with Nugent 4-6 showed no significant changes in 
Nugent scores when using RC-14/GR-1, but there were significant increases in 
Lactobacillus spp. and decreases in Atopobium spp.142 
L. plantarum P17630 
(Gyno-Canesflor, Bayer 
Canesten) 
1 study (N=45). An Italian study showed 34-day Gyno-Canesflor use after 
clotrimazole treatment resulted in non-significant lower VVC recurrence than placebo 
users.192 
L. rhamnosus IMC 501, L. 
paracasei IMC 502 
(SYNBIO gin; Synbiotec) 
1 study (N=35). A single-arm Italian study in women with Nugent 0-6 and seven-day 
SYNBIO use (no antibiotics) resulted in an increase of Nugent 0-3 proportions and a 
significant Lactobacillus conc. increase.143 Strains were detected in all users. 
L. fermentum LF10, L. 
acidophilus LA02 (ActiCand 
30; ItalFarmaco) 
1 study (N=30). In a single-arm Italian study in women with severe rVVC, ActiCand 
use without antifungals resulted in a significant reduction of VVC cases, with 23 out 
of 30 women being cured.191 
B. bifidum W28, L. aci-
dophilus W70, L. helveticus 
W74, L. brevis W63, L. 
plantarum W21, L. salivarius 
W24 (Ecologic Femi+; 
Winclove) 
1 study (N=17). A Rwandan study using Ecologic Femi+ intermittent therapy after 
metronidazole for BV resulted in significantly lower BV incidence during use.160 Use 
also resulted in significant higher Lactobacillus abundances, lower BV-anaerobes 
conc., and lower likelihood of having a BV-like VMB type, compared to no-
intervention controls. All effects disappeared after product use. The detectability and 
conc. of probiotic strains was low. 
L. rhamnosus GG (unnamed; 
ConAgra Foods)* 
1 study (N=5). A Canadian colonisation study showed high detection of GG strains, 
which gradually decreased over time after product cessation.196 
BV bacterial vaginosis, conc. concentration, spp. species, VMB vaginal microbiota, (r)VVC (recurrent) vulvovaginal candidiasis.  
*Only vaginal detection studies available for this product; no comprehensive BV/VMB or VVC efficacy results available.
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Table D.3: Detection and colonisation rates of probiotic strains 
Reference Probiotic(s) Short methods overview Vaginal detection Abundance/ concentration Other results of interest 
Gardiner196 RC-14/GR-1 (L. fermentum 
RC-14 + L. rhamnosus GR-
1) and L. rhamnosus GG; 
vaginal detection in healthy 
women only. 
RAPD of vaginal culture 
isolates; PFGE on selected 
samples to distinguish L. 
rhamnosus GR-1 from L. 
rhamnosus GG. 
5/5 users had at least 
one strain detected 
directly after the 3-day 
use period. Decreased 
to 1-2/10 users per 
strain at 18 days after 
use. 
NA NA 
Antonio & 
Hillier76 
L. crispatus CTV-05 (not 
Lactin-V); vaginal detection 
in healthy women only. 
DNA hybridisation with 
whole-chromosome probes 
to identify Lactobacillus 
spp.; rep-PCR to identify 
CTV-05. 
CTV-05 detected in 5/9 
users directly after the 
3-day use period. This 
increased to 6/9 users at 
6-8 days after use. 
NA CTV-05 detected in 5/5 users 
without native L. crispatus at 
baseline and in 0/4 without. 
Burton197 RC-14/GR-1 (L. fermentum 
RC-14 + L. rhamnosus GR-
1); vaginal detection in 
healthy women only. 
RAPD DNA fingerprinting 
of culture isolates. VMB 
changes after RC-14/GR-1 
use determined by DGGE 
analysis and Sanger 
sequencing of excised gel 
bands. 
10/10 users had at least 
one strain detected 
directly after the 3-day 
use period. Decreased 
to 0-2/10 users per 
strain at 18 days after 
use. 
NA NA 
Czaja187 L. crispatus CTV-05 (not 
Lactin-V) as maintenance tx 
to prevent UTIs. 
Rep-PCR for L. crispatus 
CTV-05, on culture isolates. 
Rep-PCR to identify 
Lactobacillus spp. 
CTV-05 detected in 
4/15 users during 
follow-up (one or two 
days after 5 days of use 
and at 4 weeks). 
NA NA 
Antonio150 L. crispatus CTV-05 (not 
Lactin-V) vaginal detection 
in healthy women. 
Rep-PCR for L. crispatus 
CTV-05, on culture isolates. 
Rep-PCR to identify 
Lactobacillus spp. 
After 3 days of use, 
CTV-05 detected in 
69% of 45 women at 
one or more D7 or D21 
visits, and 59% at the 
D28 visit. 
NA 28/31 without native L. 
crispatus had CTV-05 
detected, and 24/47 (51%) 
with (Fisher’s exact p<0.001). 
Sexual intercourse (with 
condoms, p=0.02; without 
condoms, p<0.001) and native 
L. crispatus (p=0.001) at 
baseline associated with lack 
of CTV-05 detection. 
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Reference Probiotic(s) Short methods overview Vaginal detection Abundance/ concentration Other results of interest 
Ehrström195 Ellen capsules (L. gasseri 
LN40 + L. fermentum LN99 
+ L. casei subsp. rhamnosus 
LN113 + Pediococcus 
acidilactici LN23) as 
maintenance tx after 
clotrimazole. 
qPCR to identify 
Lactobacillus and 
Pediococcus culture 
isolates. Strain identification 
of vaginal culture isolates 
using RAPD. 
At least one probiotic 
strain detected in 47/53 
users directly after the 
5-day use period; 27/51 
after first menses; 3/50 
at 6 months. 
NA NA 
Hemmer-
ling183 & 
Ngugi128 
L. crispatus CTV-05 (Lactin-
V) as maintenance tx after 
vaginal metronidazole. 
Rep-PCR to identify CTV-
05 strains, 16S qPCR of 
specific vaginal bacteria. 
CTV-05 detected in 
11/18 users during 
and/or up to 7 days 
after the 19-day use 
period; this was 7/9 in 
women who had used 
all seven applicators. 
NA Lack of CTV-05 detection 
associated with sexual 
intercourse with or without 
condoms and with having 
native L. crispatus at baseline; 
no association with baseline 
presence of anaerobes. 
Bisanz142 RC-14/GR-1 (L. reuteri RC-
14 + L. rhamnosus GR-1) as 
main tx for Nugent 4-6. 
16S rRNA gene V6 
sequencing. 
At least on probiotic 
strain detected in 7/12 
users directly after the 
3-day use period, but 
only in one user within 
the 17 days after 
cessation. 
GR-1 was usually far 
more abundant than 
RC-14, but never 
dominated the VMB. 
NA 
Pendharkar 
– Trial I186 
EcoVag (L. gasseri DSM 
14869 + L. rhamnosus DSM 
14870) as 
adjuvant/maintenance tx to 
prevent BV recurrence. 
Gram-positive bacilli on 
culture used for rep-PCR, 
DNA profiles were 
compared with those of 
EcoVag strains. 
Identification was 
confirmed by using RAPD 
with primers for both 
EcoVag spp. 
At least one probiotic 
strain detected in 9/10 
users during use, which 
persisted for two weeks 
after cessation in 8/10, 
two months in 3/9, and 
three months in 2/9. 
NA The proportion of women with 
EcoVag strains detected was 
non-significantly higher in 
those cured for BV compared 
to those experiencing a relapse 
(Fisher's exact p=0.16). 
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Reference Probiotic(s) Short methods overview Vaginal detection Abundance/ concentration Other results of interest 
Pendharkar 
- Trial II186 
EcoVag (L. gasseri DSM 
14869 + L. rhamnosus DSM 
14870) as adjuvant/ 
maintenance tx to prevent 
BV and VVC recurrence 
(different participant groups). 
Gram-positive bacilli on 
culture used for rep-PCR, 
DNA profiles were 
compared with those of 
EcoVag strains. 
Identification was 
confirmed by using RAPD 
with primers for both the 
EcoVag spp. 
Probiotic strains 
detected in 5/7 adherent 
women using EcoVag 
and antibiotics, and 8/9 
using EcoVag and 
antifungals, during the 
6-month intervention 
period. Detection 
decreased from two 
weeks after tx cessation 
onwards (data not 
reported). 
NA Natural lactobacilli more 
common than probiotic strains 
in 73% of the samples. 
EcoVag strains detected more 
often among women who did 
not have natural lactobacilli at 
baseline. 
Tomusiak151 InVag (L. fermentum 57A + 
L. plantarum 57B + L. 
gasseri 57C) as main tx for 
NS 4-6 or "low lacto count". 
PCR for spp. identification, 
PFGE/multilocus sequence-
typing to confirm InVag 
spp. presence. 
At least one probiotic 
strain detected in 82% 
of 86 users directly 
after use, and in 47.5% 
14 days after cessation. 
NA NA 
Verdenelli143 SYNBIO Gin (L. rhamnosus 
IMC 501 + L. paracasei IMC 
502) as maintenance tx to 
prevent BV and VVC. 
Real-time qPCR for total 
lactobacilli and SYNBIO 
strains using specific 
primers, and RAPD on 
culture isolates for SYNBIO 
strains presence. 
At least one probiotic 
strain detected in 35/35 
users directly after 7 
days of use. Decreased 
to 21/35 users 21 days 
after use. 
Proportion of total 
lactobacilli: 22.9% for 
IMC501 and 23.8% 
for IMC502 directly 
after use. Decreased to 
14.3% and 9.4% 21 
days after use. 
Significant increase in total 
Lactobacillus after SYNBIO 
use. 
Dausset155 Gynophilus (L. rhamnosus 
Lcr35 regenerans) in two 
formulations: immediate 
release and slow-release. 
Vaginal detection in healthy 
women only. 
Lcr35 by qPCR. Data are presented as 
daily mean 
concentrations per 
regimen (a total of 35 
women used the 
probiotic for 21 days 
every 3, 4 or 5 days, 
and sampled daily) but 
the means suggest that 
all women at all visits 
had Lcr35 detected. 
Mean concentration of 
0.48-1.92 log10 cells/μl 
per FU visit during the 
2-month intervention 
period. Mean relative 
abundance of 3% 
(7.7% if any strains 
detected). 
Concentrations were much 
higher (up to 4 log10 cells/μl) 
in women with any probiotic 
strain detected. There was no 
clear association with self-
reported adherence. 
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Reference Probiotic(s) Short methods overview Vaginal detection Abundance/ concentration Other results of interest 
van de 
Wijgert160 
Ecologic Femi+ (B. bifidum 
W28 + L. acidophilus W70 + 
L. helveticus W74 + L. brevis 
W63 + L. plantarum W21 + 
L. salivarius W24) as 
maintenance tx to prevent 
BV recurrence. 
16S rRNA gene V3V4 
sequencing, total 16S rRNA 
copies concentration by 
BactQuant, and estimated 
concentrations per taxon 
using both. 
At least one probiotic 
strain detected in 39.3% 
of samples during the 
2-month intermittent 
use period. No longer 
detected 4 months after 
cessation of use. 
Mean concentration of 
0.48-1.92 log10 cells/μl 
per follow-up visit 
during the 2-month 
intervention period. 
Mean relative 
abundance of 3% 
(7.7% if any strains 
detected). 
Concentrations were much 
higher (up to 4 log10 cells/μl) 
in women with any probiotic 
strain detected. There was no 
clear association with self-
reported adherence. 
van de 
Wijgert160 
Gynophilus LP (L. 
rhamnosus Lcr35 
regenerans) as maintenance 
tx to prevent BV recurrence. 
16S rRNA gene V3V4 
sequencing, total 16S rRNA 
copies concentration by 
BactQuant, and estimated 
concentrations per taxon 
using both. 
The probiotic strain 
detected in 19.8% of 
samples during the 2-
month intermittent use 
period. No longer 
detected 4 months after 
cessation of use. 
 
Mean concentration of 
0.25-1.05 log10 cells/μl 
per follow-up visit 
during the 2-month 
intervention period. 
Mean relative 
abundance of 3% 
(15.1% if any strain 
detected). 
CFU colony-forming unit, conc. concentration, DGGE denaturing gradient gel electrophoresis, EF+ Ecologic Femi+, GynLP Gynophilus LP, Lcr35 L. rhamnosus Lcr35, NA not applicable, Pb probiotic, PFGE  
pulsed-field gel electrophoresis, qPCR quantitative polymerase chain reaction, RAPD random amplification of polymorphic DNA, rep-PCR repetitive element sequence-PCR, VMB vaginal microbiota. 
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Appendix E  
 
This appendix corresponds to Chapter 6. 
Informed consent procedures 
All participants provided written informed consent. The age of majority for Rwandan women was 
lowered from 21 to 18 years in November 2016, and we also obtained parent/guardian consent for 
non-married participants aged 18-20 years until this was no longer required. Participants and/or 
parents/guardians with insufficient literacy could sign by thumbprint but the informed consent process 
was observed by an independent witness who co-signed the informed consent form. The witness could 
not be a Rinda Ubuzima staff member, but could be another participant. 
 
Selection of POCTs for evaluation in WISH 
We chose POCTs that comply with the WHO ASSURED criteria (Affordable, Sensitive, Specific, 
User-friendly, Rapid and Robust, Equipment-free, and Deliverable to end users) as much as 
possible,106,108 and that are feasible to conduct and interpret by primary care clinic staff in African 
settings. For example, some might argue that microscopy is an ‘almost ASSURED’ diagnostic method 
for diagnosing bacterial vaginosis (BV). Microscopy is not equipment-free, but microscopes are much 
more readily available than other types of equipment. However, our experience is that microscopy is 
not ‘user-friendly’. While the acts of preparing a slide and viewing it under a microscope might be 
feasible after sufficient practice, the actual recognition of human cell types and micro-organisms 
requires a much higher level of biology training than primary care clinic staff in African settings have 
typically received. Also, Gram staining requires a laboratory with dedicated sinks and running water 
for safety reasons, and it is not practical to stain one slide at a time. 
 
The development of ASSURED POCTs for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae 
(NG) has been ongoing for years. Unfortunately, lateral flow tests based on CT/NG-specific antibody, 
antigen, or enzyme detection to date have had low sensitivity.92,237 The GeneXpert CT/NG assay 
(Cepheid, Sunnyvale, USA) was the first CT/NG POCT based on nucleic acid amplification testing 
(NAAT) and has excellent performance compared to other validated CT/NG NAATs.91,238 However, it 
is not ASSURED because it requires equipment, is expensive (we paid 18.25 USD for consumables 
per test), and takes 90 minutes to return results. We chose to use this test anyway because it was the 
best CT/NG POCT available at the time of WISH study implementation, and because GeneXpert 
machines are widely available in Rwanda for tuberculosis testing. The machines are modular and can 
accommodate different types of test cartridges. Cepheid is currently considering developing next-
generation GeneXpert CT/NG assays with shorter turn-around times but development has not yet been 
initiated (personal communication with representatives of Cepheid Europe in July 2018). 
Furthermore, additional NAAT-based POCTs for CT and/or NG are under development and prices 
might decline as a result of market competition.239–241 In the WISH study, the Rwandan laboratory 
technicians were trained by a Cepheid representative based in Nairobi, Kenya. The representative 
visited the Rinda Ubuzima laboratory, assisted the team with equipment set-up, and conducted a one-
day training using this equipment so that any start-up problems could be resolved immediately. The 
University of Liverpool investigators also attended this training to be able to assist the Rwandan 
technicians with potential future problems. However, we did not experience any problems during the 
study. Also, the percentage of invalid test results throughout the study was in line with those expected 
by Cepheid (fewer than 5% of the tests overall). 
 
For Trichomonas vaginalis (TV), we chose the TV OSOM test (Sekisui Diagnostics, Lexington, 
USA) because experts consider it ASSURED and best in its class of lateral flow tests.242 It is easy and 
quick to perform, has sensitivities of 83-86% compared with NAATs,242 and is cheaper than NAATs 
(we paid 6.35 USD for consumables per test). POC NAATs that will likely have improved 
sensitivities are available or under development, including a module that can be used on the 
GeneXpert machine, but those are not ASSURED and more expensive.242 
 
175 
 
BV and vulvovaginal candidiasis (VVC) are not infections by a single pathogen but changes from an 
immuno-tolerant lactobacilli-dominated vaginal microbiological ecology towards a proinflammatory 
ecology. Knowledge about the vaginal ecology has significantly increased in recent years.4 From a 
microbiological perspective, BV is a bacterial dysbiosis, and VVC is a dysbiosis characterised by an 
overgrowth of yeasts/fungi. BV is characterised by a persistent depletion of lactobacilli and an 
increased concentration of other bacteria, most commonly – but not exclusively – a highly diverse 
mixture of anaerobes including Gardnerella vaginalis and Atopobium vaginae. From a clinical 
perspective, the gold standard BV diagnosis is a Gram stain Nugent score of 7-10,78 but the Amsel 
criteria are also often used.77 Currently, only symptomatic BV in women seeking care is treated, even 
though asymptomatic BV has been associated with pregnancy complications and other 
complications.17 There is no consensus yet about which types and levels of vaginal bacterial dysbiosis 
should be treated to prevent complications.9 The Amsel criteria include a high vaginal pH as one of 
the criteria, and in a recent study at Rinda Ubuzima, we found that a vaginal pH≥5.0 predicted a 
Nugent score of 7-10 with 71.0% sensitivity and 76.0% specificity (unpublished data). Vaginal pH 
can be measured easily and cheaply. We therefore decided to use the EcoCare vaginal pH swab 
(Merete Medical, Luckenwalde, Germany) with pH ≥5.0 as the cut-off to diagnose BV in the WISH 
study. Some BV POCTs detecting enzymes or metabolites produced by G. vaginalis and/or other 
anaerobic bacteria (e.g. sialidase, proline aminopeptidase, or amines) have been developed,46 but did 
not significantly outperform the vaginal pH results that we obtained in our previous study 
(unpublished data). VVC POCTs detecting Candida antigens/antibodies have either shown inadequate 
sensitivity and specificity,243,244,207 or have not been compared to gold standard NAAT or culture 
assays.245 Molecular tests targeting lactobacilli and/or key BV-associated bacteria and/or Candida 
species are available or being developed, but are expensive and not ASSURED.84,246–249  
 
Other POCTs offered to WISH participants 
We wanted to offer WISH participants a complete sexual health screening package and therefore 
offered them HIV, syphilis, pregnancy, and urinary tract infection (UTI) POCTs as a service. We did 
not evaluate the performance of these POCTs because they are either known to have good 
performance (HIV, syphilis, pregnancy), and/or we did not have suitable gold standard test results 
available to us to compare the POCT results to (syphilis, UTI). 
 
Validated ASSURED106,108 POCTs with good performance for HIV, syphilis, and pregnancy have 
been available for many years, including in low and middle-income countries.109,110 In WISH, we used 
locally available POCTs that were recommended by the Rwanda Ministry of Health at the time of the 
study (see legend of figure 6.1). 
 
UTIs in women can be caused by multiple pathogens. Escherichia coli is the most common cause 
(>70% of cases208), but other causes include Enterococcus species, Klebsiella pneumoniae, Proteus 
mirabilis, and STI pathogens such as NG. By far the most commonly used UTI POCTs are lateral 
flow tests detecting leukocytes, nitrites and other bacterial metabolites. These are readily available 
and cheap, but have modest performance when compared to urine culture.208 Lateral flow tests to 
detect E. coli in urine are being developed.250 The WISH study focussed on genital infections and we 
therefore elected to use a locally available urinalysis dipstick assessing leukocytes and nitrites for UTI 
POC testing (figure 6.1). While we did not formally evaluate the performance of this urinalysis 
dipstick, we compared dipstick findings with urine E. coli qPCR findings (see ‘gold standard testing’ 
below) in this Appendix (table E.6). 
 
Gold standard testing 
 
CT/NG GeneXpert at Rinda Ubuzima, Kigali, Rwanda 
The CT/NG GeneXpert assay was considered a gold standard because of its high performance 
compared to other validated CT/NG NAATs (see above). While only women who had a positive 
CT/NG score were tested that same day, GeneXpert swabs were also taken from all other women and 
tested in batches. All GeneXpert assays were performed in the onsite Rinda Ubuzima laboratory in 
Kigali, Rwanda.  
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Assays conducted at the Institute of Tropical Medicine in Antwerp, Belgium 
All other NAATs were conducted in the STI reference laboratory of the Institute of Tropical Medicine 
in Antwerp, Belgium.  
 
All women were asked to self-sample two polyester swabs during the main visit. This was optional 
but none of the women refused. Each swab head was stored in a 2 ml cryovial containing 1 ml 
RNAlater (ThermoFisher Scientific, Paisley, UK) at -80°C during study implementation. Urine 
samples from women who underwent pregnancy and/or UTI testing (N=641) were centrifuged at 
3,000g and the pellet was stored at -80°C in 2 ml cryovials. After all main visits had been completed, 
swab heads in RNAlater were defrosted and shipped to Belgium at room temperature. Urine pellets 
were transported to Belgium on dry ice. DNA was extracted from vaginal swab heads and urine 
pellets using the Abbott m2000sp automated extraction platform (Abbott Laboratories, Chicago, 
USA) and an elution volume of 200 µL, incorporating an extra lysis step.251 
 
Validated in-house polymerase chain reaction (PCR) assays were performed targeting the following 
organisms: TV, Mycoplasma genitalium (MG), Candida albicans, Lactobacillus genus, G. vaginalis, 
and A. vaginae on vaginal swabs, and E. coli on urine samples. The real time TV PCR targeted a 
fragment of 92 base pairs of a TV-specific repeat gene. In brief, the 25 µL PCR mixture contained 
12.5 µL of Platinum Q, PCR SuperMix UDG (Invitrogen, California, USA), 0.9 µL of 25 µM Primers 
TV001 (5’AAAGATGGGTGTTTTAAGCTAGATAAGG-3’) and of 25 µM Primers TV002 (5’ 
TCTGTGCCGTCTTCAAGTATGC-3’), 0.25 µL Probe TV003 (5’ /56 
FAM/AGTTCATGT/ZEN/CCTCTCCAAGCGTAACT/3IABkFQ/-3’), 10 µL DNA extract and 0.45 
µL RNAse-free water. Primers and probes were described by Pillay et al.252 The amplification 
comprised an initial heating of 50°C for 2 minutes and of 95°C for 3 minutes followed by 45 cycles of 
95°C for 20 seconds and 60°C for 60 seconds. MG was detected by applying a previously published in 
house real time PCR assay.253 The concentrations of Lactobacillus genus, G. vaginalis and A. vaginae 
were determined by quantitative (q)PCRs as previously described.83 The concentrations of C. albicans 
were determined by qPCR with primers previously published by Cools et al (CA_rRNA R 5’-
TTGAAGATATACGTGGTGG-3’ and CA_rRNA F 5’-TTTGCTTGAAAGACGGTA-3’).254 The 
25µL PCR mixture contained 12.5µL Rotor-Gene SYBR Green (Qiagen, Hilden, Germany), 2.5µL of 
10 µM of each primer, 2.5µL RNAse-free water and 5µL of DNA extract. The concentrations of E. 
coli were determined by qPCR with primers previously published by Chern et al. (EC23S857 assay, E. 
coli_rRNA R 5’-TGTCTCCCGTGATAACtTTCTC-3, E. coli_rRNA F 5’-
GGTAGAGCACTGTTTtGGCA-3’, E. coli_rRNA probe 5’-TCATCCCGACTTACCAACCCG-
3’).255 The 25µL PCR mixture contained 12.5µL Platinum Q PCR SuperMix-UDG (2x) (Invitrogen, 
California, USA, 0.9µL of 25µM of each primer, 0.7µL of 5µM probe and 10µL of DNA extract. The 
amplification protocols of C. albicans and E. coli were the same as previously described for 
Lactobacillus genus.83 All primers and probes were synthesised by Integrated DNA Technologies 
(IDT, Illinois, USA), and all amplification reactions were performed using the Corbett Life Science 
Rotor-GeneTM 6000 (Qiagen, Venlo, the Netherlands).  
 
The qPCRs for TV and MG were qualitative. The other qPCRs were quantitative and run in duplicate. 
Organism concentrations were expressed as genome equivalents per ml (geq/ml; the mean of 
duplicates) and log10-transformed. The qualitative PCR results for TV and MG were considered gold 
standards. A gold standard BV diagnosis was made when the vaginal qPCR score was below -2 (see 
next paragraph). The C. albicans qPCR was not considered a true gold standard for VVC because 
VVC can be caused by multiple yeasts/fungi. We have, however, referred to it as a gold standard test 
in this paper for convenience and readability, and would also like to point out the following: 1) it is 
estimated that 70-95% of VVC cases are caused by C. albicans;30 and 2) Candida species are known 
to be proinflammatory; asymptomatic ‘carriage’ is therefore only likely when present in low 
concentrations. In the WISH study, C. albicans was only detected by qPCR in 8.6% of the women, 
and in 68% of those women, it was present at concentrations ≥105 geq/ml. C. albicans therefore does 
not seem to qualify as a ‘harmless commensal’ in the vagina. However, it is currently not known 
above which concentration threshold on average C. albicans (plus other yeasts/fungi) causes 
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symptoms and/or complications, and more research is needed to develop an optimal gold standard 
test. Similarly, the E. coli qPCR was not considered a true gold standard for UTI because UTIs can be 
caused by multiple organisms (see above). Because UTIs are not included in the WHO syndromic 
guidelines, and we did not have optimal gold standard test results, we opted to compare the urinalysis 
dipstick and E. coli qPCR results in this Appendix (table E.6), but to not formally evaluate the 
urinalysis dipstick performance. 
 
Vaginal qPCR score to identify true BV cases 
As described above, from a clinical perspective, the gold standard BV diagnosis is a Nugent score of 
7-10.78 We followed Kenyan, Rwandan and South African women over two menstrual cycles and 
assessed their vaginal microbiota by Gram stain Nugent scoring and by conducting qPCRs of relevant 
vaginal bacteria on vaginal swabs.85 About a third of the 387 women (35.7%) had a Nugent score of 
7-10 (BV). Individual and combinations of qPCR assay results were compared to a Nugent score of 7-
10, and the highest diagnostic accuracy was achieved with what we subsequently termed the vaginal 
qPCR score [log10 geq/ml (Lactobacillus genus) - log10 geq/ml (G. vaginalis + A. vaginae)] below -2. 
The sensitivity was 93.4% and specificity 83.6%. We wanted to keep the number of research 
procedures in the WISH study to a minimum in order to mimic a real life clinic setting, and we 
therefore elected not to conduct Gram stain Nugent scoring. Instead, we collected two extra vaginal 
swabs to allow for all required gold standard testing after study completion, and used the vaginal 
qPCR score as the gold standard for BV. Please note that the use of such a continuous score 
acknowledges that the vaginal microbiota exist as a continuum from completely lactobacilli-
dominated (a typical concentration in the order of 106 lactobacilli per vaginal swab, which would 
translate into a vaginal qPCR score of 6) to completely dysbiotic (0 lactobacilli but high 
concentrations of other bacteria, which would translate into a vaginal qPCR score below 0) and 
everything in between. Some women may not reach the BV threshold of -2, but could still have too 
many inflammatory bacteria compared to immuno-tolerant lactobacilli, and even develop symptoms 
and/or complications because of this. We have termed this ‘mild dysbiosis’. It is currently not known 
above which concentration threshold on average vaginal bacterial dysbiosis causes symptoms and/or 
complications. 
 
Additional information about the WHO and WISH algorithms 
The WHO and WISH algorithms are described in detail in the text and figure 6.1. We offer additional 
clarifications here. WHO published two vaginal discharge syndrome (VDS) algorithms: one that 
incorporates speculum examinations and one that does not.40 We used the algorithm without speculum 
examination but with differentiation between not VVC-like (treated for CT, NG, TV, and BV because 
prevalences in our study population were expected to be high) and VVC-like (also treated for VVC) 
based on structural reporting instead of speculum examination findings. The WHO and WISH lower 
abdominal pain (LAP) algorithms aim to identify patients with pelvic inflammatory disease, which 
can be life-threatening: if LAP is reported, a bimanual exam is done, and pelvic inflammatory disease 
is diagnosed if there is adnexal or cervical motion tenderness during the bimanual exam. The WHO 
algorithm does not specifically mention pain during sex as a reason to do a bimanual exam, but the 
WISH study team decided that pain during sex may also be indicative of pelvic inflammatory disease. 
We therefore included it in the WISH algorithm. This resulted in only three additional patients being 
diagnosed with pelvic inflammatory disease compared to the WHO algorithm (32 and 29 cases, 
respectively; see table 6.3). Finally, the genital ulcer disease (GUD) algorithm included genital warts 
in the WISH study but not in the WHO guidelines. However, no genital warts were diagnosed during 
the study.  
 
As is described in Chapter 6, study physicians performed speculum/bimanual examinations on 
399/705 (56.6%) participants, which was more than we had anticipated. The data show that they did 
examinations in all cases of LAP and pain during sex as required, but also in almost all cases of 
participant-reported VDS that were not VVC-like (which was only recommended in cases of 
substantial VDS), and all cases of GUD/buboes (whereas genital inspection may have sufficed). 
Furthermore, we question the added value of speculum/bimanual examinations other than for 
178 
 
diagnosing pelvic inflammatory disease: participant and physician judgments on whether VDS was 
VVC-like or not were not accurate (table 6.5). 
 
Treatment, partner notification, and referral 
Urogenital infections were managed in accordance with the Republic of Rwanda National Guidelines 
for Prevention and Management of HIV, STIs & Other Blood Borne Infections (2013).24 Only 
medically qualified physicians were allowed to dispense treatments (commonly used drugs were 
stocked in the study clinic) or prescriptions for treatments, and they were instructed to refer 
complications to a qualified specialist in a referral hospital in Kigali. First and second choice 
treatment recommendations at the time of the study for the most common infections are listed in the 
table E.1 below. In some cases, etiologic diagnoses became available after the participant had already 
left the study clinic (e.g. after completion of the gold standard testing). In the case of curable STIs 
(NG, CT, TV, and syphilis), women were contacted and asked to attend the study clinic as soon as 
possible for treatment and partner notification. Pregnant women were referred to antenatal care, HIV-
positive women to HIV care, and all women were informed where they could obtain contraceptive 
methods and screening for cervical cancer.  
 
Table E.1: Treatments options for main urogenital infections 
Infection First choice treatment Second choice treatment Window periods for partner 
notification 
CT Doxycycline 100mg twice 
per day for 7 days 
Erythromycin 1g twice per 
day for 7 days 
4 weeks if symptomatic; 6 
months if asymptomatic or PID. 
NG Ciprofloxacin 1g single oral 
dose 
Ceftriaxone 250mg in one 
single IM dose [After 
discussion with Rwandan 
MoH: 500mg IM allowed in 
case of suspected resistance] 
3 months, or 6 months if PID. 
Syphilis 
(primary) 
Benzathine benzyl penicillin 
2.4 million IU IM single 
dose 
Erythromycin 1g orally 2x 
per day x 14 days OR 
Doxycycline 100mg orally 
twice per day x 14 days 
3 months 
TV Metronidazole 2g single oral 
dose OR 400 or 500mg 
orally twice per day for 7 
days 
Tinidazole 2g single oral 
dose OR 500 mg twice per 
day for 7 days 
4 weeks 
BV Metronidazole 400 or 
500mg orally twice per day 
for 7 days OR 2g single oral 
dose. 
Tinidazole 2g single oral 
dose once a day for 2 days or 
1g per day for 5 days. 
Alternative: Clindamycin 
300mg orally twice per day 
for 7 days 
NA 
VVC Fluconazole 150mg single 
oral dose 
Clotrimazole 200mg 
pessaries every night for 3 
nights 
NA 
UTI Ciprofloxacin 500mg orally 
twice per day x 7 days. 
Ceftriaxone IM 125mg twice 
per day for 5 days. 
NA 
BV bacterial vaginosis, CT Chlamydia trachomatis, IM intramuscular, IU international units, MoH Ministry of Health, NA not applicable. 
NG Neisseria gonorrhoeae, PID pelvic inflammatory disease, TV Trichomonas vaginalis, UTI urinary tract infection, VVC vulvovaginal 
candidiasis. 
 
Partner notification can cause social harms and was therefore only done in the case of laboratory-
confirmed curable STIs or pelvic inflammatory disease and when the participant consented to a 
certain partner to be notified. Women with HIV were referred to health centres that provided 
comprehensive HIV care, including partner notification for HIV. The window periods in the table E.1 
above were used to identify partners requiring notification. Partners were not tested but received 
treatment for the infection that was diagnosed in the index case with one exception: partners of 
women with pelvic inflammatory disease were tested for CT and NG and only treated for these 
infections if one or both tests were positive. 
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Women were offered partner notification choices for each partner as follows:  
1. She could give a partner notification card to the partner. This card listed the address, contact 
information, and opening hours of the studyclinic, and a request to come to the clinic as soon as 
possible for ‘medical follow-up’. 
2. She could allow study staff to notify the partner by telephone, mail or home visit. This could be 
done anonymously if preferred by the participant. 
 
As described in Chapter 6, treatments and referrals were delivered as required with few treatment 
failures, but the uptake of partner notification was suboptimal: 782 identified partners of 201 women 
(28.5%) required partner notification but only 61 (7.8%) of them were treated at the study clinic (table 
E.7). The main reasons were that many women did not consent to notifying some or all partners, or 
insisted on notifying partners themselves but likely did not follow through (we only have anecdotal 
evidence for the latter). These are well-known hurdles to partner notification, especially in 
understaffed and underresourced clinics. Partner notification results might be improved by improving 
index case privacy and confidentiality (e.g. mobile phone or internet-based notification with the 
option to notify anonymously),256 or by improving convenience (e.g. providing the index case with 
multiple treatment courses, and asking her/him to deliver these to relevant partners).257 We did not 
investigate these options in the WISH study. 
 
Steps undertaken to optimise the BV algorithm 
We first determined the optimal vaginal pH cut-off for diagnosing BV in both symptomatic (defined 
as structurally reporting genital itching/burning, any unusual vaginal discharge, lower abdominal pain 
and/or pain during sex) and asymptomatic women. This was pH 5.5, with similar performance in both 
groups (data not shown). The negative predictive value (NPV) was 92%, but the positive predictive 
value (PPV) was only 34%, in both groups. A confirmatory test in those with pH≥5.5 regardless of 
symptoms therefore seemed required to improve the PPV. We achieved the best balance between 
reducing BV false-positives and numbers of women requiring testing by determining vaginal pH in all 
women (as had previously been done), but adding a confirmatory test (the vaginal qPCR score) when 
pH≥5.5. This resulted in a sensitivity of 73.6% and specificity of 100% (table 6.4), and would require 
275/705 (39.0%) confirmatory tests (223 if women already being treated with metronidazole for TV 
are subtracted). In the performance calculations of this new optimal BV algorithm, we used the 
vaginal qPCR score as the confirmatory test (see explanation above). However, this score may not be 
practical in real life because it requires three separate qPCR assays. We therefore assessed the 
performance of Lactobacillus genus concentration on its own as a confirmatory test. We found that a 
Lactobacillus concentration of <105 geq/ml only slightly reduced algorithm performance (table E.5). 
Finally, we determined the performance of Lactobacillus genus concentration done on all women 
(compared to the vaginal qPCR score on all women as the gold standard) and achieved a sensitivity of 
78.4% and specificity of 95.0% (table E.5). Unfortunately, we did not have Nugent scores available to 
us (see explanation in ‘vaginal qPCR score to identify true BV cases’ above), but it is important to 
note that it would also be possible to screen all women for vaginal pH and use Gram stain Nugent 
scoring as the confirmatory test (see ‘selection of POCTs for evaluation in WISH’ for a more detailed 
discussion about the advantages and disadvantes of Gram stain Nugent scoring). 
 
Steps undertaken to optimise the VVC algorithm 
We did not conduct any tests for VVC in the WISH study but evaluated several potential ways to 
improve the VVC algorithm with the C. albicans qPCR data generated with stored swabs after 
completion of the WISH study. Clinicians often claim that they can recognise VVC during a 
speculum exam but our data show many false positives and low PPV both in the presence and absence 
of a speculum exam (PPV was 17.5% and 14.3%, respectively; data not shown). We also found that 
neither participant-reported symptoms nor clinician-observed signs were correlated with the presence 
of VVC or any other infection (table 6.5). We then investigated whether the presence of clinical signs 
and/or self-reported symptoms among women who tested qPCR positive for C. albicans depended on 
the C. albicans concentration. However, the median concentrations in women reporting different 
symptoms or exhibiting different signs were similar (ranging from 5.3 to 5.8 log10 geq/ml) with 
overlapping interquartile ranges (data not shown). We concluded that VVC cannot be accurately 
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diagnosed based on symptoms and signs. Next, we assessed the relationship between vaginal pH and 
VVC but found a wide pH range in women with a positive qPCR for C. albicans with and without 
symptoms (data not shown). We did observe, however, that pregnant women were more likely to have 
VVC than BV (19.4% and 6.5%, respectively). This led to the following optimal VVC algorithm: 
women would only be tested for VVC if they had VVC-like symptoms and had tested negative for 
CT, NG, TV, and BV (using the optimal algorithm) or were pregnant (regardless of symptoms). The 
sensitivity, specificity, positive predictive value and negative predictive value were 59.3%, 100%, 
100% and 96.3%, respectively. This is, however, a complex algorithm ‘by exclusion’ and better 
POCTs are therefore desirable as discussed in Chapter 6. 
 
Comparison of urinalysis dipstick and urine E. coli qPCR results 
As was mentioned in Chapter 6, 161/705 (22.8%) of WISH participants were treated for an UTI 
because urinalysis detected any nitrite and/or leukocytes in their urine. However, only 41/161 (25.5%) 
of these women had a urine E. coli concentration of ≥105 geq/ml by qPCR, and an additional 12/161 
(7.5%) had a urine E. coli concentration of >0 and <105 geq/ml (table E.6). We used a cut-off of ≥105 
geq/ml because many clinical guidelines use a cut-off of ≥105 colony forming units in culture per ml 
urine for UTI diagnosis.258 As mentioned earlier, it has been estimated that about 70% of UTIs are 
caused by E. coli,208 but this 30% gap cannot fully explain the positive urinalysis results in the 
108/161 (67.1%) of women without any E. coli in their urine. Table E.6 also shows that 19.8% of 
women without symptoms had some E. coli in their urine by qPCR, and that the correlation between 
urinalysis results and E. coli qPCR results in symptomatic women was generally poor (Pearson’s 
correlations range from -0.0423 to 0.4562; we did not have urinalysis results for asymptomatic 
women). 
 
Feasibility and acceptability 
As part of our feasibility and acceptability procedures, physicians who were not part of the day-to-day 
Rwandan study implementation team observed study staff and participants during monitoring visits to 
Rwanda. The observers were Dutch physicians with STI management and gynaecology experience. 
Participants to be observed were selected as follows: they had scheduled visits while the observers 
were in Rwanda and roughly equal proportions had a positive versus a negative CT/NG risk score 
(this was done because the CT/NG testing procedures took 90 min). In addition, care was taken to 
observe both study physicians and both study nurses roughly an equal number of times. Participants 
were observed from when they entered the study clinic until they left, and all of the procedures that 
they underwent were timed (table E.10).  
 
In addition, we conducted client satisfaction surveys with 107 participants (table E.11). We aimed to 
interview about 100 women because we estimated that we would have reached data saturation of the 
open-ended survey questions by then. We deliberately started the client satisfaction interviews after 
study staff had settled into a comfortable routine with the study procedures, about six weeks into 
study enrolment. We selected about five participants per week, and they were selected based on the 
availability of a study clinician to conduct their interview: the interviewer had to be a study clinician 
who had not personally implemented study procedures with the interviewee. 
 
One of the external observers also conducted interviews with all eight Rwandan study team members 
soon after data collection had been completed, but the information obtained during these interviews 
only confirmed the findings described in Chapter 6 and this appendix and did not add any new 
insights. These data are therefore not shown. 
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Table E.2: Spontaneously versus structurally reported symptoms 
Urogenital symptoms 
n (% of 705) in each column* 
Spontaneous  
total 
Structural  
total 
Spontaneous,  
not structural 
Structural,  
not spontaneous 
Any reported 575 (81.6) 604 (85.7)† 0 29 (4.1) 
Any unusual VDS 247 (35.0) 386 (54.8) 2 (0.3) 141 (20.0) 
 Unusual VDS, curd-like 176 (25.0) 265 (37.6) 3 (0.4) 92 (13.0) 
 Unusual VDS, offensive smell 52 (7.4) 119 (16.9) 1 (0.1) 68 (9.6) 
 Unusual VDS, other 21 (3.0)‡ 26 (3.7)§ 11 (1.6) 16 (2.3) 
Any genital itching and/or burning 384 (54.5) 470 (66.7) 1 (0.1) 87 (12.3) 
 Genital itching 344 (48.8) 409 (58.0) 5 (0.7) 70 (9.9) 
 Genital burning 65 (9.2) 212 (30.1) 0 147 (20.9) 
Any LAP and/or pain during sex 167 (23.7) 308 (43.7) 0 141 (20.0) 
 LAP 144 (20.4) 245 (34.8) 0 101 (14.3) 
 Pain during sex 33 (4.7) 142 (20.1) 0 109 (15.5) 
Any UTI symptoms 179 (25.4) 348 (49.4) 1 (0.1) 170 (24.1) 
 Burning when passing urine 133 (18.9) 262 (37.2) 6 (0.9) 135 (19.1) 
 Frequent urination/urge 54 (7.7) 176 (25.0) 0 122 (17.3) 
 Blood in urine 1 (0.1) 5 (0.7) 0 4 (0.6) 
 Other: smelly odour in urine 2 (0.3) 0 2 (0.3) 0 
Ulcers/blisters/sores genital/anal 10 (1.42) 41 (5.8) 0 31 (4.4) 
Swelling/bubo inguinal area 0 1 (0.1) 0 1 (0.1) 
Warts genital/anal 0 0 0 0 
Postcoital/intermenstrual bleeding 1 (0.1) 14 (2.0) 0 13 (1.8) 
LAP lower abdominal pain, UTI urinary tract infection, VDS vaginal discharge syndrome. 
*May total to more than 100% because the participant could report multiple symptoms. †We did not assess participant-reported severity of 
the symptoms but 43 of the 604 participants with structurally reported symptoms (7.1%) had been seeking medical care for their symptoms 
and 103 (17.1%) had used traditional medications. ‡Five participants described the VDS as having a yellow color; two as “pus-like”; and 14 
as unusual without specifying further. §18 participants described the VDS as having a yellow color; three as “pus-like”; two as “chocolate-
like”; and three as unusual without specifying further. 
 
 
Table E.3: Gold standard infections correlation matrix 
Outcome 
n (r)* 
(N=690) 
HIV† CT NG TV BV VVC Syphilis‡ MG 
HIV† 162 7 (-0.08) 
24 
(0.16) 
39 
(0.12) 
31 
(0.01) 
16 
(0.03) 
14 
(0.18) 
11 
(0.09) 
CT 7 (-0.08) 58 
10 
(0.12) 
13 
(0.05) 
14 
(0.05) 
3 
(-0.04) 
0 
(-0.05) 
4 
(0.05) 
NG 24 (0.16) 
10 
(0.12) 50 
15 
(0.11) 
8 
(-0.01) 
4 
(0) 
5 
(0.11) 
4 
(0.06) 
TV 39 (0.12) 
13 
(0.05) 
15 
(0.11) 111 
27 
(0.07) 
7 
(-0.04) 
7 
(0.08) 
7 
(0.06) 
BV 31 (0.01) 
14 
(0.05) 
8 
(-0.01) 
27 
(0.07) 125 
9 
(-0.03) 
5 
(0.03) 
8 
(0.07) 
VVC 16 (0.03) 
3 
(-0.04) 
4 
(0) 
7 
(-0.04) 
9 
(-0.03) 59 
1 
(-0.02) 
3 
(0.02) 
Syphilis‡ 14 (0.18) 
0 
(-0.05) 
5 
(0.11) 
7 
(0.08) 
5 
(0.03) 
1 
(-0.02) 21 
0 
(-0.04) 
MG 11 (0.09) 
4 
(0.05) 
4 
(0.06) 
7 
(0.06) 
8 
(0.07) 
3 
(0.02) 
0 
(-0.04) 26 
BV bacterial vaginosis, CT Chlamydia trachomatis, MG Mycoplasma genitalium, NG Neisseria gonorrhoeae, TV Trichomonas vaginalis, 
VVC vulvovaginal candidiasis.  
*Pearson correlation coefficient. †Either newly diagnosed, known infection confirmed, or known infection not tested in the WISH study but 
reported by participant. ‡Syphilis by WISH procedures: women who were positive for the syphilis risk score were tested by Syphilis 
Determine assay (with confirmation of active infection by rapid plasma reagin if needed). Women negative for the risk score were 
considered negative for syphilis. 
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Table E.4: Risk scoring results 
CT/NG risk score n (% of 705) 
Currently pregnant 62 (8.8) 
Exchanged sex for money or goods in the past 12 months* 250 (35.5) 
New sex partner in the past three months* 224 (31.8) 
Abnormal cervicovaginal discharge during speculum and/or cervical motion/adnexal 
tenderness during bimanual examination (if speculum/bimanual examination not done, the 
answer was no)† 
 
80 (11.4) 
Final CT/NG risk score positive‡ 396 (56.2) 
Syphilis risk score n (% of 705) 
Currently pregnant 62 (8.8) 
Exchanged sex for money or goods in the past 12 months* 250 (35.5) 
New sex partner in the past three months* 224 (31.8) 
Genital ulcers/blisters/sores visible during speculum examination (if not done, the answer 
was no)§ 
40 (5.7) 
Final syphilis risk score positive‡ 378 (53.6) 
CT Chlamydia trachomatis, NG Neisseria gonorrhoeae. 
*157 women reported both sex work and a new sex partner, 93 women reported sex work only, and 67 women reported a new sex partner 
only. Therefore, the risk in our population was predominanty via sex work. †75 of these 80 women reported VDS or LAP during structural 
questioning. However, 376 and 239 women in total reported VDS and/or LAP, respectively; the risk score would not have been feasible if 
we had included all women reporting VDS and/or LAP symptoms. ‡The risk score was positive if at least one of the four criteria was 
positive. §16 of these 40 women reported GUD during structural questioning. In total, 25 women reported GUD but did not actually have 
any upon speculum examination, and 24 women did not report any but turned out to have them during a speculum examination that was 
done for another reason. Therefore, GUD self-reporting is unreliable. 
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Table E.5: Performance of WISH and optimal BV/VVC algorithms compared to gold standard 
testing among women who sought care 
 GS* WISH (CT, NG, TV)* and optimal (BV, VVC)† algorithms  in women who sought care‡ 
Women who 
sought care 
(N=141)§ 
Neg 
n 
Pos 
n 
n  
POC¶ 
tested 
n  
GS¶ 
tested 
TP 
n 
FP 
n 
FN 
n 
TN 
n 
Sens 
%  
(95% CI) 
Spec 
%  
(95% CI) 
PPV 
%  
(95% CI) 
NPV 
%  
(95% CI) 
CT 131 10 74 0 6 0 4 131 60.0 
(28.1-85.2) 
100 
(100-100) 
100 
(100-100) 
97.0 
(92.3-98.9) 
NG 124 17 74 0 10 0 7 124 58.8 
(34.4-79.6) 
100 
(100-100) 
100 
(100-100) 
94.7 
(89.1-97.5) 
CT and/or NG 118 23 74 0 14 0 9 118 60.9 
(39.6-78.7) 
100 
(100-100) 
100 
(100-100) 
92.9 
(86.8-96.3) 
TV 127 12 139 0 7 0 5 127 58.3 
(29.5-82.4) 
100 
(100-100) 
100 
(100-100) 
96.2 
(91.1-98.4) 
BV 110 29 139 56 21 0 8 119 72.4 
(53.2-85.8) 
100 
(100-100) 
100 
(100-100) 
93.2 
(86.9-96.6) 
BV and/or TV 103 36 139 49 23 0 13 103 63.9 
(46.9-78.0) 
100 
(100-100) 
100 
(100-100) 
88.8 
(81.5-93.4) 
VVC 121 18 139 72 11 0 7 121 61.1 
(37.0-80.8) 
100 
(100-100) 
100 
(100-100) 
94.5 
(88.9-97.4) 
All women 
(N=690) 
GS Optimal BV/VVC algorithms but using Lactobacillus qPCR as confirmatory test|| 
BV 565 125 690 275 72 19 53 546 57.6 
(48.7-66.0) 
96.6 
(94.8-97.8) 
79.1 
(69.5-86.3) 
91.2 
(88.6-93.2) 
BV and/or TV 481 209 690 223 136 25 73 456 65.1 
(58.3-71.3) 
94.8 
(92.4-96.5) 
84.5 
(78.0-89.3) 
86.2 
(83.0-88.9) 
VVC 631 59 690 281 37 0 22 631 62.7 
(49.7-74.1) 
100 
(100-100) 
100 
(100-100) 
96.6 
(94.9-97.8) 
Women who 
sought care 
(N=139)§ 
  
BV 110 29 139 56 18 1 11 109 62.1 
(43.1-77.9) 
99.1 
(93.7-99.9) 
94.7 
(69.1-99.3) 
90.8 
(84.1-94.9) 
BV and/or TV 103 36 139 49 21 1 15 102 58.3 
(41.5-73.4) 
99.0 
(93.3-99.9) 
95.5 
(72.6-99.4) 
87.2 
(79.7-92.2) 
VVC 121 18 139 72 12 0 6 121 66.7 
(42.0-84.7) 
100 
(100-100) 
100 
(100-100) 
95.3 
(89.8-97.9) 
All women 
(N=690) 
Lactobacillus qPCR on all women to diagnose BV (with <105 geq/ml treated for BV) 
BV 565 125 690 0 98 28 27 537 78.4 
(70.3-84.8) 
95.0 
(92.9-96.6) 
77.8 
(69.6-84.2) 
95.2 
(93.1-96.7) 
BV bacterial vaginosis, CI confidence interval, CT Chlamydia trachomatis, FN false negative, FP false positive, GS gold standard, NG 
Neisseria gonorrhoeae, Neg negative, NPV negative predictive value, POC point-of-care, Pos positive, PPV positive predictive value, Sens 
sensitivity, Spec specificity, TN true negative, TP true positive, TV Trichomonas vaginalis, VDS vaginal discharge syndrome, VVC 
vulvovaginal candidiasis. 
*See table 6.1 for definitions. Performance statistics were also calculated for CT, NG combined, and BV and TV combined, because the 
former are assessed by one assay and the latter require the same treatment. †All women would have a vaginal pH determined and those with 
pH ≥5.5 would also have a vaginal qPCR score done (see methods). Only women with pH ≥5.5 and a positive vaginal qPCR score would be 
treated for BV. Women would only be tested for VVC if they had VVC-like symptoms and had tested negative for CT, NG, TV, and BV 
(by optimal algorithm), or were pregnant (regardless of symptoms). ‡Defined as women who had visited a clinic and/or women who had 
taken traditional medications for symptoms reported to be current or recent (last two weeks). §Performance measures are compared to gold 
standard testing. For TV, BV, and VVC, N=139 due to 2 invalid PCR results. ¶These are the numbers that would require POCT and gold 
standard testing if each respective algorithm were to be implemented in a real-life situation. ||Same as †, but instead of using the vaginal 
qPCR score as the confirmatory test after vaginal pH ≥5.5, we used the Lactobacillus qPCR only (with <105 geq/ml treated for BV). This 
same definition of BV was used in the VVC algorithm. The vaginal qPCR score on everyone was used as the gold standard BV result.  
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Table E.6: Urinalysis compared to Escherichia coli qPCR test results 
All women with urine samples 
(N=641)* Total n 
E. coli qPCR† 
OR (95% CI)§ 
Chi-squared p 
0 geq/ml 
(n %)‡ 
>0 to <105 geq/ml 
(n %)‡ 
≥105 
geq/ml  
(n %)‡ 
With UTI symptoms 363 262 (72.2) 32 (8.8) 69 (19.0) 2.67 (1.60-4.45) 
p<0.0001 Without symptoms 278 223 (80.2) 33 (11.9) 22 (7.9) 
Women reporting UTI symptoms 
only (N=363)* Total n 
E. coli qPCR† 
Correlation r¶ 
(95% CI) 
0 geq/ml 
(n %)‡ 
>0 to <105 geq/ml 
(n %)‡ 
≥105 
geq/ml  
(n %)‡ 
≥1+ leukocytes and/or nitrite-
positive|| 
161 108 (67.1) 12 (7.5) 41 (25.5) NA 
Nitrite negative, 0 leukocytes 202 154 (76.2) 20 (9.9) 28 (13.9) 
-0.042 
(-0.149-0.066) 
Nitrite negative, 1+ leukocytes 64 52 (81.3) 6 (9.4) 6 (9.4) 
Nitrite negative, 2+ leukocytes 46 36 (78.3) 5 (10.9) 5 (10.9) 
Nitrite negative, 3+ leukocytes 21 17 (80.9) 1 (4.8) 3 (14.3) 
Nitrite positive, 0 leukocytes 1 1 (100) 0 0 
0.186 
(-0.187-0.512) 
Nitrite positive, 1+ leukocytes 6 0 0 6 (100) 
Nitrite positive, 2+ leukocytes 14 2 (14.3) 0 12 (85.7) 
Nitrite positive, 3+ leukocytes 9 0 0 9 (100) 
CI confidence interval, Geq genome-equivalent units, ml milliliter, NA not applicable, OR odds ratio, qPCR quantitative polymerase chain 
reaction, UTI urinary tract infection. 
*363/641 women underwent urinalysis testing after reporting UTI-related symptoms. Urine was collected from the other 278/641 women for 
pregnancy testing, but these women did not undergo urinalysis testing because they did not report symptoms. All 641 urine samples were 
tested for E. coli concentration by qPCR. †E. coli qPCR concentration levels, devided into three categories: 0 geq/ml, >0 and <105 geq/ml, 
and ≥105 geq/ml. ‡Listed percentages are row percentages. §Chi-squared test for trend. The OR compares E. coli qPCR ≥105 geq/ml with 0 
geq/ml in women with and without UTI symptoms. ¶Pearson’s correlation of leukocyte level as an ordinal variable with E. coli 
concentration by qPCR in log10 geq/ml as a continuous variable. The overall correlation of the 8 nitrite/leukocyte level rows as one ordinal 
variable with E. coli concentration is r=0.4562 (95% CI 0.371-0.534). ||This is the algorithm that was used in the WISH study. All 161 
women who were positive for this algorithm were treated for a UTI. 
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Table E.7: Clinical findings and actions by study clinicians 
Speculum/bimanual exam results at main visits (study physicians) n (% of 399) 
Any abnormalities observed during speculum exam 216 (54.1) 
Abnormalities*: 
- Enlarged/tender inguinal lymph nodes 
- Abnormal (genital) odour 
- Warts or condylomata (any location genitalia) 
- Ulcers/blisters/sores suggestive of STI in vulva 
- Vulvitis 
- Any other lesion on vulva 
- Vaginal mass (polyp, myoma, etc.) 
- Ulcers/blisters/sores suggestive of STI in vagina 
- Vaginitis 
- Any other lesion on vaginal epithelium 
- Cervicitis 
- Any other lesion on cervical epithelium 
- Abnormal vaginal or cervical discharge/pus 
- Other‡ 
 
0 
34 (8.5) 
5 (1.3)† 
22 (5.5) 
21 (5.3) 
0 
4 (1.0) 
3 (0.8) 
39 (9.8) 
0 
42 (10.5) 
1 (0.2) 
138 (34.6) 
14 (3.2) 
Any abnormalities observed during bimanual exam 41 (10.3) 
Abnormalities*: 
- Any uterine or adnexal mass 
- Any uterine, adnexal or cervical motion tenderness 
- Other§ 
 
4 (9.8) 
31 (4.4) 
12 (29.3) 
Syndromic diagnoses within WISH algorithms at main visits (study physicians) n (% of 705) 
None 
VVC 
VDS – not VVC, tested negative for BV/TV/CT/NG 
LAP (with or without VDS) - no tenderness during bimanual 
LAP (with or without VDS) - tenderness during bimanual (=PID) 
Suspected PID for other reasons¶ 
GUD with or without inguinal buboes - tested negative for syphilis 
Inguinal buboes without GUD 
Genital warts/condylomata 
UTI symptoms testing negative for UTI 
Other: cervical tumor/mass 
262 (37.2) 
238 (33.8) 
12 (1.7) 
204 (28.9) 
29 (4.1) 
3 (0.4) 
16 (2.3) 
0 
3 (0.4) 
134 (19.0) 
1 (0.1) 
Delivery of positive POCT results (study physicians or nurses)|| n (% of 705) 
Had no positive results 
Received all her positive results at main visit; no pending results when leaving 
Received all her positive results at main visit; all pending results negative and received by phone/texts 
Received all her positive results at main visit; all pending results negative and received at additional visit 
A pending result came back positive and received result and/or treatment at additional visit 
A pending result came back positive and received result by phone/text 
Received all her positive results at an additional visit 
Received all positive results by phone/text 
164 (23.3) 
505 (71.6) 
26 (3.7) 
1 (0.1) 
7 (1.0) 
1 (0.1) 
1 (0.1) 
0 
Treatment failures (study physicians)** n (% of 705) 
Had at least one suspected ongoing untreated infection 4 (0.6) 
Had at least one suspected re-infection after having received appropriate treatment 2 (0.3) 
Had at least one suspected treatment failure 4 (0.6) 
Active referrals made (study physicians) n (% of 705) 
No referrals needed 
Because of new HIV diagnosis 
Because of new pregnancy 
For further gynecological evaluation/treatment 
Because of wish to start/change family planning method 
Other: For other medical specialist diagnosis & treatment 
Other: For starting antiretroviral therapy of previously known HIV infection 
At least one referral offered but declined 
626 (88.8) 
34 (4.8) 
25 (3.6) 
18 (2.6) 
0 
1 (0.1) 
4 (0.6) 
2 (0.3) 
Partner notification and treatment (study physicians or nurses) n (% of 705) 
Had at least one partner requiring notification during the study†† 201 (28.5) 
Total number of partners requiring notification during the study 782 
Median number of partners requiring notification per woman with an infection [IQR] 2 (1 – 3) 
Total numbers of partners that the women consented to being notified 238 
Number of women who agreed to: 
- All of the identified partners being notified 
- Some of the identified partners being notified 
- None of the identified partners being notified 
 
111 (15.7) 
59 (8.4) 
31 (4.4) 
Number of women who chose to: 
- Notify all partners herself 
- Have RU staff notify all partners (in agreed-upon manner) 
- Notify some partners herself and some by RU staff 
- Other: Notification by RU staff with both partners present 
 
150 (21.3) 
13 (1.8) 
2 (0.3) 
2 (0.3) 
Total number of eligible partners treated (% out of the total number of partners identified) 61 (7.8) 
186 
 
BV bacterial vaginosis, CT Chlamydia trachomatis, GUD genital ulcer disease, LAP lower abdominal pain, NG Neisseria gonorrhoeae, PID 
pelvic inflammatory disease, POCT point-of-care test, TV Trichomonas vaginalis, UTI urinary tract infection, VDS vaginal discharge 
syndrome, VVC vulvovaginal candidiasis.  
*May total to more than 100% because one woman could have multiple signs/diagnoses. †Two of these cases were a small number of warts 
that the study physician found difficult to reliably differentiate from ulcers. These participants were not treated for warts. ‡Includes 
menstrual blood from cervical os (8), Bartholin’s cyst (1), dry skin at external genitalia (1), uterine prolapse (1), acne due to shaving (1), 
depigmentation of the vulva (1), and satellite lesions suggestive of VVC (1). §Includes hard, indured cervix (4), large volume of uterus 
consistent with early pregnancy(2), abnormal pain during exam (5), and absence of cervix consistent with hysterectomy (1). ¶Two 
participants underwent a bimanual exam for reasons other than LAP, had tenderness, and were treated for PID. One participant reported 
severe LAP in the past two weeks but not during the main visit, and did not have tenderness during the bimanual exam. However, her CT 
and NG results both came back positive, and the study physician decided to treat her for PID. Her LAP disappeared after completion of the 
treatment. ||GeneXpert CT/NG counts as one result and was considered positive if the test was positive for at least one organism. 
**Treatment was in accordance with the Rwanda national treatment guidelines at the time of the study (see above). Drugs dispensed 
included metronidazole (BV, TV, PID), tinidazole (BV), fluconazole (VVC), clotrimazole (VVC), ciprofloxacin (NG, PID, UTI), 
ceftriaxone (NG), doxycycline (CT), erythromycin (CT, PID), benzyl penicillin (syphilis), acyclovir (herpes simplex virus type 2), 
pivmecillinam (UTI), and amoxicillin/clavulanic acid (UTI). ††Based on both POCT and gold standard testing results. 
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Table E.8: WISH services offered and accepted 
Services 
 
Offered 
n (% of 705) 
Accepted 
(% offered) 
Reasons for 
declininga 
Sample taken 
(% offered) 
Received result same 
day 
Received tx or referral 
same day 
HIV test 
 
700b 
(99.3%) 
Yes: 
593 (84.7%) 
 
No: 
107 (15.3%) 
-  Known HIV+: 106 
-  Other, was tested 
few months ago: 1 
-  Missing: 0 
- EDTA blood: 591 
(99.7%) 
- Fingerstick: 2 (0.3%) 
- Missing: 0 
- Yes: 590 
- No, other time: 3 
- Not at all: 0 
- Missing: 0 
55 positive 
- Yes, newly diagnosed: 31 
- Yes, known infectionc: 3 
- No, other time: 0 
- Not at alld: 21 
- Missing: 0 
Pregnancy test 702e 
(99.6%) 
Yes: 
583 (83.0%) 
 
No: 
119 (17.0%) 
- Known pregnant: 26 
- Uses reliable 
contraception: 52 
- Otherf: 38 
- Missingf: 3 
- Urine: 581 (99.7%) 
- Missing: 2 (0.3%) 
 
- Yes (offered): 579 
- Yes (mistake)g: 2 
- No, other time: 1 
- Not at all: 0 
- Missing: 3 
33 positive 
- Yes: 24 
- No, other time: 0 
- Not at allh: 9 
- Missing: 0 
UTI test 352 
(49.9%) 
All NA 
 
- Urine: 351 (99.7%) 
- Missingi: 1 (0.3%) 
- Yes (offered): 351 
- Yes (mistake)j: 12 
- No, other time: 0 
- Not at all: 0 
- Missingi: 1 
161 positive  
- Yes: 160 
- No, other time: 1 
- Not at all: 0 
- Missing: 0 
Vaginal pH 
for BV 
705 
(100%) 
All NA 
 
- pH swab: 705 
(100%) 
- NA: 0 
- Missing: 0 
- Yes: 705 
- No, other time: 0 
- Not at all: 0 
- NA: 0 
- Missing: 0 
466 positive 
- Yes: 464 
- No, other time: 1 
- Not at all: 0 
- Missingk: 1 
TV test 705 
(100%) 
All NA 
 
- Kit swab: 705 
(100%) 
- NA: 0 
- Missing: 0 
- Yes: 703 
- No, other time: 2 
- Not at all: 0 
- Missing: 0 
92 positive 
- Yes: 92 
- No, other time: 0 
- Not at all: 0 
- Missing: 0 
CT/NG testl 396 
(56.2%) 
All NA - Kit swab: 396 
(100%) 
- Urinem: 1 (0.3%) 
- Missing: 0 
- Yes: 354 
- No, other time: 42  
- Not at all: 0 
- Missing: 0 
75 positiven 
- Yes: 66 
- No, other time: 9 
- Not at all: 0 
- Missing: 0 
Syphilis test 378 
(53.6%) 
All NA 
 
- EDTA blood: 377 
(99.7%) 
- Fingersticko: 2 
(0.5%) 
- Missing: 0 
- Yes (offered): 375 
- Yes (mistake)p: 1 
- No, other time: 2 
- Not at all: 0 
- Missingq: 1 
21 positive 
- Yes: 21 
- No, other time: 0 
- Not at all: 0 
- Missing: 0 
Services 
 
Offered 
n (% 705) 
Accepted 
(% offered) 
Reasons for 
declininga 
Done the same day? 
Speculum/ 
bimanual 
examination 
 397 
 (56.3%) 
Yes: 
395 (99.5%) 
 
Nor: 
2 (0.5%) 
- Refused out of fear: 1 
- Does not tolerate speculum: 1 
- Yes: 391 
- Yes, but not offereds: 8 
- No, other time: 0 
- Missingt: 4 
Counselling  705 
 (100%) 
 All NA All 
Male condoms 
(MCs) 
 705 
 (100%) 
Yes: 
386 (54.8%) 
 
No: 
319 (45.2%) 
- Never uses MCs: 247 
- Still has MCs at home: 35 
- Partner(s) refuse(s) MCs: 20 
- Partner(s) bring(s) MCs: 10 
- Wants to get pregnant: 1 
- Missing: 9 
All 
Willing to wait for CT/NG results (women 
whose risk score was positive and who did 
not opt-out of testing) 
 
n=396 
- Yes, wanted to wait for the results: 344 (86.9%)  
- No, wanted to come back for results later: 5 (1.3%)   
- No, wanted to receive results by text/phone/letter: 41 (10.4%) 
- Missing: 6 (1.5%) 
- Never received results: 0 
ART antiretroviral treatment, BV bacterial vaginosis, CT Chlamydia trachomatis, NA not applicable, NG Neisseria gonorrhoeae, PID patient 
identification number, TV Trichomonas vaginalis, UTI urinary tract infection. 
a. May total to more than 100% because multiple answers possible. 
b. Five women were not offered HIV testing because they were known HIV-positive. 
c. These participants were known HIV-positive but had not yet been referred for ART.  
d. These participants were known HIV-positive and were in care, with some already receiving ART and others not yet. At the time of the 
WISH study, the Rwandan government was still rolling out the latest WHO recommendations of starting all HIV-positive people on 
ART regardless of CD4 count. These women opted in for HIV testing because they wanted to be retested. 
e. Three women were not offered a pregnancy test because they were visibly pregnant. 
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f. Other reasons included: is sterilised or menopausal (12), states that last sexual encounter was a long time ago (7), had menses recently 
(4), believes that she cannot get pregnant due to having given birth recently (1), recently had a pregnancy test (1). Two women who 
opted out refused to give a reason. All three women with missing reasons used an IUD.  
g. Two women who had opted out of a pregnancy test were mistakenly tested anyway.  
h. Seven women were already in antenatal care. Two women did not want to be referred. 
i. One woman was offered a urinalysis test but the urine sample was not taken. 
j. 12 women had a urine sample taken for a UTI test despite not being offered a UTI test. Of these, 5 were mistakenly ordered from the 
laboratory, and 7 were not ordered but accidentally performed (because the urine was available for pregnancy testing). 2 of the 12 
women should have been offered a UTI test because they reported relevant symptoms. 
k. Treatment information for one woman is missing.  
l. This does not include samples taken from women who had a negative risk score for testing later on in the study. That was done to 
enable test performance calculations but was not part of the WISH clinical algorithms. 
m. One woman had both a vaginal swab and a urine sample taken because swab testing came back invalid twice.  
n. 75 women had a positive CT and/or NG result: 43 positive for CT and 38 for NG (6 were positive for both CT and NG). 
o. One woman had both EDTA blood and a fingerstick sample taken for syphilis testing.  
p. One woman had a syphilis test performed despite not being offered one; the laboratory performed the test by mistake on blood 
available for an HIV test. 
q. One woman had a positive risk score and was offered syphilis testing. However, the test was not requested from the lab.  
r. One woman accepted the examination initially, which was postponed because of time contraints. However, the woman opted out of the 
exam at the additional visit because of fear. 
s. Two of these eight women requested an exam without having relevant symptoms. The other six women were symptomatic and it is 
likely that the study physician neglected to document that an exam was offered. 
t. Four women were offered an examination but not results are reported. One of these only reported "frequent urination or urgent need to 
urinate" and the physician therefore likely erroneously reported that an examination was offered. 
 
Table E.9: Counselling topics chosen by participants 
Counsellors and counselling topics Main visit 
n (% of 705) 
Additional visit 
n (% of 4) 
General counselling performed by:  
- Nurse/counsellor 
- Physician 
 
704 (99.9) 
1 (0.1) 
 
0 
4 (100) 
Topics that were discussed during general counselling*: 
 HIV basic facts 
 STIs basic facts 
 HIV & STI treatment 
 HIV & STI prevention 
 HIV & STIs: Condom use demonstration 
 BV and VVC basic facts 
 BV and VVC treatment 
 BV and VVC prevention 
 UTIs: what it is, consequences if not treated, prevention 
 Family planning 
 Domestic violence: including referrals 
 Other, specify: hepatitis 
 Other, specify: condylomata 
 
56 (7.9) 
130 (18.4) 
330 (46.8) 
652 (92.5) 
44 (6.2) 
594 (84.3) 
553 (78.4) 
694 (98.4) 
244 (34.6) 
295 (41.8) 
116 (16.5) 
1 (0.1) 
1 (0.1) 
 
1 (25.0) 
4 (100) 
4 (100) 
3 (75.0) 
1 (25.0) 
1 (25.0) 
0 
0 
1 (25.0) 
0 
1 (25.0) 
0 
0 
HIV post-test counselling performed:  
- Nurse/counsellor 
- Physician§ 
(N=588†) 
30 (5.1) 
558 (94.9) 
(N=3‡) 
0 
3 (100) 
Topics that were discussed during HIV post-test counselling: 
 Negative result for HIV test 
 Positive or equivocal result for HIV test 
(N=588†) 
534 (90.8) 
54 (9.2) 
(N=3‡) 
3 (100) 
0 
BV bacterial vaginosis, STI sexually transmitted infection, UTI urinary tract infection. 
*May total to more than 100% because women could choose multiple topics. †Numbers are lower than 705 due to 
women opting out of HIV testing. ‡No participants were tested for HIV during additional visits; these counselling 
sessions were provided to women who came with their partners for partner treatment and testing. §The study physicians 
often performed the HIV post-test counselling at the same time as giving women their other test results. This fitted better 
into the clinic flow and enabled the nurse/counsellors to see new patients. 
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Table E.10: Timing of procedures at Main Visits 
Procedures n Duration  
in median min (IQR) 
Duration of procedures at reception 14 5 (3-12) 
Duration of informed consent procedures and obtaining contact details 20 25.5 (21-32.5) 
Duration of face-to-face interview 20 23 (21.5-27) 
Duration of counselling 20 7 (6-9.5) 
Duration of blood collection 19 4 (3-5) 
Duration of vaginal swab collection 20 6 (5.5-7.5) 
Duration of urine collection 18 2 (2-3) 
Duration of speculum examination 7 4 (3-8) 
Duration of bimanual examination 6 2 (1-2) 
Duration between delivering the last sample to the lab and being called for 
results 
20 95.5 (14-104) 
Duration of diagnosing and counselling by physician 20 6.5 (5-12.5) 
Duration of treatment and partner notification procedures by physician 18 3.5 (2-6) 
Overall trajectories n Duration  
Total duration spent at RU with nurse/counsellor 20 82 (73-93) 
Total duration spent at RU with physician 20 14 (10-24.5) 
Total duration spent on laboratory testing 21 104 (26-115) 
Total duration spent at RU 20 222.5 (138-237.5) 
Total duration spent at RU without research procedures* 20 182.5 (111-216) 
 Total duration without research procedures with CT/NG testing+results† 13 212 (190-219) 
 Total duration without research procedures and without CT/NG 
testing+results‡ 
7 98 (78-123) 
CT Chlamydia trachomatis, IQR inter-quartile range, NG Neisseria gonorrhoeae, RU Rinda Ubuzima research clinic. 
*Duration excludes time for informed consent procedures and client satisfaction survey. †The participant was positive for the CT/NG risk 
score and elected to wait for the results. ‡The participant was either negative for the CT/NG risk score or chose not to wait for the results. 
 
Table E.11: Client satisfaction survey results 
Questions asked in face-to-face interview n (% of 107) 
Agreed with the following statements: 
 - “I felt welcome at RU” 
 - “The study staff were friendly” 
 - “The instructions I received along the way were clear” 
 - “The medical services I received were of good quality” 
 - “The medical services I received were useful” 
 - “The counselling/information I received was of good quality” 
 - “The counselling/information I received was useful” 
 
107 (100) 
107 (100) 
107 (100) 
107 (100) 
107 (100) 
107 (100) 
107 (100) 
Time spent at RU, estimated by the participant: median minutes (IQR) 209 (150-251) 
Feelings about the clinic visit duration: 
 - Thought it was fine 
 - Was bothered by it but not much 
 - Thought it was very long, but worth it due to all the services received 
 - Thought it was much too long and would not do it again 
 
62 (57.9) 
4 (3.8) 
41 (38.3) 
0 
Comparison of experience at RU during study visit, compared to other places where 
HIV/STI/women’s issues-related services are given:  
 - Liked RU better 
 - All services are similar 
 - Liked the other services better 
 - Has never been to other places 
 
 
104 (97.2) 
0 
0 
3 (2.8) 
Reasons for preferring RU over other clinics*: 
- Friendly staff / attention was paid to participants† 
- High number of tests performed / more useful or better-quality tests than elsewhere‡ 
- Thought that the counselling and information obtained were useful 
- Quick and well-organised services 
- Services free-of-charge 
- Unclear / very general reasons given 
(N = 104) 
58 (55.8) 
56 (53.8) 
28 (26.9) 
28 (26.9) 
24 (23.0) 
7 (6.7) 
Is willing to be tested in future, even when asymptomatic 100 (93.5) 
Is willing to pay for services such as those offered at RU (N=106) 
95 (89.6) 
IQR interquartile range, RU Rinda Ubuzima research clinic, STIs sexually transmitted infections. 
*May total to more than 100% because the participant could give multiple answers. The question was open-ended and categories were 
created during the data analysis stage. †Includes answers such as “the staff is friendly”, and comments about refreshments being offered to 
participants. ‡Includes quotes suggesting that more testing was done in WISH than at local clinics, such as “you test all the diseases”, “you 
take many samples”, “you test before treatment”, or “you examine deeply”. 
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